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Abstract 
 
The abnormal death of neurons in the central nervous system of individuals suffering from 
neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, Huntington’s 
disease and amyotrophic lateral sclerosis, takes place by an intrinsic cell suicide programme 
known as apoptosis. This process is triggered by several stimuli, and consists of numerous 
pathways and cascades which lead to the death of neuronal cells. It is this multifactorial 
nature of neurodegenerative diseases that has over the years seen many researchers develop 
compounds that may serve as multi-target directed ligands (MTDLs) which could potentially 
confer neuroprotection by acting simultaneously on different receptors and target sites 
implicated in neurodegeneration. 
 
This study was aimed at developing MTDLs that may serve as neuroprotective agents by 
simultaneously (a) inhibiting N-methyl D-aspartate receptors (NMDAR) and blocking L-type 
voltage gated calcium channels (VGCC) thus regulating the Ca
2+
 influx mediated excitotoxic 
process; (b) inhibiting the monoamine oxidase enzymes A and -B (MAO-A/B) thus allowing 
increase in dopamine levels in the central nervous system and reducing the levels of the 
highly oxidative products produced by the activity of these enzymes; (c) possessing anti-
apoptotic activity to halt the neuronal cell death process. 
 
In designing the compounds we focused on the structures of rasagiline and selegiline, two 
well-known MAO-B inhibitors and proposed neuroprotective agents, and of NGP1-01, a 
known VGCC blocker and NMDAR antagonist. The first series of compounds (reported in 
research article 1, Chapter 3), comprised polycyclic propargylamine and acetylene 
derivatives. Compounds 12, 15 and 16 from this series showed promising VGCC and NMDA 
receptor channel inhibitory activity ranging from 18 % to 59 % in micromolar concentrations, 
and compared favourably to the reference compounds. In the MAO-B assay, compound 10 
exhibited weak MAO-B inhibition of 73.32 % at 300 μM. The rest of the series showed little 
to no activity on these target sites, despite showing significant anti-apoptotic activity. This 
suggested the compounds in this series to be exhibiting their neuroprotective action through 
some other mechanism(s) unexplored in this study.  
 
Follow up work on these compounds yielded a second series of compounds which comprised 
pentacycloundecane and hexacycloundecane propargylamine derivatives (presented in 
research article 2, Chapter 4). These compounds showed the ability to significantly improve 
http://etd.uwc.ac.za/
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the viability of SH-SY5Y neuroblastoma cells, by 31% and 61% at a 1 µM concentration. 
These compounds also showed dual calcium modulation activity by blocking VGCC’s 
(26.6% to 51.3%, at 10 µM) and by blocking NMDAR (31.4% and 88.3%, at 10 µM). When 
assayed for MAO inhibition, most of the active compounds displayed selectivity to the 
MAO-B isoenzyme with IC50 values ranging from 1.70 µM to 36.31 µM and appeared to be 
reversible MAO inhibitors as defined by the time-dependency studies conducted. The 
inclusion of the propargylamine moiety in the structures of these compounds afforded them 
multi-mechanistic neuroprotective ability which most importantly included MAO-B 
inhibition.  
 
The third series of compounds (presented in research article 3, Chapter 5) comprised 
adamantane-derived compounds, structurally similar to NGP1-01. From this series, 
compounds 1, 2, 5 and 10 displayed good inhibitory activity against both NMDAR channel 
(66.7 - 89.5 % at 100 µM) and VGCC (39.6 – 85.7 % at 100 µM) ), and appeared to be 
superior calcium modulators to NGP1-01.  
 
The results obtained in this study suggests these compounds to be promising leads to multi-
mechanistic compounds that may be useful as drug agents for the treatment of 
neurodegenerative disorders. Further in vitro and in vivo studies, which may include 
mechanistic studies as well as elucidation of the actual binding mode of these compounds, 
their direct involvement in the anti-apoptotic cascade, dopamine transmission and blood-
brain barrier permeability, would provide better insight on their drugability. Also, these 
analogues may be screened for potential neuroprotective activity on various other drug 
targets such as adenosine receptors, serotonin 1A receptors and dopamine 3 (D3) receptors, 
which have now emerged as potential targets for the treatment of neurodegenerative 
disorders.  
http://etd.uwc.ac.za/
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Key terms 
 
Neurodegeneration: Umbrella term for the progressive loss of structure or function of 
neurons, including death of neurons. 
Apoptosis: Process of programed cell death in multicellular organisms. 
Excitotoxicity: Pathological process by which nerve cells are damaged and killed by 
excessive stimulation by neurotransmitters such as glutamate and similar substances. 
Neuroprotection: An effect that may result in salvage, recovery or regeneration of the 
nervous system, its cells, structure and function. 
Multitarget-directed ligands: Single molecules that exert their pharmacological effect by 
interacting with two or more drug target sites – the term ‘multifunctional drugs’ is used 
synonymously for the purpose of this thesis. 
Propargylamine derivatives: Molecules containing a 2-propynylamine moiety such as the 
MAO-B inhibitory compounds selegiline and rasagiline. 
Polycyclic scaffold: Lipophilic scaffolds with more than one cyclic component such as 
amantadine and the Cookson’s diketone. 
Monoamine oxidase: an enzyme, present in most tissues, which catalyses the oxidation and 
inactivation of monoamine neurotransmitters. 
NMDA receptors: A glutamate receptor and ion channel protein found in nerve cells. 
Voltage gated calcium channels: A group of voltage-dependent ion channels found in the 
membrane of excitable cells such as muscles, glial cells and neurons. 
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Chapter 1 
Introduction & Rational 
 
1.1. Neurodegeneration 
Neurodegenerative diseases (NDs) such as Alzheimer’s (AD), Parkinson’s (PD), and 
Huntington’s diseases (HD) and amyotrophic lateral sclerosis (ALS) form part of a group of 
age related conditions characterized by progressive loss of structure or function of neurons, 
including death of neurons. Neurodegeneration has a mean onset of 55 years and is estimated 
to affect more than 100 million people worldwide [1]. Very few of these neurological 
conditions are curable, and many worsen over time as one ages, ultimately leading to death. 
They produce a range of symptoms and functional limitations that pose daily challenges to 
individuals and their families. Further to this, neurological conditions pose an economic 
burden to society and are estimated to cost the United States nearly $800 billion per year [1]. 
These costs are projected to increase even further over the coming years as the elderly 
segment of the population nearly doubles between 2011 and 2050 [1]. 
Though the pathogenesis of NDs is yet to be fully understood, it is known that several factors 
including toxins, endogenous-, environmental- and genetic factors are involved in the 
aetiology of these disorders [2]. While each disease state has its own specific molecular 
mechanism and clinical manifestations, some general pathways can be recognized in their 
different pathogenic cascades. Disturbances in neurotransmitter systems such as the 
monoaminergic system [3,4], mitochondrial dysfunction [5], cholinergic dysfunction [6], 
oxidative stress [6] and metal dyshomeostasis [7] are some of the common theories of 
causation widely explored in the literature. The complex pathogenesis of neurodegenerative 
diseases is now known to be the reason why drugs that target a single enzymatic system or 
receptor have failed to render sufficient neuroprotective and/or neurorestorative activity for 
their treatment [8–10]. It is now widely accepted that a more effective therapy would result 
from the use of multi-target directed ligands (MTDLs) able to intervene in the different 
pathological events implicated in the aetiology of NDs [11].  
This thesis discusses a number of causation theories in greater detail in the relevant chapters, 
as well as potential drug agents that may serve as MTDLs to meet the curative needs of the 
respective NDs. It is however important to note that the core of the research herewith 
presented focused on designing MTDLs that may potentially halt the neuronal breakdown 
http://etd.uwc.ac.za/
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process by addressing particularly the disturbances in the monoaminergic system, as well as 
the excitotoxicity resulting from excessive calcium influx into neuronal cells.  
Monoaminergic system 
Activated monoamine oxidase (MAO) have been reported to play a critical role in the 
pathogenesis of NDs. The enzymatic system, which comprises of two isoenzymes, MAO-A 
and MAO-B, catalyzes the oxidative deamination of biogenic and xenobiotic amines and has 
an important role in metabolism [12]. The enzymes preferentially degrade benzylamine and 
phenylethylamine and target a wide variety of specific neurotransmitters in the brain, 
including epinephrine, norepinephrine, dopamine, serotonin, and β-phenylethylamine [13,14]. 
The role of the MAO in modulating the function of a wide range of specific neurotransmitters 
is the reason the enzymatic system is associated with various conditions, including mood 
disorders [15], anxiety and depression [16,17], schizophrenia [18], attention deficit hyper-
activity disorder [19-21], and NDs [22]. In neurodegeneration, particularly PD, the MAO-B 
enzyme, has been shown to exist in elevated levels in the brain of affected patients [23]. This 
enzyme has been shown to contribute to the neurodegenerative process through various 
mechanisms including, oxidative stress [24], neuroinflammation [25], triggering of apoptosis 
[26,27], failure of aggregated-protein clearance [28-30] and glial activation [31]. Significant 
attention has thus been duly directed to this enzymatic system as a therapeutic target in the 
design of neuroprotective agents, and as such, monoamine oxidase inhibitors (MAOI’s) such 
as selegiline and rasagiline (Figure 1) remain the mainstay therapy for the management of 
NDs. 
Calcium modulation  
Aging neurons have also been shown to have reduced cytosolic calcium buffering capacity, 
increased calcium influx through L-type voltage-gated calcium channels (VGCCs) and via N-
methyl D-aspartate receptor (NMDAR)-mediated calcium influx [32]. The resulting changes 
in neuronal calcium dynamics can cause the activation of calcium-dependent signals to 
enzymes such as phospholipases and proteases, as well as oxidative stress through reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) leading to neuronal cell death 
[33-35]. This mechanism of apoptosis has led to the extensive development of calcium 
modulators due to the neuroprotective potential they may render [36]. Examples of drugs 
currently in use as calcium modulators include nimodipine (Figure 1), which is known to 
halt/retard neuronal cell death evoked by focal cerebral ischemia by blocking VGCC [37] and 
memantine (Figure 1), a noncompetitive and low-affinity NMDAR antagonist used in AD 
[38].  
http://etd.uwc.ac.za/
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Figure 1 : Structures of nimodipine, memantine, amantadine, NGP1-01, selegiline, rasagiline and Cookson’s 
diketone. 
 
1.2. Polycyclic compounds  
Heteroatom substituted polycyclic hydrocarbon ‘cage’ compounds are receiving attention 
from several research groups as potential scaffolds for the development of new drugs. Interest 
in these compounds stems from the discovery that amantadine (Figure 1), a 1-amino 
substituted polycyclic hydrocarbon, exhibit anti-parkinsonian activity [39] attributed to its 
action on the nigrostriatal doperminergic neurons in the brain. Amantadine is an FDA 
approved drug used in PD due to its rapid and strong voltage-dependent blocking kinetics of 
the NMDA receptor channel [40], as well as its ability to increase dopamine release and 
decrease dopamine reuptake in the CNS [41]. Similar to amantadine, NGP1–01 (Figure 1), a 
pentacycloundecaneamine synthetically derived from the polycyclic hydrocarbon scaffold 
commonly known as the Cookson’s diketone (Figure 1) [42], has been shown to exhibit 
neuroprotective properties through VGCC blockade and NMDAR antagonistic activity [73]. 
NGP1-01, like amantadine, has also been shown to inhibit dopamine reuptake in vivo, with 
resulting neuroprotective activity [44–47]. It is apparent from the literature that amantadine 
and Cookson’s diketone are polycyclic moieties that can be used to modify and improve the 
pharmacokinetic and pharmacodynamic properties of drugs, and are useful as both scaffolds 
for side-chain attachment as well as for improving a drug’s lipophilicity [48]. Lipophilicity 
enhances a drug’s transport across cellular membranes, including the selectively permeable 
blood–brain barrier, and increases the drug’s affinity for lipophilic regions in target proteins 
[48,49]. The brain being the drug target site for treating NDs, the significance of these 
polycyclic moieties is clear. In addition polycyclic moieties could afford molecules with 
http://etd.uwc.ac.za/
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metabolic stability, thereby prolonging the pharmacological effect of a drug, leading to a 
reduction in dosing frequency and improved patient compliance [50]. 
 
1.3. Propargylamine derivatives  
The last few decades have seen increasing research interest and exploration of the 
neuroprotective ability of compounds bearing the propargylamine function seen in selegiline 
and rasagiline (Figure 1), two well known MAO-B inhibitors and proposed neuroprotective 
agents. The propargylamine moiety within these compounds’ structures is now known to play 
an important role in providing the neuronal and mitochondrial protective properties inherent 
in these compounds [51–53]. Other reported activities ascribed to this moiety in the literature 
include anti-apoptotic activity [54–56] and amyloid-β (Aβ) aggregation inhibition [57]. These 
features of the propargylamine moiety have logically led to its incorporation into structures of 
many drug-like compounds designed for neuroprotection, with the aim of affording the 
resultant molecules with a broader therapeutic profile that may potentially meet the curative 
needs of NDs. This approach is discussed in greater detail in a review article included in this 
thesis (Chapter 2). The review describes various strategies adopted by researchers over the 
last decade in designing and evaluating drug-like molecules incorporating this moiety.  
 
1.4. Study aim 
This study was aimed at developing several multimechanistic polycyclic derivatives, 
represented by compounds P1, P2, Y1 and 12, (Figure 2) designed to serve as potential 
neuroprotective agents. By incorporating various functional groups with known biological 
activities into single molecules, we aimed to develop analogues that showed multiple 
mechanisms of action, as exhibited by their constituting moieties. Compounds that act on the 
various pathways involved in the apoptotic process of neuronal cells have great potential to 
serve as future analogues for the treatment and management of neurodegenerative disorders.  
A main feature in the various compounds reported in this study was the polycyclic scaffold in 
the form of the Cookson’s diketone or amantadine moiety (Figure 1). The influence of these 
polycyclic compounds on the NMDAR and VGCC’s as well as their ability to impart 
desirable pharmacokinetic and pharmacodynamic properties on resultant molecules was the 
basis of their incorporation in the designed analogues. Further to the polycyclic scaffold, 
several compounds were designed to carry the propargylamine moiety, a deliberate strategy 
to impart the resultant molecules with MAO-B inhibitory activity, as well as providing them 
http://etd.uwc.ac.za/
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with neuronal and mitochondrial protective properties, among other activities ascribed to this 
moiety. 
 
Figure 2 : Representative structures of the various compounds designed and synthesized in this study. 
 
The primary objectives of this study were therefore to design and synthesize a series of 
polycyclic propargylamine derivatives and to evaluate these compounds as multimechanistic 
neuroprotective agents. The main approach was to develop multifunctional drugs which 
would halt the apoptotic neuronal breakdown process and eliminate some of the signs and 
symptoms of diseases such as AD and PD by: (a) Inhibiting NMDA receptors and blocking 
VGCC’s thus regulating the Ca2+ influx mediated excitotoxic process; (b) Inhibiting the 
MAO-B enzyme thus allowing increase in dopamine levels in the CNS and reducing the 
levels of the highly oxidative products produced by the activity of this enzyme; (c) Possess 
anti-apoptotic activity to halt the natural neuronal cell death process. 
 
The design of the various compounds was guided by preliminary in silico studies performed 
during the initial design phases. In these studies, the proposed compound structures were 
docked in computer-simulated target proteins in order to envisage their potential binding 
interaction with the proteins. This allowed for the development of analogues with the 
desirable receptor binding properties.  
 
Following the in-silico studies, the next objective was to synthesize the best ranked 
compounds utilizing various synthetic strategies. Microwave assisted methods were often 
used as the preferred method of synthesis as they present several advantages which include; 
remarkable reduction of reaction time, improved yields, cleaner reactions and reduction or 
elimination of hazardous solvents compared to reactions performed under conventional 
P1
O
NH N
P2
NH
O
NH
NH
Y112
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thermal heating conditions [58,59]. The successfully synthesized compounds were then 
evaluated in vitro for potential activity on the various target sites implicated in 
neurodegeneration.  
 
The final findings from this study were compiled into two research articles published in peer-
reviewed journals. The first article (Chapter 3) describes the design, synthesis and evaluation 
of polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective 
agents (represented by compounds P1 and P2, Figure 2). These compounds were shown to 
possess significant neuroprotective properties, but however showed little to no activity on the 
intended target sites (MAO-B, VGCC and NMDAR). The second article (Chapter 4) 
describes the expansion on the initial series of compounds reported in chapter 3. This article 
describes the modifications performed to the compounds described in the first article in order 
to afford a new series of compounds (represented by compound 12; Figure 2) which showed 
neuroprotective properties and most importantly, showed improved activity on the MAO-B, 
VGCC and NMDAR.  
 
Research article 3 (Chapter 5) describes adamantane amine derivatives designed to serve as 
dual acting NMDA receptor and voltage-gated calcium channel inhibitors for 
neuroprotection. These compounds were designed and synthesized by Yakub Kadernani as 
part of his M.Sc. degree [60]. My input to this body of work included developing the 
synthetic pathways for the synthesis of these compounds and screening the compounds for 
calcium modulatory potential by conducting NMDA and VGCC assays using protocols I 
developed and standardized during the first year of my Ph.D. This series of compounds 
(represented by compound Y1; Figure 2) lacks the proparglyamine derivative and was 
therefore not assessed for MAO-B inhibition. The design strategy with this series was 
focused on producing derivatives that could potentially exhibit similar calcium modulatory 
activity as seen with NGP1-01. These adamantane derived compounds are potentially better 
neurotherapeutic options than amantadine and memantine as they were shown to inhibit both 
NMDAR and VGCC-mediated calcium influx, whereas the base adamantine structures only 
inhibit NMDAR-mediated calcium influx. 
 
Additional research outputs include research articles 4 and 5 (Chapter 7), which describe the 
design, synthesis and evaluation of indole derivatives as multifunctional agents against 
Alzheimer's disease, and describe the versatility of 7-substituted coumarin molecules as 
antimycobacterial agents, neuronal enzyme inhibitors and neuroprotective agents, 
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respectively. The indole derivatives described in research article 4 were designed and 
synthesized by Ireen Denya as part of her M.Sc. degree [61]. The objective of this study was 
to improve the inhibitory, neuroprotective and stability profile and eliminate the 
stereochemistry associated with rasagline and ladostigil. The 7-substituted coumarin 
molecules described in research article 5 are compounds that were designed and synthesized 
by Germaine Foka as part of her M.Sc. degree [62]. These compounds were initially designed 
and synthesized to serve as multifunctional neuronal enzyme inhibitors. As part of a 
collaborative project, further evaluation of the structure-activity relationships for selectivity 
and specific characteristics of these compounds were performed in order to assess their 
viability as neuronal enzyme inhibitors and/or antimycobacterial clinical agents. My 
contribution to both these studies included conducting general cytotoxicity screening assays 
of the synthesized compounds and assessing them for potential neuroprotective ability in 
vitro. Though structurally dissimilar in that the compounds reported in this chapter lacked 
polycyclic scaffolds as well as propargylamine moieties, the compounds still showed 
promising neuroprotective potential. My contribution to this body of work as well as the 
potential these compounds may have in serving as neuroprotective agents is the reason for 
their inclusion in this thesis. 
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Abstract 
Much progress has been made in designing analogues that can potentially confer 
neuroprotection against debilitating neurodegenerative disorders, yet the multifactorial 
pathogenesis of this cluster of diseases remains a stumbling block for the successful design of 
an ‘ultimate’ drug. However, with the growing popularity of the “one drug, multiple targets” 
paradigm, many researchers have successfully synthesized and evaluated drug-like molecules 
incorporating a propargylamine function that shows potential to serve as multifunctional 
drugs or multitarget-directed ligands. It is the aim of this review to highlight the reported 
activities of these propargylamine derivatives and their prospect to serve as drug candidates 
for the treatment of neurodegenerative disorders. 
 
Key terms:  
Apoptosis: Process of programed cell death in multicellular organisms. 
Multitarget-directed ligands: Single molecules that exert their pharmacological effect by 
interacting with two or more drug target sites – term ‘multifunctional drugs’ used 
synonymously for the purpose of this review. 
Neuroprotection: An effect that may result in salvage, recovery or regeneration of the 
nervous system, its cells, structure and function. 
Neurodegeneration: Umbrella term for the progressive loss of structure or function of 
neurons, including death of neurons. 
Excitotoxicity: Pathological process by which nerve cells are damaged and killed by 
excessive stimulation by neurotransmitters such as glutamate and similar substances. 
Propargylamine derivatives: Molecules containing a 2-propynylamine moiety such as the 
MAO-B inhibitory compounds selegiline and rasagiline. 
 
2.1. Introduction 
Parkinson’s disease (PD), Alzheimer’s disease (AD) and Huntington’s disease (HD) are 
conditions constituting part of the broad cluster of diseases commonly referred to as 
neurodegenerative disorders (ND). A classical feature of these diseases is the transient loss of 
neuronal cells in the brain due to apoptosis triggered by one of many factors including toxins, 
endogenous-, environmental- and genetic factors [1]. The lack of neurorestorative 
mechanisms in these neuronal cells is a dreadful fact to patients suffering from NDs as it 
allows for the transient worsening of these conditions over a period of 5–10 years, often 
resulting in death [2]. The cardinal symptoms associated with these diseases are mostly 
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dependent on the region of the brain and the specific neuronal cells affected. For example, 
symptoms of tremor, rigidity and postural instability seen in PD result from the loss of 
dopaminergic neurons in the substantia nigra pars compacta and its projections in the 
nigrostriatal tract [3]. Although not yet fully understood, the pathogenesis of NDs is known 
to be complex in nature. Currently established theories of causation include disturbances in 
neurotransmitter systems such as the monoaminergic system [4,5], mitochondrial dysfunction 
[6], cholinergic dysfunction [7], oxidative stress [7] and metal dyshomeostasis [8]. While not 
implicated in the pathogenesis of NDs, adenosine [9], serotonin 1A [10,11] and dopamine 3 
(D3) [12] receptors have also now emerged as targets for the treatment of PD. These 
causation theories and treatment concepts are discussed in greater detail under the relevant 
sections of this paper as we discuss the recent findings reported in the field. It is important to 
note that the theories herewith discussed do not constitute the entirety of current knowledge 
and concepts, and other approaches not included are beyond the scope of this review. 
Acknowledging the multifactorial nature of NDs suggests that targeting any single 
mechanistic site will not result in successful retardation of the disease progression, and as 
such, many ‘single-site-targeting’ drugs have failed to render sufficient neuroprotective 
and/or neurorestorative activity. The use of ‘magic bullets’ targeting a single receptor or 
enzymatic system is thus insufficient for treatment of these multifactorial diseases [13–15]. 
Current treatment options include the use of monoamine oxidase inhibitors (MAOI’s) like 
selegiline (1) and rasagiline (2) (Figure 1) in the treatment of PD.  
 
Figure 1. The MAO-B inhibitors. Selegiline (1) and rasagiline (2) with the propargylamine moiety indicated. 
h: Human; SEM: Standard error of the mean. Data taken from [17,18]. 
 
These drugs are aimed at correcting disturbances in the monoaminergic neurotransmitter 
system by virtue of inhibiting the MAO-B enzyme that is responsible for catalyzing the 
oxidative degradation of dopamine. The production of free radicals from this oxidative 
reaction, which could contribute to the degenerative process, is also attenuated by inhibition 
of this enzyme. The importance of MAO-B in the aetiology of PD is however challenged in 
           IC50 ± SEM 
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hMAO-B =  69.00 ± 0.4 nM
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that MAO-B itself may not directly contribute to the cell death of dopamine neurons in PD 
[16] and that MAOI’s may not necessarily depend on MAO-B inhibition to exert their 
clinical effects. Recently developed MAOI’s are also not specific to the MAO-B enzyme. It 
is now widely accepted that a more effective therapy would result from the use of 
multitarget-directed ligands (MTDLs) able to intervene in the different pathological events 
underlying the aetiology of neuronal disorders [19]. This design strategy involves the 
incorporation of distinct pharmacophores of different drugs in the same structure to develop 
hybrid molecules. Each pharmacophore of the hybrid drug should essentially retain the ability 
to interact with its specific site(s) on the target, producing the consequent pharmacological 
response [19]. The advent of this MTDL approach has now seen many researchers develop a 
number of compounds that can potentially confer neuroprotection by acting simultaneously 
on different receptors and target sites implicated in NDs. This approach has yielded resultant 
molecules which combine MAO inhibition with cholinesterase inhibition and/or metal 
homeostasis, MAO inhibition with calcium homeostasis modulation, MAO inhibition with 
antioxidant and free radical scavenging activity, and MAO inhibition with adenosine receptor 
antagonism, among others. The last few decades have seen increasing research interest and 
exploration of the neuroprotective ability of compounds bearing propargylamine function 
seen in selegiline and rasagiline. The propargylamine moiety is now known to play an 
important role in providing the neuronal and mitochondrial protective properties inherent in 
these compounds [20–22] and other reported activities ascribed to this moiety in the literature 
include antiapoptotic [23–25] and amyloid-β (Aβ) aggregation inhibition [26]. These features 
of the propargylamine moiety have logically led to its incorporation into structures of many 
drug like compounds designed for neuroprotection to afford resultant molecules with broader 
therapeutic profiles that may potentially meet the curative needs of multifactorial NDs 
(Figure 2). It is the aim of this review to highlight the progress made in this field over the last 
decade in the quest to design the ‘ideal’ multifunctional neuroprotective agent.  
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Figure 2. Various propargyl and propargylamine derivatives and their resultant activities. 
Aβ: Amyloid-β; NMDAR: N-methyl-d-aspartate receptors; nNOS: Neuronal nitric oxide; VGCC: Voltage gated 
calcium channels. 
 
2.2. Strategies involving MAO inhibition  
2.2.1. MAO inhibition & cholinesterase inhibition 
The MAO enzyme is responsible for the oxidative deamination of a wide range of biogenic 
and xenobiotic amines, including dopamine (DA), noradrenaline, adrenaline, tyramine, 
serotonin, β-phenylethylamine, N-methylhistamine, benzylamine and methoxy metabolites of 
the parent amines, such as metanephrine and normetanephrine [27]. This enzyme is known to 
exist in two isoforms, namely MAO-A and MAO-B, which show different selectivities for 
substrates and inhibitors [28]. Excessive oxidative deamination, due to the age-related 
elevated levels of MAO-B in patients affected by neurodegenerative disorders [29], sees the 
depletion of these vital neurotransmitters with the concomitant production of hydrogen 
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peroxide and other neuronal-cell-damaging free radicals. This excessive deamination does 
not only act indirectly as a trigger to the apoptotic process, but also gives rise to some of the 
signs and symptoms associated with these disorders [29–31]. Replenishing the depleted 
levels of DA in the nigro-striatal pathway to alleviate symptoms [32] has been a successful 
therapeutic strategy as seen in several currently available drugs such as rasagiline and 
selegiline. These drugs are aimed at increasing DA levels by inhibiting its oxidative 
breakdown by the MAO enzyme in the striatum. The inhibition of MAO enzymes, 
particularly MAO-B, may also exert neuroprotective effects by inhibiting the formation of 
toxic byproducts of MAO-B-catalyzedoxidation of neurotransmitters [33]. The latter may be 
beneficial in various NDs, particularly where neurotoxic product formation promotes the 
generation of reactive oxygen species (ROS), leading to oxidative stress and ultimately 
contributing to increased neuronal damage [34,35]. Though unquestionably beneficial, this 
strategy fails to meet the curative needs of the diverse cerebral mechanisms implicated in the 
control of NDs [36,37]. This shortfall has seen the exploration of a MTDL approach that 
combines inhibition of the MAO enzyme and the inhibition of cholinesterase, which are 
major enzymatic systems also implicated in NDs. 
 
Low levels of acetylcholine are also thought to play a significant role in the pathophysiology 
of NDs [36]. During the progression of these diseases, there is loss of cholinergic neurons 
which results in a deficit of acetylcholine (ACh) in the specific brain regions that mediate 
learning and memory functions [37]. Consequently, acetylcholinesterase inhibitors (AChEI) 
such as tacrine (3), rivastigmine (4), donepezil (5) and galanthamine (6) form the mainstay of 
currently available treatment options for AD (Figure 3). These drugs are known to improve 
symptoms of AD by inhibiting AChE thereby raising the levels of ACh in the synaptic cleft 
[38]. AChE has also been implicated in accelerating the formation of amyloid fibrils in the 
brain and forming stable complexes with amyloid-β (Aβ) [39]. These complexes are thought 
to play a significant role in the pathology of NDs [38] and inhibiting the activity of AChE 
thus offers neuroprotective activity by retarding the formation of these amyloid fibrils and Aβ 
complexes [39]. In healthy human brain, AChE predominates over butyrylcholinesterase 
(BuChE) activity [40], but the activity of the latter seems to have been underestimated [41]. 
While AChE is localized mainly to neurons, BuChE is associated primarily with glial cells as 
well as endothelial cells [42] where it serves a possible role of supportive hydrolysis of ACh 
[43]. Augmenting cholinergic function by inhibiting both AChE and BuChE pathways may 
therefore be of clinical value. Clinical studies with the dual ChEI, rivastigmine (4), support 
the concept of centrally inhibiting BuChE in addition to AChE inhibition in AD therapy 
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based on the high correlation of the former with cognitive improvement [44]. A variety of 
MTDLs that possess cholinesterase inhibitory activity have therefore been designed and 
synthesized using these known inhibitors (3–6) as lead structures. 
 
Figure 3. Acetylcholinesterase inhibitors. Tacrine (3), rivastigmine (4), donepezil (5) & galanthamine (6); the 
multifunctional monoamine oxidase and ChE inhibitors ladostigil (7) and PF9601N (8). SEM: Standard error of 
the mean. Data taken from [45,46]. 
 
Youdim and Weinstock (2001) designed and synthesized ladostigil (7) by incorporating the 
carbamate moiety of rivastigmine (4) into position 6 of the well-known MAO-I rasagiline (2) 
with the intention of yielding a molecule that could potentially exhibit inhibitory activity 
against cholinesterase (ChE) and MAO enzymes (Figure 3) [47]. This molecule was 
extensively evaluated using in vitro and in vivo models for ChE and MAO-A/B inhibitory 
activity and was shown to inhibit AChE and BuChE, and showed significant memory 
improvement in rats where memory impairment was induced by scopolamine [48]. Ladostigil 
was found to have the additional advantage of a therapeutic index larger than other ChE 
inhibitors currently in clinical use for the treatment of AD and seems to excert an improved 
neuroprotective effect by additional modes not discussed here [47,49,50]. Although reported 
to be 5 times less potent than rasagiline from in vitro findings, ladostigil was shown to be a 
brainselective MAO-A and MAO-B inhibitor at similar doses required for ChE inhibition 
following repeated oral and intraperitoneal (IP) administration to rats and mice [48,51–52]. A 
once daily administration of ladostigil (26 mg/kg) for 2 weeks inhibited brain MAO-A by 
66% and MAO-B by 71%, with very little or no effect on the peripheral MAO enzymes in the 
           IC50 ± SEM 
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liver and intestine [48,52–53]. The time dependent effect observed is consistent with the 
irreversible inhibition of the MAO enzyme by ladostigil and its active metabolites. A school 
of thought support the notion of selectively targeting the MAO-B enzyme, based on the fact 
that the extrapyramidal region of the human brain has approximately 4-times more MAO-B 
than MAO-A [54]. However, it has been reported that unless both forms of the enzyme are 
inhibited, L-DOPA administration neither produces the rise of brain dopamine nor the 
behavioral changes seen after administration of a nonspecific inhibitor such as 
tranylcypromine [55]. This phenomenon is best explained by the fact that dopamine is a 
substrate for both MAO-A and MAO-B [56] and hence when one form of the enzyme is 
selectively inhibited, the other enzyme metabolizes the dopamine. This concept thus suggests 
nonselective brain specific MAOI’s such as ladostigil to be superior to its selective 
counterparts in treating NDs characterized by dopamine depletion. Further to this approach, 
Samadi et al. (2011) designed multitarget-directed MAO and ChE inhibitors by connecting 
N-benzyl piperidine and the propargylamine moieties present in the AChEI donepezil (4) 
[57], and the well-known MAO-I PF9601N (8) [46], respectively, through an appropriate 
linker to a central naphthyridine moiety to afford compound 9 (Figure 4) [58]. PF9601N is 
also an effective neuroprotective agent in several in vivo models of PD by attenuating the 
MPTP-induced striatal dopamine depletion in young-adult and old-adult C57/BL mice, 
reducing the loss of tyrosine hydroxylase positive neurons after nigrostriatal injection of 6-
hydroxydopamine (6-OHDA) in rats [59], and enhancing the duration of l-3,4-
dihydroxyphenylalanine induced contralateral turning in 6-OHDA lesioned rats [60]. From 
their findings, Samadi and colleagues reported compound 9 to exhibit promising MAO and 
ChE inhibitory activity. In vitro analysis of compound 9 using Ellman’s method [63] against 
Electrophorus electricus AChE (EeAChE) and horse serum butyrylcholinesterase (eqBuChE) 
with tacrine (3) and donepezil (5) as reference compounds led to its identification as a 
multifunctional drug-like molecule showing potent and selective AChE inhibitory activity 
(IC50 = 37 ±4 nM) and a moderate MAO-A inhibitory profile (IC50 = 41 ±7 μM) [58]. 
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Figure 4. Compound 9 showing the N-benzyl piperidine and the propargylamine moieties as seen in 
donepezil (5) and PF9601N (8), respectively, and the structurally similar derivatives, 10 - 12. SEM: 
Standard error of the mean. Data taken from [58,61–62] 
 
The group also noted the need for an appropriate length spacer between the N-benzyl 
piperidine and the propargylamine moieties to modulate AChE inhibition. The length of the 
spacer is reported to control the dual interaction of these moieties with both the catalytic 
active site (CAS) and peripheral anionic site (PAS) of the enzyme, improving inhibition 
when both binding sites are spatially targeted at the same time [58].  
Using a similar approach, Bautista-Aguilera et al. (2014a) designed several hybrids of 
donepezil (5) and PF9601N (8) [64]. The hybrids are exemplified by ASS234 (10), which 
was shown to inhibit MAO A/B, AChE and BuChE enzymes (Figure 4) [61]. The IC50 values 
obtained after performing in vitro biological assays against EeAChE and eqBuChE using the 
Ellman method [63] and also against human MAO A/B following a fluorometric method [65] 
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indicated compound 11 to be a potent human MAO-A (hMAO-A, IC50 = 5.5 ±1.4 nM) and 
moderately potent hMAO-B (IC50 = 150 ±31 nM), EeAChE (IC50 = 190 ±10 nM), and 
eqBuChE (IC50 = 830 ±160 nM) inhibitor. Compared to 10, the donepezileindolyl-based 
amine analog 11 was 1.8-fold more potent for the inhibition of AChE but 1.8-fold less active 
regarding BuChE inhibition, however their IC50 values were still comparable. To shed light 
on the orientation of the cholinesterase inhibitor 11 in both cholinesterases, molecular 
modeling studies were carried out using Autodock Vina® software [66] where a structure of 
EeAChE (PDB: 1C2B) was used for the in silico studies. Analysis of the intermolecular 
interactions indicated that the propargylamine group is likely an important feature for these 
derivatives to exhibit both AChE- and BuChE-inhibitory activities [64]. They also noted the 
linear conformation to be key in allowing compound 11 to span both the CAS and PAS sites, 
contributing to its superior binding affinity toward AChE. By virtue of theoretical studies 
using 3D-QSAR models, they noted the amine feature as imperative for activity as similar 
amides showed no activity [64]. The same was true for ChE inhibitory activity, as the amide 
derivatives had a less potent activity profile. 
Bautista-Aguilera et al. (2014b) expanded on their series to afford a new series of donepezil 
and PF9601N hybrids connected through an appropriate linker [62]. When assayed for MAO 
inhibition against recombinant human MAO-A/B, compound 12 was shown to selectively 
inhibit hMAO-B (IC50 = 3.950 ±0.940 nM). The mechanism of hMAO-B inhibition by 
compound 12 was further characterized by employing dose-response curves (IC50) with 
varied preincubation times. A time-dependent inhibition was observed and IC50 values were 
found to decrease in a time-dependent manner [62]. This observation and the failure to 
recover the initial inhibition of compound 12 after a 100-fold dilution in saturated-substrate 
concentration, suggested an irreversible MAO-B inhibition by compound 12. Based on 
results obtained from performing inhibitory assays on EeAChE, human recombinant AChE 
(hAChE), eqBuChE and human recombinant BuChE (hBuChE), they reported compound 12 
to be a highly active ChE inhibitor (EeAChE: IC50 = 1.1 ±0.3 nM; eqBuChE: IC50 = 600 ±80 
nM; hAChE: IC50 = 13.1 ±2.1 nM; hBuChE: IC50 = 835 ±139 nM). Compared to the 
reference compound ASS234, compound 12 was 318-fold more potent for the inhibition of 
EeAChE, but 1.3-fold less active for the inhibition of eqBuChE. In comparison with 
donepezil, compound 12 was 11.8-fold and 11.5-fold more active at inhibiting EeAChE and 
eqBuChE, respectively [62]. Docking simulations of EeAChE (PDB: 1C2B) and compound 
12 were performed and the ligand-enzyme binding interactions of this ChE inhibitor were 
investigated. From the docking study, Bautista-Aguilera and colleagues proposed two major 
binding modes at the enzyme-binding site (Figure 5). In both modes, compound 12 showed 
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an extended conformation and interacted simultaneously with both CAS and PAS sites of 
EeAChE.  
Similar to observations made by Samadi et al. (2011), a linker of appropriate length was 
reported to facilitate the binding of both N-benzylpiperidine and indole-propargylamine 
moieties at CAS and PAS, respectively [62]. The approach of dually inhibiting the MAO and 
AChE enzymatic systems may find significant application in the treatment of NDs as 
compounds with such activity profiles may potentially serve as drugs for the treatment of PD 
and AD. While several authors seem to ascribe MAOI’s to treating PD and AChEI’s to AD, 
the last decade has seen the exploration of the use of MAO inhibitors as potential drugs for 
AD [14,67–69]. In fact, a clinical trial assessing the beneficial properties of selegiline, a 
MAO-B inhibitor, showed a cognition improving efficacy in subjects treated with donepezil, 
suggesting a synergistic effect [70]. This observation further suggests an interlink between 
the various patholological events implicated in NDs and the need for MTDLs as treatment 
strategies.  
 
Figure 5. Binding modes A and B exhibited by compound 12. The compound is represented as violet and 
blue balls and sticks in the simulated binding mode (A) and (B), respectively. Note that compound 12 interacts 
with both the peripheral anionic site site in both conformations (composed of amino acid residues shown in light 
violet in mode (A) and light blue in mode (B)) and catalytic active site site (composed of amino acid residues 
shown in green, pink and orange) of EeAChE from the Research Collaboratory for Structural Bioinformatics 
(Protein Data Bank: 1C2B). In yellow are amino acid residues making up the acyl binding pocket. Reproduced 
with permission from [62] © Dove Press Limited (2014). 
For color images please see online www.future-science.com/doi/full/10.4155/FMC.15.12 
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2.2.2. MAO inhibition & calcium homeostasis modulation 
Activation of the postsynaptic N-methyl-d-aspartate receptors (NMDAR), 2-amino-3-(3-
hydroxy-5-methylisoxazol-4-yl)proprionate receptors and kainate receptors allows for 
opening of their associated ion channels to allow the influx of Ca
2+
 and Na
+
 ions. Calcium 
entry may also occur through L-type voltage gated calcium channels (VGCC) and result in 
both calcium overload and mitochondrial disruption [71]. Excessive influx of calcium can 
overwhelm Ca
2+
-regulatory mechanisms and lead to excitotoxicity and cell death. This 
mechanism of apoptosis has led to the extensive development of NMDAR antagonists in the 
last few decades due to the neuroprotective potential such compounds may render [72]. 
While much progress has been made, the unfavorable side effect profiles of many lead 
compounds have seen them fail to surpass the clinical trials arena, leaving only a few to reach 
the market. Examples of drugs currently in use include nimodipine (13), which is known to 
halt/retard neuronal cell death evoked by focal cerebral ischemia [73], memantine (14), a 
noncompetitive and low-affinity NMDAR antagonist used in AD [74], and amantadine (15), 
a drug that is used in PD due to its beneficial effects on the NMDAR (Figure 6) [75]. 
Heteroatom substituted polycyclic cage amines are also receiving attention as potential 
scaffolds for the development of new drugs, with examples including NGP1–01 (16) that has 
been shown to have neuroprotective properties through VGCC blockade and NMDAR 
antagonistic activity [76]. The activity of these polycyclic compounds on the NMDAR and 
calcium channels is the basis of incorporating polycyclic moieties in analogues designed for 
neuroprotection [76]. A recent approach has seen the incorporation of the propargylamine 
moiety into the structures of such polycyclic compounds. As such, polycyclic propargylamine 
derivatives were synthesized and evaluated in an effort to potentially afford molecules with 
inherent MAO inhibitory capacity as well as calcium modulatory activity as exhibited by 
their parent polycyclic scaffolds [76,80–83].  
In this regard, Duque et al. (2010) reported several polycyclic amines to have NMDAR 
antagonistic activity by measuring their effect on the increase in intracellular calcium evoked 
by glutamate or NMDA (both at 100 μM, in the presence of 10 μM of glycine) on rat cultured 
cerebellar granule neurons [77]. Although most compounds in their series of propargylamine 
derivatives were shown to be inactive, as seen with compound 17, they reported compound 
18 to have moderate NMDAR antagonism (IC50 = 34 ±2.3 μM, Figure 6). Following up on 
their work, the group synthesized a modified series, represented by compounds 19 and 20, 
devoid of the hemiaminal unit seen in both compounds 17 and 18 [78]. The presence of a 
hemiaminal subunit in these compounds is anticipated to result in a compromised stability 
and therefore hinder the further development of such compounds as therapeutic agents [78]. 
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This is derived from the knowledge that NGP1–01 (16), containing an hemiaminal unit [76], 
decomposes easily in aqueous medium [84,85]. Though compounds 19 and 20 were 12.9-fold 
and 18.3-fold less potent than memantine (14) for NMDAR antagonism, respectively, when 
compared with amantadine (15) they exhibited a 4.7-fold and 3.3-fold more potent activity, 
respectively. 
Several interesting structure activity relationships can be deduced from these polycyclic 
compounds. For example comparison of the activity profile of compounds 17 and 18 seems 
to suggest that attaching an ethyl moiety to the polycyclic system of these compounds results 
in reduced Glutamate and NMDAR antagonism (Figure 6). In addition, compound 20, which 
is devoid of the hemianimal unit but contains a methyl group on the polycyclic system, shows 
improved NMDAR antagonism (IC50 = 27.5 ±13.2 μM) when compared with the structurally 
similar compound 18 (IC50 = 34 ±2.3 μM). An interesting observation is that the inclusion of 
a propargyl moiety, as seen in compound 20, might be responsible for the decreased 
NMDAR antagonism of this compound when compared with compound 19 (IC50 = 19.4 ±3.3 
μM), which lacks this moiety.  
Based on the same concept, Zindo et al. (2014) described polycyclic propargylamine 
derivatives represented by compounds 21 and 22 [79]. These compounds were assessed for 
calcium flux modulation by virtue of NMDAR antagonism and VGCC blockade in freshly 
prepared synaptoneurosomes [86] using the fluorescent ratiometric calcium indicator,  
FURA2-AM (Figure 6). Although their findings showed compound 21 to be inactive on both 
these sites when screened at 100 μM, they noticed the positive effect of having a methyl 
group directly attached to the polycyclic structure of 21 to afford 22. This substitution 
rendered the methyl derivative (22) an improved inhibitory activity profile of 26 and 38% on 
the VGCC and NMDAR, respectively [79]. Similarly, amantadine (15) is about 60 times less 
active as an NMDAR antagonist than its dimethyl derivative, memantine (14) [77]. Although 
these compounds (17–22) were also designed to render MAO inhibitory activity by virtue of 
incorporating a propargylamine moiety, they showed minimal or no MAO-B inhibitory 
activity when tested at 10, 50 and 300 μM. The lack of MAO-B inhibitory activity of these 
compounds is most likely attributed to their failure to adequately occupy the MAO enzyme 
cavity and form productive interactions with the FAD (flavin adenine dinucleotide) co-factor 
as shown in Figure 7. 
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Figure 6. N-methyl-d-aspartate receptor and calcium channel modulators. Nimodipine (13), memantine 
(14), amantadine (15) and NGP1–01 (16); Polycyclic propargylamine derived compounds (17–22). NMDAR: 
N-methyl-d-aspartate receptors; PI: Percentage inhibition; SEM: Standard error of the mean; VGCC: Voltage 
gated calcium channels. Data taken from [77–79]. 
 
Research on such heteroatom substituted polycyclic cage amines is gradually receiving 
increasing attention. These compounds can be used to modify and improve the 
pharmacokinetic and pharmacodynamic properties of drugs and it is apparent from the 
literature that the polycyclic cage is useful as both a scaffold for side-chain attachment as 
well as for improving a drug’s lipophilicity [88]. This lipophilicity enhances a drug’s 
transport across cellular membranes, including the selectively permeable blood–brain barrier, 
and increases its affinity for lipophilic regions in target proteins [88,89]. The brain being the 
drug target site for treating NDs, the significance of these polycyclic moieties is clear. In 
addition polycyclic moieties could afford metabolic stability, thereby prolonging the 
pharmacological effect of a drug, leading to a reduction in dosing frequency and improved 
patient compliance [90]. 
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Figure 7. Inactive compound 22 and selegiline. (A) The inactive compound 22 and (B) selegiline a known 
irreversible and selective MAO-B inhibitor in a computer simulated MAO-B enzyme cavity (PDB: 2V5Z). Note 
that compound 22 merely occupies the entrance cavity of the enzyme, unlike selegiline, that traverses deeper 
into the enzyme cavity to proximate the flavin adenine dinucleotide co-factor and allow for binding interactions 
which result in MAO-B activity. The compounds are shown in green with the flavin adenine dinucleotide co-
factor indicated in red. Generated from Molecular Operating Environment software [87] For color images please 
see online www.future-science.com/doi/full/10.4155/FMC.15.12 
 
2.2.3. MAO inhibition & metal homeostasis 
The increase in brain levels of copper, zinc and particularly iron is reported to actively 
contribute to the formation of senile plaques by generating more ROS through the Aβ1–42-
metal complex [91]. Although iron is an essential element in the metabolism of all cells, its 
homeostasis is crucial in relation to PD. Beneficially, the metal acts as a co-factor that dose 
dependently stimulates tyrosine hydroxylase, the enzyme at the rate-limiting step in the 
synthesis of dopamine [92]. Disturbances in brain iron homeostasis, which is usually a tightly 
regulated process, play a significant role in the death of dopaminergic neurons [93]. This 
mechanism of apoptosis is further confirmed by the presence of accumulated iron in affected 
neurons and associated microglia in the substantia nigra of PD patients [94–96]. The 
additional free-iron has the capacity to generate ROS, promote the aggregation of α-synuclein 
protein and exacerbate or even cause neurodegeneration [93]. Iron chelators would therefore 
be beneficial in the attenuation of progression of PD and other neurodegenerative diseases, 
such as AD and HD [97]. The correlation between iron accumulation in the brain and 
progression of ND’s has logically led to the exploration of iron chelators as possible 
neuroprotective agents that could help slow the development of the disease by scavenging 
unbound, free radical-enhancing iron in the brain [93]. Such an approach has been evidently 
successful in VK 28 (23, Figure 8), a potent BBB permeable iron chelator that exerts 
neuroprotective activity against 6-OHDA toxicity in rats, when given either by intravenous or 
intraperitoneal routes, without altering peripheral iron metabolism [98]. 
A B 
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M30 (24) is a multitarget iron chelator designed by Zheng et al. (2005) (Figure 8) [106]. This 
molecule was designed by replacing the piperazine moiety of the known metal chelator, VK 
28 (23), with a propargylamine moiety. In addition to its ‘iron chelator radical scavenging’ 
properties and in vivo brain selective inhibition of MAO-A and MAO-B [(IC50, MAO-A = 
0.037 ±0.02 μM; MAO-B = 0.057 ±0.01 μM)] [99,100], M30 showed significant 
dopaminergic neuroprotective and neurorestorative activities in the classical MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine) [99] and lactacystin [107] animal models. 
Among the many other unique properties demonstrated by M30, this compound has shown 
significant cognitive enhancement in double transgenic Swedish Mutation/PSI1 mice [101–
103] suggesting potential benefits in AD. It also possesses antioxidant activities, reduces 
apoptosis and ameliorates the fall in mitochondrial membrane potential resulting from 
oxidative stress in neuronal cell cultures [101–103]. 
Figure 8. Metal chelator VK 28 (23) with the piperazine moiety replaced by a propargylamine moiety to 
afford M30 (24) and compound 25, a new multifunctional MAO-I, ChE-I and metal chelating agent. 
SEM: Standard error of the mean. Data taken from [99–105]. 
M30 also has antidepressant activity similar to that of amitriptyline and moclobemide but 
with an additional advantage of not causing clinically significant potentiation of the ‘pressor 
Metal chelator
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response’ to oral tyramine [104], a common adverse effect associated with ingesting tyramine 
containing foods together with MAOI’s. 
 
2.2.4. MAO inhibition, metal homeostasis & cholinesterase inhibition 
Following up on their work on ASS234 (10), which was shown to inhibit Aβ aggregation, 
possess antioxidant properties, protect from Aβ-induced apoptosis in vitro and to inhibit 
MAO A/B, AChE and BuChE enzymes [61], Wang et al. (2014) designed DPH6 (25), a 
multifunctional lead molecule with an improved therapeutic profile, for the potential 
treatment of AD (Figure 8) [105]. This donepezil, propargylamine and 8-hydroxyquinoline 
(DPH) hybrid was a result of the juxtaposition of donepezil (5) and M30 (24). DPH6 
exhibited some MAO inhibitory effect on both enzyme isoforms (MAO-A IC50 = 6.2 ±0.7 
μM; MAO-B IC50 = 10.2 ±0.9 μM) upon evaluation using [14C]-5HT and [14C]-
phenylethylamine as substrates, respectively [108]. This activity however was 166- and 179-
fold less potent, respectively, than M30 [109]. From dose-response curves, DPH6 showed 
nonselective MAO inhibition in comparison to standard selective MAO-A and MAO-B 
inhibitors clorgyline [110] and selegiline (1) [111], respectively. When assessed for in vitro 
cholinesterase inhibitory activity using the Ellman method [63] and Lineweaver-Burk 
reciprocal plots, DPH6 was suggested to be a mixed type reversible inhibitor (Ki = 1.21 ±0.25 
μM) of EeAChE (IC50 = 1.8 ±0.1 μM) and eqBuChE (IC50 = 1.6 ±0.25 μM). The need for an 
appropriate chain length for connecting the N-benzyl-piperidin-4’-yl residue to the 
propargylamine moiety was evident in their series of compounds, with the three carbon 
spacer as in DPH6, being reported to confer the molecule the greatest cholinesterase 
inhibitory activity. This allows the compound to interact simultaneously with both catalytic 
and peripheral site of EeAChE. Although less active as an EeAChE inhibitor than donepezil 
(5), DPH6 exhibited a 4.5-fold greater activity at inhibiting eqBuChE and when compared 
with one of its lead compounds M30, it was 64-fold more potent at inhibiting both 
cholinesterases, a feature the lead metal chelator lacks. In addition, Wang and colleagues 
discovered an essential role for the cyano group in properly positioning the ligand by 
hydrogen bond formation with the amino acid residues of the binding sites of AChE, BuChE 
and MAO-A enzymes [105]. Compounds lacking this cyano motif in their series showed 
drastically lowered inhibitory activities. DPH6 was also assessed for metal-chelating 
properties toward the biometals Cu(II), Fe(III) and Zn(II) by UV-VIS spectrometry and 
significant variations on complexation times were observed depending on the metal. The 
observed DPH6-Cu(II) spectral differences occurring after only 5-min of incubation of DPH6 
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with Cu(II) indicated preferential and selective binding for Cu(II) salts compared with Zn(II) 
and Fe(II) which required an incubation time of at least 1 h for complex formation. By use of 
Job’s method [112], a molar fraction of 0.65 for DPH6 complexing Cu(II) was established, 
revealing a 2:1 stoichiometry for the complex formation. While DPH6 failed to show closely 
comparable cholinesterase inhibitory activity to donepezil, it was shown to be less toxic than 
donepezil at high concentrations in an in vitro model of toxicity in HepG2 cells [105]. At 
these high concentrations donepezil is known to produce a wide assortment of side effects 
including bradycardia, nausea, diarrhea, loss of appetite and stomach pain [113]. Important to 
note is the similar cell viability profile displayed by DPH6 and donepezil at low 
concentrations [105]. DPH6’s significant interaction in the two key enzymatic systems 
implicated in neurodegeneration combined with its reported metal chelating properties make 
this an attractive compound in neurodegenerative drug design.  
 
2.2.5. MAO inhibition, antioxidant & free radical scavenging 
Considerable evidence has shown oxidative stress and oxidative damage, mostly due to the 
actions of nitric oxide (NO), to be implicated in NDs [114]. Indirect evidence similarly 
implicates NO in the mechanisms underlying nigral cell degeneration as nitric oxide synthase 
(NOS) inhibitors protect against MPTP/MPP
+
- induced experimental PD in mice and 
monkeys [115,116]. The toxicity associated with NO is due to its reactivity and its reaction 
with superoxide to form peroxynitrite (ONOO
-
), a highly oxidizing agent that also degrades 
to form hydroxyl radicals, among other radical species [117]. This reactivity of NO and the 
subsequent oxidative stress are thought to be important contributors to neuronal damage in 
NDs as they initiate and promote the oxidation of different cellular components such as 
lipids, proteins and DNA, causing the loss of neurons in different brain areas [114]. In this 
regard, molecules with the capacity to reduce oxidative stress and thereby decrease the rate of 
neuronal degeneration may find potential as neuroprotective agents. As discussed under 
section 2.2.1., PF9601N (8) was shown to have neuroprotective effects in several 
experimental models of PD. Although designed as a MAO-B inhibitor [118,119], PF9601N 
has in the last decade been shown to protect nigrostriatal dopamine neurons against MPTP 
neurotoxicity in C57BL/6 adult mice [120], protect rat nigral neurons after 6-OHDA striatal 
lesion [121] and also demonstrated in vitro antioxidant neuroprotective effects in SHSY5Y 
dopaminergic cells [122]. Following from this established multiple activities of PF9601N, 
Bellik et al. (2010) investigated its protective effects on the NO system by measuring the 
compounds’ effect on peroxynitritemediated oxidation and influence on both neuronal and 
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inducible NOS isoform activity [123]. From their findings, they postulated the presence of 
the two reactive nitrogen atoms in the structures of PF9601N and its CYP-dependent 
metabolite, FA72, to be imperative for reaction with ONOO
-
. This notion emanated from the 
observation that selegiline (1), which lacks an indole nitrogen atom, showed approximately 
3-fold less activity for peroxynitrite inhibition. In a similar manner, PF9601N and FA72 were 
more efficient than selegiline in inhibiting rat brain NOS. Although the presence of the 
propargylamine moiety seemed to be responsible for the decreased inducible NOS inhibitory 
effect observed for selegiline and PF9601N, its contribution to the MAO inhibitory capacity 
of these molecules remains a preferred feature. In addition to its more effective MAO-B 
inhibition and its antiapoptotic activity [124], PF9601N also undergoes CYP-dependent 
metabolism in the brain [125] affording its active metabolite FA72 which, like its precursor 
molecule, inhibits NOS and forms interactions with ONOO
-
. These unique features therefore 
suggest PF9601N to be a better neuroprotective compound than selegiline.  
 
2.2.6. MAO inhibition & adenosine receptor antagonism 
Adenosine receptors (ARs) have emerged as potential targets for the treatment of PD in 
recent years [9]. An approach of dually antagonizing A1- and A2AARs was found to be highly 
effective in different models of PD [126,127]. For example, Mihara et al. (2007) reported on 
a dual A1/A2AAR antagonist which decreased neuronal degeneration and improved motor 
impairment via A2AAR blockade, and showed positive effects on cognitive impairment 
associated with the disease by blocking A1ARs [128]. In Japan, the 8-styrylxanthine 
derivative istradefylline (Nouriast®) an adenosine A2AAR antagonist, was recently approved 
for use as an adjunct treatment for PD [129]. Several other selective AR antagonists are being 
explored in the preclinical and clinical trials arena for potential use in NDs [9,130]. Petzer et 
al. (2009) also suggested a multitarget approach that entails inhibiting both ARs and the 
MAO-B enzyme which may be more advantageous for the treatment of PD [131]. This notion 
is supported by findings from preclinical studies that have shown A1 and A2AAR antagonists 
as well as MAO-B inhibitors to potentially exhibit neuroprotective effects [132–135]. While 
A2A antagonism and MAO-B inhibition may confer anti-PD effects combined with 
neuroprotective properties, A1 antagonism may ameliorate cognitive deficits associated with 
the disease [136]. Utilizing this strategy, Koch et al. (2013) synthesized and evaluated the 
tetrahydropyridione-based propargylamine derivatives 27 and 28 (Figure 9) [136]. These 
compounds were a result of structural modifications to 26, a tricyclic compound they 
previously reported to be a relatively potent and highly selective rat A2AAR antagonist [Ki-
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value of 0.147 μM] [137], but with a lower affinity at human A2AARs. The resultant 
compounds 27 and 28 were evaluated in radioligand binding assays for their affinity at A1AR 
in rat brain cortical membrane and at A2AARs in rat brain striatal membrane preparations, 
then further investigated at human A1 and A2AARs recombinantly expressed in Chinese 
hamster ovary cells. Based on their findings, Koch et al., reported compound 27 to be a 
potent dually active A1/A2A AR antagonist (Ki, human receptors, A1: 0.249 μM, A2A: 0.253 
μM), a significant improvement on the low affinity for human A2AAR reported for the lead 
compound 26.  
 
Figure 9: Tetrahydropyridione based propargylamine derivatives 26 – 28. Data taken from [136,137]. 
 
To ascertain selectivity for the various AR’s, these compounds were additionally investigated 
in binding studies at human A2B and A3ARs expressed in Chinese hamster ovary cells. 
Among the structure activity relationships reported by Koch et al. for their series of propargyl 
tetrahydropyrimidione’s, they noted the unsubstituted N9-benzyl derivative 27 to be a 
relatively potent dual human A1/A2AAR antagonist with only low affinity at the A2BAR. The 
introduction of a methoxy group in the ortho-position of the benzyl ring (compound 28) 
resulted in a decrease of A1 and A2BAR affinity, but in an increase in affinity for the A3AR 
[136]. A more attractive activity profile was seen in compound 28 which showed triple-target 
inhibition (Ki A1: 0.605 μM, Ki A2A: 0.417 μM, IC50 MAO-B: 1.80 μM). By exhibiting dual 
(A1/A2A, 27) or triple (A1/A2A/MAO-B, 28) activity, which is expected to result in additive or 
even synergistic effect, these compounds may be relevant considerations for treatment of 
neurodegenerative diseases.  
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2.3. Other multifunctional strategies 
2.3.1. Cholinesterase & apoptosis inhibition 
Samadi et al. (2011) successfully synthesized compound 29 by a Friedländer-type reaction 
(Figure 10) [138]. This tacrine-based propargylamine derivative was assessed for its 
neuroprotective potential against an oxidative stress model in which the mitochondria in SH-
SY5Y neuroblastoma cells were stressed with a mixture of oligomycin-A/rotenone [63]. The 
results showed compound 29 to have a modest neuroprotective effect against oxidative stress, 
in the same range of the well-known reference antioxidant N-acetylcysteine [139]. This 
molecule was also evaluated as an inhibitor of EeAChE, bovine erythrocytes AChE 
(beAChE), and eqBuChE. It was not surprising to note the ability of compound 29 to inhibit 
beAChE (IC50 = 1.53 ±0.04 μM), EeAChE (IC50 = 0.030 ±0.003 μM) and eqBuChE (IC50 = 
2.6 ±0.3 μM) as it contains a pharmacophoric group resembling tacrine, a known AChE 
inhibitor. This finding suggests the structural modifications of the tacrine (2) molecule, 
specifically the inclusion of a propargylamine moiety, to be acceptable for retaining the 
inherent AChE inhibitory capacity and yet provide the resultant molecule with in vitro 
neuroprotection against oxidative stress.  
 
2.3.2. Calcium homeostasis & antioxidant effects 
The 1,4-dihydropyridine (1,4-DHP) functionality is a key scaffold used in drug design and a 
wide variety of pharmacological activities have been reported, such as cardioprotective 
[142,143], anti-inflammatory, anti-ischemic, neuroprotective and many other actions [144]. 
This may particularly be due to the calcium channel modulating properties of 1,4-DHP. 
Based on the above considerations, Rucinns et al. (2014) synthesized and evaluated a series 
of 1,4-DHP derivatives containing a cationic pyridine moiety at position 4, and a 
propargylamine group as a substituent at position 1 of the 1,4-DHP cycle as potential 
multifunctional ligands [140]. Among the novel derivatives reported in their work, compound 
30 (Figure 10) demonstrated significant calcium antagonistic properties in neuroblastoma 
SH-SY5Y cell lines (IC50 = 14 μM) when compared with known calcium channel inhibitors 
amlodipine and nimodipine (13) (IC50 = 11 μM and IC50 = 53 μM, respectively). This 
compound also showed a slight total antioxidant effect, did not affect mitochondrial 
functioning and no toxicity was observed in vivo. 
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Figure 10. Compounds 29 – 31, each having distinct structural features and multiple activities. 
5-HT: Serotonin receptor; D: Dopamine receptor; SEM: Standard error of the mean; VGCC: Voltage gated 
calcium channels. Data taken from [138,140–141]. 
 
2.3.3. Serotonin 1A receptor & dopamine 3 receptor agonism 
The D3 receptor is implicated in a variety of brain functions and is a promising therapeutic 
target for a number of neurological disorders, including PD [145–150]. Therefore selective 
D3 receptor agonists will be of therapeutic value for patients suffering from PD. For example, 
the well-known anti-PD drug pramipexole is a D3 receptor agonist currently in use, but with 
limited dopamine receptor selectivity [12,151]. In addition, a number of studies have 
indicated the serotonin 1A (5-HT1A) receptor to be associated with neuroprotection [152,153], 
PD [154–156] and AD [157]. Agents selectively acting at both D3 and 5-HT1A receptors may 
thus hold significant therapeutic benefit in NDs. The 11-propargyloxyaporphine derivative 
(31) developed by Liu et al. (2010), displayed high affinity for the 5-HT1A receptor with a Ki 
value of 14.0 nM (Figure 10) [141]. The [35S]GTPγS function assay indicated that this 
compound is a partial 5-HT1A receptor agonist. Compared to its 11-hydroxylaporphine 
analogue, a fourfold increase in 5-HT1A receptor activity was observed with the incorporation 
of the propargyl moiety at position 11. The propargyl moiety may also improve and add to 
the neuroprotective ability of this compound [20–22]. Compound 31 was also evaluated at 
the dopamine receptor and showed no affinity at either the D1 or D2 receptor. However, 
significant potency was observed at the D3 receptor (Ki = 2.4 μM). In view of the promising 
role of the 5-HT1A receptor and the D3 receptor in NDs, such a D3/5-HT1A dual action 
propargyl-incorporated compound may find use in the treatment of NDs. 
Although the compounds reported in sections 2.3.1 to 2.3.3 were not assessed for potential 
MAO inhibitory activity it will be interesting to investigate the MAO and antiapoptotic 
activity of these propargyl containing derivatives. 
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2.4. Conclusion 
The complex pathogenesis and aetiology of neurodegenerative diseases make it clear that 
drugs targeting a single receptor or enzymatic system will not result in successful retardation 
and treatment of these multifactorial diseases. This is futher evident in that drugs used in the 
symptomatic treatment of these diseases fail to render sufficient neuroprotective and/or 
neurorestorative activity. The advent of the multitarget-directed ligand approach has however 
seen the development of compounds that combine symptomatic treatment and 
neuroprotection in one molecule by acting simultaneously on different receptors and target 
sites implicated in NDs. Compounds bearing the propargylamine function have received 
significant attention based on the neuroprotective ability observed for the MAO-B inhibitors 
selegiline and rasagiline. This has led to its incorporation into many drug-like compounds 
designed for neuroprotection and to afford molecules with broader therapeutic profiles to 
potentially meet the curative needs of the multifactorial NDs. The role of the propargylamine 
moiety in providing neuronal and mitochondrial protective properties [20–22] antiapoptosis 
activity [23–25] and Aβ aggregation inhibition [26] is clear in the literature. Its direct role in 
the discussed multifunctional compounds to target specific pathological sites however 
remains uncertain. This is partially due to the chemical diversity of the compounds as well as 
the molecular and conformational requirements for interaction with the diverse biological 
systems. 
 
2.5. Future perspective 
Much progress has been made in developing compounds that exhibit 
neurorestorative/neuroprotective activity for treatment of NDs and for some drug targets, the 
propargylamine moiety has proven to be a key feature. The propargylamine derivatives 
developed in the last few decades show promising potential for application in clinical use and 
further exploration of these compounds with a focus on the following aspects is anticipated: 
 
 Despite the wide array of activities reported, the exact mechanisms in which most of 
these compounds exhibit their respective biological actions still remain speculative 
and mechanistic studies are becoming essential to define the role of the propargyl 
moiety in the activity of these compounds. Using x-ray crystallography to identify the 
molecular interactions of the ligand and receptor/enzyme should lead to better insight 
with regards to the binding of these structures to specific sites and bioisosteric 
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substitution of the propargylamine moiety may confirm the pharmacophoric value of 
this group in neuroprotective drug design; 
 
 Pharmacokinetic studies to establish ADME properties of these structures are 
imperative for further development and blood–brain barrier permeation is an obvious 
requirement. Here lipophilicity and other characteristics determining the ability of 
these compounds to cross this barrier and reach their target sites in the brain would be 
essential; 
 
 Though many of the discussed compounds have been reported to exhibit significant 
multifunctional activity based on in vitro and in vivo findings, not many have thus far 
progressed to the clinical trials arena. An exception being Ladostigil which is 
presently in year two of a three year Phase 2b clinical trial. Interim results from 200 
patients diagnosed with mild cognitive impairment that have completed at least one 
year of treatment showed no serious or unexpected adverse events related to the drug, 
or safety issues preventing continuation of the trial. Interim results also point to a 
positive trend in the efficacy of the drug. This includes reduced loss of brain volume 
as determined by MRI, improved immune system parameters and trends in 
improvement of cognitive parameters [158]; 
 
 Establishing the exact pathophysiology of NDs is vital, yet remains a challenge. A 
well described disease pathophysiology will shed light on the ‘ideal’ combination of 
drug target sites to consider when designing the ultimate drug for each of the defined 
neurodegenerative diseases. With growing insight into the pathogenesis of 
neurodegeneration and with the use of computer simulation software, the ultimate 
MTDL could potentially be designed. 
 
Normal rate of progress in biological and medicinal chemistry techniques and application of 
sound drug design strategies should therefore in the near future lead to the development of 
more specific and effective neuroprotective agents. The following decade will no doubt see 
the development of more tailored drug ligands that may confer the desired, or at least 
improved, therapeutic profile lacking in currently available treatments for neuronal diseases. 
This will include multifunctional drugs or multitarget-directed ligands to address the 
multifactorial aetiology of the neurodegenerative diseases. 
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2.6. Executive summary 
Background: propargylamine in treatment of neurodegenerative diseases 
• The multifactorial nature of neurodegenerative diseases (ND) suggests that targeting any 
single mechanism will not result in successful retardation of the disease progression and 
‘single-site-targeting’ drugs have failed to render sufficient neuroprotective and/or 
neurorestorative activity. 
• More effective therapy would result from the use of multifunctional compounds able to 
intervene in the different pathological events underlying the aetiology of neuronal disorders. 
• The success of selegiline and rasagiline in the treatment of Parkinson’s disease (PD) has led 
to growing research interest and exploration of the neuroprotective ability of compounds 
bearing the propargylamine function to serve as multitarget-directed ligands. 
Propargylamine in MAO & cholinesterase inhibition 
• Excessive deamination of neurotransmitters by MAO enzymes acts indirectly as a trigger to 
the apoptotic process and also gives rise to some of the signs and symptoms associated with 
these disorders. 
• Low levels of acetylcholine and the activity of cholinerasterase enzymes play a significant 
role in the pathophysiology of NDs such as Alzheimer’s disease (AD). 
• Combining the structural features of donepezil and PF9601N provided a drug compound 
that was shown to selectively inhibit hMAO-B and to be a highly active ChE inhibitor. A 
linker of appropriate length was reported to facilitate the binding of both the N-
benzylpiperidine and indole-propargylamine moieties of this compound at the CAS and PAS 
of AChE, respectively. 
Propargylamine in MAO inhibition & calcium homeostasis modulation 
• Activation of the postsynaptic NMDA receptors and kainate receptors allows for opening of 
the associated ion channels to allow the influx of Ca
2+
 and Na
+
 ions. Excessive influx of 
calcium may also occur through VGCC and can overwhelm Ca
2+
-regulatory mechanisms 
leading to excitotoxicity and ultimately cell death. 
• Polycyclic propargylamine derivatives showed promising inhibitory activity on the VGCC 
and NMDAR and inclusion of a methyl group directly attached to the polycyclic structure of 
the derivative rendered improved activity. 
• The limited MAO-B inhibitory activity of the polycyclic propargylamine derivatives is 
attributed to their failure to adequately occupy the MAO enzyme cavity and form productive 
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interactions with the FAD cofactor. 
Propargylamine in MAO inhibition, metal homeostasis & cholinesterase inhibition 
• Disturbances in brain iron homeostasis, which is usually a tightly regulated process, play a 
significant role in the death of dopaminergic neurons. 
• M30, a multitarget iron chelator showed in vivo brain selective inhibition of MAO-A and 
MAO-B in addition to its iron chelator radical scavenging properties without clinically 
significant potentiation of the pressor response to oral tyramine. 
• DPH6, a multifunctional molecule with an improved therapeutic profile for the treatment of 
AD exhibited MAO inhibitory effect on both MAO isoforms and was suggested to be a 
mixed type reversible inhibitor of EeAChE and eqBuChE. It also exhibited Cu
2+
-chelating 
properties and was found to be less toxic than donepezil at high concentrations in HepG2 
cells. 
Propargylamine in MAO inhibition & adenosine receptor antagonism 
• The emergence of adenosine receptors (AR) as potential targets for the treatment of PD led 
to the synthesis of tetrahydropyridione based propargylamine derivatives which were found 
to be triple-target antagonist/inhibitors on A1AR, A2A and MAO-B. 
Serotonin 1A receptor & dopamine 3 receptor agonism 
• The D3 receptor and serotonin 1A (5-HT1A) receptor have been implicated in a variety of 
brain functions, and are promising therapeutic targets for a number of neurological disorders. 
The D3/5-HT1A dual action shown by a propargyl-incorporated compound developed could 
find application in the treatment of NDs. 
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Abstract 
The aim of this study was to design drug-like molecules with multiple neuroprotective 
mechanisms which would ultimately inhibit N-methyl-D-aspartate (NMDA) receptors, block 
L-type voltage gated calcium channels (VGCC) and inhibit apoptotic processes as well as the 
monoamine oxidase-B (MAO-B) enzyme in the central nervous system. These types of 
compounds may act as neuroprotective and symptomatic drugs for disorders such as 
Alzheimer’s and Parkinson’s disease. In designing the compounds we focused on the 
structures of rasagiline and selegiline, two well known MAO-B inhibitors and proposed 
neuroprotective agents. Based on this consideration, the compounds synthesized all contain 
the propargylamine functional group of rasagiline and selegiline or a derivative thereof, 
conjugated to various polycyclic cage moieties. Being non-polar, these polycyclic moieties 
have been shown to aid in the transport of conjugated compounds across the blood-brain 
barrier, as well as cell membranes and have secondary positive neuroprotective effects. All 
novel synthesized polycyclic derivatives proved to have significant anti-apoptotic activity (p 
< 0.05) which was comparable to the positive control, selegiline. Four compounds (12, 15 
and 16) showed promising VGCC and NMDA receptor channel inhibitory activity ranging 
from 18 % to 59 % in micromolar concentrations and compared favourably to the reference 
compounds. In the MAO-B assay, 8-phenyl-ethynyl-8-hydroxypentacycloundecane (10), 
exhibited MAO-B inhibition of 73.32 % at 300 μM. This compound also reduced the 
percentage of apoptotic cells by as much as 40 % when compared to the control experiments. 
 
Keywords: 
Polycyclic, Propargylamine, Neuroprotection, Apoptosis. 
 
3.1. Introduction 
The pathology of neurodegenerative disorders, such as Parkinson’s disease (PD) and 
Alzheimer’s disease (AD), is caused by the abnormal loss of neuronal cells in certain areas of 
the brain.
1
 It consequently causes an imbalance of certain neurotransmitter levels in the brain, 
giving rise to the characteristic signs and symptoms of these disorders.
2,3
 Ultimately, it 
compromises the normal functionality and well-being of the individual suffering from the 
disease,
3
 thus making it an absolute necessity to create drugs which would halt this neuronal 
breakdown process and aid in treating the signs and symptoms of neurodegenerative 
disorders. The abnormal death of neurons in the central nervous system of individuals 
suffering from neurodegenerative diseases takes place by an intrinsic cell suicide program 
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known as apoptosis.
4-7
 This process is triggered by several stimuli, and consists of numerous 
pathways and cascades, each one having an influence on the other, ultimately leading to cell 
death.
4-7
 One such pathway is the excitotoxic process which leads to apoptosis. Excitotoxicity 
is a result of activation of postsynaptic receptors; including NMDA receptors, 2-amino-3-(3-
hydroxy-5-methylisoxazol-4-yl) proprionate (AMPA), and kainate receptors. Upon their 
activation, these receptors open their associated ion channel to allow the influx of Ca
2+
 and 
Na
+
 ions. The excessive influx of calcium together with any calcium release from 
intracellular compartments can overwhelm Ca
2+
-regulatory mechanisms and lead to cell 
death.
8  
This mechanism of cell death suggests that the receptors and their associated calcium 
channels serve as drug target sites for curbing neurodegeneration. Several compounds, 
including polycyclic amines such as amantadine (2), NGP1-01 (3), MK-801 (4), and 
phencyclidine (PCP, 5) have been reported to show inhibitory activities on NMDA receptors 
and calcium channels (Figure 1).
10 
The oxidative deamination reaction catalysed by monoamine oxidase B (MAO-B) is one of 
the major catabolic pathways of dopamine in the brain. Inhibition of this enzyme leads to 
enhanced dopaminergic neurotransmission and is currently used in the symptomatic 
treatment of PD.
11-14
 Furthermore, MAO-B inhibitors may also exert a neuroprotective effect 
by reducing the concentrations of potentially hazardous by-products produced by MAO-B-
catalysed dopamine oxidation.
15
 In PD and AD it has been shown that there are age-related 
elevated levels of MAO-B, which not only act indirectly as a trigger to the apoptotic process, 
but also give rise to some of the signs and symptoms associated with these disorders.
16–18 
In the current study, the approach was to develop multifunctional drugs which would halt the 
apoptotic neuronal breakdown process and eliminate some of the signs and symptoms of 
diseases such as AD and PD by: (a) Inhibiting NMDA receptors and blocking L-type voltage 
gated calcium channels (VGCC) thus regulating the Ca
2+
 influx mediated excitotoxic process; 
(b) Inhibiting the MAO-B enzyme thus allowing increase in dopamine levels in the CNS and 
reducing the levels of the highly oxidative products produced by the activity of this enzyme; 
(c) Possess anti-apoptotic activity to halt the natural neuronal cell death process. With this in 
mind, we focused on the structures of pentacycloundecane (1), amantadine (2), rasagiline (6) 
and selegiline (7, Figure 1).  
Rasagiline and selegiline are second generation propargylamine derivatives that irreversibly 
inhibit brain MAO-B, and have promising neuroprotective activities.
19
 After several years of 
study and research, it has been established that the neuroprotective effects of rasagiline and 
selegiline can be attributed to its propargyl moiety.
16-18
 This observation was made on the 
grounds that propargylamine (8), itself exerts the same neuroprotective effects as offered by 
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rasagiline. It has also been established that the MAO-B inhibiting activity is not a prerequisite 
for the neuroprotection provided by rasagiline, selegiline and propargylamine as these 
compounds have been shown to inhibit apoptosis through other anti-apoptotic mechanisms 
that may contribute to their possible disease-modifying activities.
20,21 
Since MAO-B activity 
is increased in both AD and PD, MAO-B inhibitors may be of further therapeutic benefit.
22 
 
Figure 1: Representative polycyclic cage compounds (1 - 3), NMDA receptor and calcium channel modulators - 
NGP1-01 (3), MK-801 (4) and phencyclidine (PCP, 5), the neuroprotective MAO-B inhibitors - rasagiline (6) 
and selegiline (7), and propargylamine (8). 
 
Polycyclic cage compounds, such as pentacyloundecane (PCU, 1), amantadine (2) and 
NGP1-01 (3) have various biological applications, with special interest in the symptomatic 
and proposed curative treatment of neurodegenerative diseases.
23
 These compounds can be 
used to modify and improve the pharmacokinetic and pharmacodynamic properties of drugs 
and it is apparent from literature that the polycyclic cage is useful as both a scaffold for side-
chain attachment as well as for improving a drug’s lipophilicity.23 This lipophilicity enhances 
a drug’s transport across cellular membranes, including the selectively permeable blood-brain 
barrier, and increases its affinity for lipophilic regions in target proteins.
23,24
 In addition, these 
polycyclic moieties afford metabolic stability, thereby prolonging the pharmacological effect 
of a drug, leading to a reduction of dosing frequency and improving patient compliance 
thereof.
25
 The known NMDA receptor channel antagonism of these cage compounds, 
combined with their L-type calcium channel blocking activity, suggest that these polycyclic 
cage moieties may potentially serve as therapeutic agents for neurodegenerative 
disorders.
10,23,26-28
  
With the focus being on the development of multifunctional drugs, it was thus a rational 
decision to incorporate polycyclic cage moieties and propargylamine functional groups or 
derivatives thereof into the structures of the novel compounds to be synthesized, thus giving 
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rise to a series of compounds with the inherent therapeutic profiles of the contributing 
moieties (i.e. NMDA receptor channel antagonism, L-type calcium channel blocking activity, 
MAO-B inhibitory activity and anti-apoptotic activity).  A single compound exhibiting such 
an array of multifunctional neuroprotective activities may curb the neurodegenerative process 
more effectively than a compound which functions on only one of the many drug target sites 
available. 
 
3.2. Results and discussion 
3.2.1. Synthesis 
In synthesising the novel polycyclic compounds (9 – 16, Figure 2), propargylamine, 
propargylbromide or ethynyl magnesium bromide was reacted with the PCU (1, Cookson’s 
diketone) or amantadine (2) scaffold to give the final compounds (Figure 2). Each compound 
was synthesized to evaluate the activity and benefit of the presence of a certain group of 
atoms in the molecule. These groups included the following: a terminal acetylene group (9), 
an acetylene group between two non-polar groups (10), a secondary propargylamine 
connected to an oxa-PCU structure (11, 12), a tertiary propargylamine conjugated to an aza-
PCU structure (13, 14) and an adamantane structure (15, 16). 
 
Figure 2: Synthesized acetylene (9 and 10) and propagylamine (11 – 16) polycyclic compounds evaluated for 
anti-apoptotic activity, calcium modulating effects and MAO-B inhibition. 
Starting from the PCU diketone (1) or the methyl-diketone (a, Scheme 1), depending on the 
compound to be synthesized, the reaction proceeded by conjugation of propargylamine 
through reductive amination with sodium borohydride, following steps i-iv to give the oxa-
derivatives, 11 and 12. The aza derivatives, 13 and 14, were synthesized utilising sodium 
cyanoborohydride as reducing agent. Compound 9 was synthesized via the Grignard reaction 
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through conjugation of ethynyl magnesium bromide with the methyl-diketone producing the 
title compound 9 (Scheme 1).  
 
Scheme 1: Reagents and conditions: (i) THF, -10°C, 45 min; ii) benzene, Dean-Stark, reflux, 1 h; (iii) 
THF/MeOH, NaBH4, rt, 24 h; 11, 10 %; 12, 27% (iv) THF/MeOH, NaCNBH4,  rt, 24 h; 13, 16 %; 14, 4 %; (v) 
THF, ethynyl magnesium bromide, rt, 21 h, 9, 16 %.  
 
The synthesis of compound 10 commenced with the Cookson’s diketone (Scheme 2), which 
was mono-protected as the corresponding ethylene acetal. The remaining ketone was reduced 
with lithium aluminium hydride and subsequent hydrolysis furnished the hydroxyl-ketone. 
Wolff-Kisher reduction of the hydroxyl-ketone under Huang-Minlon conditions gave the 
mono-alcohol, followed by oxidation with chromium trioxide to yield the mono-ketone (b). 
The mono-ketone (b) was conjugated to phenylacetelene in the presence of a potassium 
fluoride and alumina solution to yield the title compound 10 (Scheme 2). 
 
The synthesis of compound 15 commenced through the conjugation of the primary amine of 
amantadine (2) and benzaldehyde with subsequent reduction, utilising LiAlH to give N-
benzyl-adamantan-1-amine (c, Scheme 3). Propargylbromide was conjugated to (c), via a 
nucleophilic SN2 substitution reaction, to produce compound 15. Compound 16 was 
synthesized by means of microwave irradiation in the presence of an excess amount of 
propargylbromide (Scheme 3). The PCU structures, compounds (9-14), were obtained and 
evaluated as racemic mixtures and the structure and geometry of representative compounds 
were recently confirmed using single Xray crystallography and standard spectroscopy 
techniques.
29
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Scheme 2: Reagents and conditions: (i) p-TsOH (cat), benzene, Dean-Stark, reflux, 3.5 h, 95 % (ii) LiAlH4, 
Et2O, reflux, 2 h then 6 % aq HCl, rt, 2 h, 61 %; (iii) NH2.NH2.H2O, diethylene glycol, 120°C, 1.5 h, then KOH, 
190°C, 3 h, 33 %; (iv) CrO3, H2O, 94 % aq CH3COOH, 90°C, 4 h, b, 84 %; (v) KF/alumina, 60°C, 12 h, 10, 73 
%. 
 
 
Scheme 3: Reagents and conditions: (i) EtOH, rt, 4 days, 59 %; (ii) –H2O; (iii) NaBH4, reflux, 12 h, c, 59 %; 
(iv) DMF, rt, 24 h; 15, 25 %; (v) Excess propargylbromide, aq NaOH, microwave (25 min, 80 °C – 100 °C, 250 
W); 16, 91 %. 
 
3.2.2. Anti-apoptotic activity 
The compounds’ anti-apoptotic activity were evaluated in vitro using the DePsipherTM kit, 
which marks changes in the mitochondrial membrane potential that takes place during 
apoptosis.
30
 The quantitative and qualitative detection of apoptosis were done by means of 
flow cytometry, which made it possible to determine the percentage of cells that were still 
viable in the samples after treatment with the synthesized compounds. For this purpose SK-
NBE(2) neuroblastoma cells were used, and apoptosis was induced using a serum-deprivation 
model. Control experiment 1 was included to evaluate the viability status of the cells, in the 
absence of test compound, with 1.25 % dimethyl sulphoxide (DMSO, Figure 3). The viability 
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data was used to compare the data generated with the test compounds in order to determine if 
the test compounds attenuated the progression of the apoptotic process. With this control 
experiment the effect of 1.25 % DMSO was also evaluated. Control experiment 2 was used to 
evaluate the viability of the cells and the progression of the apoptotic process in the absence 
of DMSO. When comparing the values of control experiments 1 and 2, it is clear that even 
though the final DMSO concentration in the samples was only 1.25 %, it had a negative 
effect on the viability of the cells. In control experiment 2, which did not contain any DMSO, 
cell viability increased with 7.19 %. It can thus be argued that the serum deprivation was not 
the only factor inducing apoptosis, but also the DMSO, which served as co-solvent for the 
test compounds. Control experiment 3 was used to evaluate the influence of re-introduction 
of serum rich medium, which significantly attenuated the apoptotic process. This control 
experiment was used to estimate the potencies of the test compounds as anti-apoptotic agents. 
Control experiment 4 was included to analyse and determine the viability status of the cells, 
when no apoptosis had been induced, and conditions had been favourable to the end of the 
experiment. It was also included to ensure that the cells analysed were indeed healthy before 
inducing apoptosis (see section 4.3.1. for a complete explanation of the experimental 
procedure).  
The novel compounds were all tested in triplicate at three different concentrations (1 mM, 
100 μM and 10 μM). The positive control, selegiline, was evaluated in triplicate at two 
concentrations (100 μM and 10 μM, Figure 3). Included in the assay was the prototype 
polycyclic cage moiety, 8-benzylamino-8,11-oxapentacyclo[5.4.0
2,6
.0
3,10
.0
5,9
]undecane 
(NGP1-01),
31
 which was also evaluated in triplicate at the highest concentration (1 mM). 
NGP1-01 is a well-known NMDA receptor channel inhibitor and calcium channel antagonist, 
and was evaluated for anti-apoptotic activity, as an abnormal increase in calcium levels can 
act as a trigger for apoptosis.
10
 The positive control, selegiline, had 12-19 % more cells that 
were healthy and wherein apoptosis had either not been induced or reached the level of 
mitochondrial depolarisation, compared to control experiment 1 (Figure 3). When compared 
to control experiment 1, compounds 9 – 16 and NGP1-01 (3) all had significant anti-
apoptotic activity improving cell health between 9 % and 41 %. The anti-apoptotic activity of 
9 - 15 were the most significant (p < 0.001; Figure 3). The compound with the highest anti-
apoptotic activity was 9, where all cultures treated exhibited only 0.5 % apoptotic cells in the 
analysed samples. Compound 10 was slightly less active than compound 9, with only 2.8 % 
of the cells showing apoptosis (Figure 3). Studying the results of these experiments, it is clear 
that the anti-apoptotic activity of propargylamine can most probably be attributed to the 
acetylene group, as compounds 9 and 10 have equivalent or even higher activity than 
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compounds 11 - 16. For activity, this acetylene group can either be terminal (9) or between 
two non-polar groups (10), with the terminal acetylene group having slightly higher activity. 
It was also confirmed that when linked to a polycyclic cage structure, propargylamine and 
acetylene derivatives displayed increased anti-apoptotic activity. Further investigation must 
be conducted to ascertain whether this reported activity is solely due to the acetylene group, 
the cage moiety, or the acetylene group in conjunction with a nearby electronegative 
atom/group.  
Comparing the activity of compounds 11 and 13, it seems that the tertiary propargylamine 
had slightly higher activity than the secondary propargylamine, but the oxa- and aza-
compounds in general had comparable activity activities. In the case of the oxa-compounds 
(11, 12), the methylated cage showed increased activity. With the aza compounds (13, 14), 
this was not observed. The adamantane compounds (15, 16) had significantly lower activities 
than that of the pentacycloundecane compounds 9 – 13. Solubility problems were also 
experienced with compounds 15 and 16 at higher concentrations, which may contribute to the 
observed lower anti-apoptotic action. It could also be attributed to the possibility that the 
pentacycloundecanes may have an increased ability to cross cell membranes due to their high 
degree of lipophilicity,
23
 which would result in increased intracellular concentrations of the 
compounds. Comparing the percentage healthy cells of the samples treated with test 
compounds 9, 10, 12 and 13, with that of the control experiment 4, which is representative of 
healthy cells in a favourable environment, it is interesting to note that these samples had more 
healthy cells than that of control experiment 4. This may be attributed to the compounds 
inhibiting even baseline apoptotic processes.  
Although NGP1-01 exhibited significant anti-apoptotic activity, the activities of the 
synthesized compounds (9 - 16) were shown to be higher in comparison. This might be due to 
NGP1-01 only inhibiting one of the triggers of apoptosis, namely excitotoxicity due to 
calcium flux into the neuronal cells, whereas the newly synthesized compounds possibly 
inhibit the apoptotic cascade, directly or indirectly, at more than one point. However, further 
evaluations of these compounds are necessary to ascertain this.  
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Figure 3: Anti-apoptotic activity of the test compounds (*p < 0.05; **p < 0.01; ***p < 0.001) 
 
3.2.3. VGCC and NMDA receptor channel activity 
All polycyclic propargylamine and acetylene derivatives (9-16) were screened at 100 µM for 
their potential inhibitory activity on VGCC and/or NMDA receptor (NMDAR) channel. They 
were assessed using the fluorescent ratiometric indicator, Mag-Fura-2/AM, and a fluorescent 
plate reader. KCl mediated calcium influx in murine synaptoneurosomes was used to evaluate 
the influence of the test compounds on the calcium influx via VGCC. NMDA/Glycine 
mediated calcium influx was used to evaluate the influence of the test compounds on calcium 
influx via the NMDA receptor channel. Both assays were carried out with reference to 
standard controls. Results are shown in Table 1. 
Fresh synaptoneurosomes were prepared
32
 from rat brain homogenate and incubated with the 
ratiometric fluorescent calcium indicator, Fura-2/AM. The synthesized compounds were 
incubated for 30 minutes and a 140 mM KCl or a 100 µM NMDA/Glycine solution, in the 
VGCC and NMDA assay respectively, was added to depolarize the cell membranes or to 
stimulate calcium flux through the respective channels. Calcium influx was then monitored 
based on the fluorescence intensity relative to that of a negative control (without inhibiting 
compound) over a 5 min period. Two positive controls were included in the VGCC assay; 
nimodipine, a commercially available dihydropyridine L-type calcium channel blocker and 
the prototype pentacycloundecane compound NGP1-01. Two positive controls were also 
included in the NMDAR assay; MK-801, a commercially available potent high affinity 
NMDAR channel blocker and NGP1-01. 
The results obtained showed variable activities from the compound series (Table 1). 
Compound 16, an adamantane derivative, showed the best VGCC inhibitory activity within 
this series (45 %). This adamantine derived propargylamine compound showed activity 
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higher compared to that of NGP1-01 (7, 27 %). Although structurally similar to 16, the 
substitution of the aromatic moiety of 16 with a propargyl moiety to give the di-substituted 
propargylamine adamantane compound (15), led to a significant decrease in VGCC activity 
(18 %). This observation indicates the importance of including the benzylamine moiety 
within these structures for optimal VGCC activity. The exact mechanism in which these 
compounds interact with the VGCC for activity is thus far unexplored. The presence of the 
polycyclic cage moieties in the series of compounds and similarities to NGP1-01 and other 
polycyclic cage benzylamines, supports a mechanism earlier described for NGP1-01 as being 
frequency- and voltage- dependent open calcium channel blockers.
33 
 
These compounds also exhibited of the highest NMDAR channel inhibitory activities within 
this test series (52 % and 59 % for 15 and 16 respectively). This high activity might be 
attributed to the inclusion of the adamantane moiety, which has known NMDAR inhibitory 
activity. Within the pentacycloundecane (PCU) test series, compounds 10 (19 %), 12 (26 %) 
and 13 (18 %) showed moderate VGCC blocking effects when compared to that of NGP1-01 
(27 %). The remaining PCU derivatives showed low (9 and 14) to no VGCC activity (11). It 
is interesting that the inclusion of a methyl group to the structure of the inactive oxa-PCU 
compound 11 to give compound 12 improved the VGCC activity by 26 %. However, this 
trend was not observed for the aza-PCU compounds 13 (11 %) and 14 (18 %). NMDAR 
channel inhibition was observed for PCU compounds 10 (23 %) and 12 (38 %), which 
showed improved inhibitory activity when compared to NGP1-01 (18%). Compound 12 
showed dual action on both VGCC (26 %) and NMDAR (38 %). This finding suggests that 
the inclusion of the methyl substituent contributes towards binding and activity on both these 
drug targets as the compound exhibited activity comparable to, and better than NGP1-01 on 
both the VGCC and NMDAR. Comparing the activities obtained with compound 12 to that of 
compound 14 (VGCC – 11 %, NMDAR – 11 %), suggests that the oxa compounds have 
better VGCC and NMDAR inhibitory activity compared to aza compounds. Removal of the 
methyl substituent from 14 to give compound 13 increased VGCC inhibitory activity to 18 % 
but decreased NMDAR inhibitory action to only 4 %. Compound 10, which resembles 
NGP1-01 in the aromatic moiety, also showed dual action on the VGCC (19 %) and 
NMDAR (23%) as seen with NGP1-01, a known VGCC and NMDAR antagonist. It is 
suggested that these compounds (9-16) exhibit a blockade of the NMDA channel which is 
consistent with uncompetitive antagonism, similar to that reported for memantine. 
Memantine shares the phencyclidine (PCP)/tenocyclidine (TCP)/MK-801/ketamine binding 
site inside the NMDA channel pore. Radio-ligand binding studies with [3H]MK-801 and 
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[3H]TCP, however, showed little or no displacement of PCU compounds, including NGP1-
01, from this binding site. The functional block of calcium observed for the PCU structures 
needs to be further explored to elucidate the exact mechanism of action. We hypothesize that 
the series described in this paper will exhibit a similar mechanism of action and act as direct 
NMDA channel blockers.
10
 
 
3.2.4. MAO-B inhibitory activity 
The synthesized compounds were also evaluated in vitro at various concentrations as 
inhibitors of MAO-B, using a spectrophotometric assay that utilised MMTP, an analogue of 
the neurotoxin MPTP as substrate, with baboon liver mitochondria serving as enzyme source. 
The potency of MAO-B inhibition was expressed as percentage inhibition of the MAO-B 
enzyme (Table 1). Only compound 10 showed significant MAO-B inhibition activity when 
compared to that of selegiline (93.22%), inhibiting the MAO-B enzyme by 73.32% at 300 
µM. The rest of the compounds in the series either had no activity (9, 11) or exhibited very 
limited inhibition, ranging from 5.83 to 20.13% (12-16). Comparing the MAO-B inhibition 
potencies of 11 with 12 and 13 with 14 reveals that in both cases the methyl group on the 
polycyclic cage, appeared to slightly increase MAO-B inhibition activity of the compounds. 
This may be ascribed to the enhanced interaction obtained with the non-polar entrance 
regions of the MAO-B enzyme. For comparison, NGP1-01 was also evaluated as a MAO-B 
inhibitor, but no significant activity was observed. The compounds containing a phenyl side 
chain (10, 15 and selegiline), were consistently better inhibitors than the rest of the series and 
it can be speculated that these compounds were able to block the entrance cavity of the 
MAO-B enzyme active site (see Fig. 4). This may possibly be attributed to the planar 
character of the phenyl ring and possibly to the extended planar character of compound 10. 
It has also been reported in literature that planar compounds frequently act as potent 
inhibitors of MAO-B.
34,35
 Compound 10 contains both a hydroxyl and an extended planar 
phenyl moiety, which might further explain the significantly higher activity of 10 compared 
to that of the other synthesized compounds.  
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3.2.5. MAO-B molecular modelling 
Computer-assisted simulated docking of compounds 9-16, using Molecular Operating 
Environment (MOE), was carried out in an attempt to clarify the MAO-B inhibition activity – 
or lack thereof – for these structures36. The best-ranked docking solutions of the test 
compounds examined, showed that the proposed inhibitors occupy only the entrance cavity 
and barely access the substrate cavity of the MAO-B enzyme (PDB ID: 2V5Z, Fig. 4)
37
. In 
general, the amino acid residues between 120 and 220 are important in conferring substrate 
selectivity of MAO-B
38
, most importantly residues Ile-199 (situated in the entrance cavity) 
and Gln-205 (situated in the substrate cavity). Interaction with these amino acid residues may 
confer a compound MAO-B inhibitory activity as shown by safinamide (Fig. 4), a known 
MAO-B inhibitor.  
Figure 4: Comparison between the putative binding modes of safinamide and compound 10 to the human 
MAO-B enzyme active site. The compounds and FAD cofactor in bold lines (online indicated in green and red 
respectively) with their respective binding interactions with the amino acid residues (sticks) shown on the right 
of each enzyme cavity representation. Safinamide and compound 10 show productive interactions with amino 
acid residues Ile-199 and Gln 205, and Ile-199, respectively. 
 
For compound 10 it was shown that the polycyclic moiety is stabilized within the entrance 
cavity with the extended planar phenyl moiety able to traverse deeper into the enzyme cavity 
and form the necessary interactions with Ile-199 (Fig. 4). This productive interaction between 
the phenyl function and the active site residue Ile-199 of the substrate cavity and/or the 
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stabilisation of the polycyclic moiety to actively block the entrance cavity, might explain the 
MAO-B inhibitory activity observed for 10. All the polycyclic moieties are stabilised within 
the hydrophobic entrance cavity and were unable to traverse deeper into the substrate cavity, 
to from the necessary binding interactions with the flavin adenine dinucleotide (FAD) 
cofactor, which would have resulted in binding interactions and an increase the activity of 
these compounds (Fig. 4)
39,40
.  
Based on the molecular modelling results we are currently in process of developing a series 
of optimized PCUpropargylamine hybrid molecules with binding interactions and molecular 
orientations which might lead to enhanced MAO-B activity for these compounds. This series 
will enable the propargyl moiety to penetrate deeper into the cavity within close proximity of 
the FAD co-factor, similar to selegiline and rasagiline (data not shown)
19
. We also envision 
that the multifunctional activities shown for the current propargylamine derivatives will be 
retained in the new series. 
 
3.3. Conclusion 
This study aimed to develop compounds that would ultimately inhibit NMDA receptors, 
block VGCC and inhibit apoptotic processes as well as the MAO-B enzyme. Based on the 
results it can be concluded that compounds 10, 12, 15 and 16 showed the best range of 
activities. These compounds however showed little to no activity on the MAO-B enzyme 
except for 8-phenyl-ethynyl-8-hydroxypentacycloundecane (10) which inhibited the MAO-B 
enzyme by 73.32% at 300 µM. The compounds in the series all had significant anti-apoptotic 
activity comparable (14-16) to and better (9-13) than selegiline. Although the findings 
suggest compounds 9 and 11 to have little or no activity on the VGCC, NMDA receptors and 
MAO-B enzyme, the ability of these compounds to significantly inhibit apoptosis suggests 
that the compounds exhibit their neuroprotective action through some other mechanism(s) 
unexplored in this study. Having significant anti-apoptotic activity, this series of compounds 
might present interesting lead compounds in the design and development of more potent 
inhibitors. Further in vitro and in vivo studies into the anti-apoptotic cascade, dopamine 
transmission and blood-brain barrier permeability of these novel compounds are in process. 
Findings from these studies will elaborate on their potential as neuroprotective agents and 
might identify the point(s) at which these compounds inhibit the apoptotic process. The 
polycyclic propargylamines and acetylene derivatives thus have potential as novel 
multifunctional neuroprotective agents and further investigation is necessary to determine 
their maximum benefit in the treatment of neurodegenerative disorders. 
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3.4. Experimental 
3.4.1. General procedures 
Unless otherwise specified, materials were obtained from commercial suppliers and used 
without further purification. All reactions were monitored by thin-layer chromatography on 
0.20 mm thick aluminium silica gel sheets (Alugram
®
 SIL G/UV254, Kieselgel 60, Macherey-
Nagel, Düren, Germany). Visualisation was achieved using UV light (254 nm and 366 nm), 
an ethanol solution of ninhydrin or iodine vapours, with mobile phases prepared on a volume-
to-volume basis. Chromatographic purifications were performed on silica gel (0.063–0.2 mm, 
Merck) except when otherwise stated. The mass spectra (MS) were recorded on an analytical 
VG 70-70E mass spectrometer using electron ionisation (EI) at 70 eV. Infra-red (IR) spectra 
were recorded on a Shimadzo IR prestige – 21 Fourier transform infrared spectrophotometer 
using KBr. Melting points were determined using a Gallenkamp and Stuart SMP-300 melting 
point apparatus and capillary tubes. All the melting points determined were recorded 
uncorrected. High resolution electron spray ionisation (HREI) mass spectra for all 
compounds were recorded on a Waters API Q-Tof Ultima mass spectrometer at 70 eV and 
100 °C. All HREI samples were introduced by a heated probe and perfluorokerosene was 
used as reference standard. 
1
H and 
13
C NMR spectra were acquired on a Bruker Avance III 
600 MHz spectrometer, with the 
1
H spectra recorded at a frequency of 600.170 MHz and the 
13
C spectra at 150.913 MHz. Tetramethylsilane (TMS) was used as internal standard, with 
CDCl3 as solvent. All chemical shifts are reported in parts per million (ppm), relative to the 
internal standard. The following abbreviations are used to indicate the multiplicities of the 
respective signals: s - singlet; br s - broad singlet; d - doublet; dd - doublet of doublets; t - 
triplet; m - multiplet; and AB-q - AB quartet. The multiplicity of the identified carbons was 
confirmed with DEPT-spectra. Microwave synthesis was performed using a CEM 
Discover
TM
 microwave synthesis system. 
 
3.4.2. Synthesis of compounds 
3.4.2.1. Pentacyclo[5.4.1.0
2,6
.0
3,10
.0
5,9
]undecane-8-11-dione (1)  
As described by Cookson et al. (1958, 1964).
41
 
 
3.4.2.2. 1-Methyl-pentacyclo[5.4.1.0
2,6
.0
3,10
.0
5,9
]undecane-8-11-dione (a)  
As described by Marchand et al. (1984).
42 
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3.4.2.3. Pentacyclo[5.4.1.0
2,6
.0
3,10
.0
5,9
]undecane-8-one (b)  
As described by Dekker and Oliver (1979).
43
 
 
3.4.2.4. 8-Benzylamino-8,11-oxapentacyclo[5.4.0
2,6
.0
3,10
.0
5,9
]undecane (NGP1-01, 3)  
As described by Van der Schyf et al. (1986).
31
 
 
3.4.2.5. 1-Methyl-8-ethynyl-11-hydroxy-8,11-oxapentacyclo[5.4.0
2,6
.0
3,10
.0
5,9
]undecane (9) 
A solution of 1-methyl-pentacyclo[5.4.1.0
2,6
.0
3,10
.0
5,9
]undecane-8-11-dione (a) (1.88 g; 10 
mmol) in dry tetrahydrofuran (10 mL) was added to an excess of ethynyl magnesium 
bromide (1.0 M solution in tetrahydrofuran) (2.838 mL; 22 mmol) under argon, whilst 
stirring. The resulting mixture was stirred at ambient temperature for 21 hours. The reaction 
mixture was poured over saturated aqueous ammonium chloride (NH4Cl) solution (100 mL), 
and the resulting suspension was extracted with diethyl ether (3 x 25 mL). The combined 
organic extracts were washed sequentially with water (25 mL) and brine (25 mL). The 
solvent was dried (Na2SO4) and filtered, and the filtrate was concentrated under reduced 
pressure. The residue, pale yellow oil, was successfully purified by precipitation from a 
mixture of ethyl acetate/petroleum ether (1:3), over a period of 24 hours at ambient 
temperature. This yielded the pure product as a light brown powder (yield: 0.762 g; 3.170 
mmol; 15.87 %).  
 
C14H14O2; MW, 214.3 g/mol; mp. 126 °C; IR (KBr) vmax: 3260, 2125, 1211, 1031 cm
-1
; 
MS (EI, 70 eV) m/z: 214 (M+), 186, 169, 158, 116, 91, 77, 39; HR-ESI [M+H]
+
: calc. 
215.1067, exp. 215.1069. 
1
H NMR (600 MHz, CDCl3) δH: 3.72 (s, OH), 3.12 - 2.37 (m, 7H, 
H- 2,3,5,6,7,9,10), 2.31 (s, 1H, H-13), 1.88:1.54 (AB-q, 2H, J = 10.4 Hz, H-4a,4b), 1.10 (s, 
3H, CH3); 
13
C NMR (150 MHz, CDCl3) δc: 116.87 (1C, C-11), 81.18 (1C, C-8), 75.30 (1C, 
C-12), 61.84 (1C, C-13), 57.24 (1C, C-9), 56.91 (1C, C-7), 50.75 (1C), 47.46 (1C), 45.22 
(1C), 43.49 (1C, C-4), 41.56 (1C), 39.19 (1C, C-1), 15.29 (1C, C-14). 
 
3.4.2.6. 8-Phenylethynyl-8-hydroxy-pentacyclo[5.4.0
2,6
.0
3,10
.0
5,9
]undecane (10) 
Neutral alumina (60–80 mesh, 30 g) in water (150 mL) was added to a stirred solution of 
potassium fluoride (20 g) in water (150 mL). After 30 minutes the water was evaporated in a 
rotary evaporator at 80 °C. When most of the water had been removed, the remaining mixture 
was heated to, and maintained at 140–150 °C under vacuum (5 mm Hg) overnight to afford 
50 g of KF/alumina reagent. Phenylacetylene (255.350 mg; 2.500 mmol), 
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pentacyclo[5.4.0
2,6
.0
3,10
.0
5,9
]undecane-8-one (b, 480.650 mg; 3 mmol), and KF/alumina 
(2.500 g) were mixed in a 25 mL flask at 60 °C . The progress of the reaction was monitored 
by TLC. After 12 hours the reaction mixture was washed with petroleum ether, filtered, and 
the solvent was evaporated under vacuum, affording a clear yellow oil. The residue was 
purified by means of column chromatography, by using a versa flash silica-gel column with 
petroleum ether/ethyl acetate (10:2) as eluent, to afford the product as a light yellow wax 
(yield: 480 mg; 1.830 mmol; 73.18 %).  
 
C19H18O; MW, 262.4 g/mol; mp. 90 °C; IR (KBr) vmax: 3069, 2225, 1599, 1491, 1125, 752 
cm
-1
; MS (EI, 70 eV) m/z: 262 (M+), 196, 183, 165, 129, 115, 91, 77; HR-ESI
 
[M+H]
+
: 
calc. 263.1430 exp. 263.1439; 
1
H NMR (600 MHz, CDCl3) δH 7.36 – 7.13 (m, 5H, H 
15,16,17,18,19), 2.77 – 2.28 (m, 8H, H-1,2,3,5,6,7,9,10), 1.93:1.60 (AB-q, 2H, H-11a,11b), 
1.72:1.18 (AB-q, 2H, J = 10.4 Hz, H-4a,4b); 
13
C NMR (150 MHz, CDCl3) δc: 131.51 (1C, 
C-14), 128.23 (2C, C-15,19), 128.10 (2C, C-16,18), 123.02 (1C, C-17), 94.15 (1C, C-8), 
83.21 (1C, C-13), 75.91 (1C, C-12), 51.50 (1C), 47.27 (1C), 45.20 (1C), 44.95 (1C), 42.73 
(1C, C-4), 41.50 (1C), 40.61 (1C), 36.62 (1C), 34.73 (1C), 28.98 (1C, C-11). 
 
3.4.2.7. 8-(N)-Propargylamino-8,11-oxapentacyclo[5.4.0
2,6
.0
3,10
.0
5,9
]undecane (11) 
Pentacyclo-[5.4.0
2,6
.0
3,10
.0
5,9
]undecane-8-11-dione (1, 5 g; 0,029 mol) was dissolved in 
tetrahydrofuran (50 mL) and cooled to ± -10 °C, while stirring on an external bath, containing 
an acetone/NaCl/ice mixture. Propargylamine (1.600 g; 0.029 mol) was added drop-wise, 
with continued stirring of the reaction mixture at lowered temperature. The carbinolamine 
started precipitating after approximately 15 minutes, but the reaction was allowed to stir for 
an additional 30 minutes to reach completion. The carbinolamine was isolated by filtration 
and washed with ice cold THF. Water was removed azeotropically by refluxing the material 
in dry benzene (60 mL), under Dean–Stark dehydrating conditions for 1 hour, or until no 
more water was collected in the trap. The benzene was removed under reduced pressure, 
which yielded the Schiff base as yellow oil. The Schiff base (imine) was then dissolved in a 
mixture of anhydrous methanol (30 mL) and anhydrous tetrahydrofuran (THF) (150 mL). 
Reduction was carried out by adding sodium borohydride (NaBH4) (1.500 g; 0.040 mol) in 
excess, and stirring the mixture for 24 hours at room temperature. The solvents were removed 
under reduced pressure, the residue suspended in water (100 mL) and extracted with 
methylene chloride (4 x 50 mL). The combined organic fractions were washed with water (2 
x 100 mL), dried over anhydrous MgSO4 and evaporated under reduced pressure to yield a 
milky yellowish oil. Purification of the product mixture was accomplished using column 
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chromatography on silica gel, with ethyl acetate/methylene chloride/petroleum ether (1:1:1) 
as eluent. This yielded the desired amine as a light yellow precipitate. Recrystallisation from 
absolute ethanol rendered the final product as a colourless microcrystalline solid (yield: 600 
mg; 2.827 mmol; 9.75 %).  
 
C14H15O1N1; MW, 213.28 g/mol; mp. 113 °C; IR (KBr) vmax: 3306, 3238, 2124, 1485, 
1153, 1000 cm
-1
; MS (EI, 70 eV) m/z: 213 (M+), 184, 134, 118, 91, 77, 39; HR-ESI
 
[M+H]
+
: calc. 214.1226, exp. 214.1225. 
1
H NMR (600 MHz, CDCl3) δH: 4.63 (t, 1H, J = 5 
Hz, H-11), 3.57:3.56 (dd, 2H, J = 2.5 Hz, H-12a,12b), 2.80 – 2.39 (m, 8H, H-
1,2,3,5,6,7,9,10), 2.26 (br s, NH), 2.21 (s, 1H, H-14), 1.88:1.52 (AB-q, 2H, J = 10.4 Hz, H-
4a,4b); 
13
C NMR (150 MHz, CDCl3) δc: 108.98 (1C, C-8), 82.81 (1C, C-11), 82.76 (1C, C-
13), 70.92 (1C, C-14), 55.46 (1C, C-7/9), 54.76 (1C, C-7/9), 44.84 (1C), 44.65 (1C), 44.54 
(1C), 43.3 (1C), 43.07 (1C, C-12), 42.04 (1C), 41.54 (1C), 33.07 (1C). 
 
3.4.2.8. 1-Methyl-8-(N)-propargylamino-8,11-oxapentacyclo[5.4.0
2,6
.0
3,10
.0
5,9
]undecane (12) 
1-Methyl-penta-cyclo[5.4.0
2,6
.0
3,10
.0
5,9
]undecane-8-11-dione (a, 5.460 g; 0.029 mol) was 
dissolved in tetrahydrofuran (50 mL) and cooled to ± -10 °C, while stirring on an external 
bath containing an acetone/NaCl/ice mixture. Propargylamine (1.600 g; 0.029 mol) was 
slowly added with continued stirring of the reaction mixture at lowered temperature. The 
reaction mixture was stirred for an additional 1½ hours to reach completion. The THF was 
removed under reduced pressure, affording the carbinolamine as a red/brown oil. Water was 
removed azeotropically by refluxing this material in dry benzene (60 mL), under Dean–Stark 
dehydrating conditions for 1 hour, or until no more water was collected in the trap. The 
benzene was removed under reduced pressure, which yielded the Schiff base as a brown oil. 
The Schiff base (imine) was dissolved in a mixture of anhydrous methanol (30 mL) and 
anhydrous tetrahydrofuran (150 mL). Reduction was carried out by adding sodium 
borohydride (1.500 g; 0.040 mol) in excess and stirring the mixture for 24 hours at room 
temperature. The solvents were removed under reduced pressure, the residue suspended in 
water (100 mL) and extracted with methylene chloride (4 x 50 mL). The combined organic 
fractions were washed with water (2 x 100 mL), dried over anhydrous MgSO4 and evaporated 
under reduced pressure to yield a dark brown oil. Purification of the product mixture was 
accomplished using column chromatography, with ethyl acetate/methylene 
chloride/petroleum ether (1:1:1) as eluent, yielding the desired amine as a dark brown oil 
(Yield: 1.753 g; 7.746 mmol; 26.71 %).  
 
http://etd.uwc.ac.za/
72 
 
C15H17O1N1; MW, 227.3 g/mol; IR (KBr) vmax: 3310, 3250, 2100, 1452, 1153, 1007cm
-1
; 
MS (EI, 70 eV) m/z: 227 (M+), 212, 198, 184, 158, 145, 131, 91, 77, 39; HR-ESI
 
[M+H]
+
: 
calc. 228.1383, exp. 228.1395. 
1
H NMR (600 MHz, CDCl3) δH: 4.08 (d, 1H, J = 4.4 Hz, H-
11), 3.57 (m, 2H, H-12a,12b), 2.73 – 2.20 (m, 7H, H- 2,3,5,6,7,9,10), 2.14 (br s, NH), 2.06 
(d, 1H, J = 5.28 Hz, H-14), 1.86:1.51 (AB-q, 2H, J = 10.4 Hz, H-4a,4b), 1.15 (s, 3H, CH3); 
13
C NMR (150 MHz, CDCl3) δc: 109.73 (1C, C-8), 87.15 (1C, C-11), 82.65 (1C, C-13), 
70.95 (1C, C-14), 54.97 (1C, C-9), 54.66 (1C, C-7), 50.74 (1C), 46.99 (1C), 43.58 (1C), 
43.18 (1C), 38.91 (1C, C-1), 33.07 (1C, C-12), 19.85 (1C, C-15). 
 
3.4.2.9. 8-Hydroxy-(N)-propargyl-8,11-azapentacyclo[5.4.0
2,6
.0
3,10
.0
5,9
]undecane (13) 
Pentacyclo-[5.4.0
2,6
.0
3,10
.0
5,9
]undecane-8-11-dione (1, 5 g; 0.029 mol) was dissolved in 
tetrahydrofuran (50 mL) and cooled to ± -10 °C, while stirring on an external bath, containing 
an acetone/NaCl/ice mixture. Propargylamine (1.600 g; 0.029 mol) was added slowly with 
continued stirring of the reaction mixture at lowered temperature. The carbinolamine started 
precipitating after approximately 60 minutes, but the reaction was stirred for an additional 45 
minutes to reach completion. This carbinolamine was isolated by filtration. Water was 
removed azeotropically by refluxing this material in dry benzene (60 mL), under Dean–Stark 
dehydrating conditions for 1 hour, or until no more water was collected in the trap. The 
benzene was removed under reduced pressure and the Schiff base was used without further 
purification. It was dissolved in a solution of acetic acid (15 mL) and dry methanol (250 mL). 
To the resulting solution was added sodium cyanoborohydride (NaBH3CN) (2.510 g; 40 
mmol) portion wise, with stirring at room temperature over a period of 5 minutes. The 
resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was then 
concentrated under reduced pressure, and water (100 mL) was added to the residue. The 
resulting suspension was stirred and solid sodium bicarbonate was added portion wise until 
evolution of carbon dioxide ceased. Excess solid sodium bicarbonate (2.000 g) was added, 
and the aqueous suspension was extracted with methylene chloride (4 x 50 mL). The 
combined extracts were washed with water (2 x 100 mL), dried with anhydrous magnesium 
sulphate and filtered. The filtrate was concentrated under reduced pressure. A yellow solid 
was thereby obtained. Purification of the product mixture was accomplished using column 
chromatography on silica, with ethyl acetate/methylene chloride/ethanol (10:5:1) as eluent. 
The desired amine was obtained as an off-white powder. Recrystallisation from cyclohexane 
rendered the final product as an off white microcrystalline solid (Yield: 960 mg; 4.501 mmol; 
15.52 %).  
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C14H15O1N1; MW, 213.3 g/mol; mp. 140 °C; IR (KBr) vmax: 3225, 3100, 2114, 1120, 
1070, cm
-1
; MS (EI, 70 eV) m/z: 213 (M+), 196, 174, 147, 134, 118, 91, 77, 39; HR-ESI
 
[M+H]
+
: calc. 214.1226, exp. 214.1222; 
1
H NMR (600 MHz, CDCl3) δH: 3.71 (s, 1H, H-
12), 3.35 (d, 1H, J = 16.5 Hz, H-11), 3.00 – 2.43 (m, 8H, H-1,2,3,5,6,7,9,10), 2.25 (s, 1H, H-
14), 1.82:1.49 (AB-q, 2H, J = 10.4 Hz, H-4a,4b); 
13
C NMR (150 MHz, CDCl3) δc: 125.53 
(1C, C-8), 81.23 (1C, C-13), 71.37 (1C, C-14), 65.52 (1C, C-11), 45.62 (1C, C-7/9), 43.12 
(1C, C-7/9), 41.74 (1C, C-4), 41.60 (1C), 36.79 (1C), 30.33 (1C, C-12 
 
3.4.2.10. 1-Methyl-8-hydroxy-(N)-propargyl-8,11-azapentacyclo[5.4.0
2,6
.0
3,10
.0
5,9
]undecane 
(14) 
1-Methyl-pentacyclo[5.4.0
2,6
.0
3,10
.0
5,9
]undecane-8-11-dione (b, 10.658 g; 56.620 mmol) was 
dissolved in tetrahydrofuran (50 mL) and cooled to ± -10 °C, while stirring on an external 
bath containing an acetone/NaCl/ice mixture. Propargylamine (3.119 g; 56.620 mmol) was 
added drop wise with continued stirring of the reaction mixture at lowered temperature. The 
reaction mixture was stirred for 5½ hours to reach completion. The THF was removed under 
reduced pressure, affording a red/brown oil, the carbinolamine. Water was removed 
azeotropically by refluxing this material in dry benzene (60 mL), under Dean–Stark 
dehydrating conditions for 1 hour, or until no more water was collected in the trap. The 
benzene was removed under reduced pressure, which yielded the Schiff base as a dark brown 
oil. The Schiff base was used without further purification. It was dissolved in a solution of 
acetic acid (30 mL) in dry methanol (500 mL). To the resulting solution, sodium 
cyanoborohydride (3.970 g; 63 mmol) was added portion wise, with stirring at room 
temperature over a period of 5 minutes. The resulting mixture was stirred at room 
temperature for 14 hours. The reaction mixture was then concentrated under reduced 
pressure, and water (150 mL) was added to the residue. The resulting suspension was stirred, 
and solid sodium bicarbonate was added portion wise until evolution of carbon dioxide 
ceased. Excess solid sodium bicarbonate (3.000 g) was added, and the aqueous suspension 
was extracted with methylene chloride (4 x 50 mL). The combined extracts were washed with 
water (2 x 100 mL), dried with anhydrous magnesium sulphate, and filtered. The filtrate was 
concentrated under reduced pressure, leaving a deep orange oil as residue. Purification of the 
product mixture was accomplished using column chromatography on silica, with ethyl 
acetate/tetrahydrofuran (5:1) as eluent. This yielded the desired amine as a light yellow oil, 
which precipitated when ethanol was added. Recrystallisation from ethanol rendered the final 
product as a light yellow microcrystalline solid (Yield: 555 mg; 2.442 mmol; 4.31 %).  
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C15H17O1N1; MW, 227.3 g/mol; mp. 125 °C; IR (KBr) vmax: 3225, 3078, 2124, 1119, 1070 
cm
-1
; MS (EI, 70 eV) m/z: 227 (M+), 188, 134, 118, 91, 77, 39; HR-ESI
 
[M+H]
+
: calc. 
228.1388, exp. 228.1392; 
1
H NMR (600 MHz, CDCl3) δH: 3.46 - 3.34 (m, 1H, H-11), 
3.22:3.09 (d, 2H, J = 17.3 Hz, H-12a,12b), 2.57 – 2.09 (m, 8H, H-2,3,5,6,7,9,10,14), 
1.60:1.06 (AB-q, 2H, J = 10.4 Hz, H-4a,4b), 1.19 (s, 3H, CH3); 
13
C NMR (150 MHz, 
CDCl3) δc: 125.53 (1C, C-8), 80.31 (1C, C-13), 72.68 (1C, C-14), 57.40 (1C, C-11), 46.62 
(1C, C-9), 46.10 (1C, C-7), 45.09 (1C), 41.54 (1C, C-4), 37.63 (1C), 36.33 (1C), 34.52 (1C), 
30.32 (1C, C-12), 21.98 (1C, C-15). 
 
3.4.2.11. N,N-Dipropargyl-adamantan-1-amine (15) 
Excess propargylbromide (0.595 mL; 6.677 mmol), amantadine (2, 302.49 mg; 2 mmol) and 
aqueous sodium hydroxide (NaOH) solution (180 mg in 6 mL water; 4.5 mmol) were placed 
in a round-bottom glass flask equipped with a condenser and a magnetic stirrer. The flask 
was placed in a CEM discover focused microwave synthesis system, and subjected to 
microwave irradiation at 80–100 °C (power 250 Watt) for 25 minutes. After completion of 
the reaction, the product was extracted into ethyl acetate. The solvent was then removed 
under reduced pressure. The unreacted amantadine was removed from the residue by adding 
acetone to the residue and collecting the amantadine by filtration. The acetone was then 
removed under reduced pressure from the filtrate, affording orange crystals which were 
recrystallised out of ethyl acetate to afford the pure product as light yellow crystals (412 mg; 
1.812 mmol; 90.61 %).  
 
C16H21N1; MW, 227.35 g/mol; mp. 76 °C; IR (KBr) vmax: 3237, 2099, 1119 cm
-1
; MS (EI, 
70 eV) m/z: 227 (M+), 184, 144, 132, 91, 79, 53, 39; HR-ESI
 
[M+H]
+
: calc. 228.1752, exp. 
228.1755; 
1
H NMR (600 MHz, CDCl3) δH: 3.65 (s, 4H, H 11a,11b,14a,14b), 2.17 (s, 2H, H-
13,16), 2.06 (s, 3H, H-3,5,8), 1.80 (s, 6H, H-2a,2b,6a,6b,7a,7b), 1.63 – 1.46 (m, 6H, H-
4a,4b,9a,9b,10a,10b);
13
C NMR (150 MHz, CDCl3) δc: 82.12 (2C, C-12,15), 72.08 (2C, C-
13,16), 55.45 (1C, C-1), 39.96 (3C, C-3,5,8), 36.54 (3C, C-2,6,7), 35.03 (2C, C- 11,14), 
29.70 (3C, C-4,9,10). 
 
3.4.2.12. N-Propargyl-N-benzyl-adamantan-1-amine (16) 
A solution of amantadine (2, 5 g; 33.056 mmol) and benzaldehyde (3.51 g; 33.073 mmol) in 
ethanol (60 mL) was stirred for 4 days at ambient temperature under nitrogen atmosphere. 
The solvents were removed in vacuo. The resulting oil was dissolved in 80 ml benzene and 
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refluxed under Dean-Stark conditions for 6 hours, where after the benzene was removed in 
vacou.  The resulting reaction mixture was dissolved in 60 ml ethanol and solid sodium 
borohydride (NaBH4) (2.5 g; 66.085 mmol) was then added slowly in small portions over 30 
minutes, and stirring of the resulting suspension was continued at room temperature for 30 
minutes under nitrogen atmosphere. The reaction mixture was refluxed for 12 hours. After 
cooling to ambient temperature, the mixture was diluted with ethanol (60 mL), and the excess 
sodium borohydride was destroyed by adding aqueous hydrochloric acid (HCl) (10 mL, 5 M) 
drop wise. The reaction mixture was then made alkaline, to pH 12, by adding aqueous 
sodium hydroxide (NaOH) solution.  Finally, the desired product was extracted to methylene 
chloride (4 x 10 mL) and dried over anhydrous magnesium sulphate (MgSO4). The solvent 
was evaporated under reduced pressure to afford the intermediate product, N-benzyl-
adamantan-1-amine (c), as white crystals (yield: 4.757 g; 19.6 mmol; 59.29 %). This 
intermediate product was subsequently used in the following steps without any further 
purification. A solution was made of N-benzyl-adamantan-1-amine (c, 4.757 g; 19.6 mmol) 
and excess propargylbromide (2.3 ml; 25.81 mmol) in dry dimethylformamide (30 mL), and 
left for 24 hours to react at ambient temperature. After this period of time the mixture was 
diluted with water (50 mL), and an extraction was done using methylene chloride (DCM) (3 
x 50 mL) and dried over anhydrous sodium sulphate (Na2SO4). The solvent was removed 
under reduced pressure to afford a thick dark orange residue. The desired product was 
precipitated out of the residue by the addition of chloroform (30 mL), which allowed the 
collection of the final product by filtration as an off-white powder (yield: 1.352 g; 4.82 
mmol; 24.59 %).  
 
C20H25N1; MW, 279.3 g/mol; mp. 81 °C; IR (KBr) vmax: 3210, 3062, 2091, 1495, 1130, 
748cm
-1
; MS (EI, 70 eV) m/z: 279 (M+), 236, 222, 185, 135, 91; HR-ESI
 
[M+H]
+
: calc. 
280.2065, exp. 280.2063; 
1
H NMR (600 MHz, CDCl3) δH: 7.35-7.20 (m, 5H, H- 
16,17,18,19,20), 3.84 (s, 2H, H-14a,14b), 3.32 (s, 2H, H-11a,11b), 2.15 (s, 3H, H-3,5,8), 2.09 
(s, 1H, H-13), 1.90 (s, 6H, H-2a,2b,6a,6b,7a,7b), 1.65 (s, 6H, H-4a,4b,9a,9b,10a,10b); 
13
C 
NMR (150 MHz, CDCl3) δc: 141.11 (1C, C-15), 128.65 (2C, C-16,20), 128.18 (2C, C-
17,19), 126.66 (1C, C-18), 83.22 (1C, C 12), 72.08 (1C, C-13), 55.05 (1C, C-1), 48.98 (1C, 
C-14), 40.53 (3C, C-3,5,8), 36.77 (3C, C-2,6,7), 34.79 (1C, C-11), 29.86 (3C, C-4,9,10). 
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3.4.3. Biological evaluations 
3.4.3.1. Apoptosis detection - DePsipher
TM
 assay 
DePsipher™ utilises a lipophilic cation (5,5´,6,6´-tetrachloro-1,1´,3,3´-
tetraethylbenzimidazolyl carbocyaniniodide), which can be used as a mitochondrial activity 
marker to evaluate the viability of a cell population, detecting early apoptosis, and evaluating 
the effect of drugs on the cell population.
30
 The cation aggregates upon membrane 
polarisation, forming an orange-red fluorescent compound. If the potential is disturbed, the 
dye cannot access the transmembrane space and remains orange-red or reverts to its green 
monomeric form. Thus, healthy cells present both the polymeric (orange-red) and monomeric 
(green) form of the cation, with the monomeric form residing in the cytoplasm and the 
aggregated form in the transmembrane space. It can be concluded that in comparison with 
healthy cells, wherein apoptosis has not been induced, the ratio of orange-red fluorescence to 
green fluorescence of apoptotic cells will be lower. The fluorescence can be observed and 
measured by flow cytometry with the red aggregates having absorption/emission maxima of 
585/590 nm, and the green monomers absorption/emission maxima of 510/527 nm. 
 
3.4.3.1.1. Biological material 
3.4.3.1.1.1. Cell cultivation 
In the current study the SK-N-BE(2) neuroblastoma cells were used to evaluate the anti-
apoptotic activity of the synthesized compounds. The cells were cultivated in serum-rich 
growing medium, consisting of F12 nutrient (F12) supplemented with 10 % foetal bovine 
serum (FBS), 1 % penicillin/streptomycin (Pen/Strep) (10 000 units/100 mL stock) and 0.1 % 
fungizone (FZ) (2.5 μg/mL units stock). They were incubated at 37 °C in a 5 % CO2 and 95 
% O2 humidified atmosphere. The cells duplicated every 30-48 hours and when a confluency 
of 80 % was reached, the adherent cells were detached from the flask bottom by means of 
trypsination. To ensure complete detachment of the cells, they were incubated with trypsine 
for approximately 10 minutes. After trypsination, the cells were seeded in new flasks at a 
density of no less than 1/6 confluency. 
 
3.4.3.1.1.2. Induction of apoptosis 
In the current study, trophic factor deprivation/serum starvation was used to induce apoptosis 
in cells. With growth factors being essential to the normal development and survival of 
neuronal cells, a shortage thereof would cause neurons to compete with one another for 
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neurotrophic factors, with the unsuccessful ones dying. With no serum (neurotrophic factors) 
available, all the cells will die in a given time. The serum deprived medium consisted of F12, 
Pen/Strep and FZ in the same ratio as mentioned in section 3.4.3.2.2. 
 
3.4.3.1.1.3. Cells used to evaluate anti-apoptotic activity of compounds 
After the cells reached 80 % confluency, the serum rich medium was replaced with serum 
deprived medium. The cells were then incubated under normal conditions (see section 
4.3.2.2) for a period of 24 hours, which was sufficient time for apoptosis to be induced. 
Examining the cells under the microscope after this period of time, it was clear that their 
morphology had changed. The cells were no longer attached to the bottom of the flask, and 
their shape had also changed from the sprouting appearance to a spherical shape, being 
indicative of unhealthy cells. After being incubated in the serum deprived medium for the 
indicated time, the medium was removed, using centrifugation. The cells were then seeded in 
24-well plates, with each well containing a concentration of 1 x 106 cells per 2 mL of serum 
deprived medium containing the test compounds, which were dissolved in dimethyl 
sulphoxide. Final concentrations of samples to be analysed contained 1.25 % (v/v) DMSO. 
The cells were then incubated under normal conditions for a period of 36 hours before being 
analysed. The test compounds (6 - 13) were all tested in triplicate at three different 
concentrations (1 mM, 100 μM and 10 μM). The positive control, selegiline, was tested in 
triplicate at two concentrations (100 μM and 10 μM). Included into the research was NGP1-
01 which was also tested in triplicate at the highest concentration (1 mM). 
 
3.4.3.1.1.4. Cells used for control experiments 
In this study four control experiments were included. 
 
3.4.3.1.1.4.1. Control experiment 1 
After the cells reached 80 % confluency, the serum rich medium was replaced with serum 
deprived medium. The cells were then incubated under normal conditions for a period of 24 
hours. After being incubated in the serum deprived medium, the medium was removed by 
centrifugation. The cells were subsequently seeded in 24-well plates, with each well 
containing a concentration of 1 x 106 cells per 2 mL of serum deprived medium and DMSO 
(1.25 % (v/v)). After this, the cells were incubated under normal conditions (37 °C in a 5 % 
CO2 and 95 % O2 humidified atmosphere) for a period of 36 hours before being analysed. 
Control experiment 1 was included to evaluate the viability status of the cells in the absence 
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of test compound. The viability data will be compared to the data generated with the test 
compounds in order to determine if the test compounds attenuated the progression of the 
apoptotic process. With this control experiment, the effect of DMSO was also evaluated. 
 
3.4.3.1.1.4.2. Control experiment 2 
After the cells reached 80 % confluency, the serum rich medium was replaced with serum 
deprived medium. The cells were then incubated under normal conditions for a period of 24 
hours. After being incubated in the serum deprived medium, the medium was removed by 
centrifugation. The cells were subsequently seeded in 24-well plates, with each well 
containing a concentration of 1 x 10
6
 cells per 2 mL of serum deprived medium with no 
DMSO content. The cells were incubated under normal conditions for a period of 36 hours 
before being analysed. Control experiment 2 was used to evaluate the effect of DMSO on the 
viability of the cells and on the progression of the apoptotic process. 
 
3.4.3.1.1.4.3. Control experiment 3 
After the cells reached 80 % confluency, the serum rich medium was replaced with serum 
deprived medium. The cells were subsequently incubated under normal conditions for a 
period of 24 hours. After being incubated in the serum deprived medium, the medium was 
removed by centrifugation. The cells were then seeded in 24-well plates, with each well 
containing a concentration of 1 x 106 cells per 2 mL of fresh serum rich medium with no 
DMSO present. After this the cells were incubated under normal conditions for a period of 36 
hours before being analysed. Since the re-introduction of serum rich medium is expected to 
significantly attenuate the apoptotic process, this control experiment will be used to estimate 
the potencies of the test compounds as anti-apoptotic agents. 
 
3.4.3.1.1.4.4. Control experiment 4 
After the cells reached 80 % confluency, the serum rich medium was replaced with fresh 
serum rich medium. The cells were then incubated under normal conditions for a period of 24 
hours. After being incubated in the serum rich medium, the medium was removed by 
centrifugation. The cells were subsequently seeded in 24-well plates, with each well 
containing a concentration of 1 x 106 cells per 2 mL of serum rich medium with no DMSO 
present. The cells were incubated under normal conditions for a period of 36 hours before 
being analysed. Control experiment 4 was included to analyse and determine the viability 
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status of the cells, when no apoptosis had been induced, and conditions had been favourable 
to the end. It was also included to ensure that the cells analysed were indeed healthy before 
inducing apoptosis. 
 
3.4.3.1.2. Assay procedure 
The cells of each sample were harvested consecutively as follows: After incubating the cells 
for 36 hours, the medium was removed from the cells using centrifugation. The cells that had 
adhered to the bottom of the flasks were removed by trypsination. The trypsine/cell mixture 
was added to the cells from which the medium had been removed. The trypsine was removed 
from the cells by centrifugation at 500 x g for five minutes at room temperature. The cells of 
each sample were then resuspended in 1 mL of diluted DePsipher solution, consisting of 1 μL 
DePsipher dye and 1 mL of pre-warmed F12 medium. The cells were incubated for 20 
minutes at 37 °C and 5 % CO2. The samples were washed twice in PBS, and centrifuged at 
500 x g between each wash. The cells were subsequently resuspended in 1 mL PBS and 
immediately taken to be analysed on the flow cytometer. The samples were kept shielded 
from light until analysis, since the DePsipher™ agent is light sensitive.  
 
3.4.3.1.3. Data analysis  
Analysis of the samples were performed on a BD FacsCalibur® flow cytometer [Becton 
Dickinson, San Jose (USA)], equipped with a 15 mV 488 nm, air-cooled argon-ion laser. 
Cells were gated in a forward scatter/side scatter plot to exclude debris. Green and red 
fluorescence were detected in the corresponding FL-1 and FL-2 photomultipliers through 530 
nm (FITC) or 585 nm (PE/PI) bandpass filters respectively. In generating the data, the flow 
cytometer was set to analyse 50 000 events/cells. Figures 1-3 (supplementary material) 
contains representative pseudo-colour graphs of every sample, which was generated using 
FlowJo
®
, based on the data of the flow cytometry. On the x-axis the FL-1 (green) 
fluorescence intensity is plotted, and on the y-axis the FL-2 (red) fluorescence intensity is 
plotted. Both intensities are measured in MFI (mean fluorescence intensity). Each spot is 
representative of a single cell analysed with the flow cytometer. The graphs are divided into 
four separate quadrants, each containing a population of cells, which exhibit the same 
characteristics. In the upper left quadrant (Q1) lies all the cells which emit only red 
fluorescence, whereas the cells which emit only green fluorescence can be found in the lower 
right quadrant (Q4). The cells which emit both wavelengths of fluorescence can be found in 
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the upper right quadrant (Q2), and the cells emitting neither of the two in the lower left 
quadrant (Q3). The following can be concluded by taking note of the explanations of the 
different quadrants as well as the characteristics of cells in each of these quadrants: As 
healthy cells contain both the monomeric and polymeric form of the cation dye, and would 
thus have intensity in both the FL1 and FL2 channels used to analyse the samples, the MFI 
values of these cells will lie in Q2 (see control experiment 4). The cells with MFI values in 
Q1 have only red fluorescence, which might be due to low concentrations of the dye inside 
the cell, indicating that all the monomers were polymerised. All these cells can thus also be 
said to be healthy, together with these found in Q2. Cells wherein apoptosis have been 
induced only contain the monomeric form of the dye, will not colour red at all, and will thus 
have MFI values in Q4. The cells lying in Q3 have not been dyed successfully or intensively 
enough, and have thus not coloured either red or green. From the pseudo-colour graphs it is 
clear that there was a difference in the number of apoptotic/healthy cells present in the 
different samples. Control experiment 1 had the least MFI values in Q1+Q2, and control 
experiment 4 the most. The MFI values of the other samples were either between the values 
of control experiments 1 and 4, or just above that of control experiment 4 (All pseudo-colour 
graphs are supplied in the supplementary material). 
The data generated by these flow cytometry experiments were used to determine if the test 
compounds have anti-apoptotic properties on cultured cells. The values utilised to quantify 
cell viability were determined by the flow cytometer. Equation 1 was used to calculate the 
percentage of cells which were still viable in the samples analysed. In determining this value, 
the amount of cells in quadrant 1 (Q1), quadrant 2 (Q2) and quadrant 3 (Q3) and the total 
amount of events analysed (Qtotal) were utilised. 
% Viable cells = [(Q1 + Q2)/(Qtotal - Q3)] x 100      -       Equation 1 
The results confirmed that a significant percentage of the cells had indeed coloured 
successfully with the dye. The percentage of the coloured cells that had fluorescence intensity 
in the FL2 channel, gave a quantitative indication of the number of healthy cells present in 
each sample, wherein apoptosis had not progressed or been induced. In control experiment 1, 
41.62 % of the cells were apoptotic, with only 58.38 % remaining healthy. This indicates that 
the method of apoptosis induction had indeed been successful. Comparing the values of 
control experiments 1 and 2, it is clear that even though the final DMSO content in the 
samples was only 1.25 %, it had a negative effect on the health of the cells. In control 
experiment 2, which did not contain any DMSO, there were 7.19 % more cells that were 
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healthy. It can thus be said that the serum deprivation was not the only factor inducing 
apoptosis, but also the DMSO which served as solvent for the test compounds. 
 
3.4.3.2. NMDA and VGCC 
3.4.3.2.1. Animals 
The study protocol was approved by the Ethics Committee for Research on Experimental 
Animals of the University of the Western Cape (SRIRC 2012/06/13). Adult Winstar rats were 
sacrificed by decapitation and the brain tissue was removed and kept on ice for 
homogenation. After homogenation, the alliquoted brain homogenate was immediately used 
in the subsequent assay. 
 
3.4.3.2.2. Methods 
The fluorescent ratiometric indicator, Mag-Fura-2/AM, and a Bio-Tek
®
  fluorescence plate 
reader were used to evaluate the influence of the test compounds on calcium homeostasis via 
the VGCC and NMDA receptor channels utilizing murine synaptoneurosomes. Preparation of 
synaptoneurosomes, solutions and experimental techniques were similar to those of published 
studies.
26,44
 All data analysis, calculation and graphs were done using Prism 6.0
®
 
(GraphPhad, La Jolla, CA). Data analysis was carried out using the Student Newman Keuls 
multiple range test and the level of significance was accepted at p < 0.05.  
 
3.4.3.2.3. Preparation of synaptoneuromes 
Adult Winstar rats were used. Rats were sacrificed by decapitation, and the whole brains 
were removed. Whole-brain synaptoneurosomes were prepared by the techniques of 
Hollingsworth et al.
45
, modified slightly. The brain from one rat was homogenized (8 strokes 
by hand using a glass homogenizer) in 30 ml of ice–cold incubation buffer (NaCl, 118 mM; 
KCl, 4.7 mM; MgCl, 1.18 mM; CaCl2 0.1 mM; HEPES, 20 mM and glucose, 30.9 mM. pH 
7.4). From this step forward the homogenate was kept ice–cold at all times to minimize 
proteolysis throughout the isolation procedure. The tissue suspension was placed in a 50 ml 
polycarbonate tube and then centrifuged for 5 min at 1000 g and 0 ºC using a Labofuge 20
®
 
centrifuge. After centrifugation, the supernatant was decanted into a 50 ml polycarbonate 
tube and placed on ice. The supernatant was then divided into 2 ml eppendorf vials whose 
weight had been previously recorded. This was followed by a second centrifugation at 15000 
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g for 20 min at 0 ºC. The supernatant was discarded and the mass of the resulting pellet was 
calculated. Sufficient calcium-free buffer (NaCl, 118 mM; KCl, 4.7 mM; MgCl, 1.18 mM; 
HEPES, 20 mM and glucose, 30.9 mM. pH 7.4) was added to obtain a 3 mg/ml protein 
concentration (protein yield is approximately 10 mg/g of tissue).
45
 
 
3.4.3.2.4. General procedure for loading FURA-2 AM and incubating test compounds 
Experiments were carried out at 37 ºC and fluorescence was measured with a flourescent 
plate reader (Bio-Tek
®
). 1990 µl of synaptoneurosome suspension prepared above was 
allowed to reach room temperature, thereafter 10 µl of Fura-2 AM (1 mM in DMSO) was 
added to produce a final concentration of 5 µM. Synaptoneurosomes were then incubated at 
37 ºC for 30 min after which the suspension was centrifuged on a desktop centrifuge at 7000 
g for 5 min and the supernatant decanted to remove all extracellular Fura-2 AM. The 
resulting pellet was resuspended in 2 mM CaCl2 containing buffer to obtain a final protein 
concentration of 0.6 mg/ml.  
 
3.4.3.2.5. Measurement of intracellular calcium 
For the screening test 10 mM stock solutions of the compounds in DMSO were prepared, 
with the control containing 1% DMSO and no test compound. 2 µl of the individual stock 
solutions were added to a 96 well plate in triplicate followed by the addition of 200 µl of 
synaptoneurosomal-Fura-2 AM solution prepared above. This gave rise to a final 
concentration of 100 µM of the compounds. The 96 well plate was shaken and incubated for 
30 min at 37 ºC and used immediately after incubation. The measurement was then 
performed at 37 ºC in a 96 well plate using dual wavelength excitation at 340 nm and 380 
nm. The resting fluorescence was measured at 510 nm after which the changes in 
fluorescence intensity following the addition of 10 µl depolarizing solution using auto-
injectors was recorded over a period of 5 min. The changes in fluorescence indicated the 
effect of the test compound on calcium flux. 
 
3.4.3.2.6. KCl mediated calcium stimulation 
The wavelengths selected were 340 nm and 380 nm for excitation and 510 nm for emission, 
with a runtime of 5 min with 5 ms intervals. The test compound was incubated for 30 min at 
37 ºC and used immediately after incubation. The procedure was initiated and kept at 37 ºC. 
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At 10 s into the recording 10 µl of KCl (140 mM) depolarization solution (5.4 mM NaCl, 140 
mM KCl, 10 mM NaHCO3, 1.4 mM CaCl2, 0.9 mM MgSO4, 5.5 mM Glucose monohydrate, 
0.6 mM KH2PO4, 0.6 mM Na2HPO4, and 20 mM HEPES. pH adjusted to 7.4 with NaOH) 
was added to the membrane preparation to depolarize the synaptoneurosomes and activate the 
calcium flux (addition was done using auto-injectors). Experiments were repeated three times 
on different tissue preparations with three determinations in each replicate 
 
3.4.3.2.7. NMDA/Glycine mediated calcium stimulation 
The wavelengths selected were 340 nm and 380 nm (excitation) and 510 nm (emission) with 
a runtime of 5 min with 5 ms intervals. The test compound was incubated for 30 min at 37 ºC 
and used immediately after incubation. The procedure was initiated and kept at 37 ºC. At 10 s 
into the recording 10 µl of NMDA/Glycine (0.1 mM) depolarization solution (0.1 mM 
CaCl2.2H2O, 0.1 mM NMDA, 0.1 mM Glycine, 118 mM NaCl, 4.7 mM KCl, 30.9 mM 
Glucose monohydrate and 20 mM HEPES. pH adjusted to 7.4 with NaOH) was added to the 
membrane preparation to depolarize the synaptoneurosomes and activate the calcium flux 
(Addition was done using auto-injectors). The addition of NMDA (0.1 mM) and Gly (0.1 
mM) resulted in activation of NMDAR mediated calcium flux. Experiments were repeated 
three times on different tissue preparations with three determinations in each replicate. 
 
3.4.3.2.8. Percentage inhibition calculations  
The data obtained from the fluorescent readings of each well were expressed in the form of a 
ratio (340 nm reading / 380 nm reading). This ratio indicated the net movement of Ca
2+
 ions 
across the membrane as it represents the ratio between unbound-Ca
2+
 and Ca
2+
-bound to 
Fura-2 AM. The average ratio over a 10 s interval after 1 min of stimulation was then 
subtracted from the average ratio of over the last 10 s interval to give the net change in Ca
2+
 
movement (Nc) across the membrane over the 5 min period. This calculation was performed 
for each individual well and the averages of wells containing the same test compound were 
calculated (NcAve). These averages were used to calculate the percentage inhibition of the test 
compounds relative to the control by use of the following equation: 
% inhibition = [NcAve (Control) – NcAve (Test compound)] / NcAve (Control) x 100 % - 
Equation 2 
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3.4.3.3. MAO-B inhibition 
The mitochondrial fraction of baboon liver tissue, as source of the MAO-B enzyme, was 
isolated as described previously by Salach & Wyler, 1987,
46
 and stored at -70 ºC. Following 
addition of an equal volume of sodium phosphate buffer (100 mM, pH 7.4) containing 
glycerol (50 %, w/v) to the mitochondrial isolate, the protein concentration was determined 
by the method of Bradford using bovine serum albumin as reference standard.
47
 In the current 
study, MMTP (Km = 68.3 ± 1.60 μM for baboon liver MAO-B) served as substrate for the 
inhibition studies.
 
The enzymatic reactions were conducted in sodium phosphate buffer (100 mM, pH 7.4) and 
contained MMTP (50 μM), the mitochondrial isolate (0.15 mg protein/mL) and various 
concentrations of the test compounds, spanning at least three orders of magnitude (0.3 – 300 
μM). The concentration of the test compounds used in this study were 0.3 μM, 1 μM, 3 μM, 
10 μM, 30 μM, 100 μM and 300 μM. The final volume of the incubations was 500 μL. The 
stock solutions of the inhibitors were prepared in DMSO and were added to the incubation 
mixtures to yield a final DMSO concentration of 4 % (v/v) as concentrations higher than 4 % 
are reported to inhibit MAO-B.
48
 The reactions were incubated at 37 ºC for 10 minutes and 
then terminated by the addition of 10 μL perchloric acid (70 %). The samples were 
centrifuged at 16,000 g for 10 minutes, and the concentrations of the MAO-B generated 
product, MMDP
+
,
49
 were measured spectrophotometrically at 420 nm (ε = 25,000 M-1) in the 
supernatant fractions. 
The enzyme inhibition activities of the test compounds were determined using equation 2 to 
calculate the inhibition potencies of the compounds. These potencies are expressed as 
percentage inhibition (% inh) of the enzyme. In determining these values, the concentration 
of MMDP
+
 produced in the absence of a test compound (C0) and the concentration of 
MMDP
+
 produced by MAO-B in the presence of a maximal concentration of the test 
compound (C300) were utilised. All determinations were conducted in duplicate, yielding the 
percentage inhibition as an average of the two sets of data. 
% inhibition = 100 – [(C300 x 100)/C0]        -       Equation 3 
 
3.4.4. Molecular modeling 
Computer-assisted docking were carried out using the CHARMm force field and the human 
MAO-B crystal structure (PDB ID: 2V5Z)
37
, which were recovered from the Brookhaven 
Protein Database (www.rcsb.org/pdb). Docking simulations were performed on the 
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synthesized compounds (9-16) using Molecular Operating Environment (MOE)
36
 with the 
following protocol. (1) Enzyme structures were checked for missing atoms, bonds and 
contacts. (2) Hydrogen atoms were added to the enzyme structure. Bound ligands were 
manually deleted and the ordered water molecules including 58W and 47W retained 
(important for the formation of a triad [Lys-H2O-flavin N(5)] and the hydrophilic section 
required for recognition and directionality of the substrate amine functionality)
50
 as seen with 
safinamide (Fig. 4). (3) The ligand molecules were constructed using the builder module and 
were energy minimized. (4) The active sitewas generated using the MOE-Alpha Site Finder. 
(5) Ligands were docked within the MAO-B active site using MOEDock with simulated 
annealing utilised as the search protocol and CHARMm molecular mechanics force field. (6) 
The lowest energy conformation of the docked ligand complex was selected and subjected to 
a further energy minimization using CHARMm force field with all possible bond rotations 
and chiralities explored. To determine the accuracy of this docking protocol, the co-
crystallised ligand, safinamide (PDB ID: 2V5Z), was re-docked into the MAO-B active site. 
This procedure was repeated three times and the best ranked solutions of safinamide 
exhibited an RMSD value of 1.34 Å from the position of the co-crystallised ligand. In 
general, RMSD values smaller than 2.0 Å generally indicate that the docking protocol is 
capable of accurately predicting the binding orientation of the co-crystallised ligand
50,51
. This 
protocol was thus deemed to be suitable for the docking of inhibitors into the active site 
model of MAO-B. 
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Abstract 
The multifactorial pathophysiology of neurodegenerative disorders remains one of the main 
challenges in the design of a single molecule that may ultimately prevent the progression of 
these disorders in affected patients. In this article, we report on twelve novel polycyclic 
amine cage derivatives, synthesized with or without a propargylamine function, designed to 
possess inherent multifunctional neuroprotective activity. The MTT cytotoxicity assay results 
showed the SH-SY5Y human neuroblastoma cells to be viable with the twelve compounds, 
particularly at concentrations less than 10 μM. The compounds also showed significant 
neuroprotective activity, ranging from 31% to 66% at 1 μM, when assayed on SH-SY5Y 
human neuroblastoma cells in which neurodegeneration was induced by MPP
+
. Calcium 
regulation assays conducted on the same cell line showed the compounds to be significant 
VGCC blockers with activity ranging from 26.6% to 51.3% at 10 µM; as well as significant 
NMDAr antagonists, with compound 5 showing the best activity of 88.3% at 10 µM. When 
assayed on human MAO isoenzymes, most of the compounds showed significant inhibitory 
activity, with compound 5 showing the best activity (MAO-B: IC50 = 1.70 µM). Generally, 
the compounds were about 3 – 52 times more selective to the MAO-B isoenzyme than the 
MAO-A isoenzyme. Based on the time-dependency studies conducted, the compounds can be 
defined as  reversible MAO inhibitors. Several structure activity relationships were derived 
from the various assays conducted, and the compounds’ possible putative binding modes 
within the MAO-B enzyme cavity were assessed in silico. 
 
Keywords: Neurodegeneration, apoptosis, neuroprotection, multifunctional, polycyclic 
amine, propargylamine, excitotoxicity, monoamine oxidase. 
 
4.1. Introduction 
Neurodegenerative disorders (NDs) refers to a cluster of neuronal diseases that are 
characterised by transient and irreversible loss of neuronal cells in the brain due to apoptosis 
[1]. Examples of these diseases include Alzheimer’s Disease (AD), Huntington’s Disease 
(HD) and Parkinson’s Disease (PD). Though the pathogenesis is yet to be fully understood, it 
is known that several factors are involved in the etiology of these disorders. Some of the 
established theories of disease causation include, but are not limited to, disturbances in 
neurotransmitter systems such as the monoaminergic system [2,3], as well as excitotoxicity 
resulting from excessive calcium influx into neuronal cells [4,5].  
http://etd.uwc.ac.za/
92 
 
Patients with PD and AD have been shown to have age-related elevated levels of the B-type 
monoamine oxidase isoenzyme (MAO-B) in the brain [6]. This enzyme does not only act 
indirectly as a trigger to the apoptotic process in neuronal cells, but together with the A-type 
isoenzyme (MAO-A), they form the major catabolic pathways of dopamine [7] and give rise 
to some of the signs and symptoms associated with these disorders [8].
 
Both these 
isoenzymes are therefore promising drug target sites for the treatment of NDs and as such, 
monoamine oxidase enzyme inhibitors (MAOI’s) have been the mainstay therapy for the 
management of NDs. By inhibiting the activity of the MAO isoenzymes, MAOI’s may exert 
neuroprotective effects by inhibiting the formation of toxic by-products of MAO-catalyzed 
oxidation of neurotransmitters [9]. Further to this, MAOI’s enhance dopaminergic 
neurotransmission in the nigro-striatal pathway, thereby providing symptomatic relief in 
patients with PD [10].  
The first generation of MAOI’s such as tranylcypromine are nonspecific and irreversible 
inhibitors of both isoforms of MAO. While these dual inhibiting compounds produce a 
significant rise in dopamine levels and behavioural changes after administration [11],
 
they 
present a drawback of causing clinically significant potentiation of the ‘pressor response’, a 
common adverse effect associated with ingesting tyramine containing foods together with 
nonspecific MAOI’s. Potentiation of this adverse effect is mainly influenced by the 
irreversibility of the inhibitor and the degree of MAO-A inhibition [12].
  
This has been shown 
to be due to MAO-A being the major form of MAO in the liver and stomach. Reversible 
inhibitors of MAO-A are therefore preferred to their irreversible counterparts as they show a 
reduced hypertensive response [13].
 
A more widely explored strategy entails selectively inhibiting the MAO-B isoenzyme by 
inhibitors such as rasagiline and selegiline (Figure 1). This approach is based on the fact that 
the extrapyramidal region of the human brain has approximately 4-times more MAO-B 
isoenzyme than the MAO-A isoenzyme [14]. Rasagiline and selegiline are second generation 
propargylamine derivatives that irreversibly inhibit brain MAO-B, and have promising 
neuroprotective activities [15]. Their activity can be attributed to the propargyl moiety [8], 
that after oxidation, reacts with the flavin prosthetic group in the active site of the MAO-B 
enzyme, forming a covalent adduct at the N5 position of the flavin adenine dinucleotide 
(FAD) [16]. The propargyl moiety is also now known to play an important role in providing 
neuronal and mitochondrial protective properties [17] as well as anti-apoptotic properties 
[18]. This moiety has been particularly useful for incorporation into multi-target compounds 
with inherent MAO-B inhibitory capacity [19].   
http://etd.uwc.ac.za/
93 
 
While inhibiting the oxidative deamination reaction catalysed by the MAO isoenzymes is a 
useful strategy in managing NDs, targeting a single enzymatic system or receptor has proved 
to be insufficient for the treatment of these multifactorial diseases [20]. A more effective 
therapy would result from the use of multi-target directed ligands (MTDLs) able to intervene 
in the different pathological events implicated in the etiology of neuronal disorders [21].  
Calcium homeostasis in neuronal cells has also been implicated in the pathogenesis of NDs. 
Given the crucial and widespread role calcium signalling has in excitable cells, it is not 
surprising that alterations in calcium homeostasis is linked to several NDs [22,23]. 
Maintenance of intracellular calcium homeostasis is essential for the functioning and survival 
of neurons and is a fundamental component of synaptic transmission for both pre- and 
postsynaptic mechanisms [24]. Excessive influx of calcium can therefore overwhelm Ca
2+
-
regulatory mechanisms and lead to excitotoxicity and neuronal cell death [25]. The activation 
of the postsynaptic N-methyl-D-aspartate receptors (NMDAr), 2-amino-3-(3-hydroxy-5-
methylisoxazol-4-yl)proprionate receptors and kainate receptors allows for opening of their 
associated ion channels to allow the influx of Ca
2+
 and Na
+
 ions into the neuronal cells. 
Calcium entry may also occur through L-type voltage gated calcium channels (VGCC) and 
result in both calcium overload and mitochondrial disruption [25]. This mechanism of cell 
death suggests these receptors and their associated calcium channels to be supplementary 
drug target sites for the treatment of NDs.  
Figure 1. The molecular structures of the selective MAO-B inhibitors selegiline and rasagiline, the VGCC 
blocker and NMDAr antagonist NGP1-01, compounds from a previous study P1 and P2, and the new series 
represented by compound 12, with the polycyclic scaffold, benzylamine and propargylamine moieties 
highlighted.  
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In our previous work [26], we designed and synthesized polycyclic propargylamines, 
represented by P1 and P2 (Figure 1), to serve as multifunctional drug ligands by inhibiting 
MAO-B enzyme activity, and as regulators of cytosolic calcium entry predominantly 
mediated by NMDAr and VGCC. While these compounds showed good in vitro anti-
apoptotic activity, they showed little to no MAO-B inhibitory activity and were inactive as 
NMDAr antagonist and VGCC blockers. These findings suggested that P1 and P2 exhibit 
their neuroprotective effect through some other mechanism(s) implicated in the complex 
etiology of neurodegeneration unexplored in the study. We further postulated that the lack of 
calcium regulatory activity in P1 and P2 was due to the absence of a benzylamine moiety 
within their structures. This moiety, which is present in structure of NGP1-01, a molecule 
known to have neuroprotective properties through VGCC blockade and NMDAr antagonistic 
activity [27], seems to be vital for calcium modulatory activity in such polycyclic analogues. 
It is for this reason that we incorporated a benzylamine moiety in the design of a new series 
of compounds reported in this current study (represented by compound 12, Figure 1).  
Further investigation to clarify the lack of MAO-B inhibitory activity in these compounds 
was carried out by performing computer-assisted simulated docking in the MAO-B enzyme 
(PDB ID: 2V5Z) [28], utilizing Molecular Operating Environment (MOE) as previously 
described [29]. The best-ranked docking solutions showed that compound P1 and P2 occupy 
only the entrance cavity of the MAO-B enzyme and barely access the substrate cavity to form 
the necessary binding interactions with the FAD cofactor, which could have resulted in 
increased activity of these compounds (Figure 2). With the inclusion of a benzylamine 
moiety in the structures of the new series of compounds, as seen in compound 12 (Figure 1 
and Figure 2), we envisaged better MAO-B inhibitory activity as this moiety significantly 
elongates the compound allowing the adjacent propargylamine moiety to come in close 
proximity to the FAD cofactor of the enzyme.  
  
http://etd.uwc.ac.za/
95 
 
Figure 2. Schematics showing inactive compound P1 (left) and a representative of the new polycyclic 
propargylamine derived series compound 12 (Right) in a computer simulated MAO-B enzyme cavity. The 
compounds are shown in yellow and the FAD co-factor in green. Note that compound P1 merely occupies the 
entrance cavity of the enzyme pocket and remains distant from the FAD co-factor rendering it inactive, while 
the new series traverses deeper into the enzyme cavity to come in close proximity with the FAD co-factor 
allowing for potential binding interactions which may result in improved MAO-B activity. 
The findings from our previous work have thus inspired the design, synthesis and evaluation 
of a new series of twelve pentacycloundecane and hexacycloundecane derivatives, 
synthesized with or without a propargylamine function. The compounds in this series, 
represented by compound 12 (Figure 1 and Figure 2), carry some or all of the following 
features; (a) a polycyclic cage scaffold - for side-chain attachment as well as for improving 
the drug’s lipophilicity [30] and enhance drug transport across cellular membranes, including 
the selectively permeable blood–brain barrier, and also to increase drug affinity for lipophilic 
regions in target proteins [30,31]; (b) a benzylamine moiety - as present in the structure of 
NGP1-01, for improved VGCC blockade and NMDAr antagonism [27]; (c) a propargylamine 
moiety - for inherent MAO inhibitory capacity and to provide neuronal and mitochondrial 
protective properties [17], as well as anti-apoptotic properties [18]; (d) an elongated 
orientation – resulting from the inclusion of a benzylamine moiety, to promote molecular 
interaction between the propargylamine function and the FAD cofactor of the MAO enzyme. 
Compounds that show such multi-mechanistic activity may have promising potential to 
curtail the multifactorial etiology of neurodegenerative disorders.  
The novel compounds were therefore synthesized and screened for cytotoxicity, 
neuroprotection, NMDAr antagonism and VGCC blockade by performing in vitro assays on 
human neuroblastoma SH-SY5Y cells. Further to this, in vitro assays on the human MAO–A 
and MAO–B enzymes were performed in order to determine their inhibitory potential on the 
respective isoenzymes. 
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4.2. Results and discussion 
4.2.1. Chemistry 
Each compound was synthesised to evaluate the activity and benefit of the presence of certain 
functional groups in the molecule. These groups included the following; a terminal 
propargylamine (5, 6, 9 and 12), a terminal secondary amine (1, 2, 4 and 10), as well as the 
ketal (1 - 6), aza (7 - 9) and oxa (10 - 12) variations of the polycyclic cage scaffold. The 
common starting Cookson’s diketone (a), was prepared according to the method of Cookson 
et al. [32] From the Cookson’s diketone, the monoprotected ketal polycyclic cage (b) was 
prepared according to the method of Dekker et al. [33] NGP1-01 was synthesized according 
to an adaptation of the microwave assisted method (MWAM) described by Joubert et al. [34] 
To synthesize the mono amine cage (c), debenzylation of NGP1-01 was carried out under 
high-pressure catalytic hydrogenation as reported by Marchand et al. [35] (Scheme 1).  
Compounds 1 – 12, were subsequently synthesized by direct conjugation of various 
analogues to the three polycyclic cage scaffolds (a – c) using microwave irradiation. 
MWAMs present several advantages which include; remarkable reduction of reaction time, 
improved yields, cleaner reactions and reduction or elimination of hazardous solvents 
compared to reactions performed under conventional thermal heating conditions [36,37]. As 
such, MWAMs have since been adopted by several researchers as the preferred strategy for 
the synthesis of these cage-derived organic compounds [34,38].  
The synthesis of compounds 1, 2 and 3 was performed by conjugating their respective 
primary diamines to the mono ketal polycyclic cage (b) through a direct amination reaction 
using microwave irradiation (Scheme 2). An excess amount of p-xylylenediamine (5.0 equiv) 
was used for the synthesis of compound 2 in order to promote the formation of a mono-
substituted amine, however, a significant percentage of the di-substituted derivative 3 formed 
during the reaction and was successfully isolated giving respective yields of 32% and 13%. 
The serendipitously synthesized compound 3 was also included in the series of compounds 
for screening of potential activity. Propargyl chloride was conjugated to compound 2 using 
MWAMs through an SN2 nucleophilic substitution reaction, in the presence of K2CO3, to 
produce compound 5. To synthesize compounds 4 and 6, reductive amination of the imines 2 
and 5 was carried out using NaBH4. A comparison of the biological activities of these four 
compounds provides insight on the influence of the imine bond on their activity. The 
reduction of the imines 1 and 2 with NaBH4, followed by acid hydrolysed transanular 
cyclization using HCl, gave the desired aza-bridged compounds 7 and 8 respectively. 
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Propargyl chloride was conjugated to compound 8 through a nucleophilic SN2 substitution 
reaction using MWAMs to yield compound 9 (Scheme 2). 
Compound 10, which is an oxa analogue and structural isomer of 7, was synthesized by 
conjugating 4-amino benzylamine to the Cookson’s diketone (a), followed by reduction with 
NaBH4 (Scheme 3). A microwave assisted nucleophilic SN2 substitution reaction was 
employed to conjugate the mono amine cage (c) to p-xylylene dichloride to yield compound 
11 and to conjugate propargyl chloride to 11 and yield final compound 12 (Scheme 3). 
Compounds 1, 7 and 10 were synthesized to serve as intermediates to potential subsequent 
propargyl derivatives. However, due to the low reactivity of the aniline amine, reactions with 
halopropargyls in the form of propargyl chloride and propargyl bromide could not yield the 
desired derivatives. All compounds (1 – 12) were protected from light after synthesis and 
were appropriately stored at -84 °C to prevent degradation. 
 
Scheme 1: Reagents and conditions for the synthesis of diketone (a), ketal (b) and monoamine (c) polycyclic 
scaffolds: (i) benzene, 0 °C, 1 h, 74%; (ii) benzene, p-TsOH (cat), Dean–Stark reflux, 5 h, 72%; (iii) ethanol, 
MW, 80 °C, 100 W, 100 psi, 2 h, quantitative yield; (iv) ethanol, NaBH4, rt, 8 h, 62%; (v) ethanol, 10% Pd/C, 
H2, 206 kPa, 50 °C, 14 h, 32%.  
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Scheme 2: Reagents and conditions for the synthesis of ketal- and aza-polycyclic derivatives (compounds 1 – 
9): (i, a: n = 0) ethanol, MW, 80W, 150 psi, 100 °C, 30 min, 65%; (i, b: n = 1) ethanol, rt 1 h, then MW, 60 W, 
80 psi, 100 °C, 3 h, 32%; (i, c) ethanol, rt 1 h, then MW, 60 W, 80 psi, 100 °C, 3 h, 13%; (ii) acetonitrile, 
K2CO3, 60 °C, 4 h, 21%; (iii) ethanol, NaBH4, rt, 8 h, 72%; (iv) ethanol, NaBH4, rt, 8 h, 69%; (v) acetone, 4 M 
HCl, rt, 12 h, 42% and 78%; (vi) acetonitrile, K2CO3, MW, 60 W, 60 °C, 2.5 h, 18%. 
Scheme 3: Reagents and conditions for the synthesis of oxa-polycyclic derivatives (compounds 10 – 12): (i) 
ethanol, MW, 100 W, 100 psi, 80 °C, 2 h; (ii) ethanol, NaBH4, rt, 8 h, 32%; (iii) acetonitrile, K2CO3, MW, 150 
W, 20 psi, 70 °C, 1 h, 19%; (iv) acetonitrile, K2CO3, MW, 150 W, 20 psi, 70 °C, 1 h, 21%. 
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Characterization of all the compounds was carried out by means of 
1
H-, 
13
C-NMR, IR and 
HREI-mass spectra. A common structural feature in all the synthesized compounds was the 
polycyclic cage moiety. This structural moiety showed characteristic signal peaks on the 
1
H-
NMR spectra which included a characteristic AB quartet signal, due to the two 
unsymmetrical protons on the bridgehead. This signal appeared at a chemical shift in the 
range of δ 1.10–1.91 ppm, with a coupling constant in the range of 10.6–10.8 Hz. The rest of 
the protons making up the polycyclic cage appeared as multiplets or groups of multiplets, 
apparent quartets, and apparent triplets in the range of δ 2.30–3.00 ppm. These signals 
confirmed the presence of the polycyclic scaffold in the compound structures [38]. 
All ketal derivatives (1 – 6) showed a characteristic multiplet signal in the range of δ 3.70–
3.95 ppm, owing to the four protons on the ketal carbons. In compounds were the polycyclic 
cage scaffold was linked to the rest of the molecule via a rigid imine bond (1, 2, 3 and 5), the 
ketal moiety seemed to influence the signal of the two protons of the -N-CH2- linker by virtue 
of long-range coupling. Due to this coupling, the two protons appeared on the 
1
H-NMR 
spectra as apparent doublet of doublets at about δ 4.30–4.60 ppm, with a coupling constant of 
3.2 Hz. When the imine bond was reduced to a rotatable amine bond, in the case of 4 and 6, 
this coupling effect was lost and the signal appeared as a multiplet at an upfield shift of about 
δ 3.95 ppm.  
A typical signal for the presence of the aza-cage moiety (7 – 9), was a triplet at a chemical 
shift in the range of δ 3.21–3.95 ppm, with coupling constants in the range of 4.8–5.2 MHz. 
This triplet corresponded to the single proton at the -CH-N- position, and its multiplicity is 
attributed to the presence of two protons at the adjacent carbons atoms within the polycyclic 
cage [38].
 
In the case of the oxa-cage moiety (10 – 12), this triplet signal was at a range of 
about δ 4.65–4.73 ppm with a coupling constant in the range of 4.8–5.0 Hz. The downfield 
shift of this methine hydrogen resulted from the deshielding effect of the adjacent oxygen 
atom. This downfield shift, compared with that of its aza analogues, is attributed to the 
electronegativity difference between nitrogen and oxygen, and thus, an increased deshielding 
effect compared to the aza derivatives. 
 
The presence of a propargyl moiety in the structures of compounds 5, 6, 9 and 12 was 
confirmed by a characteristic 
1
H-NMR triplet at a chemical shift in the range of δ 2.20–2.30 
ppm, with a coupling constant of about 2.4 Hz. This triplet corresponds to the terminal 
acetylene proton and its multiplicity is attributed to the neighbouring methylene protons 
which influence it via long-range coupling. The terminal acetylene proton equally influenced 
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the two symmetrical methylene protons, which form part of the propargyl moiety, to appear 
as a doublet in the range of δ 3.40–3.50 ppm, with a coupling constant of about 2.4 Hz.  
Further characterization of these compounds was carried out by means of 
13
C-NMR, IR and 
HREI-mass spectra, which all supplemented the 
1
H-NMR spectra findings, further 
confirming the structures of the compounds.  
 
4.2.2. Cytotoxicity 
Compounds 1-12 were assayed for cell viability on SH-SY5Y human neuroblatoma cells 
using a standard 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay 
method [39]. The results are depicted in Figure 3 and Table 1. This assay, which measures 
cell metabolic activity, was used to determine the cytotoxicity of the test compounds at 10 
µM, 50 µM and 100 µM concentrations. The cells were exposed to test compounds for 48 
hours, after which cell viability was determined spectrophotometrically. Vehicle control cells 
were treated with dimethyl sulfoxide (DMSO, solvent for dissolving test compounds) and 
served as a reference for 100% cell viability. NGP1-01, known to have neuroprotective 
properties [27], was also used as a reference control for relative comparison. 
Figure 3. Percentage cell viability of compounds 1-12 assessed by means of measuring the metabolic activity of 
SH-SY5Y neuroblatoma cells, after 48 h exposure to test compound, relatcive to a control of untreated viable 
cells. Data are mean ± SEM (n = 3, four fields per repeat). Data were subjected to an ANOVA statistical 
analysis and significance was defined as [(*) p < 0.05, (**) p < 0.001, (***) p < 0.0001]. 
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The results from this assay suggested the SH-SY5Y human neuroblastoma cells to be viable 
with the test compounds, particularly at 10 μM, as none of the compounds showed 
statistically significant cytotoxicity on the cell line at this concentration (Figure 3). 
Percentage cell viability at this concentration ranged from 84% to 116% relative to the 
untreated control. This was comparable to NGP1-01, which was found to be 86% viable at 
the same concentration. The influence of the propargyl moiety was evident at higher 
concentrations of test compound as seen when comparing the propargyl containing 
compound 5, which was 99% viable at 100 μM, with its precursor devoid of this moiety, 
compound 2, which was only 32% viable at the same concentration. This observation 
suggests compound 2 to be 3-times more toxic than its propargyl containing derivative. The 
same observation was made when comparing compound 6, which was 70% viable at 100 μM, 
to its precursor compound 4, which was only 5% viable at the same concentration, suggesting 
the inclusion of a propargyl moiety to be responsible for a 14-fold decrease in cytotoxicity. 
 
4.2.3. Neuroprotection 
The SH-SY5Y cytotoxicity assay results were used to determine the test concentration of 
compounds 1-12 which would insignificantly affect the viability of the SH-SY5Y cells. 
Based on the SH-SY5Y cytotoxicity analysis, it was decided to conduct the neuroprotection 
studies at test concentrations between 1 μM and 10 μM, in order to maintain cell viability. 
In this study, we employed a widely used cellular model in which neurotoxicity was induced 
by 1-methyl-4-phenyl pyridinium (MPP
+
) in SH-SY5Y neuroblastoma cells [40,41]. MPP
+
 is 
highly toxic to neurons and has been widely used to induce neurodegeneration in various in 
vitro and in vivo models [40,41]. Several signaling pathways have been suggested to be 
responsible for MPP
+
-mediated neurotoxicity in SH-SY5Y cells, for instance, trigger of 
oxidative stress [42], induction of apoptosis [43], and inactivation of pro-survival 
phosphoinositide 3-kinase (PI3-K)/Akt cascade [44,45]. This assay was deemed appropriate 
to test for initial neuroprotective ability of the compounds because of the multitude of 
pathways involved in MPP
+
 mediated neurotoxicity and the potential multifunctional 
inhibitory abilities of the test compounds. 
Briefly, the assay entailed treating the SH-SY5Y cell line with different concentrations (1 
μM, 5 μM, 10 μM) of test compounds two hours prior to MPP+ treatment. After 48 hours of 
incubation, the neuroprotective effect of the compounds was assessed by means of the MTT 
mitochondrial function assay which measured cell viability. Vehicle control cells were 
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treated with DMSO (solvent for dissolving test compounds) and served as a reference for 
100% cell viability. Percentage neuroprotection values were calculated as the difference 
between the final percentage cell viability of the test compound treated cell line and that of 
the MPP
+ 
only treated cell line. These values are presented in Figure 4 and Table 1. NGP1-
01, known to have neuroprotective properties [27], was also used as a reference control for 
relative comparison.  
As illustrated in Figure 4, after the exposure to 1000 μM MPP+ for 48 hours, the cell viability 
declined significantly to around 45%.  However, its cytotoxic effects were significantly 
ameliorated in the presence of the test compounds at 1 µM, 5 µM and 10 µM concentrations. 
All compounds in the series exhibited significant neuroprotective effects at a 1 μM 
concentration as they managed to improve cell viability to values between 86% and 110%. 
This was expected from these compounds as they all share molecular similarities with NGP1-
01 which is known to have neuroprotective properties as confirmed in this assay [27]. At 5 
µM and 10 µM a slight decrease in cytoprotection was observed for most of the compounds. 
This may indicate that the neurotoxin challenged state of the SH-SY5Y cells may be more 
sensitive to the cytotoxic effect of the test compounds at higher concentrations. 
Figure 4. The effects of compounds 1-12 on MPP+-induced (1000 μM) cytotoxicity in SH-SY5Y cells. The 
viability of the untreated control was defined as 100%. MPP+ without test compound showed a significant 
decrease in cell viability relative to the control (#, p < 0.05). Data are mean ± SEM (n = 3, four fields per 
repeat). The level of statistical significance for the test compounds is set at * p < 0.05 compared to the MPP+ 
only treated control. Tukey's multiple comparisons statistical analysis was performed on all raw data and 
significant neuroprotective effect was defined as [(*) p < 0.05, (**) p < 0.01, (***) p < 0.001, (****) p < 
0.0001]. 
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4.2.4. VGCC assay 
To investigate the test compounds’ potential VGCC blocking effect, we developed an assay 
based on the methods described by Young et al. [46] and León et al. [47] Briefly, SH-SY5Y 
human neuroblastoma cells loaded with the ratiometric fluorescent calcium indicator, Mag-
Fura-2/AM, were incubated at 37 ºC in the presence of the test compounds at a 10 µM 
concentration for 30 mins, then stimulated with a concentrated solution of KCl to allow 
opening of the calcium channels. The assay was performed at a 10 µM concentration as 
determined by the cytotoxicity assay performed on the same cell line. Changes in 
fluorescence as a consequence of an increase in cytosolic calcium elicited by high K
+
 
concentrations were measured in a Biotek
®
 fluorescent microplate reader. Two positive 
controls were included in the VGCC assay; nimodipine, a commercially available 
dihydropyridine L-type calcium channel blocker [48], and the prototype polycyclic amine 
cage compound, NGP1-01 [49]. The percentage VGCC blockade of each compound was 
calculated relative to the activity of nimodipine and the data is presented in Table 1.  
Based on the assay results, all compounds, except 3, 6 and 10, showed significant VGCC 
inhibitory activity; ranging from 26.6% to 51.3%, relative to a 10 µM solution of nimodipine. 
This activity is comparable to that of NGP1-01, which inhibited calcium influx by 25.7% at 
the same concentration. This general improvement in activity, compared to P1 and P2 which 
were inactive as VGCC blockers at 100 µM [26], emphasizes the need to include a 
benzylamine moiety in the structure of polycyclic amine cage derived compounds designed 
for VGCC blockade as we previously postulated [26].  
It seems that a primary terminal amine imparts the molecules with increased VGCC 
inhibition. This was seen in compounds 1, 2, 4, 7 and 8, which showed activities of 40%, 
35%, 43%, 36% and 51% respectively, a significant improvement to the activity noted for 
NGP1-01. When this primary amine terminal was converted to a secondary amine, by 
conjugating a propargyl moiety, in the case of compounds 5, 6 and 9, the VGCC inhibitory 
activity notably decreased to 26%, 22.9% and 39% respectively, when compared to their 
primary amine carrying precursors (2, 35%; 4, 43% and 8, 51%). A terminal primary amine 
could be necessary for the formation of productive binding interactions between the 
respective compounds and the binding site of the VGCC resulting in their blockade. 
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4.2.5. NMDA assay 
To assess the compounds’ ability to block Ca2+ influx via the NMDAr channels, a similar 
method as in the VGCC assay was used. However, a concentrated NMDA/Glycine solution, 
instead of KCl, was used to stimulate calcium flux through the NMDAr. Two positive 
controls were included in this assay; MK-801, a commercially available non-
competitive antagonist of the NMDAr [50], and NGP1-01 [49]. All compounds were assayed 
at 10 µM and the percentage NMDAr inhibition of each compound was calculated relative to 
the activity of MK-801. The calculated percentage inhibition values are presented in Table 1.  
Several compounds showed great NMDAr antagonism, with compound 5 showing the 
highest activity of 88.3%. Compounds 1, 3 and 6 also showed good activity with percentage 
inhibition values of 63.1%, 70.5% and 63.9% respectively. These four compounds, as well as 
compound 2, which showed significant activity of 49.5%, showed NMDAr antagonism 
comparable to NGP1-01, which exhibited 32.5% inhibition at the same concentration. A 
common structural feature of these five compounds is a ketal moiety which seemed to be 
important for increased NMDAr antagonism. This observation was more compelling when 
considering that compounds 9 and 10, which were devoid of this functional moiety, were 
both inactive; as well as compounds 7 and 11, which also lacked the ketal moiety, showed 
statistically insignificant activity of 11.9% and 26.1% respectively. The ketal moiety could be 
providing necessary bulk and charge which could allow for productive ligand-NMDAr 
binding interactions. Further mechanistic studies could provide further insight on the putative 
binding mode of these compounds.   
The inclusion of a propargyl moiety in the compound structures seemed to contribute to 
improved NMDAr antagonism. This was evident when comparing the propargyl carrying 
compounds 5 and 6, which were 88.3% and 63.9% active respectively, to their precursor 
compounds 2 and 4, devoid of this moiety, which were 49.5% active and inactive 
respectively. An imine bond between the polycyclic cage and the benzylamine moiety, as 
seen in compounds 2 and 5, seemed to be ideal for NMDAr inhibitory activity compared to 
the simple amine bond contained in the structures of compounds 4 and 6. When the imine 
bond in compound 2 is reduced to a simple amine bond in compound 4, the NMDAr 
antagonistic activity was completely lost. Similarly, there was about 25% decrease in activity 
when the imine bond in compound 5 was reduced to afford compound 6. The rigid imine 
bond seemed to be ideal for NMDAr inhibition. A probable explanation for this could be that 
the rigid ligand confirmation allows the compounds to adequately traverse the ligand-
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recognition region of the NMDAr subunit which is defined by two polypeptide segments, S1 
and S2 [51]. 
Generally, these compounds seem to possess calcium regulatory potential comparable to the 
prototype NGP1-01 by acting on both VGCC and NMDAr. However, the compounds 
appeared to be more active as NMDAr antagonists than they are VGCC blockers. 
 
4.2.6. MAO-A and MAO-B inhibition studies 
The target compounds were investigated for their inhibitory activity against human MAO 
(hMAO) by measuring the extent to which the test compounds reduce the oxidative catalysis 
of kynuramine, a mixed MAO-A/B substrate, by the respective MAO enzymes [52]. The 
fluorescence of the MAO generated 4-hydroxyquinoline in the supernatant fractions were 
measured using a Biotek
®
 fluorescent microplate reader at an excitation wavelength of 310 
nm and an emission wavelength of 400 nm. IC50 values were calculated as the compound 
concentration that produces 50% enzyme activity inhibition. The inhibition potencies of the 
test compounds and reference compounds, selegiline and clorgyline, are presented in Table 1.  
Based on the results, most of the active compounds displayed higher inhibitory potencies 
against the MAO-B compared to the MAO-A isoenzyme as suggested by the selectivity index 
(SI) values. The only exception was compound 10, which showed selectivity to the MAO-A 
isoenzyme. The ketal moiety seemed to be influential in conferring the molecules MAO-B 
selectivity as observed from the high SI values of compounds 1, 2, 5 and 6, which all carry 
this moiety. These compounds were about 3 to 52 times more selective to the MAO-B 
compared to the MAO-A isoenzyme. Conversely, compounds 9 and 12, though devoid of the 
ketal moiety, also showed selectivity to MAO-B with SI values of 14.8 and 3.6 respectively. 
Several structure activity relationships could be derived from comparing the MAO IC50 
values of the various compounds in the series. Interesting to note, was that the 
propargylamine carrying compounds 5, 6, 9 and 12 showed MAO-B inhibition values which 
ranged between 1.7 µM and 36.31 µM (IC50). This was a significant improvement from the 
activities shown by the previously reported compounds P1 and P2, which were inactive as 
MAO-B inhibitors [26]. This improved activity can be attributed to the increased molecular 
length of these compounds as a result of the incorporation of a benzylamine moiety into their 
structures.  
The data from this study suggests the juxtapositioned benzylamine and propargyl moieties 
are imperative in rendering the compounds better MAO-B inhibitory activity. This 
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observation was noted by comparing the activity of compounds 4 and 8, which both lacked 
the propargyl moiety but carried the benzylamine moiety, to the activity of compounds 6 and 
9, with both moieties. Compounds 4 and 8 showed IC50 values of more than 100 µM, while 
compounds 6 and 9 showed values of 36.31 µM and 3.89 µM respectively. It is important to 
note that when the benzylamine moiety is absent in the molecular structure of these 
compounds, as in the case of P1 and P2, the propargylamine moiety alone fails to render 
significant activity on the MAO-B enzyme, thus further supporting the need for both moieties 
in the structures of these type of compounds for activity.  
Table 1: The biological activity profiles of compounds 1-12 and related reference compounds.  
Compound Cell 
Viability 
%
 
Neuro-
protection 
%
a 
   VGCC 
       % 
  NMDA 
      % 
MAO- A
 
 
MAO-B
 
 
SI  
MAO-B
b 
10 μM 1 μM 10 μM    10 μM IC50 µM IC50 µM  
Selegiline -       -         -         - - <10 nM - 
Clorgyline -       -         -         - <10 nM - - 
MK-801 -       -   Inactive
 
      100.0 - - - 
Nimodipine -       -      100.0    Inactive - - - 
NGP1-01   86 ± 7.8  66 ± 6.9**** 25.7 ± 9.2*  32.5 ± 9.9* >100 >100 - 
P1
[26]
         -       -   Inactive    Inactive - Inactive - 
P2
[26]
         -       -        18
          4 -       6%
 
- 
1 97 ± 7.9 59 ± 7.2**** 40.1 ± 3.1***  63.1 ± 11.3**** >100     1.91**
 >52.4 
2   96 ± 11.4 60 ± 1.3**** 35.0 ± 10.2**  49.5 ± 6.0** >100   13.80*
 >7.2 
3 88 ± 6.8 61 ± 5.9**** 24.3 ± 15.7  70.5 ± 4.2*** >100 100 - 
4   84 ± 12.0 54 ± 8.5**** 43.2 ± 3.9***     Inactive >100 >100 - 
5 114 ± 25.3 53 ± 3.5**** 26.6 ± 3.9*  88.3 ± 7.9**** >100      1.70* >58.8 
6 116 ± 10.4 38 ± 9.4** 22.9 ± 5.5  63.9 ± 13.4
** >100    36.31* >2.8 
7 101 ± 6.0 31 ± 13.0* 36.5 ± 8.2***   11.9 ± 7.8 >100 >100 - 
8 107 ± 5.5 46 ± 13.2*** 51.3 ± 10.4**** 59.0 ± 4.7**** >100 >100 - 
9   98 ± 14.2 43 ± 9.2*** 39.4 ± 8.0***    0.6 ± 8.1 56.23 3.80*
 14.8 
10 104 ± 13.4 46 ± 1.2****   7.6 ± 1.3    Inactive     2.37
** 100 0.02 
11 98 ± 2.7 48 ± 4.1**** 31.6 ± 1.7**  26.1 ± 2.0 >100 14.13**
 7.08 
12 116 ± 18.8 54 ± 7.8**** 29.1 ± 5.8**  31.4 ± 6.8*    >100 28.18**
 3.55 
 
By comparing derivatives 5 and 6, whose IC50 values were 1.70 µM and 36.31 µM 
respectively, the influence of the imine bond between the polycyclic scaffold and the 
benzylamine moiety could be appreciated. This bond seemed to confer compound 5 a 16-fold 
increase in activity when compared to compound 6, in which the imine bond was reduced to a 
secondary amine. The same was true for the precursors of compounds 5 and 6, compounds 2 
(imine) and 4 (amine), whose IC50’s were 13.8 µM and >100 µM respectively. Perhaps this is 
because the imine bond, present in compounds 2 and 5, is more rigid than the rotatable amine 
bond present in compounds 4 and 6, thus allowing compounds 2 and 5 to be confined to a 
fixed region of the MAO-B enzyme active site allowing for more productive binding 
interactions.   
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When compound 2 is di-substituted with the ketal-polycyclic moiety to give compound 3, 
MAO-B inhibitory activity is lost. The di-substituted molecule appears to be bulky and 
probably fails to make access into the enzyme active pocket, rendering it inactive. The 
absence of a propargyl function within the structure of compound 3 further explains the lack 
of MAO inhibition observed from this compound. 
NGP1-01 showed little activity on both MAO-A and MAO-B enzymes, IC50 >100 µM on 
both isoenzymes, but when para-substituted with a primary amine to give compound 10, 
MAO-A inhibition improved (IC50 = 2.37 µM). This improved activity may be due to the 
involvement of the amine group in the formation of binding interactions with amino acid 
residues found in the substrate cavity of the MAO-A enzyme. Contrary to this, compound 4, 
which was also para-substituted with a secondary amine, showed little activity on the MAO-
A isoenzyme. This could be due to the presence of the bulk ketal moiety attached to the 
polycyclic cage scaffold, which may be hindering the entrance of the molecule into the 
enzyme substrate cavity. It is important to note that all ketal derivatives 1 – 6 showed little 
activity on the MAO-A isoenzyme of IC50 > 100 µM. 
In general, compounds 1, 2, 5, 6, 9 and 12 showed the best overall MAO inhibitory activity 
and appear to be selective for the MAO-B isoenzyme. Although the MAO-B inhibitory 
activity herewith reported was a significant improvement in comparison to the previously 
reported compounds P1 and P2, it is important to note that this activity was still about 1000-
fold weaker than selegiline. Further structural modifications of these compounds may 
therefore be necessary to afford molecules which may potentially show improved MAO-B 
inhibition. 
 
4.2.7. MAO reversibility studies 
To determine the binding mode of the studied compounds on MAO-A and/or -B, a time 
dependency of enzyme inhibition was measured. If the compounds form a covalent adduct 
with the enzyme, a time-dependent reduction of enzyme activity would be expected. In this 
regard, the time dependent inhibition of MAO-A and-B by the active compounds 1, 5, 6, 9 
and 12, were evaluated (Figure 5). Briefly, recombinant human MAO-A and MAO-B was 
preincubated with the test compounds for periods of 0, 15, 30 and 60 min prior to starting the 
enzyme reaction and the residual rates of the MAO-A and -B catalysed oxidation of 
kynuramine were measured. For this purpose, the concentrations of the test compounds 
chosen were approximately twofold the measured IC50 values for the inhibition of the 
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respective enzymes. Clorgyline, with known irreversible inhibition for MAO-A [53], and 
selegiline, with known irreversible inhibition for the MAO-B [54], were used as a reference 
compounds. 
As shown in Figure 5, only compound 9 showed a significant reduction in enzymatic activity 
with increased preincubation time when assayed on the MAO-A isoenzyme, suggesting 
compound 9 to be an irreversible inhibitor of MAO-A. MAO-B enzyme activity was not 
reduced by compounds 1, 5, 6, 9 and 12 with increased preincubation time. This indicates 
that the selected compounds were reversible inhibitors of MAO-B. Preliminary MAO-A 
molecular modelling studies performed on compound 9 (data not shown) showed potential 
involvement of the free hydroxyl group attached to the polycyclic moiety in forming covalent 
binding interactions with amino acid residue Gln215 of the MAO-A substrate cavity. This 
interaction could be the explanation for the observed irreversible MAO-A inhibition 
exhibited by compound 9. No covalent interactions were observed between compound 9 and 
the MAO-B isoenzyme (see Figure 7), perhaps explaining the reversible MAO-B inhibition 
observed for compound 9. It also was interesting to note that compounds 1 and 5 showed a 
notable increase in enzymatic activity over time. This might be due to test compound 
degradation in the aqueous medium as both compounds possess a ketal moiety as well as an 
imine bond. The imine function is known to undergo hydrolysis in aqueous medium [55], 
however, further degradation studies on these compounds are necessary to validate this 
notion. 
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Figure 5. Time-dependent inhibition of the recombinant human MAO-A (top) and MAO-B (bottom) catalysed 
oxidation of kynuramine by the selected active compounds. The enzymes were preincubated for various periods 
of time (0–60 min, x-axis) Data are expressed as the mean RFU (relative fluorescent units) ± SEM of three 
independent experiments. 
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4.2.8. MAO-B molecular modelling studies 
With most compounds showing selectivity for the MAO-B isoenzymes, the binding modes of 
all twelve compounds in the MAO-B substrate cavity were examined in silico. Docking 
simulations were performed on the human MAO-B crystal structure (PDB ID: 2V5Z) [28],
 
using the Molecular Operating Environment (MOE) software [29]. In general, the amino acid 
residues between 120 and 220, as well as the FAD cofactor, are important in conferring 
substrate selectivity of MAO-B [56], most importantly residues Ile-199, situated in the 
entrance cavity, and Gln-206, situated in the substrate cavity. Interaction with these amino 
acid residues may confer a compound MAO-B inhibitory activity as shown by safinamide 
(Figure 6), a known MAO-B inhibitor. 
Figure 6. The putative binding modes of safinamide within the human MAO-B enzyme active site. Safinamide 
and the FAD cofactor are shown in the docking simulation on the left as bold lines (indicated in yellow and 
green respectively), and the binding interactions with the amino acid residues shown on the right. Safinamide 
shows productive interactions with amino acid residues Ile-199 and Gln-206. 
The docking simulation results generally showed that the lipophilic polycyclic cage unit, 
carried by all the test compounds, stabilized within the hydrophobic environment of the 
enzymes entrance cavity, while the rest of the molecular structure traversed deep into the 
substrate cavity (see Figure 7). Further analysis of the best-ranked docking solutions showed 
all active compounds to be forming productive binding interactions with the MAO-B 
substrate cavity. Interestingly, most of the active compounds, particularly compounds 1, 2, 5, 
9, 11 and 12, seemed to be forming binding interactions specifically with Ile-199, an 
observation which could explain their noted in vitro activity. The electron-rich π system, 
presented by the aromatic ring within these compounds’ structures, appeared to be vital for 
the formation of ‘arene-hydrogen’ interactions with the amino acid Ile-199. 
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Figure 7: MOE generated binding interactions of compounds 1, 2, 5, 6, 9 and 12 with the respective amino acid 
residues within the human MAO-B enzyme active site. 
In the case of compounds 1 and 2, the ketal moiety also seemed to be involved in the 
formation of binding interactions with Ile-199. This interaction may be due to the 
electronegative oxygen atom which creates a slightly positive environment on the adjacent -
CH2 group causing it to serve as a proton donor to the amino acid residue. While the aromatic 
system and ketal moiety seemed to be important for the formation of productive interactions 
with the enzyme cavity, it appeared as though these interactions were dependent on the 
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presence of an imine bond between the polycyclic cage and the benzylamine moiety. This 
was evident when comparing binding interactions observed for compounds 1, 2 and 5, which 
all carried this bond and showed interactions with Ile-199, to the binding interactions 
observed for compounds 4 and 6, which lacked this bond and hence failed to interact with Ile-
199. This observation suggests the imine bond to be important for stabilizing the molecules’ 
benzylamine moiety within the MAO-B enzyme cavity, thus allowing for the formation of 
productive binding interactions. The observation correlates with the observed in vitro activity 
of compounds 1, 2 and 5, which all showed significant MAO-B inhibition of IC50: 1.91 µM, 
13.80 µM and 1.70 µM, respectively. While compound 6, shows no interaction with Ile-199 
due to the absence of an imine linkage, the compound remains active due to the presence of a 
propargylamine group which forms interactions with the FAD cofactor.  
The inactive compounds 7, 8 and 10, the oxa- and aza-type derivatives with a terminal 
primary amine group, showed no interaction with any amino acid residues within the MAO-B 
active site. This observation may be the explanation to these compounds’ lack of activity. 
Interesting to note was that when the secondary amine group was conjugated to a propargyl 
function, as seen in compound 9, the resultant compound showed interactions with Ile-199 
and the FAD cofactor. The role of the propargyl moiety seems to be particularly important 
for MAO-B inhibitory activity as suggested by the in vitro activities of compounds 5, 6, 9 
and 12 (IC50: 1.70 µM, 36.31 µM, 3.80 µM and 28.18 µM, respectively). Molecular 
modelling findings showed the propargyl moieties of these four compounds to either be in 
close proximity to the FAD cofactor, in the case of compounds 5 and 12, or to be forming 
binding interactions with the FAD cofactor, in the case of compounds 6 and 9. 
 
4.3. Conclusion 
We have successfully designed and synthesized twelve novel pentacycloundecane and 
hexacycloundecane derived compounds which showed promising neuroprotective potential. 
Regarding cytotoxicity, the SH-SY5Y human neuroblastoma cells seemed to be viable with 
all the test compounds, particularly at 10 μM, as none of the compounds showed statistically 
significant cytotoxicity at this concentration. At a 1 µM concentration, the compounds 
significantly improved the viability of SH-SY5Y neuroblastoma cells, previously exposed to 
the neurotoxin MPP
+
, from about 45% to values between 86% and 110%.  
Most of the compounds, except 3, 6 and 10, showed statistically significant VGCC inhibitory 
activity ranging from 26.6% to 51.3%, relative to a 10 µM solution of nimodipine. This was 
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comparable to that of NGP1-01, which inhibited calcium influx by 25.7% at the same 
concentration. Compounds 1, 2, 3, 5, 6, 8 and 12, showed significant NMDAr inhibitory 
activity ranging between 31.4% and 88.3%, relative to a 10 µM solution of MK-801. 
When assayed for MAO inhibition, most of the active compounds (1, 2, 5, 6, 9, 11 and 12) 
displayed selectivity to the MAO-B isoenzyme with IC50 values ranging from 1.70 µM to 
36.31 µM, with the only exception being compound 10, which showed selectivity to the 
MAO-A isoenzyme. The most active MAO-A inhibitor, compound 10, as well as the MAO-B 
inhibitors, compounds 1, 5, 6, 9 and 12, all appeared to be reversible MAO inhibitors as 
defined by the time-dependency studies conducted. Compound 9 however, seemed to be an 
irreversible inhibitor of the MAO-A isoenzyme, an undesirable type of inhibition which has 
been shown to cause the unwanted hypertensive response in patients [13]. Further structural 
modifications to compound 9 are therefore necessary in order to afford a resultant molecule 
with the desired reversible MAO-A inhibitory potential.  
Molecular modelling studies gave some insight on the compounds’ potential binding 
interactions with the MAO-B isoenzyme. Based on the in silico studies, the benzylamine 
moiety seemed to be a very important structural component in affording this series MAO-B 
inhibitory activity. Not only was it important for elongating the molecules to allow for the 
propargylamine moiety to interact with the isoenzyme’s FAD cofactor, but it also seemed to 
be involved in most of the binding interactions observed in silico with the MAO-B substrate 
cavity, particularly with Ile-199.  
Various other structure-activity relationships were derived from the series of compounds, and 
these include the influence of; (a) the propargyl moiety, in reduced cytotoxicity, improved 
NMDAr antagonism and improved MAO-B inhibition, (b) a terminal primary amine, which 
improved VGCC blockade (c) a benzylamine moiety for improved VGCC blockade as well 
as MAO-B inhibition, (d) an imine bond between the polycyclic cage and the benzylamine 
moiety, which was ideal for NMDAr antagonism and MAO-B inhibition, (e) a ketal moiety, 
which seemed to be important for increased NMDAr antagonism and conferring the 
compounds MAO-B selectivity. 
When considering multifunctionality, compounds 1, 2, 5 and 12 showed the best overall 
activity as viable neuroprotective agents with inherent calcium regulatory potential, by 
blocking VGCC and NMDAr, and MAO-B inhibitory capacity. More importantly, due to the 
inclusion of a propargyl moiety within their structures, compounds 5 and 12 are promising 
leads to multi-mechanistic compounds the may be useful as drug agents for the treatment of 
neurodegenerative disorders. Further in vitro and in vivo studies, which may include 
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mechanistic studies as well as elucidation of the actual binding mode of these compounds, 
would provide better insight on their drugability. Also, these analogues may be screened for 
potential neuroprotective activity on various other drug targets implicated in 
neurodegeneration. 
 
4.4. Experimental 
4.4.1. Chemistry 
General procedures 
Unless otherwise specified, materials were obtained from commercial suppliers and used 
without further purification. Microwave synthesis was performed using a CEM 
Discover_SP
®
 microwave synthesis system. All reactions were monitored by thin-layer 
chromatography on 0.20 mm thick aluminium silica gel sheets (Alugram
®
 SIL G/UV254, 
Kieselgel 60, Macherey-Nagel, Düren, Germany). Visualisation was achieved using a 
variable wavelength UV-detector, iodine vapours or an ethanol solution of ninhydrin, with 
mobile phases prepared on a volume-to-volume basis. Chromatographic purifications were 
performed on silica gel (0.063–0.2 mm, Sigma Aldrich) or versa flash silica gel apparatus (20 
– 45 μm, VersaPakTM, Sigma Aldrich). High resolution electron spray ionisation (HREI) 
mass spectra for all compounds were recorded on a Waters API Q-Tof Ultima mass 
spectrometer at 70 eV and 100 °C. The IR spectra were recorded on a Perkin Elmer Spectrum 
400 spectrometer, fitted with a diamond attenuated total reflectance (ATR) attachment. 
Melting points were determined using a Stuart SMP-10 melting point apparatus and capillary 
tubes. All the melting points determined were recorded uncorrected. 
1
H and 
13
C NMR spectra 
were determined using a Bruker Avance III HD spectrometer at a frequency of 400 MHz and 
100 MHz, respectively. Both 
1
H NMR and 
13
C NMR spectra were referenced internally on 
CDCl3 (δ: 
1
H 7.26, 
13
C 77.20). All chemical shifts are reported in parts per million (ppm), 
relative to the internal standards. The following abbreviations are used to indicate the 
multiplicities of the respective signals: s – singlet; br s – broad singlet; d – doublet; dd – 
doublet of doublets; t – triplet and m – multiplet; and AB-q – AB quartet. 
 
Synthesis of pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecane-8,11-dione (a) 
A stiochiometric volume of freshly monomerised cyclopentadiene (15.26 ml; 92.5mmol) was 
slowly added drop-wise (1 g every 10 mins) to a solution of p-benzoquinone (10 g; 92.5 
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mmol) in dry benzene (400 ml). The reaction was maintained on an ice bath at a temperature 
below ± 5 °C, to prevent the formation of the undesired Diels Alder di-adduct. The reaction 
was protected from light and left to stir for 1 hour to reach completion. The reaction was 
complete when the p-benzoquinone spot was no longer visible on TLC analysis. This was 
followed by the addition of 3 spatula scoops of activated charcoal (± 0.50g) and the mixture 
was stirred for a further 30-60 minutes. After filtration through Celite® to remove the 
activated charcoal, the solvent was evaporated in vacuo and the residue, a yellow syrupy oil, 
was left overnight in a dark fume hood. This allowed full evaporation of the benzene, 
affording the Diels Alder adduct as yellow crystals. The Diels Alder adduct was dissolved in 
ethyl acetate (± 4 g/100 ml) and irradiated for ± 6 hours in a photochemical reactor (1000 W 
medium pressure UV lamp, Phillips HPA 1000/20). Decolouration of the solution confirmed 
complete cyclization of the adduct. The solvent was subsequently removed in vacuo to afford 
the impure pentacyclo-dione as a beige/yellow residue. This residue was purified in 2 cycles 
of Soxhlett extractions in cyclohexane to produce the pure diketone as a waxy, off-white 
precipitate (a; yield = 12.040 g, 74.72%, m.p.: 242 ºC). The data from the physical 
characterisation of the obtained compound correlates with that of the 
pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecane-8,11-dione as described by Cookson et al. (1958).
[74]  
 
Synthesis of spiro[1,3-dioxolane-2,8'-pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecan]-11'-one (b) 
A mixture of pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecane-8,11-dione (a: 2.0 g 11.48 mmol), 
ethylene glycol (0.642 ml 11.48 mmol, 1.0 equiv.) and p-toluenesulfonic acid monohydrate 
(21.87 mg, 0.1148 mmol, 0.01 equiv.) was prepared in 35 ml of benzene and refluxed under 
Dean-Stark conditions for 5 hours with stirring. The reaction mixture was cooled and slowly 
poured into an ice cold saturated aqueous sodium carbonate (Na2CO3) solution (10 ml) for 
neutralisation. This was followed by extraction with DCM (3 x 25 ml). The organic phase 
was dried over anhydrous magnesium sulphate (MgSO4) then filtered and concentrated in 
vacuo. The crude material was crystallised from hexane to afford colourless oxo-acetal white 
crystals (b; yield = 1.820 g, 72.02%, m.p.: 71 ºC). The data from the physical characterisation 
of the obtained compound correlates with that of the spiro[1,3-dioxolane-2,8'-
pentacyclo[5.4.0.0²,⁶.0³,¹⁰.0⁵,⁹]undecan]-11'-one described by Dekker et al. (1979).[75]  
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Synthesis of N-benzyl-5-oxahexacyclo[5.4.1.0
2,6
.0
3,10
.0
4,8
.0
9,12
]dodecan-4-amine (NGP1-
01) 
Pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecane-8,11-dione (a, 2.012 g, 11.55 mmol) and 
benzylamine (1.238 g, 11.55 mmol) were dissolved in EtOH (20 ml) and transferred to a 
sealed microwave vessel (35 ml capacity). The mixture was placed in a CEM Discover_SP 
microwave reactor and irradiated for 2 h at 100 W, 80 °C and 100 psi. The mixture was 
removed from the microwave reactor and NaBH4 (0.870 g, 23.10 mmol) was added 
portionwise in excess. This mixture was stirred at room temperature for 8 h, after which the 
solvents were removed in vacuo. The residue was suspended in water (20 ml) and extracted 
with DCM (3 x 20 ml). The combined organic fractions were washed with water (2 x 20 mL), 
dried (anhydrous MgSO4), filtered and evaporated in vacuo to yield a light-yellow oil. 
Crystallisation from ethyl acetate rendered the final product as a colourless microcrystalline 
solid (NGP1-01; yield = 1.908 g, 62.26%, m.p.: 86 ºC). The physical characteristics of this 
compound were the same as those described in the literature.
[50,51]
  
 
Synthesis of 5-oxahexacyclo[5.4.1.0
2,6
.0
3,10
.0
4,8
.0
9,12
]dodecan-4-amine (c) 
A solution of NGP1-01 (3.501 g, 13.19 mmol) in ethanol (50 ml) was prepared in a pressure 
tube along with a stirring bar. To this solution, 10% Pd/C (0.659 g; calculated as 50 mg per 
mmol of compound) was added. Special care was taken to make sure that Pd/C is added in 
small amounts while opening the pressure reactor for as little time as possible considering the 
pyrophoric nature of dry Pd/C. After the addition of Pd/C the pressure tube was sealed 
properly and attached to the hydrogen supply. Hydrogen was flushed through the sealed 
pressure reactor six times before filling it with hydrogen gas at 206 kPa pressure. The 
pressure tube was stirred for 14 h maintaining the internal temperature of the reaction mixture 
at 50 °C. Upon reaction completion, the mixture was filtered under vacuum through a 
sintered glass funnel. Residual Pd/C waste was transferred to a labelled container which 
contained water. The filtrate was concentrated in vacuo and 20 ml of saturated NaHCO3 was 
added. Resulting reaction mixture was extracted with DCM (3 x 15 ml), dried (anhydrous 
MgSO4) and filtered to get a clear organic layer. The DCM was evaporated in vacuo to get a 
white solid. Pure mono amine cage product (c; yield = 0.739 g, 31.99%, m.p.: 166 – 168 ºC) 
was obtained by crystallisation using DCM/hexane (1:1). The physical characteristics of this 
compound were the same as those described in the literature.
[51]
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Synthesis of 4-[({spiro[1,3-dioxolane-2,8'-pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecan]-11'-
ylidene}amino)methyl]aniline (1) 
A mixture of b (1.0 g; 4.58 mmol), 4-amino benzylamine (0.559 g; 4.58 mmol; 1.0 equiv.) 
was prepared in ethanol (30 ml). The mixture was reacted under microwave conditions of 80 
W and 150 psi at 100 °C for 30 minutes. The reaction mixture was concentrated in vacuo and 
30 ml of water was added followed by extraction with DCM (3 x 15 ml). The organic extracts 
were washed sequentially with water (25 mL) and brine (25 mL). The organic fraction was 
dried over anhydrous MgSO4, filtered and concentrated in vacuo. The resultant crude mixture 
was purified using a versa flash silica-gel column with ethanol/ethyl acetate (1:1) as eluent, to 
give a brown wax (1; yield = 0.969 g, 65.59%). 
C20H22N2O2; MW, 322.40 g/mol; mp: wax; IR (ATR) Vmax: 3351, 2969, 2864, 1604, 1516, 
1336, 1088, 823 cm
-1
; HR-ESI [M+H]
+
: calc. 323.1760, exp. 323.1765; 
1
H NMR (400 MHz, 
CDCl3) δH: 7.26 - 7.08 (m, 2H), 6.65 - 6.62 (m, 2H), 4.46 - 4.34 (m, 2H), 3.93 - 3.73 (m, 4H), 
2.81 – 2.39 (m, 8H), 1.82:1.51 (AB-q, 2H, J = 10.4 Hz); 13C NMR (100 MHz, CDCl3) δC: 
129.1, 115.1, 65.5, 63.8, 56.6, 53.1, 51.9, 50.5, 45.4, 43.8, 42.7, 41.5, 39.4, 38.7, 38.0, 37.4, 
36.3, 32.1. 
 
Synthesis of 1-[4-(aminomethyl)phenyl]-N-{spiro[1,3-dioxolane-2,8'-
pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecan]-11'-ylidene}methanamine (2) and N-{spiro[1,3-
dioxolane-2,8'-pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecan]-11'-ylidene}-1-{4-[({spiro[1,3-
dioxolane-2,8'-pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecan]-11'-
ylidene}amino)methyl]phenyl}methanamine (3)
 
A 10 ml ethanol solution of b (2.001 g; 9.17 mmol) was added drop-wise to a 20 ml ethanol 
solution of p-xylylenediamine (6.240 g; 45.81 mmol; 5.0 equiv.) on ice. After complete 
addition of b, the mixture was stirred at room temperature for 1 hour then reacted under 
microwave conditions of 60 W and 80 psi at 100 °C for 3 hours. Upon completion, the 
reaction mixture was concentrated in vacuo and 30 ml of water was added, followed by 
extraction with DCM (3 x 15 ml). The organic extracts were washed sequentially with water 
(25 mL) and brine (25 mL). The organic fraction was dried over anhydrous MgSO4 then 
filtered and concentrated in vacuo. The resultant crude mixture was purified by gradient 
column chromatography using ethanol and ammonia solution/methanol/DCM (1:9:90) as 
eluents, respectively to give a light-yellow wax (2; yield = 0.998 g, 32.42%) and a yellow 
clear wax (3; yield = 0.148 g, 12.91%).  
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Compound 2: C21H24N2O2; MW, 336.43 g/mol; mp: wax; IR (ATR) Vmax: 3356, 2970, 
2864, 1683, 1336, 1105, 811 cm
-1
; HR-ESI [M+H]
+
: calc. 336.1600, exp. 336.1601; 
1
H 
NMR (400 MHz, CDCl3) δH: 7.32 - 7.24 (m, 4H), 4.54 - 4.42 (m, 2H), 3.90 - 3.83 (m, 6H), 
2.92 - 2.42 (m, 8H), 1.83:1.53 (AB-q, 2H, J = 10.4 Hz); 
13
C NMR (100 MHz, CDCl3) δC: 
128.3, 127.0, 65.5, 63.7, 56.8, 51.2, 50.5, 46.2, 45.3, 45.0, 43.7, 42.7, 41.9, 40.7, 40.6, 39.4, 
38.0, 37.3, 32.1. 
Compound 3: C34H36N2O4; MW, 536.66 g/mol; mp: wax; IR (ATR) Vmax: 2971, 2864, 
1683, 1337, 1104, 730 cm
-1
; HR-ESI [M+H]
+
: calc. 537.2753, exp. 537.2756; 
1
H NMR (400 
MHz, CDCl3) δH: 7.27 - 7.24 (m, 4H), 4.56 - 4.43 (m, 4H), 3.95 - 3.83 (m, 8H), 2.92 - 2.40 
(m, 16H), 1.83:1.53 (AB-q, 4H, J = 10.4 Hz); 
13
C NMR (100 MHz, CDCl3) δC: 138.3, 127.9, 
65.5, 63.7, 56.9, 51.2, 50.7, 45.3, 45.0, 43.7, 42.7, 41.9, 40.8, 39.4, 38.7, 37.7, 32.1. 
 
Synthesis of N-{[4-(aminomethyl)phenyl]methyl}spiro[1,3-dioxolane-2,8'-
pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecan]-11'-amine (4) 
To a 15 ml ethanol solution of compound 2 (0.050 g; 0.149 mmol), NaBH4 (0.0112 g; 0.298 
mmol 2.0 equiv.) was added. The reaction mixture was stirred at room temperature for 8 
hours. Upon reaction completion, the crude mixture was concentrated in vacuo and 30 ml of 
water was added, followed by extraction with DCM (3 x 15 ml). The collected organic 
extract was washed sequentially with water (25 ml) and brine (25 ml). The organic fraction 
was dried over anhydrous MgSO4 then filtered and concentrated in vacuo without further 
purification, to yield a yellow wax (4; yield = 0.035 g, 69.40%).  
C21H26N2O2; MW, 338.44 g/mol; mp: wax; IR (ATR) Vmax: 3353, 2956, 2862, 1473, 1344, 
1097, 816 cm
-1
; HR-ESI [M+H]
+
: calc. 339.2073, exp. 339.2074; 
1
H NMR (400 MHz, 
CDCl3) δH: 7.31 (d, 2H, J = 8.0 Hz), 7.24 (d, 2H, J = 8.0 Hz), 3.95 - 3.92 (m, 2H), 3.87 - 3.78 
(m, 4H), 3.76 (d, 2H, J = 3.2 Hz), 2.70 (t, 1H, J = 2.8 Hz,), 2.56 - 2.14 (m, 8H), 1.62:1.14 
(AB-q, 2H, J = 10.4 Hz); 
13
C NMR (100 MHz, CDCl3) δC: 141.8, 138.8, 128.4, 127.1, 115.6, 
65.7, 62.5, 59.9, 52.2, 46.6, 46.2, 45.4, 44.9, 44.3, 39.8, 36.6, 34.53, 30.9, 22.8. 
 
Synthesis of 1-(4-{[(prop-2-yn-1-yl)amino]methyl}phenyl)-N-{spiro[1,3-dioxolane-2,8'-
pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecan]-11'-ylidene}methanamine (5) 
Propargyl chloride (0.179 g; 2.399 mmol) was dissolved in 5 ml acetonitrile and added drop-
wise to a 15 ml acetonitrile mixture of compound 2 (0.807 g; 2.399 mmol; 1.0 equiv.) and 
potassium carbonate (0.398 g; 2.878 mmol; 1.2 equiv.). The mixture was refluxed at 60 °C 
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for 4 hours. Upon reaction completion, the crude mixture was concentrated in vacuo to 
remove acetonitrile and 30 ml of water was added, followed by extraction with DCM (3 x 15 
ml). The collected organic fraction was washed sequentially with water (25 ml) and brine (25 
ml). The organic fraction was dried over anhydrous MgSO4 then filtered and concentrated in 
vacuo. The resultant crude mixture was purified by gradient column chromatography with 
DCM/ethyl acetate/petroleum ether (1:1:1) and ammonia solution/methanol/DCM (1:9:90) as 
eluents respectively, yielding a brown oil (5; yield – 0.192 g; 21.37%). 
C24H26N2O2; MW, 374.48 g/mol; mp: oil; IR (ATR) Vmax: 3274, 2973, 1743, 1681, 1337, 
1105, 934 cm
-1
; HR-ESI [M+H]
+
: calc. 375.2073, exp. 375.2074; 
1
H NMR (400 MHz, 
CDCl3): 7.27 - 7.24 (m, 4H), 4.54 - 4.38 (m, 2H), 3.87 - 3.77 (m, 6H), 3.38 (d, 2H, J = 2.4 
Hz), 2.79 - 2.35 (m, 8H), 2.22 (t, 1H, J = 6 Hz) 1.84:1.47 (AB-q, 2H, J = 10.4 Hz); 
13
C NMR 
(100 MHz, CDCl3) δC: 139.2, 137.4, 128.4, 128.2, 114.9, 113.9, 82.0, 71.5, 65.7, 64.5, 63.82, 
56.9, 53.0, 50.7, 45.8, 42.9, 42.3, 41.5, 39.4, 38.7, 36.3, 32.1. 
 
Synthesis of N-[(4-{[(prop-2-yn-1-yl)amino]methyl}phenyl)methyl]spiro[1,3-dioxolane-
2,8'-pentacyclo[5.4.0.0
2,6
.0
3,10
.0
5,9
]undecan]-11'-amine (6)  
To a 10 ml ethanol solution of compound 5 (0.065 g; 0.174 mmol), NaBH4 (0.0131 g; 0.348 
mmol 2.0 equiv.) was added. The reaction mixture was stirred at room temperature for 8 
hours. Upon complete reduction, the crude mixture was concentrated in vacuo and 20 ml of 
water was added, followed by extraction with DCM (3 x 15 ml). The collected organic 
extract was washed sequentially with water (20 ml) and brine (20 ml). The organic fraction 
was dried over anhydrous MgSO4 then filtered and concentrated in vacuo to yield a light-
yellow oil (6; yield = 0.047 g, 72.35%). 
C24H28N2O2; MW, 376.49 g/mol; mp: oil; IR (ATR) Vmax: 3288, 2960, 2888, 2360, 1454, 
1345, 1098, 802 cm
-1
; HR-ESI [M+H]
+
: calc. 377.2229, exp. 377.2227; 
1
H NMR (400 MHz, 
CDCl3) δH: 7.34 - 7.31 (m, 4H), 3.96 - 3.78 (m, 6H), 3.66 (m, 2H), 3.39 (d, 2H, J = 2.4 Hz), 
2.92 (t, 1H, J = 3.6 Hz), 2.67 - 2.25 (m, 8H), 2.15 (t, 1H, J = 6.0 Hz), 1.66:1.18 (AB-q, 2H, J 
= 10.4 Hz); 
13
C NMR (100 MHz, CDCl3) δC: 136.9, 129.4, 128.7, 127.2, 115.5, 78.7, 73.2, 
72.3, 65.7, 62.74, 59.2, 56.7, 51.7, 46.5, 45.3, 44.8, 43.9, 41.7, 39.8, 36.1, 34.5, 29.6. 
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Synthesis of 5-[(4-aminophenyl)methyl]-5-azahexacyclo[5.4.1.0
2,6
.0
3,10
.0
4,8
.0
9,12
]dodecan-
4-ol (7)  
Compound 1 (0.450 g; 1.396 mmol) was dissolved in ethanol (20 ml) and a spatula point (± 
0.15 g) of sodium borohydride was added to the solution. The mixture was allowed to stir at 
room temperature for 8 hours. The reaction was concentrated in vacuo, distilled water (20 ml) 
was added, followed by extraction with DCM (3 x 15 ml). The combined organic layers were 
washed with brine (30 ml) then dried (anhydrous MgSO4) and filtered. The collected filtrate 
was concentrated in vacuo. To the crude residue, acetone (10 ml) and aqueous 4M HCl (10 
ml) was added. This reaction mixture was stirred at room temperature for 12 h. Water (150 
ml) was added to the reaction solution and basified to pH 14 with 1 M NaOH. This was 
followed by extraction with DCM (3 x 25 ml) and the combined organic layers were dried 
(anhydrous MgSO4) and filtered. The filtrate was concentrated in vacuo to give the crude 
residue. The resultant crude residue was purified by column chromatography, using 
EtOAc/DCM (7:3) as eluent, to yield a yellow amorphous powder (7; yield = 0.167 g, 
42.75%). 
C18H20N2O; MW, 280.36 g/mol; mp: 120 °C; IR (ATR) Vmax: 3368, 2955, 2861, 2827, 
1615, 1518, 1325, 1107, 809 cm
-1
; HR-ESI [M+H]
+
: calc. 281.1654, exp. 281.1655; 
1
H 
NMR (400 MHz, CDCl3) δH: 7.18 (d, 2H, J = 8.4 Hz), 6.66 (d, 2H, J = 8.4 Hz), 3.85 (d, 2H, 
J = 13.2 Hz), 3.37 (t, 1H, J = 5.2 Hz), 2.78 - 2.60 (m, 8H), 1.86:1.53 (AB-q, 2H, J = 10.4 
Hz); 
13
C NMR (100 MHz, CDCl3) δC: 145.8, 129.4, 128.5, 115.1, 72.1, 58.3, 52.3, 45.9, 
45.1, 44.4, 43.0, 40.8, 39.9, 37.4, 35.2, 34.2. 
 
Synthesis of 5-{[4-(aminomethyl)phenyl]methyl}-5-
azahexacyclo[5.4.1.0
2,6
.0
3,10
.0
4,8
.0
9,12
]dodecan-4-ol (8) 
Compound 4 (0.15 g; 0.443 mmol) was dissolved in acetone (15 ml) and aqueous 4M HCl 
(15 ml) was added. This reaction mixture was stirred at room temperature for 12 h. Water (20 
ml) was added to the reaction solution and basified to pH 14 with 1 M NaOH. This was 
followed by extraction with DCM (3 x 25 ml) and the combined organic layers were dried 
(anhydrous MgSO4) and filtered. The filtrate was concentrated in vacuo to give the crude 
residue. The resultant crude residue was purified by column chromatography, using ammonia 
solution/methanol/DCM (1:9:90) as eluent, yielding an off-white amorphous powder (8; yield 
= 0.102 g; 78.26%). 
http://etd.uwc.ac.za/
121 
 
C19H22N2O; MW, 294.39 g/mol; mp: 145 °C; IR (ATR) Vmax: 3308, 2961, 2863, 2783, 
1327, 1109, 767 cm
-1
; HR-ESI [M+H]
+
: calc. 295.1810, exp. 295.1812; 
1
H NMR (400 MHz, 
CDCl3) δH: 7.29 - 7.25 (m, 4H), 3.84 (m, 3H), 3.43 (d, 1H), 3.29 (t, 1H, J = 5.2 Hz), 2.84 - 
2.57 (m, 8H), 1.83:1.50 (AB-q, 2H, J = 10.4 Hz); 
13
C NMR (100 MHz, CDCl3) δC: 142.0, 
140.4, 137.6, 128.9, 128.2, 127.1, 106.4, 64.2, 51.4, 51.0, 46.2, 45.6, 44.3, 42.8, 42.1, 41.8, 
41.0. 
 
Synthesis of 5-[(4-{[(prop-2-yn-1-yl)amino]methyl}phenyl)methyl]-5-
azahexacyclo[5.4.1.0
2,6
.0
3,10
.0
4,8
.0
9,12
]dodecan-4-ol (9) 
Propargyl chloride (0.070 g; 0.942 mmol) was dissolved in 5 ml acetonitrile and added drop-
wise to a 15 ml acetonitrile mixture of compound 8 (0.277 g; 0.942 mmol; 1.0 equiv.) and 
potassium carbonate (0.156 g; 1.131 mmol; 1.2 equiv.). The mixture was reacted under 
microwave conditions of 60 W, in a closed vessel at 60 °C for 2.5 hours. Upon reaction 
completion, the crude mixture was concentrated in vacuo to remove acetonitrile and 30 ml of 
water was added, followed by extraction with DCM (3 x 15 ml). The collected organic 
fraction was washed sequentially with water (25 ml) and brine (25 ml). The organic fraction 
was dried over anhydrous MgSO4 then filtered and concentrated in vacuo. The resultant 
crude mixture was purified by column chromatography with ammonia 
solution/methanol/DCM (1:9:90) as eluent, yielding a yellow-orange wax (9; yield = 0.057 g, 
18.07%). 
C22H24N2O; MW, 332.43 g/mol; mp: wax; IR (ATR) Vmax: 3298, 2963, 2863, 2829, 1727, 
1323, 1107, 732 cm
-1
; HR-ESI [M+H]
+
: calc. 333.1967, exp. 333.1967; 
1
H NMR (400 MHz, 
CDCl3) δH: 7.32 (m, 4H), 3.86 (m, 3H), 3.65 (s, 1H), 3.41 (t, 1H, J = 5.2 Hz), 3.31 (m, 2H), 
2.63 - 2.38 (m, 8H), 1.80:1.48 (AB-q, 2H, J = 10.4 Hz); 
13
C NMR (100 MHz, CDCl3) δC: 
137.9, 136.6, 129.2, 128.7, 128.4, 127.1, 82.0, 71.5, 62.4, 51.9, 51.3, 50.8, 49.8, 46.2, 45.5, 
42.9, 41.6, 41.3, 40.7, 37.2. 
 
Synthesis of N-[(4-aminophenyl)methyl]-5-oxahexacyclo[5.4.1.0
2,6
.0
3,10
.0
4,8
.0
9,12
]dodecan-
4-amine (10)  
The diketone cage (a: 1.0 g; 5.74 mmol) was dissolved in ethanol (25 ml) and cooled down to 
0 °C while stirring on an external ice bath. 4-amino benzylamine (0.7 g; 5.74 mmol) 
dissolved in 5 ml ethanol was added drop-wise with continuous stirring. The reaction mixture 
was stirred for 30 mins on an ice bath after which it was reacted under microwave conditions 
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of 100 W, 100 psi, at 80 °C for 2 hours. NaBH4 (± 0.30g) was added to the reaction and 
stirred at room temperature for 8 hours. The reaction mixture was concentrated in vacuo to 
remove the ethanol. The resulting residue was dissolved in DCM (25 ml) then washed with 
brine (50 ml). The collected DCM fraction was dried using anhydrous MgSO4, filtered and 
concentrated in vacuo. The resultant crude mixture was purified using column 
chromatography with ethanol/ethyl acetate (1:1) as eluent, yielding a light yellow amorphous 
powder (10; yield = 0.518 g, 32.21%). 
C18H20N2O; MW, 280.36 g/mol; mp: 116 °C; IR (ATR) Vmax: 3251, 2969, 2859, 1615, 
1513, 1357, 1015, 825 cm
-1
; HR-ESI [M+H]
+
: calc. 281.1654, exp. 281.1653; 
1
H NMR (400 
MHz, CDCl3) δH: 7.12 (d, 2H, J = 8.4 Hz), 6.83 (d, 2H, J = 8.4 Hz), 4.72 (t, 1H, J = 5.2 Hz), 
3.74 (s, 2H), 2.85-2.50 (m, 8H), 1.90:1.58 (AB-q, 2H, J = 10.4 Hz); 
13
C NMR (100 MHz, 
CDCl3) δC: 143.3, 134.2, 127.7, 116.7, 105.6, 82.7, 55.9, 54.5, 46.1, 44.9, 44.5, 44.4, 43.3, 
42.9, 41.6, 41.5.  
 
Synthesis of N-{[4-(chloromethyl)phenyl]methyl}-5-
oxahexacyclo[5.4.1.0
2,6
.0
3,10
.0
4,8
.0
9,12
]dodecan-4-amine (11) 
A 20 ml acetonitrile solution of c (0.50 g; 2.85 mmol) was added drop-wise to a 60 ml 
acetonitrile solution of p-xylylene dichloride (2.498 g; 14.27 mmol; 5.0 equiv.) and 
potassium carbonate (0.473 g; 3.42 mmol; 1.2 equiv.) on ice. After complete addition of c, 
the mixture was stirred at room temperature for 1 hour then reacted under microwave 
conditions of 150 W and 20 psi at 70 °C for 1 hour. Upon completion, the reaction mixture 
was concentrated in vacuo and 40 ml of water was added, followed by extraction with DCM 
(3 x 25 ml). The organic extracts were washed sequentially with water (25 mL) and brine (25 
mL). The organic fraction was dried over anhydrous MgSO4 then filtered and concentrated in 
vacuo. The resultant crude mixture was purified using a flash silica-gel column with 
petroleum ether/ethyl acetate/DCM (1:1:1) as eluent, to give a yellowish oil (11; yield = 
0.172 g, 19.19%). 
C19H20ClNO; MW, 313.82 g/mol; mp: oil;  IR (ATR) Vmax:
 
3321, 3208, 2960, 2860, 1513, 
1444, 1265,1012, 821 cm
-1
; HR-ESI [M+H]
+
: calc. 314.1312, exp. 314.1315; 
1
H NMR (400 
MHz, CDCl3) δH: 7.35 - 7.32 (m, 4H), 4.65 (t, 1H, J = 5.2 Hz), 4.67 (s, 2H), 4.02 (s, 2H), 
2.86 - 2.54 (m, 8H), 1.91:1.56 (AB-q, 2H, J = 10.4 Hz); 
13
C NMR (100 MHz, CDCl3) δC: 
137.6, 128.9, 128.7, 128.3, 127.9, 127.8, 55.0, 46.1, 46.0, 45.7, 45.6, 44.7, 43.4, 43.0, 41.5, 
41.2, 29.6.  
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Synthesis of N-[(4-{[(prop-2-yn-1-yl)amino]methyl}phenyl)methyl]-5-
oxahexacyclo[5.4.1.0
2,6
.0
3,10
.0
4,8
.0
9,12
]dodecan-4-amine (12)  
A mixture of compound 11 (0.123 g; 0.392 mmol), propargylamine (0.022 g; 0.392 mmol; 
1.0 equiv.) and potassium carbonate (0.065 g; 0.47 mmol; 1.2 equiv.) was prepared in 30 ml 
acetonitrile. The mixture was stirred at room temperature for 1 hour then reacted under 
microwave conditions of 150 W and 20 psi at 70 °C for 1 hour. Upon completion, the 
reaction mixture was concentrated in vacuo and 40 ml of water was added, followed by 
extraction with DCM (3 x 25 ml). The organic extracts were washed sequentially with water 
(25 mL) and brine (25 mL). The organic fraction was dried over anhydrous MgSO4 then 
filtered and concentrated in vacuo. The resultant crude mixture was purified using gradient 
column chromatography with DCM/ethyl acetate/petroleum ether (1:1:1) and ethyl acetate as 
eluents respectively, yielding a yellow oil (12; yield = 0.028 g; 21.57%). 
C22H24N2O; MW, 332.44 g/mol; mp: oil; IR (ATR) Vmax: 3299, 2959, 2925, 2857, 1734, 
1353, 1014, 858 cm
-1
; HR-ESI [M+H]
+
: calc. 333.1967, exp. 333.1972; 
1
H NMR (400 MHz, 
CDCl3) δH: 7.33 - 7.27 (m, 4H), 4.66 (t, 1H, J = 5.2 Hz), 3.98 (d, 2H, J = 4.8 Hz), 3.86 (s, 
2H), 3.41 (d, 2H, J = 2.4 Hz), 2.84 - 2.54 (m, 8H), 2.25 (t, 1H, J = 2.4 Hz), 1.91:1.55 (AB-q, 
2H, J = 10.4 Hz); 
13
C NMR (100 MHz, CDCl3) δC: 139.7, 137.9, 128.5, 128.0, 109.6, 82.5, 
82.0, 71.5, 55.2, 54.8, 51.9, 47.5, 44.8, 44.5, 43.7, 42.0, 41.56, 38.7, 37.2, 29.6. 
 
4.4.2. Biological evaluation 
Cell line and culture conditions 
The human neuroblastoma cell line SH-SY5Y was generously donated by our collaborator at 
the Division of Molecular Biology and Human Biology, Stellenbosch University, Tygerberg, 
Cape Town. Cells were cultured in monolayer using Dulbeco Modified Eagles Medium 
(DMEM, Gibco, Life Technologies Ltd) supplemented with 10% foetal bovine serum (FBS, 
Gibco, Life Technologies Ltd.) and 1% 100 U/mL penicillin and 100 μg/mL streptomycin 
(Lonza Group Ltd., Base Switzerland). Cells were grown at 37 °C, in a humidified 
atmosphere consisting of 5% CO2 and 95% air. Media was replaced every two to three days 
and cells were sub-cultured by splitting with trypsin (Lonza Group Ltd., Base Switzerland). 
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SH-SY5Y cytotoxicity assay  
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) is a yellow 
tetrazolium salt that is reduced to purple formazan in the presence of living cells. This assay 
which measures cell metabolic activity was used to determine cytotoxicity as described by 
Mosmann, (1983).
[55]
 Briefly, SH-SY5Y cells were plated in flat bottom 96 well plates in 
growth medium as stated above at a density of 7,500 cells/well. Cells were allowed to adhere 
to the plate surface for 24 hours and used media were replenished with fresh media 
containing test compounds at 10 µM, 50 µM and 100 µM. Vehicle control cells were treated 
with dimethyl sulfoxide (DMSO, solvent for dissolving test compounds) at a concentration 
similar to that contained in the highest concentration of test compounds. After 48 hours, 10 
µL of MTT solution (5 mg/mL) was added to each well and incubated for 4 hours and the 
purple formazan formed was solubilized with 100 µL DMSO and plates were read 
spectrophotometrically to determine absorbance at 570 nm using a BMG Labtech Omega® 
POLARStar multimodal plate reader. Percentage cell viability was calculated relative to 
control using the formula below: 
                 
                         
                           
       
 
SH-SY5Y neuroprotection assay  
1-Methyl-4-phenyl pyridinium (MPP
+
), the active metabolite of 1-methyl-4-phenyl-1,2,6-
tetrahydropyridine (MPTP), is highly toxic to dopaminergic neurons and has been widely 
used to induce Parkinson-like syndromes in various in vitro and in vivo models associated 
with PD.
[56,57]
 The ability of the novel compounds to restore cell viability to MPP
+
 stressed 
SH-SY5Y cells was thus evaluated. In this assay, SH-SY5Y cells were seeded onto a 96-well 
plate at a density of 7,500 cells/well and treated with 1000 μM MPP+ for approximately 48 
hours to induce cytotoxicity. Different concentrations (1 μM, 5 μM, 10 μM) of test 
compounds were administrated two hours prior to MPP
+
 treatment. Afterwards, cell viability 
was measured by MTT colorimetric assay and performed as stated in the cytotoxicity assay.  
To determine the data’s statistical significance, a Turkey’s multiple comparison test was 
conducted on all experimental replicates using GraphPad Prism
®
. 
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VGCC and NMDAr modulation assays  
For these experiments, SH-SY5Y human neuroblastoma cells were sub-cultured at a seeding 
density of 1 × 10
5
 cells per well in 96-well black plates and incubated at 37 °C for 24 hours to 
allow for cell adherence. On the day of the experiment, the DMEM solution was replaced 
with a 5 µM Fura-2/AM-DMEM solution and incubated for 1 h at 37 °C. The Fura-2/AM 
loaded DMEM was removed from each well and the extracellular Fura-2/AM was washed 
twice with Ca
2+
-free Krebs–Hepes solution. 98 µL of calcium containing buffer was added to 
each well and kept at 37 °C for 30 min before beginning the experiment, to allow for 
complete dye de-esterification. 2 µL of test compound, dissolved in DMSO, was added to 
each well (10 µM final concentration). Two positive controls were included in the VGCC 
assay; nimodipine, a commercially available dihydropyridine L-type calcium channel blocker 
and the prototype polycyclic amine compound NGP1- 01. Two positive controls were also 
included in the NMDAr assay; MK-801, a commercially available potent high affinity 
NMDAr channel blocker and NGP1-01. The 96 well plate was allowed to incubate at 37 °C 
in a Biotek
® 
fluorescent microplate reader for 10 mins with shaking every minute. A 10 μL 
solution of a 770 mM KCl buffer or 0.55 mM NMDA/Glycine solution, in the VGCC and 
NMDA assay respectively, was used to stimulate the opening of the respective calcium 
channels and allow for calcium entry. Calcium influx was monitored over a 35 s period, at 
wavelengths of excitation and emission of 340 and 380 nm, respectively and the resting 
fluorescence measured at 510 nm. Percentage inhibition values were calculated relative to the 
positive controls nimodipine and MK-801 for the VGCC and NMDAr assays, respectively. 
To determine the data’s statistical significance, a One-way ANOVA; multiple comparison 
test was conducted on all experimental replicates using GraphPad Prism
®
. 
 
MAO-A and MAO-B assays 
The MAO assays were conducted using a similar procedure as previously described.
[69]
 
Recombinant human MAO-A and -B (5 mg/mL) were obtained from Sigma–Aldrich and 
were pre-aliquoted and stored at -80 °C. All enzymatic reactions were carried out to a final 
volume of 250 μL in potassium phosphate buffer (100 mM, pH 7.4, made isotonic with 
NaCl) and contained kynuramine as substrate, MAO-A or MAO-B (0.0075 mg/mL) and 
various concentrations of the test inhibitor (0.01 – 100 μM). The final concentration of 
kynuramine in the reactions was 45 μM and 30 μM for MAO-A and -B, respectively. Stock 
solutions of the test inhibitors were prepared in DMSO and added to the reactions to yield a 
final concentration of 2% (v/v) DMSO. The reactions were incubated for 20 min at 37 °C and 
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were terminated with the addition of 200 μL NaOH (2 N). Finally, 100 μL from each 
eppendorf vial was added to individual black plate wells. The fluorescence of the MAO 
generated 4-hydroxyquinoline in the supernatant fractions were measured using a Biotek
® 
fluorescent microplate reader at an excitation wavelength of 310 nm and an emission 
wavelength of 400 nm. IC50 values were calculated as concentration of the compound that 
produced 50% enzyme activity inhibition, using the Graph Pad Prism 6 software (San Diego, 
CA, USA). 
 
Time-dependent inhibition studies 
To investigate the reversibility of the observed MAO enzyme inhibition, time-dependent 
inhibition studies were carried out on the active inhibitors. Briefly, recombinant human 
MAO-A or human MAO-B (0.0075 mg/mL) enzymes were preincubated with inhibitor for 
periods of 0, 15, 30, 60 min at 37 °C. The concentration of inhibitor in these incubations was 
approximately twofold the measured IC50 values for the inhibition of the respective MAO 
enzymes. Potassium phosphate buffer (100 mM, pH 7.4, made isotonic with NaCl) was used 
as the incubation medium. A final concentration of 45 μM kynuramine for MAO-A and 30 
μM kynuramine for MAO-B were then added to the preincubated enzyme preparations and 
the resulting 250 μL reactions were incubated at 37 °C for 15 min. The reactions were 
terminated with the addition of 200 μL NaOH (2 N) and a volume of 600 μL distilled water 
was added to each reaction. The fluorescence of the MAO generated 4-hydroxyquinoline in 
the supernatant fractions were measured using a Biotek fluorescent microplate reader at an 
excitation wavelength of 310 nm and an emission wavelength of 400 nm. Time dependent 
graphs were plotted against the relative fluorescent unit readings (RFU). 
 
4.4.3. Molecular modelling 
Computer-assisted docking were carried out using the CHARMm force field and the human 
MAO-B crystal structure (PDB ID: 2V5Z),
[44]
 which were recovered from the Brookhaven 
Protein Database (www.rcsb.org/pdb). Docking simulation was performed on the test 
compounds using Molecular Operating Environment (MOE)
[45]
 with the following protocol. 
(1) Enzyme structures were checked for missing atoms, bonds and contacts. (2) Hydrogen 
atoms were added to the enzyme structure. Bound ligands were manually deleted and the 
ordered water molecules were retained (3) The ligand molecules were constructed using the 
builder module and were energy minimized. (4) The active site was generated using the 
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MOE-Alpha Site Finder. (5) Ligands were docked within the MAO-B active sites using 
MOEDock with simulated annealing utilised as the search protocol and CHARMm molecular 
mechanics force field. (6) The lowest energy conformation of the docked ligand complex was 
selected and subjected to a further energy minimization using CHARMm force field with all 
possible bond rotations and chiralities explored. To determine the accuracy of this docking 
protocol, the co-crystallised ligand, safinamide (PDB ID: 2V5Z), was re-docked into the 
MAO-B active site. This procedure was repeated three times and the best ranked solutions of 
safinamide exhibited RMSD values of 1.34 Å from the position of the co-crystallised ligand. 
In general, RMSD values smaller than 2.0 Å indicate that the docking protocol is capable of 
accurately predicting the binding orientation of the co-crystallised ligand.
[76,77]
 These 
protocols were thus deemed to be suitable for the docking of inhibitors into the active site 
model of MAO-B. 
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Abstract 
The pathology of neurodegenerative disorders involves multiple steps, and it is probably for 
this reason that targeting one particular step in a multi-step process has only yielded limited 
results. In the CNS, the N-methyl-D-aspartate receptor (NMDAR) channel in its active state 
allows the influx of calcium ions for normal neuronal functioning. Over activation of the 
NMDAR channel leads to excitotoxicity, this can ultimately contribute to neuronal cell death. 
Calcium entry through voltage-gated calcium channels (VGCC) may also contribute to this 
process. In previous studies, the pentacycloundecylamine, NGP1-01 and a number of its 
derivatives showed promising dual acting NMDAR and VGCC inhibition. This paper 
describes the synthesis of a series of adamantane-derived compounds, structurally similar to 
NGP1-01, to act as dual channel inhibitors. By conjugating benzyl and phenylethyl moieties 
with different functional groups (-H, -NO2, -NH2, -OCH3) to the structure of amantadine, we 
were able to synthesize compounds that display both VGCC and NMDAR channel inhibition. 
Compounds 1, 2, 5 and 10 displayed good inhibitory activity against both NMDAR channel 
(66.7 - 89.5 % at 100 µM) and VGCC (39.6 – 85.7 % at 100 µM). The results obtained 
indicate that these compounds hold potential as neuroprotective drug candidates. 
 
Keywords: Amantadine, Neurodegeneration, NMDA receptors, voltage gated calcium 
channels. 
 
5.1. Introduction 
An important drug target for the treatment of neurodegenerative disorders is the ionotropic 
glutamate N-methyl-D-aspartate receptor (NMDAR) which is thought to play a role in 
multiple neurodegenerative disorders including Parkinson's disease (PD) and Alzheimer's 
disease (AD).
1
 The NMDAR is unique in that it requires the binding of two agonists, namely 
glutamate and glycine, for activation. In its active state the channel allows the influx of 
sodium and calcium ions. Although calcium ions are important for cell growth, survival and 
physiological functioning, an excess is responsible for excitotoxicity, ultimately leading to 
neurodegeneration.
2
 Blockers of NMDAR have been shown to have neuroprotective activity
3
 
and it is therefore a prime drug target for neurodegenerative diseases where excitotoxicity is 
involved.
4
 Unfortunately, NMDAR antagonists are associated with adverse central nervous 
system (CNS) side effects which include hallucinations.
4
 These effects are especially seen 
with highaffinity NMDAR channel blockers such as phencyclidine (PCP) and dizocilpine 
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(MK-801). MK-801 and PCP bind in a use-dependant manner to the MK-801/PCP binding 
site located in the inner pore of the NMDAR channel when it is activated and in its open 
state.
1
 The amino-adamantane derivatives amantadine and memantine are low affinity 
uncompetitive NMDAR antagonists which also bind to the MK-801/PCP binding site and 
display a better side effect profile compared to MK-801 and PCP.
1,5–7
 Both amantadine and 
memantine are FDA approved for PD and AD respectively and are safe and effective 
treatment options. Amantadine expresses additional neurotherapeutic ability through the 
increment of extracellular dopamine levels via dopamine re-uptake inhibition and increased 
dopamine release,
8
 which may be additionally useful in treatment of the motor symptoms of 
PD.
9
 In addition to calcium overload associated with NMDAR, excessive calcium influx 
through voltagegated calcium channels (VGCC) may also contribute to excitotoxicity and 
mitochondrial dysfunction.
10,11
 Studies have shown that calcium channel blockers such as 
nimodipine have a synergistic effect when combined with NMDAR inhibitors in 
neuroprotective studies.
12,13
 A compound with multimodal activity, including NMDAR 
antagonism, calcium channel blocking activity and the ability to increase dopamine levels, 
could be a valuable treatment option for neurodegenerative disorders.
14
 NGP1-01 is a 
multifunctional agent which blocks both the NMDAR as well as VGCC and also inhibits 
dopamine reuptake, with resulting neuroprotective activity shown in vivo.
15–18
 Several (2-
oxaadamant-1-yl)amines, structurally similar to NGP1-01 have also shown improved 
NMDAR activity when compared to amantadine.
19 
Fig. 1 Structures of the high affinity NMDAR blockers MK-801 and PCP, and amantadine, memantine and 
NGP1-01. 
Therefore the aim of this study was to synthesize compounds containing different aromatic 
moieties attached via the amine to the adamantine scaffold of amantadine. It was postulated 
that these compounds would display improved multifunctional neuroprotective effects 
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compared to NGP1-01, especially NMDAR antagonism, because of the adamantane scaffold 
(Fig. 1).  
 
5.2. Results and discussion 
The target adamantane amine derivatives (1,
20
 3–8, 10) were synthesized by reacting 
amantadine with the respective benzylbromide moieties by means of SN2 nucleophilic 
addition (Scheme 1). Compound 2 (ref. 21) was synthesized using 2-bromoethylbenzene to 
provide the ethyl linkage between the adamantane amine and the phenyl moiety as opposed 
to compound 1, which was synthesized using benzylbromide. Both these compounds were 
synthesized utilizing microwave irradiation, (MW, 100 ºC, 100 W, 1 atm, 1 hour) in yields of 
48% and 47%, respectively. In both these cases the reaction time was reduced from 12 hours 
to 1 hour and the yields significantly improved when compared to the traditional method 
where only thermal heating was applied. The general synthetic route followed for the 
synthesis of compounds 3–5 (ref. 22) was initiated through the conjugation of a nitrobenzyl 
bromide to amantadine, followed by reduction of the nitro groups to the respective amines 
(6–8)23 with tin powder over 10% HCl in ethanol. The synthesis of compounds 9 (ref. 24) and 
10 (ref. 25) and the corresponding ortho-methoxy derivative were attempted utilizing both 
conventional thermal heating as described for 3,4,5 and through MW irradiation. The 
conventional method was found to be ineffective as no or only trace amounts of the 
compounds formed after 24 hours of reflux (as per TLC). This might be because the 
methoxybenzyl bromide derivatives were not as reactive as the other corresponding 
benzylbromide moieties. Utilizing MW irradiation with conditions set at 100 ºC, 100 W, 1 
atm (open vessel) for 1 hour only compound 9 was synthesized in sufficient yield (18%). 
Both the synthesis of compounds 10 and the corresponding ortho-methoxy derivative were 
attempted in the same manner as 9, however, both reactions did not proceed successfully. The 
MW irradiation conditions were increased up to 150 ºC, 250 W, 240 psi (closed vessel) for 24 
hours with still no compound formed in sufficient yield. A different strategy was employed 
where 1-bromo-adamantane and the ortho- or para-methoxybenzyl amine were used as 
starting reagents and conjugated via SN2 nucleophilic substitution with MW irradiation (150 
ºC, 250 W, 240 psi). Utilizing this method we were able to synthesize compound 10 in an 
25% yield. The synthesis of the ortho-methoxy derivative using this method was 
unsuccessful. This could have resulted because of a chemical hindrance or deactivation of the 
reagent due to the methoxy substituent being in the ortho position of the benzyl moiety. All 
final compounds were confirmed by NMR, MS and IR.
20–25
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Scheme 1 General reaction schemes for the synthesis of compounds 1–10. 
All synthesized amantadine derivatives (1–10) were screened at 100 µM for their potential 
inhibitory activity on the VGCC and NMDAR channel exactly as previously described,
26
 
using the fluorescent ratiometric indicator, Fura-2 AM. Fresh synaptoneurosomes were 
prepared from rat brain homogenate
27
 and incubated with Fura-2 AM. Thereafter the 
synthesized compounds were incubated for 30 minutes and a 140 mM KCl or a 100 mM 
NMDA/glycine solution, in the VGCC and NMDAR assay respectively, was added to 
depolarize the cell membranes or to stimulate calcium influx through the NMDAR channels. 
Calcium influux was then monitored based on the fluorescence intensity relative to that of a 
blank control (without inhibiting compound) over a 5 minute period. Two positive controls 
were included in the VGCC assay; nimodipine, a commercially available dihydropyridine 
calcium channel blocker and the prototype pentacycloundecane compound NGP1-01. Four 
positive controls, MK-801, NGP1-01, amantadine and memantine, were included in the 
NMDAR assay. Results are shown in Table 1 and Fig. 2.  
  
NH.HCl NH2 +
Br NO2 NH NO2
NH NH2
NH R
Br R
NaOH
H2O
CH3CN
Sn, 10% HCl
K2CO3
EtOH
CH3CN
K2CO3
MW, 100 
o
C, 
6 = o-NH2, 7 = m-NH2, 8 = p-NH2
1 (R = H, n = 1), 2 (R = H, n = 2), 
10 (R = p-OMe, n = 1)
3 (o-NO2, n = 1), 4 (m-NO2, n = 1), 
5 (p-NO2, n = 1)
3 - 5
Amantadine
Br
n
100 W, 1 hr
n
NH2
O
CH3
+ NH
O
CH3K2CO3
CH3CN, MW, 150 
oC, 
250 W, 240 Psi, 1 hr 
n = 1, 2
(9)
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Table 1: Summary of effects the adamantane derivatives and related compounds on inhibition of 
NMDA/glycine induced calcium influx (at 100 μM) and KCl induced calcium influx inhibition (at 100 μM). 
Test compound Structure 
a
%NMDA activity 
a
%VGCC activity 
NGP1-01 
O
NH
 
22.2** 38.4** 
(1) NH
 
66.7*** 39.6*** 
(2) NH
 
89.5*** 42.0*** 
(3) NH
NO2
 
60.6*** 49.2*** 
(4) NH NO2
 
36.6*** 14.3* 
(5) NH
NO2 
74.8*** 85.7*** 
(6) NH
NH2
 
31.3*** 37.1*** 
(7) NH NH2
 
48.3*** 30.0*** 
(8) NH
NH2 
50.4*** 49.5*** 
(9) NH O
CH3
 
70.2*** 44.7*** 
(10) NH
O
CH3 
79.2*** 71.2*** 
Nimodipine - inactive 100*** 
MK-801 - 100*** inactive 
Amantadine - 84.6*** 2.76 
Memantine - 92.5*** 5.20 
aControl was taken as 0 % inhibition. Asterisks signifying statistical significance, (*) p < 0.05, (**) p < 0.01 and 
(***) p < 0.001.  
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Fig. 2 Screening of test compounds (100 mM, n ¼ 9) for inhibition of NMDAR-mediated (left) and VGCC-
mediated (right) calcium influx into murine synaptoneurosomes. Each bar represents mean percentage inhibition 
_ SEM. Abbreviations are: MK-801 (MK), NGP1-01 (P), amantadine (A), memantine (M) and nimodipine (N). 
Statistical analysis was performed on raw data (t-test, Prism 4.03) with asterisks signifying significant inhibitory 
effect [(*) p < 0.05, (**) p < 0.01, (***) p < 0.001] Compounds showing significant decrease in activity 
compared to amantadine are indicated by ($) p < 0.05, and compounds showing significant increase in 
inhibitory activity compared to amantadine are indicated by (#) p < 0.05. 
In the NMDAR experiments, synaptoneurosomes incubated with test compounds 1 (66.7%), 
2 (89.5%), 3 (60.6%), 5 (74.8%), 9 (70.2%) and 10 (79.2%) showed promising inhibitory 
activity of NMDA/glycine-mediated calcium influx (Table 1 and Fig. 2). Compounds 4 
(47.2%), 6 (31.3%), 7 (48.3%) and 8 (50.4%) showed weaker inhibitory activity, although 
better than the reference compound NGP1-01 (22.2%). Of the controls, MK-801 (100%) was 
the most potent inhibitor followed by memantine (92.5%) and amantadine (84.6%). This was 
in agreement with previous studies.
9,14,15
 MK-801 showed a complete blockage of NMDAR-
mediated calcium entry. Compound 2 showed the highest percentage NMDAR inhibition 
(89.5%) of all synthesized compounds. An increase in chain length between the amantadine 
moiety and the aromatic group thus led to a significant increase (p < 0.05) in NMDAR 
inhibitory activity as can be seen when the activities of 1 (66.7%) and 2 (89.5%) are 
compared. Although both compounds are thought to fit into the channel in such a way as to 
allow free movement of the polycyclic adamantane structure to a certain degree, the ethyl 
linker is thought to enable the compound to penetrate deeper into the channel lumen thereby 
enabling more favourable interactions with the PCP-binding site. Geldenhuys and colleagues 
(2004, 2007) observed similar results in their work on NGP1-01 and its phenethyl 
derivative.
15,18
 Further research will be conducted using radio-ligand and/or fluorescent 
ligand binding studies using techniques and compounds as described in one of our previous 
papers to confirm these observations.
28
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Of the three nitro containing compounds, 4 showed the weakest, albeit still moderate, activity 
with 36.6% inhibition. Compound 5 showed the highest activity with 74.8% inhibition and 
the rank order that is followed for these compounds is para > ortho > meta. The good 
inhibitory activity of the nitro compounds may be as a result of the nitro group contributing 
to the S-nitrosylation of cysteine residues in the NMDAR channels, thus increasing NMDAR 
activity compared to 1 and NGP1- 01.
29,30
 The weaker activity of 3 (60.1%) and 4 (36.6%) 
compared to 5 (74.8%) may be attributed to steric or conformational effects of the aromatic 
ring due to the nitro group being in the ortho or meta position. The nitro group in the para 
position in 5 may thus enable the compound to fit better at the site of interaction. The amine 
compounds (6–8) show weaker activity (31–51%) than their respective nitro counterparts 
(3,4,5), as well as the methoxy compounds (9 and 10). This could indicate that the nitro 
group was involved in favourable binding interactions with NMDAR channels, and the 
reduction to the amines led to a decrease in activity. The methoxy derivatives 9 and 10 both 
showed good and improved inhibitory activity (70.2% and 79.2%, respectively) compared to 
1 and NGP1-01. All the tested compounds showed better activity than NGP1-01 and none of 
them showed better NMDAR inhibitory activity than memantine. All the inhibitors and 
controls displayed statistically significant activity (p < 0.05), but very little or no 
improvement on the base structure, amantadine. Significant decreased activity, compared to 
amantadine (Fig. 2), was observed for compounds 4, 6 and 7. 
For the VGCC assay, the controls that were tested included nimodipine (100%), NGP1-01 
(38.40%), amantadine (2.76%) and memantine (5.20%). Of the polycyclic structures, NGP1-
01 was the only control compound that displayed statistically significant (p < 0.05) inhibition 
of calcium influx via VGCC. Both amantadine and memantine showed little or no activity. In 
murine synaptoneurosomes incubated with the test compounds, 5 (85.7%) and 10 (71.2%) 
displayed promising inhibitory activity (Table 1) of calcium influx through VGCC. Both 
these compounds showed significantly better activity than NGP1-01. Compounds 1–3, 6–8 
and 9 showed moderate VGCC inhibitory ability within the same range as NGP1-01. All the 
test compounds, except 4, showed a significant improvement on VGCC blocking activity 
when compared to amantadine (Fig. 2).  
The para-nitro compound (5, 85.7%) displayed the best inhibition of calcium influx through 
VGCCs. The other nitro-derivatives compounds 3 (49.2%) and especially 4 (14.3%) showed 
significantly weaker inhibitory activity (p < 0.05) than 5. This may also be attributed to steric 
or conformational effects on the aromatic ring due to the nitro group being in the ortho or 
meta position. The good inhibitory activity of 5 may be as a result of the nitro group being in 
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the para position, which enables the compound to fit better in the binding pocket at the site of 
interaction. Compound 2 (42.0%) showed slightly, though not significantly, better activity 
than 1 (39.6%) and the length of the linker does not exert the same effect as observed with 
the NMDAR assay. The amine compounds (6 and 8) show weaker activity (30–49.5%) than 
their respective nitro counterparts (3 and 5). However, 7 (30.0%) displayed better inhibitory 
activity than 4 (14.3%) indicating that the smaller NH2 moiety had a reduced effect on the 
possible binding conformation of these structures. The rank order for the amines is the same 
as that of the nitro compounds, para > ortho > meta. The para-methoxy derivative 10 
(71.2%) showed better inhibitory activity than the meta-methoxy compound (9, 44.7%).  
Test compounds 1, 2, 5 and 10 showed promising dual NMDAR and VGCC inhibitory 
activity. NGP1-01 also had significant inhibition on both NMDAR and VGCC calcium 
influx. Compounds 1 and 2 showed VGCC inhibition in the same range as NGP1-01, 
however their NMDAR channel inhibitory activity was significantly improved. This could 
largely be attributed to the incorporation of the amantadine moiety in 1 and 2. The activity of 
2 shows that a two carbon spacer provides improved dual channel blocking activity and 
future studies will include investigation of optimal chain length of the adamantine derivatives 
described in this study. Both compounds 1 and 2 may be better therapeutic options than 
NGP1-01 and amantadine or memantine because of this improved dual acting ability. The 
incorporation of the para-nitro and para-methoxy moieties on the benzyl function of 5 and 9 
respectively, further improved this dual activity (Table 1). This is in agreement with previous 
studies done on similar pentacycloundecane derivatives.
18,31
 Amantadine and memantine are 
known NMDAR channel inhibitors, but have no VGCC activity. Therefore, the dual acting 
adamantane derivatives may enhance the neuroprotective effects known for amantadine and 
memantine by inhibiting two excitotoxic pathways simultaneously. Amantadine is also 
known to increase dopamine release and decrease dopamine reuptake in the CNS
8
 and we 
expect that the new compounds could show similar activity. This needs to be confirmed in 
future studies.  
 
  
http://etd.uwc.ac.za/
142 
 
5.3. Conclusion 
We described the synthesis and biological evaluation of 10 adamantane amine compounds as 
potential dual VGCC blockers and NMDAR antagonists. Compounds 1, 2, 5 and 10 
displayed significant inhibitory activity against both NMDAR and VGCC calcium influx. 
These adamantane derived compounds are potentially better neurotherapeutic options than 
amantadine and memantine as they inhibit both NMDAR and VGCC-mediated calcium 
influx, whereas the base adamantine structures only inhibit NMDAR-mediated calcium 
influx. Additional assays on the influence of these compounds on dopamine transmission and 
apoptosis, and in in vivo models will elaborate on the potential neuroprotective value.  
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Bioorg. Med. Chem., 2004, 12, 1799. 
19. M. D. Duque, P. Camps, L. Pro re, S. Montaner, S. V´azquez, F. X. Sureda, J. Mallol, 
M. L´opez-Querol, L. Naesens, E. De Clercq, S. R. Prathalingam and J. M. Kelly, Bioorg. 
Med. Chem., 2009, 17, 3198. 
20. Synthesis of 1: Amantadine (11.4 mmol) and benzyl bromide (10.3 mmol) were added to 
a mixture of acetonitrile (10 ml) and K2CO3 (15.5 mmol). The reaction vial was placed in a 
CEM Discover Labmate (model number 908010) microwave reactor and reacted at 100 
o
C 
and 100 W for 60 min. After irradiation, the mixture was filtered to remove the K2CO3 and 
unreacted amantadine free base. The filtrate was collected and the excess solvent evaporated 
in vacuo. The reaction mixture was then acidified using 30 ml water which was made acidic 
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with HCl until the pH was 3. This was followed by an extraction with DCM (3 x 30 ml). The 
combined aqueous layers were collected and made basic (pH = 12-14) using water saturated 
with NaOH and this was followed by a second extraction with DCM (3 x 30 ml). The 
combined organic layers were dried over anhydrous MgSO4, filtered and the solvent 
evaporated in vacuo to yield N-benzyltricyclo[3.3.1.1
3,7
]decan-1-amine (1) as a light yellow 
oil. C17H23N; Yield: 48%; mp: oil; 
1
H NMR (200 MHz, CDCl3) δH: 7.4-7.1 (m, 5H), 3.8-3.6 
(s, 2H), 2.2-2.0 (m, 3H), 1.8-1.4 (m, 12H); 
13
C NMR (50 MHz, CDCl3) δC: 141.4, 128.3, 
128.3, 126.7, 50.9, 45.1, 42.8, 36.7, 29.6; MS (ESI-MS) m/z: 242.12 (M
+
), 134.97, 78.94; IR 
(ATR; cm
-1
): 3025.9, 2900.9, 2845.9, 1603.7, 1451.3, 1146.4, 734.2, 694.6. 
21. Synthesis of 2: Amantadine (3.3 mmol) and 2-bromoethylbenzene (3.3 mmol) were added 
to a mixture of acetonitrile (10 ml) and K2CO3 (4.5 mmol). The synthetic procedure from this 
point was the same as described for 1 which yielded N-(2-
phenylethyl)tricyclo[3.3.1.1
3,7
]decan-1-amine (2) as a white wax. Physical data: C18H25N; 
Yield: 47 %; mp: wax; 
1
H NMR (200 MHz, CDCl3) δH: 7.4-7.1 (m, 5H), 3.6-3.5 (t, 2H), 3.1-
3.0 (t, 2H), 1.9-1.5 (m, 3H), 1.4-1.1 (m, 12H); 
13
C NMR (50 MHz, CDCl3) δC: 138.9, 128.8, 
128.6, 126.9, 50.00, 42.77, 41.63, 36.8, 35.4, 29.7; MS (ESI-MS) m/z: 256.15 (M
+
), 134.96, 
78.95; IR (ATR; cm
-1
): 2912.2, 2891.9, 2802.6, 1603.4, 1455.2, 1362.8, 1075.0, 776.9, 695.8. 
22. Synthesis of 3-5: Amantadine (11.4 mmol) and the appropriate nitrobenzyl bromide 
derivative (10.3 mmol) were added to a round-bottomed flask followed by acetonitrile (10 
ml) and K2CO3 (15.5 mmol). This mixture was refluxed for 24 hours where after it was 
filtered. The filtrate was collected and the excess solvent evaporated in vacuo. The mixture 
was purified via flash chromatography to yield the title compounds (3-5) as yellow 
amorphous solids.  
N-(2-nitrobenzyl)tricyclo[3.3.1.1
3,7
]decan-1-amine (3): C17H22N2O2; Yield: 32 %; mp: 94 
o
C; 
1
H NMR (200 MHz, CDCl3) δH: 7.9-7.8 (dd, J = 8.11 Hz, 1.37 Hz), 7.7-7.5 (m, 2H), 7.4-7.3 
(m, 1H), 4.0-3.8 (s, 2H, CH2), 2.2-1.9 (m, 3H), 1.8-1.4 (m, 12H); 
13
C NMR (50 MHz, CDCl3) 
δC: 149.6, 136.2, 133.3, 132.1, 127.8, 124.5, 51.1, 45.13, 42.4, 36.6, 29.5; MS (ESI-MS) m/z: 
287.17 (M
+
), 214.02, 135.00, 79.89; IR (ATR; cm
-1
): 2900.3, 2848.6, 1524.1, 1463.3, 1355.3, 
1133.8, 779.4, 739.6. 
N-(3-nitrobenzyl)tricyclo[3.3.1.1
3,7
]decan-1-amine (4): C17H22N2O2; Yield: 54 %; mp: 61 
o
C; 
1
H NMR (200 MHz, CDCl3) δH: 8.3-8.2 (s, 1H), 8.1-8.0 (m, 1H), 7.7-7.6 (dd, 1H, J = 7.83 
Hz, 1.64 Hz), 7.5-7.4 (m, 1H), 3.9-3.8 (s, 2H, CH2), 2.2-2.0 (m, 3H), 1.8-1.4 (m, 12H); 
13
C 
NMR (50 MHz, CDCl3) δC: 144.3, 134.3, 129.1, 123.0, 121.7, 51.0, 45.1, 42.9, 36.7, 29.6; 
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MS (ESI-MS) m/z: 287.17 (M
+
), 214.04, 135.00, 79.98; IR (ATR; cm
-1
): 2898.3, 2847.1, 
1524.5, 1463.3, 1359.3, 1133.5, 778.8, 715.8. 
N-(4-nitrobenzyl)tricyclo[3.3.1.1
3,7
]decan-1-amine (5): C17H22N2O2; Yield: 57 %; mp: 94 
o
C; 
1
H NMR (200 MHz, CDCl3) δH: 8.1-8.0 (d, 2H, J = 8.9 Hz), 7.6-7.4 (d, 2H, J = 8.9 Hz), 4.0-
3.8 (s, 2H, CH2), 2.2-2.0 (m, 3H), 1.8-1.4 (m, 12H); 
13
C NMR (50 MHz, CDCl3) δC: 149.9, 
146.1, 128.7, 123.5, 51.0, 44.5, 42.9, 36.6, 29.8; MS (ESI-MS) m/z: 287.14 (M
+
), 214.00, 
134.94, 78.95; IR (ATR; cm
-1
): 2900.0, 2848.5, 1523.8, 1477.3, 1354.9, 1133.8, 779.5, 716.5. 
23. Synthesis of 6-8: Previously prepared nitrobenzyltricyclo[3.3.1.1
3,7
]decan-1-amines (3, 4 
or 5, 0.5 mmol) and tin powder (0.8 mmol) were added to a round-bottomed flask and set up 
under reflux conditions. This was followed by addition of 10 % hydrochloric acid (1.5 ml) 
down the condenser with continuous stirring, while elevating the temperature to reflux 
conditions. Ethanol (5 ml) was added as a solubilisation agent. Further HCl additions (2 x 2.3 
ml) were made at 10 minute intervals. The reaction was refluxed overnight followed by an 
aqueous extraction with DCM (3 x 20 ml). The water phase was collected and alkalinised 
using a 40 % NaOH solution just past the turning point, and then extracted with DCM (3 x 20 
ml). The combined organic fractions were washed with brine (2 x 15 ml), dried with 
anhydrous MgSO4 and the solvent evaporated in vacuo to yield the products (6-8) as light 
brown amorphous solids.  
N-(2-aminobenzyl)tricyclo[3.3.1.1
3,7
]decan-1-amine (6): C17H24N2; Yield: 70 %; mp: 71 
o
C; 
1
H NMR (200 MHz, CDCl3) δH: 6.9-6.8 (m, 2H), 6.5-6.3 (m, 2H), 3.6-3.4 (s, 2H, CH2), 2.1-
1.8 (m, 3H), 1.8-1.4 (m, 12H); 
13
C NMR (50 MHz, CDCl3) δC: 146.9, 129.5, 128.0, 125.3, 
117.7, 115.7, 50.5, 43.9, 42.7, 36.7, 29.5; MS (ESI-MS) m/z: 257.14 (M
+
), 105.94, 78.95; IR 
(ATR; cm
-1
): 3402.2, 3282.5, 2903.1, 2849.3, 1616.9, 1494.4, 1357.8, 1072.3, 785.1, 710.0. 
N-(3-aminobenzyl)tricyclo[3.3.1.1
3,7
]decan-1-amine (7): C17H24N2; Yield: 75 %; mp: 79 
o
C; 
1
H NMR (200 MHz, CDCl3) δH: 6.9-6.7 (m, 1H), 6.5-6.2 (m, 3H), 3.6-3.4 (s, 2H, CH2), 2.1-
1.8 (m, 3H), 1.8-1.4 (m, 12H); 
13
C NMR (50 MHz, CDCl3) δC: 146.4, 142.7, 129.2, 118.4, 
115.0, 113.5, 50.7, 45.0, 42.7, 36.7, 29.5; MS (ESI-MS) m/z: 257.13 (M
+
), 76.99; IR (ATR; 
cm
-1
): 3399.9, 3174.3, 2897.4, 2845.9, 1603.7, 1493.6, 1356.6, 1343.0, 1067.8, 1038.0, 
773.5, 708.4. 
N-(4-aminobenzyl)tricyclo[3.3.1.1
3,7
]decan-1-amine (8): C17H24N2; Yield: 90 %; mp: 91 
o
C; 
1
H NMR (200 MHz, CDCl3) δH: 6.9-6.8 (d, 2H, J = 8.8 Hz), 6.4-6.3 (d, 2H, J = 8.8 Hz), 3.6-
3.4 (s, 2H, CH2), 2.1-1.8 (m, 3H), 1.8-1.4 (m, 12H); 
13
C NMR (50 MHz, CDCl3) δC: 145.0, 
129.3, 128.8, 115.1, 50.7, 44.5, 42.7, 36.7, 29.5; MS (ESI-MS) m/z: 257.15 (M
+
), 105.93, 
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78.95; IR (ATR; cm
-1
): 3429.1, 3315.8, 2898.2, 2847.5, 1610.1, 1518.8, 1357.2, 1069.7, 
1038.9, 761.6, 708.4. 
24. Synthesis of 9: Amantadine free base (3.3 mmol) were added to a round-bottomed flask 
containing acetonitrile (10 ml), K2CO3 (4.5 mmol) and 3-methoxybenzylchloride (3.3 mmol). 
The synthetic procedure from this point was the same as described for 1 which yielded N-(3-
methoxybenzyl)tricyclo[3.3.1.1
3,7
]decan-1-amine (9) as a white powder. Physical data: 
C18H25NO; Yield: 18 %; mp: 124 
o
C; 
1
H NMR (200 MHz, CDCl3) δH: 7.7-7.5 (m, 1H), 7.4-
6.7 (m, 2H), 4.6-4.2 (bs, NH), 4.0-3.7 (2 x s, 5H), 2.1-1.8 (m, 3H), 1.8-1.4 (m, 12H); 
13
C 
NMR (50 MHz, CDCl3) δC: 162.5, 132.1, 129.7, 121.7, 110.6, 110.2, 55.2, 44.4, 42.5, 35.3, 
29.2; MS (ESI-MS) m/z: 313.23, [M+ACN+H] 151.98, 78.91; IR (ATR; cm
-1
): 2934.6, 
2864.2, 1586.1, 1454,8, 1265.0, 1174.7, 1075.2, 852.2. 
25. Synthesis of 10: 1-Bromoadamantane (2.3 mmol) were added to the reaction vessel 
containing acetonitrile (3 ml), K2CO3 (3.5 mmol) and 4-methoxybenzylamine (2.3 mmol). 
The mixture was placed in the microwave reactor (240 Psi, 300 W, 150 
o
C, 60 min). After 
irradiation, the mixture was filtered by vacuum filtration to remove the K2CO3. The filtrate 
was collected and the excess solvent evaporated in vacuo and purified via flash 
chromatography to yield N-(4-methoxybenzyl)tricyclo[3.3.1.1
3,7
]decan-1-amine (10) as a 
white powder. Physical data: C18H25NO; Yield: 25 %; mp: 225 
o
C; 
1
H NMR (200 MHz, 
CDCl3) δH: 7.3-7.1 (dd, 2H J = 6.62 Hz, 2.16 Hz), 6.9-6.7 (dd, 2H, J = 6.62 Hz, 2.16 Hz), 5.2-
4.6 (bs, NH), 4.0-3.7 (2 x s, 5H), 2.2-1.8 (m, 3H), 1.8-1.4 (m, 12H); 
13
C NMR (50 MHz, 
CDCl3) δC: 158.5, 129.7, 128.4, 114.4, 55.2, 51.6, 45.2, 42.4, 35.5, 29.2; MS (ESI-MS) m/z: 
313.23, [M+ACN+H] 78.95; IR (ATR; cm
-1
) : 2905.9, 2849.6, 1627.7, 1453.7, 1248.0, 
1176.7, 1087.8, 813.0. 
26. F. T. Zindo, Q. R. Barber, J. Joubert, J. J. Bergh, J. P. Petzer and S. F. Malan, Eur. J. 
Med. Chem., 2014, 80, 122. 
27. E. B. Hollingsworth, E. T. McNeal, J. L. Burton, R. J. Williams, J. W. Daly and C. R. 
Creveling, J. Neurosci., 1985, 5, 2240. 
28. J. Joubert, S. Van Dyk, I. R. Green and S. F. Malan, Eur. J. Med. Chem., 2011, 46, 5010–
5020. 
29. H. J. R. Lemmer, J. Joubert, S. van Dyk, F. H. van der Westhuizen and S. F. Malan, Med. 
Chem., 2012, 8, 361. 
30. S. A. Lipton, Nat. Res. Drug. Discovery, 2006, 5, 160. 
31. W. Liebenberg, J. J. Van der Walt and C. J. Van der Schyf, Pharmazie, 2000, 833. 
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Chapter 6 
Conclusion 
 
 
The complex pathogenesis and aetiology of neurodegenerative diseases (NDs) make it clear 
that drugs targeting a single receptor or enzymatic system will not result in successful 
retardation and treatment of these multifactorial diseases. As highlighted in the review article 
presented in chapter 2 [1], the advent of the multitarget-directed ligand (MTDL) approach 
has over the last few decades seen the development of compounds that combine symptomatic 
treatment and neuroprotection in one molecule by acting simultaneously on different 
receptors and target sites implicated in NDs.  
 
This study focused on the development of novel MTDL’s using polycyclic structures as 
scaffolds with inherent activity and the ability to promote favourable pharmacokinetic and 
pharmacodynamic properties of the resultant MTDL’s. The resultant compounds were 
designed to serve as neuroprotective agents by inhibiting NMDA receptors, blockade of 
VGCC’s and by inhibiting the apoptotic process resulting from the activity of the MAO 
isoenzymes. 
 
Figure 8.1: Representative structures of the various compounds designed and synthesised in this study and 
NGP1-01, a known neuroprotective agent. 
 
As reported in research article 1 (Chapter 3) [2], a series of polycyclic propargylamine and 
acetylene derivatives, represented by P1 and P2 (Figure 8.1), showed significant anti-
apoptotic activity comparable to selegiline at 10 µM. The results of the anti-apoptotic assay 
suggested the anti-apoptotic activity of the propargylamine moiety to be attributed to the 
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O
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acetylene group. For activity, this acetylene group can either be terminal (P1) or between two 
non-polar groups (P2), with the terminal acetylene group having slightly higher activity. It 
was also confirmed that when linked to a polycyclic cage structure, propargylamine and 
acetylene derivatives displayed increased anti-apoptotic activity. Further investigation must 
however be conducted to ascertain whether this reported anti-apoptotic activity is solely due 
to the acetylene group, the cage moiety, or the acetylene group in conjunction with a nearby 
electronegative atom/group. When assayed for multifunctional activity, this series showed 
little to no activity on the VGCC, NMDA receptors and MAO-B enzyme even at 
concentrations above 100 µM. The ability of these compounds to significantly inhibit 
apoptosis suggests that these compounds exhibited their neuroprotective action through some 
other mechanism(s) unexplored in this study.  
 
Follow up work on P1 and P2 successfully yielded a series of pentacycloundecane and 
hexacycloundecane propargylamine derivatives presented in research article 2 (Chapter 4) 
[3], represented by Q1 and Q2 (Figure 8.1), which showed promising neuroprotective 
potential. These compounds showed the ability to significantly improve the viability of SH-
SY5Y neuroblastoma cells, previously exposed to the neurotoxin MPP
+
, by 31% and 61% at 
a 1 µM concentration. The influence of the acetylene moiety in reducing the cytotoxicity of 
this series was evident at 100 μM. By comparing the cytotoxicity displayed by the propargyl 
containing compounds within this series with their respective precursors devoid of this 
moiety, it was observed that the propargyl moiety was responsible for a decrease in 
cytotoxicty by about 3-14 times at 100 µM. These compounds also showed dual calcium 
modulation activity by blocking VGCC’s (26.6% to 51.3%, at 10 µM) and by blocking 
NMDAR (31.4% and 88.3%, at 10 µM). This activity was comparable to that of NGP1-01, a 
known dual acting calcium channel blocker [4]. This general improvement in activity, 
compared to P1 which was inactive as a VGCC blocker at 100 µM, emphasizes the need to 
include a benzylamine moiety in the structure of polycyclic amine derived compounds 
designed to possess inherent VGCC blockade activity. The inclusion of a propargyl moiety in 
the compound structures seemed to contribute to improved NMDAR antagonism as 
compounds devoid of this moiety within the series generally showed lower NMDAR 
inhibitory potentials compared to the propargyl carrying compounds. When assayed for 
MAO inhibition, most of the active compounds displayed selectivity to the MAO-B 
isoenzyme with IC50 values ranging from 1.70 µM to 36.31 µM and appeared to be reversible 
MAO inhibitors as defined by the time-dependency studies conducted. This improved 
activity, compared to P1 and P2, can be attributed to the increased molecular length of these 
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compounds as a result of the incorporation of a benzylamine moiety into their structures. The 
juxtapositioned benzylamine and propargyl moieties seemed to be imperative in rendering the 
compounds better MAO-B inhibitory activity and afforded them multi-mechanistic 
neuroprotective potential. Inhibiting the MAO-B enzyme is an important feature of these 
compounds as this enzyme has been reported to play a critical role in the pathogenesis of 
NDs. Although the MAO-B inhibitory activity of these compounds was a significant 
improvement in comparison to the previously reported compounds P1 and P2, it remains 
about 1000-fold weaker than the activity of selegiline. Further structural modifications of 
these compounds may therefore be necessary to afford molecules which may potentially 
show improved MAO-B inhibition.  
In research article 3 (Chapter 5) [5], several compounds represented by Y1 (Figure 8.1) were 
designed to carry the adamantane amine moiety as a polycyclic scaffold rather than the 
pentacycloundecane moiety seen in P1, P2, Q1, Q2 and NGP1-01. These compounds 
displayed good inhibitory activity against both NMDAR channel (66.7 - 89.5 % at 100 µM) 
and VGCC (39.6 – 85.7 % at 100 µM), and appeared to be superior calcium modulators to 
NGP1-01. These adamantane derived compounds are potentially better neurotherapeutic 
options than amantadine as they were shown to inhibit both NMDAR and VGCC-mediated 
calcium influx, whereas the base adamantine structures only inhibit NMDAR-mediated 
calcium influx. Various structure-activity relationships were drawn from this study. For 
example, an increase in chain length between the amantadine moiety and the aromatic group 
was shown to significantly increase the NMDAR inhibitory activity. An ethyl linker in 
particular, was thought to enable the compound to penetrate deeper into the channel lumen 
thereby enabling more favourable interactions with the PCP-binding site of the receptor. Of 
the nitro containing compounds of this series, the rank order of NMDAR antagonistic activity 
that was followed was para > ortho > meta. The weaker activity of the ortho or meta 
substituted nitro containing compounds may be attributed to steric or conformational effects 
of the ortho or meta substituted aromatic ring. The nitro group in the para position seemed to 
enable the compounds better fit at the site of interaction rendering them activity as NMDAR 
antagonists.  
In conclusion, the compounds presented in this thesis are promising leads to multi-
mechanistic compounds that may be useful as drug agents for the treatment of 
neurodegenerative disorders. Further in vitro and in vivo studies, which may include 
mechanistic studies as well as elucidation of the actual binding mode of these compounds, 
their direct involvement in the anti-apoptotic cascade, dopamine transmission and blood-
http://etd.uwc.ac.za/
150 
 
brain barrier permeability, would provide better insight on their drugability. Also, these 
analogues may be screened for potential neuroprotective activity on various other drug 
targets implicated in neurodegeneration. 
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Chapter 7 
 Additional research outputs 
 
7.1. Research Article 4: Design, synthesis and evaluation of indole 
derivatives as multifunctional agents against Alzheimer's disease 
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Graphical Abstract 
  
Indole polycyclic ring could 
contribute to improved MAO and 
NOS inhibition as well as eliminate 
chirality seen in ladostigil. 
 
Propargylamine moiety: could interact 
with the FAD co-factor of the MAO 
enzyme and confer neuroprotection 
independently as well. 
 
The carbamate/ urea 
moiety may enhance 
AChE & BuChE 
inhibitory activity. 
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Abstract 
A series of indole derivatives was designed and synthesized to improve on activity and 
circumvent pharmacokinetic limitations experienced with the structurally related compound, 
ladostigil. The compounds consisted of a propargylamine moiety (a known MAO inhibitor 
and neuroprotector) at the N1 position and a ChE inhibiting diethyl-carbamate/urea moiety at 
the 5 or 6 position of the indole ring. In order to prevent or slow down the in vivo hydrolysis 
and deactivation associated with the carbamate function of ladostigil, a urea moeity was 
incorporated into selected compounds to obtain more metabolically stable structures. The 
majority of the synthesized compounds showed improved MAO-A inhibitory activity 
compared to ladostigil. The compounds possessing the propargylamine moiety showed good 
MAO-B inhibitory activity with 6 and 8 portraying IC50 values between 14 – 20 fold better 
than ladostigil. The ChE assay results indicated that the compounds have non-selective 
inhibitory activities on eeAChE and eqBuChE regardless of the type or position of 
substitution (IC50: 2-5 μM). MAO-A and MAO-B docking results showed that the 
propargylamine moiety was positioned in close proximity to the FAD cofactor suggesting 
that the good inhibitory activity may be attributed to the propargylamine moiety and 
irreversible inhibition as confirmed in the reversibility studies. Docking results also indicated 
that the compounds have interactions with important amino acids in the AChE and BuChE 
catalytic sites. Compound 6 was the most potent multifunctional agent showing better in vitro 
inhibitory activity than ladostigil on all enzymes tested (hMAO-A IC50 = 4.31 μM, hMAO-B 
IC50 = 2.62 μM, eeAChE IC50 = 3.70 μM, eqBuChE IC50 = 2.82 μM). Chemical stability tests 
confirmed the diethyl-urea containing compound 6 to be more stable than its diethyl-
carbamate containing counterpart compound 8. Compound 6 also exerted significant 
neuroprotection (52.62 % at 1 μM) against MPP+ insult to SH-SY5Y neural cells and have 
good in silico predicted ADMET properties. The favourable neuronal enzyme inhibitory 
activity, likely improved pharmacokinetic properties in vivo and the potent neuroprotective 
ability of compound 6 make it a promising compound for further development. 
 
Keywords: Alzheimer’s disease, Indole, Propargylamine, Monoamine oxidase, 
Cholinesterase, Ladostigil 
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7.1.1. Introduction 
Alzheimer’s disease (AD) is an age related neurodegenerative disorder characterised by 
progressive memory loss and cognitive impairment occurring as a result of a process of 
programmed cell death known as apoptosis.
1,2
 Over the years several pathways have been 
indicated in the pathology of the disease. The cholinergic hypothesis states that there is an 
extensive loss of cholinergic neurons in the central nervous system that contributes to 
impairment in the cognitive and memory symptoms of the affected person.
3
 Oxidative stress 
and amyloid β (Aβ) plaque formation have been shown to be involved in the pathophysiology 
of the disease.
4,5
 Acetylcholinesterase (AChE) inhibitors in AD act by increasing the 
endogenous levels of acetylcholine (ACh) in the brain and thereby enhance cholinergic 
transmission and improve cognitive functions (Figure 1).
6,7
 They however do not halt the 
process of apoptosis nor improve the depressive symptoms of the disease due to the 
multifactorial nature of AD. Butyrylcholinesterase (BuChE) also has the capacity to 
hydrolyse acetylcholine. Excess ACh levels in the brain cause saturation of AChE and in turn 
increase the activity of BuChE towards the neurotransmitter.
8
 Even though AChE hydrolyses 
more ACh than BuChE, the latter contributes more to AD because of the decreased levels of 
the true cholinesterase, hence its inhibition is of value to AD.
9,10
 Accordingly, a compound 
that inhibits this enzyme, in addition to AChE, would prove beneficial for treatment of AD. 
 
Figure 1: Structures of previously described cholinesterase inhibitors. 
The monoamine oxidase (MAO) enzymes natively metabolise amine neurotransmitters such 
as dopamine and 5-hydroxytryptamine
11
 and have been identified as attractive targets for the 
treatment of neurological disorders.
12
 The enzyme, occurring in two isoforms, MAO-A and 
MAO-B, produces peroxides that cause oxidative stress alongside the depletion of 
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neurotransmitters.
13
 MAO-B constitutes about 80% of the total MAO activity in the human 
brain and is the predominant form of the enzyme in the striatum, while MAO-A is mainly 
distributed peripherally.
13,14
 Inhibition of MAO-A and MAO-B permits accumulation of 
neurotransmitters and reduces the formation of oxidative free radicals to confer 
neuroprotection. Inhibitors of the enzymes are thus expected to protect from 
neurodegeneration due to their ability to reduce the formation of peroxides and radical 
species from amine catalysis.
15-18
 Although MAO-B is present in higher concentrations than 
MAO-A in the human basal ganglia, MAO-A inhibitors have also been shown to enhance 
dopamine levels in this region.
19,20
 In order to conserve dopamine in the basal ganglia, mixed 
MAO-A/B inhibitors may therefore be more efficacious than selective inhibitors and may be 
of value in the treatment of AD and other neurodegenerative disorders.
12
 Propargylamine 
derived MAO inhibitors such as rasagiline and ladostigil (Figure 2) have also shown 
antiapoptotic activity unrelated to their MAO inhibitory activity.
21,22
 
 
Figure 2: Structure of the MAO inhibitor rasagiline and the MTDL ladostigil 
All of the drugs presently approved for AD treatment offer transient symptomatic relief only. 
Current treatment options have moved towards including multiple therapies to address the 
varied pathological aspects of AD.
23
 The multi-target-directed ligand (MTDL) approach is a 
promising strategy that yielded ladostigil.
24
 Ladostigil or TV3326 is a neuroprotective 
bifunctional analogue with the aminoindan structure of rasagiline (Figure 2) and the 
carbamate cholinesterase inhibitory moiety of rivastigmine and physostigmine (Figure 1).
24,25
 
It was initially designed for AD in high doses but failed to meet its endpoint in a Phase 2b 
clinical trial in 2012. It is currently under investigation for mild cognitive impairment due to 
its neuroprotective, anti-oxidant and microglial activation abilities.
26
 Various MTDL 
combinations featuring two or more of the following properties; MAO-, cholinesterase- and 
Aβ inhibition, anti-inflammatory activity, metal and iron homeostasis and anti-apoptotic 
activity have been described in the literature.
23,27
 Recent observations have suggested that 
dual ChE and MAO inhibition, as is the case with ladostigil, is likely to be more effective 
against AD.
27
 However only the R-enantiomer of ladostigil is active, raising issues with 
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synthesis and quality control. The carbamate on ladostigil is also open to acid hydrolysis and 
enzymatic metabolism, and once this metabolism takes place, it leaves a non-enzyme 
inhibiting neuroprotective molecule TV3279.
28,29
 This loss of enzymatic ability may account 
for one of the reasons why ladostigil failed in Phase 2b AD clinical trials. In order to 
overcome these unfavourable properties of ladostigil, a series of compounds structurally 
similar to ladostigil, but based on an indole structure was designed (1 – 8, Figure 3 and 4). 
The propagylamine moiety has been shown to inhibit MAO as well as confer 
neuroprotection
22
 and was incorporated at the N1 position of compounds 5 – 8 to eliminate 
the chirality associated with rasagiline and ladostigil. The ChE inhibiting carbamoyl moiety 
in the form of a diethylcarbamate/urea was conjugated at the 5 or 6 position with the aim of 
inhibiting ACh hydrolysis by AChE and BuChE.
30
 The diethyl moeity was selected for 
conjugation over the methyl-ethyl moeity of ladostigil and rivastigmine. Preliminary 
molecular modelling studies utilising the ChE enzymes during the initial design phase of this 
study suggested that the diethyl moeity will show improved binding in the ChE active site 
pockets and stabilise the molecules leading to optimal activity. In order to prevent or slow 
down the in vivo hydrolysis associated with the carbamate function of ladostigil a urea 
moeity was incorporated into compounds 1, 2, 5 and 6. It is expected that the urea containing 
compounds will be more metabolically stable than their carbamate counterparts (3, 4, 7 and 
8) and lead to improved enzymatic inhibition in vivo. In the context of the discovery of 
neuroprotective agents an indole scaffold was selected because it possesses efficiency in 
scavenging free radicals and as an antioxidant.
31,32
 The indole heterocycle has also been 
investigated in the design of AChE-induced Aβ aggregation and neuronal nitric oxide 
synthase (nNOS) inhibitors
32
 and MAO-B inhibitors.
31,33
 
The objective of this study was therefore to improve the inhibitory, neuroprotective and 
stability profile and eliminate the stereochemistry associated with rasagline and more 
recently, ladostigil. It is expected that these novel compounds will serve as dual 
AChE/BuChE and MAO-A and MAO-B inhibitors and possess similar activity with 
improved pharmacokinetic profiles compared to ladostigil and other related anti-
AD/neuroprotective agents. 
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Figure 3: Design strategy for the novel indole derivatives incorporating the carbamoyl/urea and propargylamine 
moieties.22, 30-32 R2 = NH or O. 
 
7.1.2. Results and discussion 
7.1.2.1. Chemistry 
The synthetic strategy developed to obtain the novel MTDLs provides several advantages, 
including the elimination of the chiral centre on the indane ring of rasagiline and ladostigil,  
easy accessibility of the final product by one step or two step processes using commercially 
available starting materials and simple scale-up from grams to larger quantities. The synthesis 
utilises the commercially available 5- or 6-hydroxy/amino indole (1a – 1d) that was 
conjugated to a diethyl-carbamoyl chloride moiety at position 5 or 6 via a nucleophilic 
addition-elimination reaction using acetonitrile as solvent in the presence of potassium 
carbonate (1 – 4, Figure 4). These intermediates were then treated with sodium hydride in 
dimethylformamide and propargyl bromide and reacted under optimized microwave 
irradiation conditions (150 W, 95 °C, 2-4 hrs) to give the final compounds 5 - 8 in high yields 
(> 87 %). 
In order to characterise the novel compounds, analytical instruments and techniques as 
described in the experimental section were used. Compounds with similar substitutions 
showed similar signal patterns on their NMR and IR spectra. The five aromatic protons of the 
indole were observed between 7.70 and 6.30 ppm on the 
1
H NMR, with the carbamate/urea 
portion showing a triplet at around 1.25 ppm (CH3) and a multiplet at around 3.40 ppm 
(CH2). The presence of the propargyl moiety in compounds 5 - 8 was confirmed by a doublet 
and triplet peak at around 4.50 ppm (CH) and 2.50 ppm (CH2) respectively. The 
13
C NMR of 
the compounds showed the distinct peak of the carbonyl carbon of the carbomoyl or urea 
Indole polycyclic ring could contribute 
to improved MAO and NOS inhibition as 
well as eliminate chirality seen in 
ladostigil. 
 
Propargylamine moiety: could interact with the 
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moiety in the vicinity of 158 ppm. The molecular mass of each compound was confirmed 
using MS and HR-MS.  
 
Figure 4: Synthetic pathway of the novel compounds 1 – 8. Reagents and conditions: (i) CH3CN, K2CO3, rt, 2 
h; (ii) DMF, NaH, microwave (2-4 h, 95 ºC, 150 W) 
 
7.1.2.2. Monoamine oxidase inhibition studies 
The compounds were investigated for inhibition of human MAO-A and MAO-B using 
recombinant human enzymes. Enzyme inhibition tests of reference and test compounds were 
performed by a fluorescence based assay with the substrate kynuramine measuring the 
production of 4-hydroxyquinoline formed as a by-product of the enzymatic deamination 
reaction.
34
 The selective inhibitors clorgiline (IC50 = 1.06 nM) and selegiline (IC50 = 20 nM) 
were used as the positive controls for the MAO-A and MAO-B assays respectively. IC50 
values of the test compounds are presented in Table 1. The assay results showed that all the 
compounds, except 1, had the ability to inhibit the MAO-A enzyme at concentrations below 
100 μM. As observed from the IC50 values the compounds that did not possess the 
propargylamine moiety (1 – 4) had, in general, lower activity when compared to their 
propargylamine containing counterparts (5 – 8). Literature confirms that the propargylamine 
moiety is responsible for the MAO inhibitory properties of compounds containing this 
functional group.
29
 The results obtained agree with this, as can be seen by the more potent 
IC50 values upon inclusion of this moiety. The presence of a urea moiety (compounds 5 and 
6) resulted in compounds that have comparably better inhibitory abilities than the carbamate 
compounds 7 and 8. Compound 6 had the lowest IC50 within the series (IC50 = 4.31 μM) 
towards MAO-A. The comparable compound 8 with similar orientation, except for a 
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carbamate instead of the urea, is 12 times less potent (IC50 = 52.64 μM) towards the enzyme. 
This may indicate that the hydrogen donating ability of the secondary amine in the urea 
moieties may contribute to important interactions with amino acids in the active site of the 
enzyme. Overall the compounds were moderately good inhibitors of the MAO-A enzyme 
showing better activity compared to ladostigil in vitro.  
 
Table 1: In vitro IC50 values (µM) of test compounds for hMAO-A, hMAO-B, eeAChE and eqBuChE 
Compound MAO-A MAO-B SI MAO-B
a
 AChE BuChE SI AChE
b 
1 >100 >100 n.d. 1.97 3.48 1.77 
2 20.37 >100 < 0.20 2.28 4.55 2.0 
3 13.15 >100 < 0.13 2.78 2.29 0.82 
4 88.11 >100 < 0.88 3.72 3.18 0.86 
5 33.42 28.84 1.16 2.77 3.96 1.43 
6 4.31 2.62 1.65 3.70 2.82 0.76 
7 99.08 16.52 6.00 2.57 3.01 1.17 
8 51.64 1.84 28.06 2.41 5.01 2.08 
Ladostigil
c >100 37.1 - 31.80 1.98 16.10 
ahMAO-B selectivity index = IC50(hMAO-A)/IC50(hMAO-B); 
bAChE selectivity index = IC50 (eeBuChE)/IC50 
(eqAChE); cIC50 values of ladostigil obtained from references 21 and 37; n.d. = not determined. 
The results of the MAO-B assay indicated that compounds 1-4 had MAO-B IC50 values 
above 100 μM. These compounds did not possess the propargylamine substitution at position 
N1 and may lack vital interactions with the flavin adenine dinucleotide (FAD) co-factor as 
observed for the propargylamine containing compounds, rasagiline and selegiline.
29
 The 
conjugation of the propargylamine moiety (5-8) led to a significant improvement in MAO-B 
inhibition. This is in line with literature that suggests that the propargylamine moiety is a 
good contributor towards MAO-B inhibitory capacity.
29
 The compounds that contain a 
carbamate showed, in general, slightly better MAO-B activity (although not significantly, p > 
0.05) compared to their urea counterparts. This is observed when compound 5 is compared 
with 7 and 6 with 8. This observation may indicate that the electron accepting abilities of the 
oxygen molecule contributes to some interaction in the MAO-B active site. Compounds 6 
and 8 had the lowest MAO-B IC50 values of 2.62 μM and 1.84 μM, respectively. These 
compounds had the carbamate/urea at the 6 position and the N1 propargylamine moiety 
similar to ladostigil. This orientation of the propargylamine to the carbamoyl/urea moiety 
seems to be favourable for good MAO inhibitory activity of these compounds. 
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7.1.2.3. MAO reversibility studies 
Compound 6 was selected for MAO reversibility studies because it showed the most 
promising activities on both enzymes. This study aimed to investigate if the interaction 
between the propargyl moiety of 6 and the FAD co-factor is reversible or irreversible. For 
this purpose the time dependence of MAO-A and -B inhibition by compound 6 was 
evaluated. Recombinant human MAO-A and MAO-B was preincubated with the test 
compounds for periods of 0, 15, 30 and 60 min and the residual rates of the MAO-A and –B 
catalysed oxidation of kynuramine were measured. The concentration of compound 6 used 
was approximately twofold the measured IC50 value for the inhibition of the respective 
enzymes. Clorgyline and selegiline, known irreversible inhibitors of MAO-A and MAO-B 
respectively, were used as a reference compounds. As shown in Figure 5 and Figure 6, both 
clorgyline and selegiline showed a time-dependent reduction in the rates of MAO-A and –B 
catalysed oxidation of kynuramine, confirming irreversible inhibition. Compounds 6 also 
showed time-dependent reduction in the rates of MAO-A and –B catalysed oxidation of 
kynuramine. From these results it can be concluded that the inhibition of MAO-A and -B by 
compound 6 is irreversible, at least for the time period (60 min) and at the inhibitor 
concentrations (2 x IC50) evaluated. This irreversible MAO inhibition of compound 6 
indicates that the interaction between the propargyl moiety and the FAD cofactor of MAO-A 
and MAO-B is also present in these structures as is the case for the irreversible MAO 
inhibitor ladostigil.
24,25
 This finding also shows that the propargylamine can be incorporated 
within the heterocycle and retain its irreversible MAO inhibition. 
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Figure 5: Time-dependent inhibition of the recombinant human MAO-A catalysed oxidation of kynuramine by 
clorgyline and 6. The enzyme was preincubated for various periods of time (0–60 min, x-axis) with clorgyline 
and 6 at concentrations of 0.002 μM and 8.62 μM. The concentration of kynuramine used was 45 μM. 
 
Figure 6: Time-dependent inhibition of the recombinant human MAO-B (Panel B) catalysed oxidation of 
kynuramine by selegiline and 6. The enzymes were preincubated for various periods of time (0–60 min, x-axis) 
with selegiline and 6 at concentrations of 0.040 μM and 5.24 μM. The concentration of kynuramine used was 30 
μM. 
 
7.1.2.4. Cholinesterase inhibition studies 
The compounds were also evaluated for inhibitory activity on eeAChE (electric eel) and 
eqBuChE (equine serum) according to Ellman’s method,36 with tacrine (AChE IC50 = 0.11 
μM; BuChE IC50 = 0.017) as positive control. All the compounds were able to inhibit AChE  
with IC50 values between 1 μM and 4 μM (Table 1). This illustrates that both the carbamate 
and urea functional groups contributes to inhibition of the AChE enzyme. Also, the 
compounds exerted good activity regardless of the position of the carbamate or urea function. 
Addition of the propargylamine moiety did not affect the inhibitory capacity of the 
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compounds indicating that the carbamate and urea moieties are highly involved in activity. 
Comparing the IC50 values of the test compounds to that of ladostigil shows that the test 
compounds more active AChE inhibitors. The role that BuChE plays in the progression of 
AD is its ability to hydrolyse acetylcholine in the event of AChE saturation.
8
 Accordingly, a 
compound that inhibits this enzyme, in addition to AChE, would prove beneficial for the 
treatment of AD. Carbamoyl containing compounds have also been shown to be BuChE 
enzyme substrates
37
 and it is postulated that the diethylcarbamoyl moiety interacts with the 
enzyme to block its catalytic activity. The results showed that the synthesized compounds 
had good activity in inhibiting the BuChE enzyme with IC50 values between 2 and 5 μM 
comparable to that of ladostigil. When the different substitutions of the test compounds are 
compared, it is observed that the 5 substituted compounds yielded similar results compared to 
the 6 substituted compounds. Selectivity indices were close enough for the compounds to be 
classified as non-selective ChE inhibitors in vitro with a good balance between AChE and 
BuChE activities. Importantly, the compounds portray non-selective inhibitory activities 
compared to ladostigil, which is 16 times more selective towards BuChE over AChE in 
vitro.
21,35
 Moreover, literature has reported that AChE promotes the assembly of Aβ into 
amyloid fibrils hence these compounds, with the improved AChE inhibitory activity 
compared to ladostigil, may also prove to reduce the conglomeration of amyloid fibrils into 
plaques in addition to reducing ACh hydrolysis.
38,39
 
 
7.1.2.5. Molecular modelling 
To provide insight, the binding mode of compounds 1-8 in hMAO-A, hMAO-B, eeAChE and 
eqBuChE were examined using molecular docking. The structures of human MAO-A 
cocrystallized with clorgiline (PDB entry: 2BXS),
40
 human MAO-B co-crystallized with 
safinamide (PDB entry: 2V5Z)
41
 and eeAChE co-crystallized with donepezil (PDB entry: 
1EVE)
42
 were retrieved from the Brookhaven Protein Data Bank (www.rcsb.org/pdb) and the 
docking was carried out with the Dock application of the Molecular Operating Environment 
(MOE) software.
43
 In the absence of a X-ray structure of eqBuChE, a homology model was 
used to rationalize the experimental data. The modeling of the 3D structure was performed by 
an automated homology-modeling program (SWISS-MODEL).
44,45
 The putative 3D structure 
of eqBuChE has been created based on the crystal structure of hBuChE (PDB: 2PM8) as 
these two enzymes exhibited 89% sequence identity. The docking of the compounds into this 
homology model of eqBuChE was carried out with Autodock Vina.
46
 The docking results 
were analyzed with MOE. 
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7.1.2.5.1. MAO molecular modelling studies 
Docking results showed that as expected compounds 1-4 lacked interactions with vital 
residues in the active site of MAO-A (Figure 7). The indole heterocyclic ring of 1-4 was best 
orientated towards the FAD cofactor in the substrate cavity with the diethylcabamoyl/urea 
moiety occupying the entrance cavity. In the compounds that contained the propargylamine 
moiety (5-8), this moiety is found within close proximity to the FAD cofactor with the rest of 
the molecule occupying the active site (Figure 7). This orientation has been reported to be 
essential for MAO inhibitory capacity.
47
 The indole heterocyclic ring did not portray any 
significant interactions with the MAO-A active site, but the compounds were well 
accommodated within in the active site which may account for the good inhibitory activities 
observed for some of these compounds. 
 
Figure 7: The MAO-A active site cavity displaying the binding and interactions of compounds 1-4 (left) and 
compounds 5-8 (right). Compound 1 and 5 are shown in green, compound 2 and 6 in light blue, compound 3 
and 7 in red and compound 4 and 8 in magenta. The FAD co-factor is shown to the right, in magenta, in the 
outside of the binding pocket.  
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Figure 8: The MAO-B active site cavity displaying the binding and interactions of compounds 1-4 (left) and 
compounds 5-8 (right). Compound 1 and 5 are shown in green, compound 2 and 6 in light blue, compound 3 
and 7 in red and compound 4 and 8 in magenta. The FAD co-factor is shown to the right, in red, in the outside 
of the binding pocket. 
The MAO-B molecular docking experiments showed that compounds 1-4 were not able to 
reach the substrate cavity but rather maintained interactions in the entrance cavity (Figure 8). 
This inability of 1-4 to reach the substrate cavity may indicate the reason why these 
compounds did not show MAO-B activity. The propargylamine containing compounds (5-8) 
were able to reach the substrate cavity and compounds 6 and 8 showed π-H interactions 
between the propargylamine moiety and the FAD co-factor (Figure 8). Compounds 5 and 7 
adopted an inverted orientation compared to 6 and 8, and lacked the π-H interaction. This 
observation may account for the improved MAO-B inhibitory activity of the 6-substituted 
indole derivatives, 6 and 8 (Table 1). 
 
7.1.2.5.2. ChE molecular modelling studies 
The assay results indicated that all the compounds were able to inhibit ChE enzymes with 
IC50 values between 1 μM and 5 μM and molecular docking was employed to gain insight 
into the binding modes of all the compounds in the active site of AChE and BuChE. The 
docking results, Figure 8, showed that compounds 1-8 mainly interact within the CAS of 
AChE. The alkyl component of the diethyl-carbamate/urea of compounds 1-4 showed π-H 
interactions with Trp84 in the CAS. This interaction has been reported to be crucial for AChE 
inhibitory activity.
48
 The indole heterocycle of 1-4 mainly sits in the active site gorge and 
does not occupy the PAS. The indole moiety of compounds 5-8 possesses π-π stacking 
interactions with Trp334 and Phe330 (a key residue involved in ligand binding in the active 
gorge).
49
 The interaction with Trp84 was also observed for compounds 5-8. This may explain 
why the good inhibitory activities were retained across the series. It is important to note that 
http://etd.uwc.ac.za/
164 
 
the propargylamine moiety does not show any significant interactions with amino acids in the 
active site but occupied the gorge facing the PAS. 
 
Figure 8: The AChE active site cavity displaying the binding and interactions of compounds 1-4 (left) and 
compounds 5-8 (right). Compound 1 and 5 are shown in green, compound 2 and 6 in light blue, compound 3 
and 7 in red and compound 4 and 8 in magenta. 
 
The binding mode of the non-propargyl containing compounds, 1–4, at the active site of the 
eqBuChE homology model are illustrated in Figure 9. The docking results showed that the 
lowest energy binding orientation all four compounds adopted a similar conformation with 
the indole moiety forming π-π stacking interactions with Phe329 in the anionic site of the 
enzyme. The diethylcarbamate/urea moiety binds in the CAS region of the enzyme,
50
 
establishing π-π stacking interactions with Trp82 and a hydrogen bond interaction with 
His438 of the catalytic-triad. The propargylamine containing compounds, 5-8, were all well 
accommodated inside the active site gorge showing similar orientations. The lowest energy 
binding orientations enabled the indole moiety to interact with Trp82 and His438 in the CAS 
through π-π stacking interactions. The diethyl-carbamate/urea moiety is orientated away from 
the CAS region and forms an interaction with Trp231. The N1-propargyl substitution caused 
these molecules to adopt an inverted orientation compared to their non-propargyl containing 
counterparts. However, even though the adopted orientation is significantly different 
important interactions were still retained and may account for the similar BuChE activity 
observed for compounds 5-8 compared to 1-4. 
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Figure 9: Overlays of compounds 1-4 (left) and compounds 5-8 (right) in complex with the eqBuChE 
homology model. Compound 1 and 5 is shown in green, compound 2 and 6 in light blue, compound 3 and 7 in 
red and compound 4 and 8 in magenta. 
 
7.1.2.6. Chemical stability study 
Chemical stability of pharmaceutical molecules is a matter of great importance as it 
ultimately affects the stability and efficacy of the final drug product. One of the drawbacks of 
the carbamate of ladostigil is its liability to rapid hydrolysis in acidic conditions. In vivo 
ladostigil undergoes rapid acid and enzyme hydrolysed metabolism into a non-enzyme 
inhibiting neuroprotective molecule TV3279.
27,28
 Considering that compounds 1 - 8 contain a 
carbamate or urea that may affect stability and ultimately metabolism, it was decided to 
employ a forced chemical degradation test to study the stability of these moieties in both 
acidic and alkaline conditions. Compounds 6 and 8 were selected for stability testing because 
they contained both the carbamoyl/urea and propargylamine moiety and portrayed good 
activity as either a urea (6) or carbamate (8) derivative. The forced degradation study was 
done according to the slightly modified method of Blessy et al., 2014.
51
 The test compound 
(1 mg /ml) were dissolved in aqueous 0.1 M HCl or 0.1 M NaOH with DMF (5 %) as co-
solvent. The test solutions were kept at 37 ºC in an incubator for 7 days and sampled on days 
0, 1, 3, 4 and 7. UV/vis absorbance of the sample was measured at maximal wavelengths of 
232 nm for 6 and 234 nm for 8. It is important to note that both the urea and carbamate 
functional groups undergo hydrolysis but at different rates.
52
 Figure 10 shows the results of 
the compounds 6 and 8 after 7 days in 0.1 M HCl and 0.1 M NaOH. Compound 6 displayed 
an almost linear degradation rate compared to 8 that portrayed a more rapid decay. From 
these results, it is evident that the carbamate derivatives are less stable than their urea 
containing counterparts. Ladostigil is a carbamate compound and could act similarly to 8 in 
acidic conditions. Following this logic, urea (6) should prove to be more stable than the 
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carbamate derived ladostigil. This should minimise the metabolic effects that induce rapid 
hydrolysis to prevent limiting factors such as a short half-life and the rapid formation of non-
inhibiting metabolites. The compounds behaved in a similar manner in alkaline conditions. 
At this stage we are not informed as to the activity of the metabolites of the compounds, but 
like rasagiline and ladostigil whose metabolites portray neuroprotective activity
21,27
; the 
compounds described in this paper may act in a similar manner. 
Figure 10: Forced degradation results of compounds 6 (blue) and 8 (red) in acidic (left) and alkaline (right) 
conditions. 
 
7.1.2.7. SH-SY5Y cell viability studies 
In order to investigate the influence of the test compounds on neuronal cell viability, 
SHSY5Y cells were treated with various concentrations (10 μM, 50 μM and 100 μM) of 
compounds 2 and 6 for 48 hours and evaluated using the 3-[4,5-dimethylthiazol-2-yl]-2,5- 
diphenyl tetrazolium bromide (MTT) assay.
53
 Compound 6 was chosen for this assay as it 
showed the most promising inhibitory activity on all enzymes tested and contained both the 
more stable urea functional group and the N1-propargyl moiety. Compound 2 was included to 
explore the influence of the N1-propargyl moiety. Exposure of SH-SY5Y cells to compounds 
2 and 6 lead to a reduction in cell viability in a concentration-dependent manner (Figure 11). 
At 10 μM the compounds did not show any significant (p > 0.05) effect on cell viability. In 
general, based on this preliminary data, compound 6 seems to be slightly less toxic than 
compound 2 at the three concentrations tested. Another finding from these studies is that the 
CC50 values of both compounds 2 and 6 on SH-SY5Y human neuroblastoma cells are more 
than 100 μM. This indicates that at the concentrations where especially compound 6 inhibit 
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ChE and MAO (IC50 values less that 5 μM, see table 1) it will have very limited toxicity 
towards human cells.  
 
Figure 11: Cellular viability of SH-SY5Y cells treated with compounds 2 and 6 at 10 µM, 50 µM and 100 µM 
for 48 hours. Data is presented as mean ± SEM. Significance is set at a level of *p<0.05 compared to vehicle 
treated control cells (taken as 100 % cell viability). 
 
Based on the SH-SY5Y cytotoxicity analysis it was decided that the MPP
+
 neuroprotection 
studies would be done at compound concentrations between 1 μM and 10 μM in order not to 
significantly affect the viability of the cells. MPP
+
 is highly toxic to neurons and has been 
widely used to induce neurodegeneration in various in vitro and in vivo models.
54,55
 Several 
signaling pathways have been suggested to be responsible for MPP
+
-mediated neurotoxicity 
in SH-SY5Y cells, for instance, trigger of oxidative stress,
56
 induction of apoptosis,
57
 and 
inactivation of pro-survival phosphoinositide 3-kinase (PI3-K)/Akt cascade.
58-60
 This assay 
was deemed appropriate to test for initial neuroprotective ability of compounds 2 and 6 
because of the multitude of pathways involved in MPP
+
 mediated neurotoxicity and the 
multifunctional enzyme inhibitory abilities of the test compounds, especially 6. SH-SY5Y 
cells were exposed to the neurotoxin MPP
+
 with or without test compound, and cell viability 
was evaluated using the MTT mitochondrial function assay.
53
 As illustrated in Figure 12, 
after the exposure to 1000 μM MPP+ for 48 hours, the cell viability declined significantly to 
52.78 ± 7.35 %. However, its cytotoxic effects were ameliorated in the presence of 
compounds 2 and 6 at 1 μM, 5 μM and 10 μM concentrations. The compounds, at a 1 μM 
concentration, restored cell survival to 84.32 ± 4.62 % and 107.40 ± 6.26 %, respectively. At 
5 μM and 10 μM a slight decrease in cytoprotection, although still significant (p < 0.05), was 
observed for 2 and 6. This may indicate that in the neurotoxin challenged state the SH-SY5Y 
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cells may be more sensitive to the cytotoxic effect of the test compounds. Therefore, 2 and 6 
might have enhanced the toxicity of the neurotoxin which resulted in lower neuroprotection 
values observed at higher concentrations. Compound 6 containing the propargyl substitution 
at the N1 position showed significantly improved cytoprotection (p < 0.05) at all three 
concentrations tested compared to compound 2 which is devoid of the propargyl substitution. 
This observation confirms that the propargyl function improves the neuroprotective ability of 
these compounds in this assay. Thus, in general and especially at a 1 μM concentration, these 
compounds, and particularly 6, exerted highly significant cytoprotection against MPP
+
 insults 
to the SH-SY5Y neural cells. 
Figure 12: The effects of compounds 2 (left) and 6 (right) on MPP+-induced (1000 μM) cytotoxicity in SH-
SY5Y cells. The viability of untreated controls was defined as 100%. The level of significance for the test 
compounds is set at #p<0.05 compared to the MPP+ only treated control (0).  Statistical analysis (Tukey post hoc 
test) was performed on raw data, with asterisks signifying significant cytoprotection. *p<0.05; **p<0.001; 
***P<0.0001. Data are expressed as means ± S.D. (n = 12). 
 
7.1.2.8. In silico ADMET studies 
Selected ADMET properties of compounds 6, 8 and ladostigil were calculated using 
webbased applications. Compounds 6 and 8 were selected because they contained both the 
propargylamine- and urea/carbamate moiety similar to ladostigil and showed the most 
promising activities within the series. Blood–brain barrier (BBB) penetration, human 
intestinal absorption (HIA), Caco-2 cell permeability, logP and AMES test were calculated 
using https://preadmet.bmdrc.kr. The predicted ADMET data is summarized in Table 2. 
Based on the predicted values for BBB penetration, both compounds 6 and 8 should be able 
to penetrate into the central nervous system. It is interesting to note that compound 6, the 
most active compound in the series, should show better BBB penetration than 8 and ladostigil 
based on the BBB penetration and logP values. The compounds were also predicted to be 
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well absorbed based on the human intestinal absorption and Caco-2 permeability predictions. 
Moreover, the compounds did not show mutagenic effect with respect to the AMES test data. 
This data has significance indicating that the new compounds should have good ADMET 
profiles thus encouraging further drug design and development endeavours. The improved 
stability of compound 6 combined with the best overall predicted ADMET properties provide 
further evidence that it is a promising compound for further development. 
 
Table 2: Predicted ADMET properties of selected compounds. 
Compound BBB 
penetration 
HIAb (%) Caco-2 
permeabilityc 
LogP AMES toxicityd 
6 2.10 96.13 42.12 3.18 None 
8 0.47 99.55 53.80 2.95 None 
Ladostigil 0.99 95.47 33.81 2.40 None 
aBBB penetration parameters; <0.1 = low penetration; 0.1 – 2 = medium penetration; >2 = high penetration. 
bHuman intestinal absorption; values of > 70 % = high absorption. cValues between 4 and 70 indicates medium 
cell penetration. dMutagenic potential of chemicals. 
 
7.1.3. Conclusion 
The main objective of this study was to design a series of compounds with improved 
pharmacokinetic properties compared to ladostigil able to inhibit hMAO-A, hMAO-B, 
eeAChE and eqBuChE and provide neuroprotection. The results obtained indicate that the 
compounds act as dual ChE and MAO inhibitors. Molecular modelling showed significant 
interactions with vital resides in the active sites of the enzymes. Compound 6 was identified 
as a potent MTDL (IC50; MAO-A = 4.31 μM, MAO-B = 2.62 μM, AChE = 3.70 μM, BuChE 
= 2.82 μM) with AChE and MAO-B inhibitory activity 9 and 14 times that of ladostigil 
respectively (Table 1). Compound 6 also showed irreversible inhibition of MAO, similar to 
that reported for ladostigil. The results of the chemical stability tests showed that 6 is also 
more stable than the carbamate compound 8 by virtue of possessing the urea functional 
group. Compound 6 would thus probably prove more chemically and metabolically stable 
than ladostigil and lead to better enzymatic inhibition in vivo which may provide improved 
ability to treat AD. Elimination of the stereochemistry associated with ladostigil was also 
achieved while maintaining and even improving neuronal enzyme inhibitory activities. 
Compound 6 also exerted highly significant cytoprotection towards MPP
+
 insults to the 
SHSY5Y neural cells and can thus be considered for optimisation and perhaps development 
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as a multipotent drug molecule against Alzheimer’s- and/or other neurodegenerative 
disease(s).  
Further investigations exploring the pharmacokinetics and in vivo activities as well as further 
mechanism of action studies are recommended for these compounds.  
 
7.1.4. Experimental 
7.1.4.1. Chemistry 
Unless otherwise specified, materials were obtained from commercial suppliers and used 
without further purification. All reactions were monitored by thin-layer chromatography on 
0.20 mm thick aluminium silica gel sheets (Alugram
®
 SIL G/UV254, Kieselgel 60, Macherey-
Nagel, Düren, Germany). Visualisation was achieved using UV light (254 nm and 366 nm), 
an ethanol solution of ninhydrin or iodine vapours, with mobile phases prepared on a volume-
to-volume basis. Chromatographic purifications were performed on silica gel (0.063–0.2 mm, 
Sigma Aldrich) except when otherwise stated. The MS spectra were recorded on a Perkin 
Elmer Flexar SQ 300 mass spectrometer by means of direct injection with a syringe pump. 
High resolution electron spray ionisation (HREI) mass spectra for all compounds were 
recorded on a Waters API Q-Tof Ultima mass spectrometer at 70 eV and 100 °C. The IR 
spectra were recorded on a Perkin Elmer Spectrum 400 spectrometer, fitted with a diamond 
attenuated total reflectance (ATR) attachment. Melting points were determined using a Stuart 
SMP-300 melting point apparatus and capillary tubes. All the melting points determined were 
recorded uncorrected. 
1
H and 
13
C NMR spectra were determined using a Bruker Avance III 
HD spectrometer at a frequency of 400 MHz and 100 MHz, respectively. Tetramethylsilane 
(TMS) was used as internal standard. All chemical shifts are reported in parts per million 
(ppm), relative to the internal standard. The following abbreviations are used to indicate the 
multiplicities of the respective signals: s - singlet; s - broad singlet; d - doublet; dd - doublet 
of doublets; t – triplet and m - multiplet. 
 
General procedure for the synthesis of compounds 1-4 
The appropriate amino- or hydroxylindole (1 mmol) was conjugated to carbomoyl chloride at 
position 5 or 6 in a 1:1 ratio, using acetonitrile (10 ml) and 1.2 mmol K2CO3. The mixture 
was stirred for 2 hours at room temperature. Once the reaction was complete the mixture was 
filtered to remove the K2CO3 and the solvent removed in vacuo. An extraction was carried 
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out using DCM (3 x 15 ml). The organic phase was further washed with brine and water. The 
DCM was removed in vacuo to render a blackish waxy product which was purified via 
column chromatography (1:2 hexane: ethyl acetate) rendering the products as pure 
amorphous solids. 
N,N-Diethyl-N'-1H-indol-5-ylurea (1) 
Yield: 74 %; mp: 143 ºC; Rf: 0.68; 
1
H NMR: (400 MHz, CDCl3) ẟH: 7.89 (s, 1 H, H – 4), 
7.49 - 7.47 (d, 1 H, J = 8.4 Hz, H – 7), 7.11 – 7.10 (t, 1 H, J = 5.6; 2.8 Hz, H – 2), 6.77 – 6.75 
(dd, 1 H, J = 4.8; 2.4 Hz, H – 6), 6.45 – 6.34 (m, 1 H, H – 3), 3.42 – 3.37 (m, 4 H, H – 14; 
16), 1.26 – 1.24 (t, 6 H, J = 8.0; 4.0 Hz, H – 15, 17); 13C NMR (100 MHz, CD3OD): 158.15, 
137.74, 134.54, 126.26, 125.37, 120.74, 116.81, 106.73, 102.10, 42.43, 14.12; IR (FT – IR, 
cm
-1
): 3247.42, 2978.13, 1220.22; MS (EI, 70 ev) m/z: 232.10 (M+H)
+
; HR-ESI [M+H]
+
: 
calcd. 232.1443, found. 232.1447. 
N,N-Diethyl-N'-1H-indol-6-ylurea (2) 
Yield: 52 %; mp: 141 ºC; Rf: 0.71; 
1
H NMR: (400 MHz, CDCl3) ẟH: 7.63 (s, 1 H, H – 7), 
7.28 - 7.26 (d, 1 H, J = 8.0 Hz, H – 5), 7.16 – 7.15 (d, 1 H, H – 4),  6.47 – 6.46 (t, 1 H, J = 
4.8; 2.4 Hz, H – 2), 6.26 (m, 1 H, H – 3), 3.42 – 3.37 (m, 4 H, H – 14; 16), 1.26 – 1.22 (t, 6 
H, J = 14.4; 7.2 Hz, H – 15, 17); 13C NMR (400 MHz, CD3OD): 153.69, 126.35, 123.97, 
121.48, 121.23, 114.60, 106.23, 97.42, 36.97, 13.41; IR (FT – IR, cm-1): 3288.30, 2922.65, 
1760.52, 1217.09; MS (EI, 70 ev) m/z: 232.15 (M+H)
+
; HR-ESI [M+H]
+
: calcd. 232.14443, 
found. 232.1442. 
1H-Indol-5-yl-diethylcarbamate (3) 
Yield: 81 %; mp: 126 ºC; Rf: 0.71; 
1
H NMR: (400 MHz, CD3OD) ẟH: 7.19 – 7.8 (d, 1 H, J 
= 8.8 Hz, H – 7), 7.14 - 7.13 (d, 1 H, J = 2.8 Hz, H – 4), 6.92 – 6.91 (d, 1 H, J = 4.0 Hz, H – 
2), 6.60 – 6.40 (dd, 1 H, J = 8.8; 2.4 Hz, H – 6), 6.27 – 6.25 (dd, 1 H, J = 3.2; 0.8 Hz; H – 3), 
3.21 – 3.16 (m, 4 H, H – 14; 16), 1.13 – 1.09 (t, 6 H, J =14.4; 6.8 Hz, H – 15, 17); 13C NMR 
(400 MHz, CD3OD): 158.38, 137.79, 134.52, 126.28, 125.43, 120.71, 116.83, 106.66, 
102.06, 42.47, 14.13; IR (FT – IR, cm-1): 3298.82, 2971.20, 1210.75; MS (EI, 70 ev) m/z: 
233.11 (M+H)
+
; HR-ESI [M+H]
+
: calcd. 233.1285, found. 233.1289. 
1H-Indol-6-yl-diethylcarbamate (4) 
Yield: 80 %; mp: 159 ºC; Rf: 0.67; 
1
H NMR: (400 MHz, CDCl3) ẟH: 7.63 – 7.26 (d, 1 H, J 
= 1.6 Hz, H – 7), 6.95 – 6.94 (d, 1 H, J = 2.0 Hz, H – 4), 6.68 – 6.65 (dd, 1 H, J = 8.4; 2.0 Hz, 
H – 5), 6.48 – 6.46 (t, 1 H, J = 6.4; 3.2 Hz, H – 2), 6.38 – 6.36 (m, 1 H, H – 3), 3.43 – 3.37 
(m, 4 H, H – 14; 16), 1.26 – 1.22 (t, 6 H, J =14.4; 6.8 Hz, H – 15, 17); 13C NMR (400 MHz, 
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CD3OD): 158.52, 137.78, 134.55, 125.36, 122.75, 120.76, 116.79, 106.73, 101.26, 42.39, 
14.08; IR (FT – IR, cm-1): 3253.61, 1683.13, 1215.52; MS (EI, 70 ev) m/z: 233.13 (M+H)+; 
HR-ESI [M+H]
+
: calcd. 233.1285, found. 233.1287. 
 
General procedure for the synthesis of compounds 5-8 
Compounds 5 - 8 were synthesized by conjugating the propargyl bromide (1.2 mmol) to 
position N1 of the synthesized compounds, 1 – 4 (1 mmol). This mixture was stirred at room 
temperature in the presence of NaH (1 mmol) and dimethylformamide (10 ml) and irradiated 
under microwave conditions (95 °C, 150 W) for 2 to 4 hours. Once the reaction was complete 
water (30 ml) was added followed by at least five extractions with ethyl acetate (5 x 15 ml). 
Thereafter the organic phase was washed with brine and water. The ethyl acetate was 
removed in vacuo to render the pure products as amorphous solids.  
N,N-Diethyl-N'-[1-(prop-2-yn-1-yl)-1H-indol-5-yl]urea (5) 
Yield: 95 %; mp: 158 ºC; 
1
H NMR: (400 MHz, CDCl3) ẟH: 7.64 – 7.63 (d, 1 H, J = 1.6 Hz, 
H – 4), 7.29 – 7.27 (d, 1 H, J = 8.8 Hz, H – 7), 7.15 – 7.14 (m, 2 H, J = 10.4 Hz, H – 2, 6), 
6.47 – 6.46 (t, 1 H, J = 1.0, 2.0 Hz, H – 3), 4.12 – 4.11 (d, 2 H, J = 4.0 Hz, H – 18),  3.42 – 
3.37 (m, 4 H, H – 14; 16), 2.22 – 2.20 (t, 1 H, J =  4.8; 2.4 Hz), H – 20), 1.26 – 1.23 (t, 6 H, J 
=14.0; 6.8 Hz, H – 15, 17); 13C NMR (400 MHz, CD3OD): 157.03, 153.96, 147.94, 139.35, 
126.21, 120.56, 114.78, 110.24, 109.63, 105.20, 97.47, 43.55, 11.50; IR (FT – IR, cm-1): 
3293.69, 2922.34, 1761.13, 1217.23; MS (EI, 70 ev) m/z: 270.94, (M+H)
+
; HR-ESI [M+H]
+
: 
calcd. 271.1441, found. 271.1439. 
N,N-Diethyl-N'-[1-(prop-2-yn-1-yl)-1H-indol-6-yl]urea (6) 
Yield: 87 %; mp: 166 ºC; 
1
H NMR: (400 MHz, CD3OD) ẟH: 7.42 – 7.40 (m, 2 H, H – 7, 4), 
7.15 – 7.14 (d, 1 H, J = 3.8 Hz, H – 3), 6.94 – 6.92 (d, 1 H, J = 8.4 Hz, H – 5), 6.37 – 6.36 (d, 
1 H, J = 3.2 Hz, H – 2), 4.10 – 4.09 (d, 2 H, J = 4.0, H – 18), 3.46 – 3.41 (m, 4 H, H – 14, 
16), 2.18 – 2.16 (t, 1 H, J = 8.0; 4.0, H – 20); 1.23 – 1.19 (t, 6 H, J =14.4; 6.8 Hz, H – 15, 17); 
13
C NMR (400 MHz, CD3OD): 157.13, 139.29, 127.18, 126.16, 120.56, 114.69, 110.23, 
109.85, 105.26, 102.33, 97.49, 43.46, 11.61; IR (FT – IR, cm-1): 3300.95, 3194.06, 2927.43, 
1210.50; MS (EI, 70 ev) m/z: 271.15 (M+H)
+
; HR-ESI [M+H]
+
: calcd. 271.1441, found. 
271.1443. 
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1-(Prop-2-yn-1-yl)-1H-indol-5-yl-diethylcarbamate (7) 
Yield: 94 %; mp: 187 ºC; 
1
H NMR: (400 MHz, CD3OD) ẟH: 7.50 – 7.46 (d, 1 H, J = 16.0 
Hz, H – 7), 7.24 – 7.19 (dd, 2 H, J = 19.2; 3.2 Hz, H – 4, 6), 7.16 – 7.13 (dd, 1 H, J = 10.4; 
1.6 Hz, H – 2), 6.41 – 6.37 (dd, 1 H, J = 15.6; 2.8 Hz, H – 3), 4.96 – 4.95 (d, 2 H, J = 4.0, H – 
18);  3.45 – 3.40 (m, 4 H, H – 14; 16), 2.79 – 2.78 (t, 1 H, J = 4.8; 2.4 Hz, H – 20), 1.23 – 
1.19 (t, 6 H, J = 14.4; 7.2 Hz, H – 15, 17); 13C NMR (400 MHz, CD3OD): 158.52, 135.13, 
132.06, 129.38, 125.73, 120.36, 116.34, 114.23, 111.79, 107.90, 102.34, 101.38, 42.32, 
14.13; IR (FT – IR, cm-1): 3299.52, 3195.74, 1210.83; MS (EI, 70 ev) m/z: 270.11 (M+H)+; 
HR-ESI [M+H]
+
: calcd. 270.1601, found. 270.1599. 
1-(Prop-2-yn-1-yl)-1H-indol-6-yl-diethylcarbamate (8) 
Yield: 95 %; mp: 168 ºC; 
1
H NMR: (400 MHz, CD3OD) ẟH: 7.47 – 7.46 (dd, 1 H, J = 4.0, 
2.0 Hz, H – 7), 7.39 – 7.36 (d, 1 H, J = 12.0 Hz, H – 4), 7.24 – 7.23 (d, 1 H, J = 4.0 Hz, H – 
5), 7.20 – 7.19 (d, 1 H, J = 4.0 Hz, H – 2), 6.43 – 6.33 (m, 1 H, H – 3), 4.96 – 4.95 (d, 2 H, J 
= 4.0 Hz, H – 18);  3.46 – 3.40 (m, 4 H, H – 14,16), 2.79 – 2.70 (t, 1 H, J = 8.0; 4.0 Hz, H – 
20), 1.23 – 1.21 (t, 6 H, J = 8.0; 4.0 Hz, H – 15, 17); 13C NMR (400 MHz, CD3OD): 158.76, 
135.15, 132.05, 129.32, 126.16, 126.08, 124.58, 119.97, 116.27, 111.79, 102.32, 101.29, 
42.52, 14.14; IR (FT – IR, cm-1): 3291.83, 2922.52, 1761.08, 1217.03; MS (EI, 70 ev) m/z: 
270.59 (M+H)
+
; HR-ESI [M+H]
+
: calcd. 270.1601, found. 270.1609. 
 
7.1.4.2. Biological evaluation 
Recombinant human MAO-A and MAO-B inhibition studies 
Stock solutions of the test compounds and controls (clorgiline for MAO-A and selegiline for 
MAO-B) were prepared by dissolving the test compounds in DMSO and it was kept under 
refrigeration until use. The solutions were made at 10 mM concentrations and further serial 
diluted to achieve final concentrations of 100 µM, 10 µM, 1 µM, 0.1 µM and 0.01 µM. The 
potassium phosphate buffer was prepared in water at a concentration of 100 mM (adjusted to 
pH 7.4 by 2 N NaOH). It was also refrigerated until use. The stock solution of the substrate 
kynuramine was made at 750 µM (45 µM final assay concentration) for MAO-A and 500 µM 
(30 µM final assay concentration) for MAO-B. Using the phosphate buffer, MAO enzyme 
stock solution was prepared and stored in aliquots at -80 ºC until use. To each vial 207.5 µL 
of phosphate buffer and 2.5 µL of corresponding test compound or control compound was 
added. This was followed by 25 µL of the enzyme at 10 second intervals. The mixture was 
then incubated for 10 minutes at 37 ºC. Thereafter 15 µL of kynuramine was added also at 10 
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second intervals and it was then further incubated for 20 minutes. 150 µL of 2 N NaOH were 
used to stop the reaction. Finally, 200 µL of the mixture was added to each well of a black 96 
well plate, placed in the fluorescent plate reader and read at excitation/emission wavelength 
of 310 nm/400 nm. Each assay was run in triplicate and the data was analysed with Graph 
Pad Prism 7 software (San Diego, CA, USA).  
 
Time-dependent MAO inhibition studies 
To investigate whether the observed enzyme inhibition is reversible or irreversible, time-
dependant inhibition studies were carried out with the active inhibitors. Recombinant human 
MAO-A or human MAO-B (0.03 mg.ml
-1
) were preincubated for periods of 0, 15, 30, 60 min 
at 37 °C. The concentrations of inhibitor in these incubations were twofold the measured IC50 
values for the inhibition of MAO. The incubations were carried out in potassium phosphate 
buffer (100 mM, pH 7.4, made isotonic with KCl). A final concentration of 45 μM 
kynuramine for MAO-A and 30 μM kynuramine for MAO-B were then added to the 
preincubated enzyme preparations and the resulting reactions were incubated at 37 °C for 15 
min. The final volumes of these incubations were 250 μl and the final concentration of the 
inhibitors were approximately equal to the IC50 values for the inhibition of the respective 
enzyme. The final enzyme concentrations of the MAO preparations were 0.015 mg.ml
-1
. The 
reactions were terminated with 100 μL NaOH (2 N) and a volume of 600 μL distilled water 
was added to each reaction. The rates of formation of 4-hydroxyquinoline were measured and 
quantified as described above. All measurements were carried out in triplicate and are 
expressed as mean ± SD. 
Cholinesterase inhibition studies 
AChE from electric eel, BuChE from equine serum, S-butyrylthiocholine iodide (BTCI), 
acetylthiocholine iodide (ATCI), 5,5′-dithiobis-(2-nitrobenzoic acid) (Ellman’s reagent, 
DTNB), donepezil and tarcine hydrochloride were purchased from Sigma-Aldrich. The 
inhibitory activities of the test compounds were evaluated by Ellman’s method.36 The 
compounds were dissolved in DMSO and diluted with the buffer solution (50 mM Tris–HCl, 
pH = 8.0) to yield the corresponding test concentrations (DMSO less than 0.01%). In each 
well of the plate, 160 μl of 1.5 mM DTNB, 50 μl of AChE (0.22 U/ml eeAChE) or 50 μl of 
BuChE (0.12 U/ml eqBuChE) were incubated with 10 μl of different concentrations of test 
compounds (0.01–100 μM) at 37 °C for 10 min. After this period, ATCI (15 mM) or BDCI 
(15 mM) as the substrate (30 μl) was added, incubated for a further 10 minutes, and thereafter 
the absorbance was measured at a wavelength of 405 nm at different time intervals (0, 60, 
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120, and 180 s). IC50 values were calculated as concentration of the compound that produces 
50 % enzyme activity inhibition, using the Graph Pad Prism 7 software (San Diego, CA, 
USA). 
 
SH-SY5Y cell viability assays 
Cell line and culture conditions 
The human neuroblastoma cell line SH-SY5Y was generously donated by our collaborator at 
the Division of Molecular Biology and Human Biology, Stellenbosch University, Tygerberg, 
Cape Town. Cells were cultured in monolayer using Dulbeco Modified Eagles Medium 
(DMEM, Gibco, Life Technologies Ltd) supplemented with 10% foetal bovine serum (FBS, 
Gibco, Life Technologies Ltd.) and 1% 100 U/mL penicillin and 100 μg/mL streptomycin 
(Lonza Group Ltd., Base Switzerland). Cells were grown at 37 °C, in a humidified 
atmosphere consisting of 5% CO2 and 95% air. Media was replaced every two to three days 
and cells were sub-cultured by splitting with trypsin (Lonza Group Ltd., Basel Switzerland). 
 
MTT cytotoxicity assay 
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) is a yellow 
tetrazolium salt that is reduced to purple formazan in the presence of living cells. This assay 
which measures cell metabolic activity was used to determine cytotoxicity as described by 
Mosmann, (1983).
53
 Briefly, SH-SY5Y cells were plated in flat bottom 96 well plates in 
growth medium as stated above at a density of 7,500 cells/well. Cells were allowed to adhere 
to the plate surface for 24 hours and used media were replenished with fresh media 
containing test compounds at 10 µM, 50 µM and 100 µM. Vehicle control cells were treated 
with dimethyl sulfoxide (DMSO, solvent for dissolving test compounds) at a concentration 
similar to the amount contained in the highest concentration of test compounds. After 48 
hours, 10 µL of MTT solution (5 mg/mL) was added to each well and incubated for 4 hours 
and the purple formazan formed was solubilized with 100 µL DMSO and plates were read 
spectrophotometrically to determine absorbance at 570 nm using a BMG Labtech Omega® 
POLARStar multimodal plate reader.  
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MPP
+
-induced cytotoxicity in SHSY-5Y cells 
SH-SY5Y cells were seeded onto a 96-well plate and treated with 1000 μM MPP+ for 
approximately 48 hours. Different concentrations (1 μM, 5 μM, 10 μM) of test compounds 
were administrated two hours prior to MPP
+
 treatment. Afterwards, cell viability was 
measured by MTT colorimetric assay and performed as stated above 
 
7.1.4.3. Molecular modelling studies 
MAO docking studies 
Computer-assisted docking was carried out using the CHARMm force field and hMAO-A 
co-crystallized with clorgiline (PDB ID: 2BXS)
40 
and hMAO-B co-crystallized with 
safinamide (PDB ID: 2V5Z)
41
, which were recovered from the Brookhaven Protein Database 
(www.rcsb.org/pdb). Docking simulations were performed on the test compounds using 
Molecular Operating Environment (MOE)
43 
with the following protocol. (1) Enzyme 
structures were checked for missing atoms, bonds and contacts. (2) Hydrogens and partial 
charges were added using the protonate 3D application in MOE. (3) The ligands were 
constructed using the builder module and were energy minimized. (4) Ligands were docked 
within the MAO-A or MAO-B active sites using MOEDock application, the poses were 
generated by the Triangle Matcher placement method. (5) The retained best poses were 
visually inspected and the interactions with binding pocket residues were analyzed. To 
determine the accuracy of this docking protocol, the co-crystallised ligand, clorgiline (PDB 
ID: 2Z5X), was re-docked into the MAO-A active site and the co-crystallised ligand, 
safinamide (PDB ID: 2V5Z), was re-docked into the MAO-B active site. This procedure was 
repeated three times and the best ranked solutions of clorgiline and safinamide exhibited 
RMSD values of less than 2 Å from the position of the co-crystallised ligand for MAO-A and 
MAO-B, respectively. In general, RMSD values smaller than 2.0 Å, indicate that the docking 
protocol is capable of accurately predicting the binding orientation of the co-crystallised 
ligand.
63,64
 These protocols were thus deemed to be suitable for the docking of inhibitors into 
the active site models of MAO-A and MAO-B.  
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Acetylcholinesterase docking studies 
The dock function of MOE
43
 was used to predict the interactions and binding modes of the 
synthesized inhibitors in the eeAChE active site. The crystal structure of the eeAChE protein 
co-crystallized with donepezil was acquired from the Protein Data Bank (PDB ID: 1EVE).
42
 
The docking procedure followed the same protocol as described for the MAO docking. To 
determine the accuracy of this docking protocol, the co-crystallised ligand, was re-docked 
into the AChE active site. This procedure was repeated three times and the best ranked 
solution exhibited an RMSD value of 1.15 Å from the position of the co-crystallised ligand. 
The RMSD value in this case is smaller than 2.0 Å indicating that the docking protocol is 
capable of accurately predicting the binding orientation of the co-crystallised ligand.
60,61
 This 
protocol was thus deemed to be suitable for the docking of inhibitors into the active site 
model of AChE. 
 
Butyrylcholinesterase docking studies 
Because no X-ray structure exists for eqBuChE, a homology model was used to rationalize 
the experimental data. The eqBuChE model was retrieved from the SWISS-MODEL 
Repository. This is a database of annotated three-dimensional comparative protein structure 
models generated by the fully automated homology-modeling pipeline SWISS-MODEL. A 
putative three-dimensional structure of eqBuChE has been created based on the crystal 
structure of hBuChE (PDB ID: 2PM8), these two enzymes exhibited 89% sequence identity. 
Proper bonds, bond orders, hybridization and charges were assigned and CHARMm force 
field was applied using MOE.
43
 The prepared protein was directly loaded into 
AutoDockTools (ADT; version 1.5.4), hydrogens were added and partial charges for proteins 
and ligands were calculated using Gasteiger charges. Flexible torsions in the ligands were 
assigned with the AutoTors module, and the acyclic dihedral angles were allowed to rotate 
freely. Docking calculations were performed with the program Autodock Vina.
46 
Because 
VINA uses rectangular boxes for the binding site, the box center was defined and the docking 
box was displayed using ADT. All dockings were performed as blind dockings where a cube 
of 75 Ǻ with grid points separated by 1 Ǻ, was positioned in the middle of the protein (x = 
29.885; y = -54.992; z = 58.141). Default parameters were used except num_modes, which 
was set to 40. The lowest docking-energy conformation was considered as the most stable 
orientation. Finally, the docking results generated were analysed using MOE. 
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Abstract 
An in vitro medium-throughput screen using M. tuberculosis H37Rv was employed to screen 
an in-house library of structurally diverse compounds for antimycobacterial activity.  From 
this initial screen, eleven 7-substituted coumarin derivatives with confirmed monoamine 
oxidase-B and cholinesterase inhibitory activities, demonstrated growth inhibition of more 
than 50% at a 50 µM concentration. This prompted further exploration of all the 7-substituted 
coumarins in our library, nineteen in total, as potential antimycobacterial agents. Four 
derivatives showed promising antimycobacterial activity with MIC99 values of 8.31 – 29.70 
µM and 44.15 – 57.17 µM on M. tuberculosis H37Rv in independent assays using Gaste-Fe 
and 7H9 + OADC media, respectively. These compounds were found to bind to albumin 
which may explain the variations in MIC between the two assays.  Preliminary 
antimycobacterial evaluation of moxifloxacin resistant M. tuberculosis show that these 
compounds are able to maintain their activity in fluoroquinolone resistant mycobacteria. 
Analysis of structure activity relationships for antimycobacterial versus neuronal enzyme 
inhibitory activity indicate that structural modification on position 4 and/or 7 of the coumarin 
scaffold may be utilized to improve selectivity towards either inhibition of neuronal enzymes 
or antimycobacterial effect. Cytotoxicity evaluations of the compounds indicate moderate 
cytotoxicity with slight selectivity towards mycobacteria.  Further neuroprotective assays on 
SH-SY5Y human neuroblastoma cells indicate significant neuroprotection for selected 
compounds irrespective of their neuronal enzyme inhibitory properties.  These coumarin 
molecules are thus interesting lead compounds that may provide insight into the design of 
new antimicrobacterial and neuroprotective agents. 
 
Keywords: coumarin; Mycobacterium tuberculosis; cholinesterase inhibitor; monoamine 
oxidase B inhibitor; Structure-activity relationship; albumin binding, neuroprotection 
 
7.2.1. Introduction 
Progressive development of resistance to various chemotherapeutic agents used in the 
management of infectious diseases presents a very serious problem in global public health. 
Natural products have yielded various classes of effective antimicrobials over the last few 
decades and continue to play a large role in the identification of novel lead molecules for this 
purpose [1]. 
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A large variety of coumarin derivatives have been isolated from natural products and an array 
of pharmacological activities have been described for these, as well as related synthetic 
coumarins [2, 3].  The ability of the coumarin moiety to form several possible interactions 
with a particular binding site (including hydrogen bonds, electrostatic, π-π and hydrophobic 
interactions) likely stabilize target binding and contribute to the versatile pharmacological 
profile of coumarin derivatives.  Both the type and placement of functional groups on the 
coumarin scaffold determine the specific activity of the given derivative [2-4]. 
Antibacterial and more specifically, antimycobacterial activity are amongst the 
pharmacological effects that have been described for a range of structurally diverse coumarin 
derivatives. One prominent example of a coumarin based antibacterial is novobiocin. 
Novobiocin, the structurally related chlorobiocin as well as coumermycin A1 are 3-amino-
4,7-dihydroxycoumarin derivatives, alternatively referred to as the classical aminocoumarin 
antibiotics. Classical aminocoumarins act as competitive inhibitors of bacterial 
topoisomerase, more precisely DNA gyrase [5, 6].  Competitive inhibition of DNA gyrase by 
the classical aminocoumarin antibiotics results from an overlap in binding sites between the 
sugar moiety of the aminocoumarins (Figure 1, numbered in blue) and the adenine ring of 
ATP which is required for the gyrase activity [7].  The non-classical aminocoumarin, 
simocyclinone D8 (Figure 1), lacks the 7-aminosugar moiety and inhibits bacterial DNA 
gyrase through simultaneous binding to two alternate binding pockets via interactions with 
the coumarin moiety and a terminal angucyclinone group.  Simocyclinone D8 thus has a 
unique mechanism of action, despite structural similarities to the standard aminocoumarins 
[8-10].  Similarly, differences in the binding sites between the fluoroquinolone antibiotics 
(e.g. moxifloxacin which primarily inhibits topoisomerase IV but also interacts with gyrase) 
allow fluoroquinolone antibiotics to maintain potency in aminocoumarin resistant bacteria 
and vice versa [5, 6, 11]. Mycobacterial gyrase, which is a validated drug target in 
Mycobacterium tuberculosis, is also the likely target for the fluoroquinolone class antibiotics 
as M. tuberculosis does not express the topoisomerase IV enzyme [12].  
Apart from an interaction with gyrase, bacterial DNA helicase is another suggested target of 
selected coumarin derivatives [13-15].  Similar to other non-classical coumarin antibiotics, 
the 7-position on these coumarin derivatives does not contain an amino sugar, but rather a 
moiety able to undergo hydrophobic interactions with the target site [13-15]. Compound 22 
(Figure 1), a 4,8–dimethyl-3-propionic acid coumarin derivative with a 2-(4-chloro[1,1-
biphenyl]4-yl)ethyl substitution on the 7-position was the most active helicase inhibitor in 
this series of 7-substituted biphenyl coumarin derivatives [14].  In this series, the methyl 
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substitution in position 4 of the coumarin structure drastically increased the anti-helicase 
activity of the compounds.  
 
 
Figure 1: Molecular structure of novobiocin, moxifloxacin, simocyclinone D8 and Compound 22 as examples 
of antimicrobial coumarin derivatives. 
Various reports have been published on coumarin derivatives with antimycobacterial activity. 
Although most studies adequately describe and quantify the activity for respective series of 
coumarin derivatives, differences in assay methods prevent a direct comparison of 
antimycobacterial activity of these molecules.  Novobiocin as discussed above, demonstrated 
a minimum inhibitory concentration (MIC) of approximately 6.5 µM in the standard 
laboratory strain of M. tuberculosis, H37Rv [16].  Figure 2 depicts some of the most active 
compounds in their particular series as evaluated in M. tuberculosis.  Compound 3 [17] was 
identified as a likely mycobacterial gyrase inhibitor whereas inhibition of FadD32, an 
enzyme involved in mycolic acid biosynthesis, was confirmed as target for compound 6 [4]. 
Mechanisms of action were not suggested for compounds 1 [18], 2 [19], 4 [20] and 5 [21].  
As can be expected for compounds which do not necessarily attain their antimycobacterial 
effect through interaction with the same target sites, structural features important for activity 
differ between the respective series of compounds. Ultimately, various types and 
combinations of substitutions on all but position 1 and 2 of the coumarin scaffold yielded 
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generally effective antimycobacterials, though possibly through different mechanisms of 
action. This versatile nature of the coumarin scaffold may promote interaction with unique, or 
possibly multiple targets within the mycobacterial bacilli.  
Unfortunately, structure activity relationships for the activity of various classes of coumarin 
derivatives (e.g. central nervous system acting, anticoagulant and anti-cancer agents) often 
overlap with that for potent antimicrobial activity [3, 22]. A number of review papers 
describe the importance of coumarin compounds in the field of neurodegenerative disorders 
where they have shown inhibitory properties towards monoamine oxidases, cholinesterases, 
β- and γ-secretase and other targets involved in the progression of neurodegenerative 
disorders [23-25]. Similarly, coumarin derivatives described in this article also demonstrated 
neuronal enzyme inhibitory properties [26]. Therefore, the effective utilization of the 
coumarin scaffold may essentially be hampered by its versatility unless sufficient selectivity 
can be ensured. Early identification and structure activity relationship evaluation of 
alternative pharmacological effects, over-and-above standard cytotoxicity assays, may 
increase the viability of coumarin-based antimycobacterial and/or neuroprotective agents. 
 
 
Figure 2: Selected coumarin derivatives demonstrating promising M. tuberculosis activity across various 
assays. 
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As part of a collaborative project, a number of 7-substituted coumarin derivatives initially 
designed and synthesized as multifunctional neuronal enzyme inhibitors [26], were found to 
exhibit promising antimycobacterial activity (see Table 1) The compounds, originally 
designed to incorporate coumarin structures known to show monoamine oxidase B (MAO-B) 
inhibition [27] and selected structural elements of donepezil, a selective acetylcholinesterase 
(AChE) inhibitor [28], were able to selectively inhibit human MAO-B as well as electric eel 
AChE and equine butyrylcholinesterase (BuChE) [26]. Further evaluation of the structure 
activity relationships for selectivity and specific characteristics of these compounds were 
therefore required in order to assess the viability of the compounds as neuronal enzyme 
inhibitors and/or antimycobacterial clinical agents. This article describes the 
antimycobacterial activity, plasma protein binding properties, cytotoxicity and 
neuroprotection data for the series of neuronal enzyme inhibitors. Preliminary evaluations on 
antimycobacterial activity in drug resistant M. tuberculosis are described and structure 
activity relationships for neuronal enzyme inhibition versus antimycobacterial activity as well 
as a paired analysis of the neuroprotective properties of selected derivatives are discussed. 
 
7.2.2. Results and discussion 
7.2.2.1. Medium Throughput Screen 
A medium throughput screen (MTS) of various compounds from the University of the 
Western Cape, School of Pharmacy, drug-design compound library was done to identify 
novel antimycobacterial agents. A large proportion of the compounds which demonstrated 
potential antimycobacterial activity in the initial MTS, were coumarin derivatives.  A total of 
11 coumarin derivatives inhibited more than 50% mycobacterial growth at 50 µM.  Table 1 
provides the structures and activity of two series of coumarin derivatives CM1–CM19 
identified in the MTS, as classified based on the substitution on the 7-position of the 
coumarin scaffold.  The compound numbering from our library was maintained and the 
derivatives sorted in order of potency within their respective series.  Antimycobacterial 
activity is indicated as the percentage mycobacterial growth on day 5 at 100 µM, 50 µM and 
1 µM of the respective derivatives. 
Based on this screen, series 1 seems to contain more potent inhibitors of M. tuberculosis with 
the p-bromo-N-benzylpiperizine derivatives demonstrating higher activity than the benzyl 
substituted piperidine derivatives.  The exception to this is CM13 with a chloro substitution 
on the R
3 
position which reduces the antimycobacterial activity of the compound in this 
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whole cell assay.  Interestingly the chloro substitution on R
3
 improves the activity in the 
piperidine type compound, though it should be noted that the simultaneous removal of the 
bromine substitution may have contributed to the change in activity.  The small activity 
differences between the 6 most active compounds in series 1 do not allow for prediction of 
structure activity relationships within this range. It would however seem that the p-bromo-N-
benzylpiperizine derivatives can tolerate various large and small substitutions in position 4 of 
the coumarin scaffold relatively well.  No significant differences in activity were observed 
between the trifluoromethane, methyl or unsubstituted 4-substituted coumarin derivatives for 
this series.  This is not the case with series 2, where the trifluoromethane group in position 4 
of the coumarin scaffold seems to decrease the activity when compared to a methyl 
substitution in this position. The most active compound in series 2 is the R
2
-methyl 
substituted benzyl-ether (CM17) followed by a similar bromobenzyl-ether (CM2).  
Replacement of the hydrogen in position 3 of the coumarin scaffold with a nitrile moiety does 
not seem to influence activity, but a chloro-substitution in this position decreases activity 
similar to what was observed for the p-bromo-N-benzylpiperizine derivatives in series 1.  The 
combination of halogens in R
1
 and R
3
 with a methyl substitution on R
2
 seems to decrease 
activity in both series 1 and 2. Comparison of the compounds evaluated in this study with 
other antimycobacterial coumarin derivatives described in literature (see Figure 2, section 1) 
highlighted minor similarities and trends.  Many of the more active derivatives described in 
literature only have small groups substituted at positions 5, 6, 7 and 8 of the coumarin 
scaffold whereas the compounds evaluated in this study carry the larger substitution at 7 
position.  Bisubstitution on these positions seem to increase activity.  Compound 1 [18], a 4-
substituted sulfonyl-benzoxazole derivative was more active when substituted with methoxy 
groups in both the 7 and 8 positions of the coumarin, than single- or unsubstituted 
derivatives.  Compound 2 [19], a 4-substituted, triazole-linked benzimidazole coumarin with 
methyl groups at the 5, 7 or 7, 8 positions on the coumarin scaffold similarly demonstrated 
the highest activity in its series. A common trend for most of these derivatives seems to be a 
large functional group on position 3 or 4 of the coumarin moiety. Compound 3 [17], bearing 
a triazole ring on the 3 position of the coumarin scaffold, was able to achieve and MIC value 
of 6.5 µM.  Compound 4 [20], also with a large group on position 3, was the most active in a 
series of 3-substituted benzocoumarin-pyrimidine hybrid molecules. Series 1 derivatives 
evaluated in this study likewise seem to tolerate large substitutions on position 3 with no 
significant differences in activity between substituted or unsubstituted derivatives. 
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Table 1:  Molecular structure and activity of coumarin derivatives series 1 and 2 
 
                                          
 
                                       Series 1                                                                       Series 2 
      % M. tuberculosis Growth, Day 5 
Number X R1 R2 R3 100 µM 50 µM 1 µM 
Series 1        
CM12** N Br CH3 H 3.93 4.35 95.23 
CM14** N Br CH3 CN 4.44 4.40 99.53 
CM8** CH H CH3 Cl 4.62 5.69 93.59 
CM15** N Br CF3 H 4.88 6.68 106.71 
CM11* N Br H H 4.46 7.05 95.18 
CM9* CH H CH3 CN 6.19 7.75 92.82 
CM7* CH H CH3 H 8.18 29.50 95.10 
CM6 CH H H H 15.43 52.71 98.19 
CM13* N Br CH3 Cl 32.06 42.47 97.03 
Series 2 
CM17* H CH3 H 19.81 28.65 97.59 
CM2* Br CH3 H 33.16 40.86 89.98 
CM4* Br CH3 CN 33.52 44.60 95.27 
CM5 Br CF3 H 56.09 65.04 106.87 
CM19 H CH3 CN 55.44 66.92 98.28 
CM16 H H H 50.66 72.70 97.53 
CM1 Br H H 63.63 79.77 96.28 
CM18 H CH3 Cl 75.52 87.91 97.30 
CM3 Br CH3 Cl 92.86 96.11 97.82 
*Compounds that underwent further analysis; **Compounds selected for MIC determination 
In addition to substitutions on position 4, compounds 5 and 6 carries larger morpholine-
containing moieties in positions 5 and 6 respectively. Compound 6 [4], bearing a 
comparatively larger N-benzylmorpholine substitution on the 6-position of the coumarin 
scaffold, was previously shown to inhibit mycobacteria through inhibition of FadD32, a 
newly validated and promising mycobacterial drug target involved in mycolic acid 
biosynthesis [29].  Methyl substitutions on positions 5 and 7 were again crucial for activity.  
The importance of the methyl moieties may be their influence on the geometrical 
conformation of the adjoining aryl groups, indicating conformation-specific target binding 
[4].  Similar to the piperidine and piperizine derivatives in series 1 evaluated in this study, 
compounds 5 and 6 with the larger substitutions on the benzene ring of the coumarin scaffold 
was substituted with functional groups able to form hydrogen bonds with the target site. 
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The neuronal enzyme structure activity relationships of the coumarin derivatives in table 1 
were discussed in detail in our recently published paper [26].  Briefly, the coumarin 
derivatives substituted at the 7-position with a N-benzylpiperidine or p-bromo-N-
benzylpiperazine (series 1) showed better multifunctional neuronal inhibitory activities 
compared to their 7-benzyl only substituted counterparts (series 2).  In addition, the 
substitution of a nitrile group at position 3 of the coumarin scaffold (CM9 and CM14) 
improved the multifunctional neuronal inhibitory activities of the compounds in series 1 and 
the MAO-B activity (CM4 and CM19) in series 2.  In both series 1 and 2 substitution at 
position 4 with a large trifluoromethyl group drastically decreased their neuronal enzymatic 
activities.  It was also noted that, in general, the N-benzylpiperidine substituted coumarin 
derivatives showed significantly improved activities over their p-bromo-N-benzylpiperazine 
substituted counterparts.  From these studies compound CM9 was identified as the most 
promising multifunctional neuronal enzyme inhibitor.  It may therefore be possible to 
increase the selectivity of coumarin derivatives towards either neuronal enzyme inhibitory 
activity or antimycobacterial property through selective substitution in positions 4- and 7 of 
the coumarin scaffold.  
All derivatives in series 1 and 2 that demonstrated more than 50% mycobacterial growth 
inhibition at 50 µM were further analysed at narrower concentration ranges using a similar 
method to the original MTS.  Figure 3 depicts the mycobacterial growth inhibition for 
compounds CM12 and CM17, which were the most active in their respective series in the 
initial screen. Relative fluorescence of the far-red fluorescent reporter mCHERRY was used 
as the indicator of growth during this screen which was performed once to validate the 
activity found during the initial screen. These graphs show the inhibitory effect of the 
compounds compared to the untreated as well as a known antimycobacterial rifampicin (RIF) 
at 6 µM.  From this activity validation screen CM8, CM12, CM14 and CM15 (all in series 
1) were identified as the most potent compounds and evaluated in further studies to gain 
insight into their antimicrobacterial properties. 
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Figure 3:  Mycobacterial growth inhibition by compounds CM12 and CM17 at narrower concentration 
intervals. M. tuberculosis H37Rv:pCHERRY3 was cultured in 96 well plates as described, with compounds at 
the concentrations as shown. Experiments were repeated in biological triplicates; each plot shown here shows a 
representative biological replicate with the mean and standard deviation of 3 technical replicates for each data 
point. 
7.2.2.2. Evaluation of Compound Activity in Quinolone Resistant 
Mycobacterium tuberculosis 
Various coumarin based antimicrobials have been shown to target bacterial DNA gyrase, 
which is also the suggested target of the fluoroquinolone antibiotics in mycobacteria [5, 6, 11, 
12].  It was therefore decided to evaluate whether the coumarin derivatives evaluated in this 
study would be able to maintain potency in fluoroquinolone resistant mycobacteria.  The 
activity of CM12 and CM14 were evaluated in three strains (Gly88Cys, Ala90Val and 
Asp94Gly) of M. tuberculosis demonstrating moxifloxacin resistance.  Genetic mutations in 
quinolone-resistance determining regions (QRDR) of DNA gyrase are primarily responsible 
for conferring resistance to various fluoroquinolone antibiotics.  Particularly substitutions in 
the 94 position are commonly identified in quinolone resistant strains [30].  CM12 and 
CM14 maintained potency in all evaluated strains featuring 3 different mutations in the 
QRDR region (see Figure 4).  Preliminary investigations indicate that it is likely that 
compounds in series 1 will maintain activity in fluoroquinolone resistant mycobacteria.  
Additional evaluations are required to determine the true extent of activity in resistant strains 
for series 1 as well as series 2 derivatives. 
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Figure 4:  Preliminary evidence of maintained activity of CM12 and CM14 in fluoroquinolone sensitive (A: 
H37Rv) and resistant M. tuberculosis (B, C, and D: Gly88Cys, Ala90Val, and Asp94Gly, respectively). 
Moxifloxacin (MOX) was used at a concentration of 1.2 µM. OD600: optical density measured at 600 nm. 
 
7.2.2.3. Minimum Inhibitory Concentration Determination 
MICs of the most active compounds from the initial evaluations (CM8, CM12, CM14 and 
CM15) were determined independently at the University of Stellenbosch (US) and University 
of Cape Town (UCT) utilizing different assay methods described in detail in the methodology 
section.  Briefly, the US assay (similar to the assay used for the MTS), utilized a H37Rv 
strain transformed with a plasmid encoding a red fluorescent reporter (pCHERRY3 [31]), a 
gift from Tanya Parish (Addgene plasmid # 24659)), in albumin-containing media 
[Middlebrook 7H9 broth, (Becton, Dickinson and C., USA) enriched with 10% OADC, 0.2% 
glycerol and 0.05% Tween 80; 7H9+OADC].  The UCT method utilized a standard broth 
microdilution method with M. tuberculosis H37RvMA pMSP12:GFP in glycerol-alanine-
salts with 0.05% Tween 80 and iron (GAST-Fe) [32].  Consistently lower MICs were 
observed in the GFP GAST-Fe assay.  CM8, CM12 and CM14 all showed approximately 2 
to 3-fold lower MIC90 values in the UCT laboratory assay with CM15 showing the largest 
discrepancy with a 14-fold difference between the two methods (Table 2).  For the purposes 
of comparison with standard antimycobacterials under similar conditions, CM12 and CM14 
at 25 µM was able to achieve growth inhibition in similar ranges to moxifloxacin at 1.2 µM 
A B 
D C 
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whereas rifampicin at 6 µM resulted in 100% inhibition of bacterial growth in the 
pCHERRY3 assay.  Rifampicin has a MIC of 0.0274 µM in the GFP assay. 
Table 2: Minimum inhibitory concentrations determined using two methods 
Compound 
GFP GAST-Fe mCHERRY – 7H9+OADC 
MIC90 (µM) MIC99 (µM) MIC90 (µM) St. Dev. MIC99 (µM) St. Dev. 
CM8 19.6 25.2 40.55 1.16 44.15 1.37 
CM12 14 29.7 40.89 0.06 50.40 8.96 
CM14 16.7 28 45.22 3.04 54.46 9.58 
CM15 3.2 8.31 43.78 1.46 57.17 10.05 
Abbreviations: St. Dev., standard deviation; MIC90, minimum inhibitory concentration required to inihibit 90% 
of the organism; MIC99, minimum inhibitory concentration required to inhibit 99% of the organism; GFP, green 
fluorescent protein; GAST-Fe, glycerol-alanine-salts with 0.05% Tween 80 and iron; 7H9+OADC, 
Middlebrook 7H9 broth, enriched with 10% oleic albumin dextrose catalase (OADC), 0.2% glycerol and 0.05% 
Tween 80. 
Although it is relatively common to see differences in MIC between different media types, 
the drastic differences in particularly compound CM15 warranted further investigation.  In 
the assay methods used in this study, differences in the observed MIC could be due to the 
lack and presence of albumin in GAST-Fe and 7H9+OADC media respectively; the unique 
reporters used in the two assays; the difference in inoculum size or alternatively, result 
directly from the mechanism of action of the compounds. The size of the inoculum has been 
shown to influence the MIC of antimycobacterials.  A 10-fold increase in inoculum size 
resulted in an approximately 4-fold increase in MIC of bedaquiline [33].  The OD600 of 0.004 
and 0.04 for the GAST-Fe and 7H9+OADC methods respectively, could therefore contribute 
to the higher MIC observed using the second method.  
Another likely contributor to the observed differences in MIC for the coumarin-based 
derivatives may be binding to albumin.  Various coumarin derivatives (e.g. warfarin) are 
known to bind extensively to blood-soluble proteins.  Serum albumins, which are the major 
soluble protein constituents of the circulatory system (4% w/v), have the ability to reversibly 
bind a large variety of exogenous compounds including fatty acids, amino acids, drugs and 
pharmaceuticals [34-36].  Plasma protein binding forms an integral part of distribution and 
bioavailability for numerous medications currently on the market but might also become 
problematic where binding is extensive [37, 38].  In vitro, binding to albumin would reduce 
the amount of compound available to exert an effect on the mycobacterial cell and in theory 
reduce the observed MIC of the derivative.  The impact of the albumin binding on in vivo 
MIC of compounds would however depend on the extent and nature of the binding to 
albumin within the host. 
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7.2.2.4. Albumin Binding Assay 
To better understand the observed differences in MIC between the two assays, we 
investigated possible albumin binding for the two coumarin derivatives (CM14 and CM15) 
with the largest differences in MIC between the GAST-Fe and 7H9+OADC media based 
assays.  Albumin enriched media contains approximately 0.5 % w/v bovine serum albumin 
(BSA).  Results of previous studies indicate that human serum albumin (HSA) and BSA are 
similar proteins in space structure and chemical composition [39-41].  BSA was therefore 
selected as a protein model to investigate fluorescence quenching as an indicator of the extent 
of interaction between coumarin derivatives (CM14 and CM15) and albumin, using 
fluorescence spectroscopy.  Fluorescence quenching is the decrease of the quantum yield of 
fluorescence from a fluorophore induced by a variety of molecular interactions with the 
quencher molecule.  Fluorescence quenching can be dynamic, resulting from collisional 
encounters between the fluorophore and quencher, or static, resulting from the formation of a 
ground state complex between the fluorophore and quencher [42-44].  The effects of 
compounds CM14 and CM15 on the fluorescence quenching of BSA, excited at 295 nm are 
presented in Figure 5.  
The emission spectrum of CM14 showed two maxima, the first one at 335 nm (which is 
characteristic for tryptophan in BSA [45]) and the second peak at 400 nm (which is assigned 
to fluorescence of compound CM14 at concentrations of 5 x 10
-6
 mol L
-1
 and upwards).  The 
emission spectrum of CM15 only showed one maxima at 335 nm for BSA and a weak 
emission peak of CM15 at 415 nm at higher concentrations of the compound.  The excitation 
and emission maxima of CM14 and CM15 are shown in Table 3. 
 
Figure 5: The effects of CM14 (left) and CM15 (right) on the fluorescence spectra of BSA at 22 °C. ex = 295 
nm; c(BSA) = 1.00 x 10−5 mol L−1; c(Q)/(x 10−6 mol L−1). Final concentrations of CM14 and CM15 = 0, 2.5, 
5.0, 7.5, 10, 12.5, 15.0, and 17.5 x 10−6 mol L−1, respectively. 
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The mechanism of the fluorescent quenching of CM14 and CM15 to BSA is described using 
the Stern-Volmer equation: 
F0/F = 1 + Ksv[Q] = 1 + Kq τ0[Q] 
where F0 and F are the fluorescence intensities before and after the addition of the quencher, 
respectively; Ksv is the dynamic quenching constant; Kq is the quenching rate constant; [Q] is 
the concentration of quencher; τ0 is the average lifetime of the molecule without quencher 
and its value is considered to be 10
−8
 s [46, 47]. The Stern-Volmer plot of the CM14 and 
CM15 is presented in Figure 6. 
Figure 6: Stern–Volmer plots of BSA (1.00 x 10−5 mol L−1) quenched by CM14 and CM15 at 22 °C. 
The plots show a good linear relationship within the investigated concentrations of CM14 
and CM15.  
The results in Table 3 showed that Kq were much greater than the limiting diffusion rate 
constant of the biomolecule (2.0 x 10
10
 mol L
−1
 S−1), which indicated that the probable 
quenching mechanism of BSA–CM14 and BSA-CM15 interactions was initiated by complex 
formation rather than by dynamic collision [48].  
It is evident from the results that the fluorescence intensity of BSA decreases with increasing 
concentrations of compounds CM14 and CM15.  It can also be concluded that the 
fluorescence quenching of tryptophan in BSA as observed for compounds CM14 and CM15 
results from complex formation between the two compounds and BSA.  The more extensive 
decrease in fluorescence observed at lower concentrations of compound CM15 likely 
indicate a higher binding affinity between compound CM15 and albumin.  These results 
indicate that albumin binding likely plays a large role in the observed differences in activity 
between the GAST-Fe and 7H9+OADC assays used in this study.  The higher albumin 
binding affinity of CM15 is likely the reason for the larger MIC variation perceived for this 
compound. 
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Table 3: Excitation and emission maxima of CM14 and CM15, and the quenching constant of BSA by CM14 
and CM15. 
Compound T (°C) λEx (nm) λEm (nm) ksv (mol L-1) kq (mol L-1 S-1) R2 
CM14 22 
350a 
350b 
395a 
400b 
3.80 x 105 2.63 x 1014 0.9780 
CM15 22 
335a 
335b 
415a 
415b 
4.88 x 105 2.00 x 1014 0.9927 
aMeasured in Tris-HCl buffer at 1 x 10-6 mol L-1. bMeasured in BSA (1 x 10-5 mol L-1) at 1 x 10-6 mol L-1. 
Abbreviations: λEx: excitation; λEm: emission; ksv: dynamic quenching constant; kq: quenching rate constant; R
2: 
coefficient of determination. 
In addition to providing more clarity on observed MICs, albumin binding properties may also 
provide some insight into the possible pharmacokinetic behavior of these drugs.  Binding and 
dissociation of compounds from plasma proteins is a dynamic process with only the unbound 
fraction of the drug available to exert an effect. In a clinical setting, the dosage of a drug is 
calculated to ensure that, at any point in time, sufficient free drug is available to have the 
required pharmacological effect. The same principle would apply to side effects or toxicity 
and thus, plasma protein binding becomes an important consideration, particularly in highly 
bound drugs. In light of the divergent albumin binding affinities observed in the evaluated 
compounds, it would likely be more pertinent to utilize the MIC values obtained in the 
albumin free GFP-GAST-Fe media for the purposes of determining structure activity 
relationships for antimycobacterial activity. CM15, which seems to be at least 3-fold more 
active than the other top compounds in the GFP assay, has a large CF3 substitution on the 4 
position of the coumarin scaffold, and a p-bromo-N-benzylpiperizine substitution on C7. 
Activity differences between CM8, CM12 and CM14 are not pronounced enough to draw 
structure activity relationship conclusions. 
 
7.2.2.5. Cell Viability Assays 
Cytotoxicity assays for the compounds showing the lowest MIC99 (CM8, CM12, CM14, and 
CM15) were done on Chinese hamster ovary (CHO) epithelial cells using a standard MTT 
assay method (Table 4) [49]. Data was supplemented with further cytotoxicity analysis of 
CM14 and CM15 as well as CM9 in a similar assay using the neuronal type SH-SY5Y 
neuroblastoma cells.  The SH-SY5Y cytotoxicity assay results were used to determine the 
concentration at which the compounds do not affect the viability of the SH-SY5Y cells in 
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order to determine their neuroprotective effect using the 1-methyl-4-phenyl pyridinium 
(MPP
+
) induced neurotoxicity method [50, 51].  
CM9 was included in the neuronal cell viability and MPP
+
 induced neurotoxicity assays 
because it was identified previously as the best multifunctional neuronal enzyme inhibitor 
(IC50: MAO-B = 0.30 uM; AChE = 9.10 uM; BuChE = 5.90 uM) within the series of 
coumarin derivatives (Table 4) [23]. CM9 did not show any significant antimycobacterial 
activity and was therefore not included in the CHO cytotoxicity assay.  CM14 was included 
to draw a comparison between the neurotoxicity and potential neuroprotective effect of the 3-
nitro-4-methyl-coumarin derivatives substituted at the 7-position with either a N-
benzylpiperidine (CM9) or p-bromo-N-piperazine moiety (CM14). CM15, with a large 
trifluoromethane substitution on position 4, showed the most promising antimycobacterial 
activity with minimal multifunctional neuronal enzyme inhibitory activity. It was included in 
the neurotoxicity assays to study the effect of the neuronal enzyme inhibitory activities, or 
lack thereof, on the neuroprotective ability of these compounds or if other mechanisms of 
action are involved. CM8 and CM12 were not included in the neurotoxicity assays as their 
multifunctional neuronal enzyme inhibitory properties were not as pronounced as CM9 and 
CM14. 
Table 4: Cell viability (CC50) and selectivity indices on CHO cells, cell viability on SH-SY5Y cells and enzyme 
inhibition (IC50) of selected test compounds. 
CM 
CC50 uM    
CHO 
SI 
GFPa 
SI 
mCHERRYb 
CC 50% 
SH-SY5Yc 
MAO-A 
IC50 uMd 
MAO-B 
IC50 uMd 
AChE 
IC50 uMd 
BuChE 
IC50 uMd 
CM8 33.0 1.31 0.75 ND n.a. 0.29 31.30 1.27 
CM9 
CM12 
ND 
15.5 
ND 
0.52 
ND 
0.31 
10-50 
ND 
n.a. 
n.a. 
0.30 
3.60 
9.10 
12.8 
5.90 
9.70 
CM14 41.2 1.47 0.76 50-100 n.a. 1.41 38.5 13.3 
CM15 26.3 3.16 0.46 10-50 n.a. 5.64 >100 >100 
Emetine 0.06 ND ND ND ND ND ND ND 
aSelectivity index (SI) = CC50 CHO/MIC99 GFP-GAST-Fe. 
bSelectivity index (SI) = CC50 CHO/MIC99 
mCHERRY-7H9 + OADC. cInhibition range (uM) where 50% cell toxicity will be observed. dData taken from 
Joubert et al., 2017 [23]. ND = not determined. n.a. = no activity. 
Cytotoxicity CC50 on CHO cells observed for CM8, CM12, CM14 and CM15 was moderate 
(CC50: 16.5 – 41.2 µM) indicating low toxicity compared to the cytotoxic agent emetine 
(CC50 = 0.06 uM).  These compounds however showed low selectivity indices when both the 
GFP and mCHERRY MIC99 assay results are compared to the CC50 results (Table 4). The 
compounds, in general, were slightly more selective towards the mycobacterial strain when 
using the GFP assay results, with CM15 showing the best selectivity (SI = 3.16).  The slight 
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selectivity was however not retained when the results from the mCHERRY assay were used 
in the SI calculations.  These poor selectivity indices may limit the further development of 
these coumarin derivatives.  However, the structure activity relationships identified in this 
paper may enable the design of coumarin structures with improved antimycobacterial 
activities and subsequently more favourable selectivity indices. 
The viability of SHSY-5Y human neuroblastoma cells was assessed at different 
concentrations of compounds CM9, CM14 or CM15 (Figure 6, A).  Treatment with the 
compounds at 10 µM did not significantly affect the viability of the SH-SY5Y cells (p > 
0.05).  However, at higher concentrations (50 µM and 100 µM) the viability of the cells were 
significantly (p < 0.001) affected by the test compounds, although to a lesser extent by 
CM14. These results also correlate to the CC50 CHO values obtained for CM14 and CM15 
(Table 4). 
Based on the SH-SY5Y cytotoxicity analysis it was decided that the MPP
+
 neuroprotection 
studies would be done at compound concentrations between 1 µM and 10 µM in order 
maintain the viability of the cells.  MPP
+
 is highly toxic to neurons and has been widely used 
to induce neurodegeneration in various in vitro and in vivo models [50, 51].  Several 
signaling pathways have been suggested to be responsible for MPP
+
-mediated neurotoxicity 
in SH-SY5Y cells, for instance, trigger of oxidative stress [52], induction of apoptosis [53], 
and inactivation of pro-survival phosphoinositide 3-kinase (PI3-K)/Akt cascade [54-56].  
This assay was deemed appropriate to test for initial neuroprotective ability of CM9, CM14 
and CM15 because of the multitude of pathways involved in MPP
+
 mediated neurotoxicity 
and the multifunctional enzyme inhibitory abilities of the test compounds, especially CM9. 
http://etd.uwc.ac.za/
199 
 
Figure 7: (A) Cellular viability of SH-SY5Y cells treated with compounds CM9, CM14 or CM15 at 10 µM, 50 
µM and 100 µM for 48 hours.  Data is presented as mean ± SEM. Significance is set at a level of *p<0.05 
compared to vehicle treated control cells (taken as 100 % cell viability).  (B-D) The effects of compounds CM9, 
CM14 or CM15 on MPP+-induced (1000 μM) cytotoxicity in SH-SY5Y cells.  The viability of the untreated 
control was defined as 100 %. MPP+ without test compound showed a significant decrease in cell viability 
relative to the control (#p<0.05).  The level of significance for the test compounds is set at *p<0.05 compared to 
the MPP+ only treated control (0).  Statistical analysis (Turkey’s post hoc test) was performed on all raw data, 
with asterisks signifying significant inhibitory effect.  *p<0.05; **p<0.001; ***P<0.0001. 
SH-SY5Y cells were exposed to the neurotoxin MPP
+
 with or without test compound, and 
cell viability was evaluated using the MTT mitochondrial function assay [43].  As illustrated 
in Figure 7B-D, after the exposure to 1000 μM MPP+ for 48 hours, the cell viability declined 
significantly to 51.42 ± 3.18 %.  However, its cytotoxic effects were ameliorated in the 
presence of CM9, CM14 and CM15 at 1 µM, 5 µM and 10 µM concentrations.  The 
compounds, at a 1 µM concentration, restored cell survival to 81.86 ± 3.72 %, 101.2 ± 6.00 
% and 81.05 ± 6.83 %, respectively.  CM9 showed activity in a dose dependent manner 
exerting maximal cytoprotection of 92.2 ± 4.18 % at 10 µM.  At 5 µM and 10 µM a slight 
decrease in cytoprotection was observed for CM14 and CM15.  This may indicate that in the 
neurotoxin challenged state the SH-SY5Y cells may be more sensitive to the cytotoxic effect 
of the test compounds.  Therefore, CM14 and CM15 might have enhanced the toxicity of the 
neurotoxin which resulted in lower neuroprotection values observed at higher concentrations.  
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Thus, in general and especially at a 1 µM concentration, these compounds, and part icularly 
CM14, exerted highly significant cytoprotection towards MPP
+
 insults to the SH-SY5Y 
neural cells. 
The results of the MPP
+
 neuroprotection study did not provide any information on structure 
activity relationships of these compounds as CM9, CM14 and CM15 showed similar levels 
of cytoprotection.  It was however noted that the neuronal enzyme inhibitory activity of these 
compounds is not the only factor that play a role in cytoprotection and that other mechanisms 
of action are involved. For instance, CM15 showed poor neuronal enzyme inhibitory 
activities but was still able to significantly protect the cells from MPP
+ 
induced injury. CM9 
with the best multifunctional enzyme inhibitory profile showed cytoprotection at the same 
level as CM15. As described in the literature coumarin derivatives may possess anti-
inflammatory, anti-apoptotic and antioxidant effect [2, 3]. These effects combined with the 
multifunctional neuronal enzyme inhibitory abilities of the compounds may explain the 
excellent neuroprotection observed. Therefore, further neuroprotection studies are necessary 
to elucidate the mechanism(s) of action of these compounds. 
 
7.2.3. Materials and Methods 
7.2.3.1. Compound Synthesis 
Synthesis methods of the compounds described in this article are described in detail in 
previous publications by the drug design group at UWC [26]. 
 
7.2.3.2. Initial Medium Throughput In Vitro Activity Screen 
This study was approved by the Stellenbosch University Health Research Ethics Committee 
(S15/06/135).  The M. tuberculosis H37Rv strain used during this study was obtained from 
the ATCC (ATCC 27294) and whole genome sequencing [57] and virulence confirmation in 
a murine infection model [58] was used to verify the strain. The episomal plasmid 
pCHERRY3, a gift from Tanya Parish (Addgene plasmid #24659) [31], which expresses the 
far-red fluorescent reporter mCHERRY and contains a hygromycin B resistance cassette, was 
transformed into this electrocompetent M. tuberculosis H37Rv.  Growth curve analysis of 
both M. tuberculosis H37Rv and M tuberculosis H37Rv:pCHERRY was performed twice to 
ensure that the plasmid did not have any deleterious effects on growth.  
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The antimycobacterial activity of the synthetic compounds was determined using a medium 
throughput 96-well plate assay.  M. tuberculosis H37Rv with and without the reporter was 
cultured in 7H9+OADC, without and with 50 µg/mL hygromycin B respectively, whereafter 
the culture was strained (40 µm; Becton, Dickinson, and Co., USA), and the OD600 was 
adjusted to 1.0. Culture was added to each well, resulting in a final OD600 of 0.02. White, flat 
bottom 96-well microtiter plates were prepared, with a final volume of 200 µL, final bacterial 
OD600 of 0.02, and final compound concentration of 100 µM, 50 µM or 1 µM,  
Controls included a gain, negative, bacterial growth, dimethyl sulfoxide (DMSO), positive, 
negative and compound control.  The background control, which contains M. tuberculosis 
H37Rv without the fluorescent reporter is subtracted from the fluorescence measurements 
since it displays the inherent fluorescence of M. tuberculosis H37Rv. Negative control is 
included as an untreated fluorescence control where the DMSO control is included to ensure 
that the maximum amount of DMSO present in the compound dilutions does not interfere 
with growth. The positive control wells contained 6 µM rifampicin (RIF) and the compound 
controls contained 100 M compound which was used to confirm that the compound does 
not autofluoresce in the absence of M. tuberculosis.  
One-hundred microliters of the M. tuberculosis H37Rv:pCHERRY3 diluted culture was 
added to each well except the gain, background and compound control wells. In the gain 
control wells, 100 µL of the undiluted M. tuberculosis H37Rv:pCHERRY3 culture was 
added and in the background control wells M. tuberculosis H37Rv without the fluorescent 
reporter was added. The plates were sealed with breathable sealing film and incubated at 
37°C for 6 days, taking readings on days 0, 2, 3, 4, 5, and 6 using a BMG Labtech 
POLARstar Omega plate reader (Excitation: 587 nm, Emission: 610 nm). During the 
readings the breathable seal was removed and an optical sealing film was adhered, whereafter 
it was removed and replaced by a new breathable sealing film. The average of the 
background control was subtracted from the fluorescence readings whereafter the data was 
visualised using GraphPad Prism v7.01, by plotting the relative fluorescence units (as a 
measure of growth) over time. The percentage inhibition was also calculated on Day 5, by 
dividing the treated by the untreated values.  Compounds that inhibited more than 50% 
growth at 50 µM were selected for further study and screened at narrower concentration 
ranges to more accurately ascertain the extent of the compound’s antimycobacterial activity. 
The second round of screening was also performed using relative fluorescence as a proxy for 
growth. The growth curves were set up similarly to the initial screen.  Five compounds which 
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showed the highest activity during the second screen were selected to undergo further 
analysis.  Of these 5 compounds, 4 were coumarin derivatives. 
 
7.2.3.3. Activity in Moxifloxacin Resistant M. tuberculosis 
Three M. tuberculosis moxifloxacin resistant mutants, carrying G88C, A90V or D94G amino 
acid changes in gyrase A, were tested for CM12 and CM14 cross-resistance.  Moxifloxacin 
stock solutions were prepared at a concentration of 25 µM in DMSO and stored at -80°C.  
The resistant mutants and an M. tuberculosis H37Rv susceptible strain were prepared as 
described in section 3.2 and subsequently exposed to 1.2 µM moxifloxacin, 25 µM CM12 
and 25 µM CM14 in technical triplicates in a black, flat, clear-bottom 96 well plate.  Each 
well containing the respective strain was inoculated to an OD600 of 0.02 in a final volume of 
200 µL.  Readings were taken as described in section 3.2 over 8 days and OD600 was plotted 
over time using GraphPad Prism v7.01.  
 
7.2.3.4. Minimum Inhibitory Concentration Determination 
MICs were determined for the four most active coumarin derivatives identified in the MTS. 
CM8, CM12, CM14 and CM15 were screened using two independent methods as described 
below. 
 
M. tuberculosis pMSP12:GFP in GAST-Fe media 
The first MIC determination was performed at the Institute of Infectious Disease & 
Molecular Medicine, University of Cape Town (UCT) at a screening facility jointly managed 
by the MRC/NHLS/UCT Molecular Mycobacteriology Research Unit (A/Prof Digby 
Warner) and the H3D Drug Discovery and Development Unit (Prof Kelly Chibale).  Here, 
the standard broth microdilution method was performed using M. tuberculosis H37RvMA 
pMSP12:GFP [32]. A 10 ml culture was grown in glycerol-alanine-salts with 0.05% Tween 
80 and iron (0.05%; GAST-Fe) pH 6.6, to an OD600 of 0.6 – 0.7. Thereafter the culture was 
diluted 1:100 in GSAT-Fe. In a 96-well microtiter plate, two-fold serial dilutions of each 
compound were prepared in GAST-Fe whereafter 50 µL of the diluted culture was added to 
each serial dilution well resulting in an OD600 of 0.004. The plate layout used was modified 
from a previously described method [59]. Controls included a bacterial growth control (5% 
DMSO in GAST-Fe) and a positive control (0.15 µM RIF). The microtiter plate was 
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incubated at 37°C with 5% CO2 and humidity, sealed within a secondary container. Using a 
platereader (FLUOstar OPTIMA, BMG Labtech; Excitation: 485nm; Emission: 520nm) 
relative fluorescence was measured on day 7 and 14. The CCD Vault from Collaborative 
Drug Discovery was used to archive and analyse the fluorescence data. Analyses included 
normalisation to the bacterial growth and antimycobacterial growth control as the maximum 
and minimum growth representations respectively generating a dose-response curve using the 
Levenberg-Marquardt damped least-squares method. This dose response curve was used to 
calculate the MIC90 and MIC99 which is described as the lowest concentration at which the 
compound inhibits growth by more than 90% and 99%, respectively (Burlingame, CA, 
www.collaborativedrug.com).  
 
M. tuberculosis H37Rv:pCHERRY3 in 7H9+OADC 
The second technique used a different fluorescent reporter (mCHERRY) and media 
(7H9+OADC). Dose-response curve analysis was carried out on the same compounds as 
above. Dose response curves were performed by exposing M. tuberculosis 
H37Rv:pCHERRY3 to increasing concentrations of each compound in white flat bottom 96 
well plates. M. tuberculosis H37Rv with and without mCHERRY was prepared as described 
in section 3.2.2. In a white, flat bottom 96 well microtiter plate two-fold serial dilutions of the 
compounds were prepared with a 100 µL final volume and final bacterial OD600 of 0.04. The 
plate layout is shown in Figure 3.3. This method was adapted from a previously described 
method [59]. The controls included were a background control (M. tuberculosis H37Rv in 
7H9+OADC), a negative control (M. tuberculosis H37Rv:pCHERRY3 in 7H9+OADC) and a 
positive control (M. tuberculosis H37Rv:pCHERRY3 in 7H9+OADC containing 2 µM RIF). 
The microtiter plate was sealed with a breathable film, placed in a secondary container and 
incubated at 37°C for 5 days, after which a relative fluorescence measurement (Excitation: 
587 nm;  Emission: 610 nm) was taken using a BMG Labtech POLARstar Omega plate 
reader. To analyse the relative fluorescence data the average of the background control was 
subtracted from each well, and the subsequent data set was analysed in GraphPad Prism 
v.7.01. Data was first normalised using built in non-linear dose-response curve analysis. This 
gave an output of IC50 as well as a Hill Slope which was used to determine the IC90 and IC99 
of each compound.  IC90 and IC99 were defined as the concentration where 90% and 99% of 
growth was inhibited, respectively. 
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7.2.3.5. Bovine Serum Albumin Binding Assay 
The interaction between coumarin derivatives (CM14 and CM15) and BSA were measured 
by fluorescence spectroscopy.  BSA (≥ 98%) was obtained from Sigma Aldrich South Africa 
and dissolved in a Tris–HCl (0.10 mol L−1, pH = 7.4) buffer to form the BSA solution with a 
concentration of 1.00 x 10
−5
 mol L
−1
.  A Tris–HCl buffer (0.10 mol L−1, pH = 7.4) containing 
0.10 mol L
−1
 NaCl was selected to keep the pH value constant and to maintain the ionic 
strength of the solution. Coumarin 14 and 15 stock solution (1.00 x 10
−3
 mol L
−1
) was 
prepared in MeOH.  All other reagents were of analytical grade and double-distilled water 
was used in the experiments. Fluorescence spectra were recorded on a Biotek Synergy Mx 
fluorescence plate reader.  Black 96 well plates were used in all experiments. The excitation 
and emission slits were 9 nm.  Fluorescence spectra were measured in the range of 315–500 
nm at the excitation wavelength of 295 nm. All experiments were done at 22 °C.  The assay 
was conducted using a 200 µL solution containing 1.00 x 10
−5 
mol L
−1
 BSA that was titrated 
by successive additions of 1.00 x 10
−3
 mol L
−1
 coumarin CM14 or CM15 solution.  The final 
concentration of the compounds varied from 0 to 1.75 x 10
−5
 mol L
−1
. Titrations were done 
manually using a micro-pipette in 2 minute intervals.  Quenching values remained unchanged 
for more than 10 minutes after individual titrations. 
 
7.2.3.6. Chinese Hamster Ovary Cell Cytotoxicity Assays 
Cytotoxicity was evaluated on CHO cells utilizing a standard MTT assay [49].  The 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) is a yellow tetrazolium salt 
that is reduced to purple formazan in the presence of living cells.  This reduction reaction was 
used to measure growth and chemosensitivity. The test samples were tested in triplicate on 
one occasion. Cells were seeded in microtiter plates at a density of 10
5
 cells/ml and incubated 
for 24 hours prior to exposure . The test samples were prepared to a 20 mg/mL stock solution 
in 10% methanol or 10% DMSO and were tested as a suspension if not properly dissolved. 
Test compounds were stored at -20˚C until use, and administered in volumes of 100 µL to the 
plated cells. Emetine was used as the reference drug in all experiments. The highest 
concentration of each compound was 100 µg/mL, which was serially diluted in complete 
medium with 10-fold dilutions to give 6 concentrations, the lowest being 0.001 µg/mL. The 
same dilution technique was applied to the all test samples. The highest concentration of 
solvent to which the cells were exposed to had no measurable effect on the cell viability (data 
not shown). Plates were developed after 44 hours of exposure to the drug by the addition of a 
solution of MTT. After four hours, further incubation at 37 °C the supernatant was removed 
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from the cells via suction and DMSO was added to each well to dissolve the reduced dye 
crystals. Plates were analysed at 540 nM wavelength using a spectrophotometer to determine 
the relative amount of formazan salt in each well. The amount of formazan produced in wells 
containing untreated cells only and growth medium only represent 100% survival and 0% 
survival respectively, and the amount in each treatment well was converted to a survival 
percentage relative to these two extremes. The 50% inhibitory concentration (IC50) values 
were obtained from full dose-response curves, using a non-linear dose-response curve fitting 
analysis via GraphPad Prism v.4 software. 
 
7.2.3.7. Human Neuroblastoma SH-SY5Y Cell Viability Assays 
Cell line and culture conditions 
The human neuroblastoma cell line SH-SY5Y was generously donated by our collaborator at 
the Division of Molecular Biology and Human Biology, Stellenbosch University, Tygerberg, 
Cape Town. Cells were cultured in monolayer using Dulbecco Modified Eagles Medium 
(DMEM, Gibco, Life Technologies Ltd) supplemented with 10% foetal bovine serum (FBS, 
Gibco, Life Technologies Ltd.) and 1% 100 U/mL penicillin and 100 μg/mL streptomycin 
(Lonza Group Ltd., Base Switzerland). Cells were grown at 37 °C, in a humidified 
atmosphere at 5% CO2. Media was replaced every two to three days and cells were sub-
cultured by splitting with trypsin (Lonza Group Ltd., Base Switzerland). 
 
SH-SY5Y cytotoxicity assays  
The standard MTT assay which measures cell metabolic activity was used to determine 
cytotoxicity of CM14, CM15 and CM9 as described by Mosmann [49].  Briefly, SH-SY5Y 
cells were plated in flat bottom 96 well plates in growth medium as stated in 3.7.1 at a 
density of 7,500 cells/well.  Cells were allowed to adhere to the plate surface for 24 hours and 
used media were replaced with fresh media containing test compounds at 10 µM, 50 µM and 
100 µM. Vehicle control cells were treated with DMSO (solvent for dissolving test 
compounds) at a concentration similar to the amount contained in the highest concentration 
of test compounds.  After 48 hours, 10 µL of MTT solution (5 mg/mL) was added to each 
well and incubated for 4 hours and the purple formazan formed was solubilized with 100 µL 
DMSO and plates were read spectrophotometrically to determine absorbance at 570 nm using 
a BMG Labtech POLARStar Omega multimodal plate reader. 
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MPP
+
-induced cytotoxicity in SH-SY5Y cells 
SH-SY5Y cells were seeded onto a 96-well plate and treated with 1000 μM MPP+ for 
approximately 48 hours. Different concentrations (1 μM, 5 μM, 10 μM) of test compounds 
were administrated two hours prior to MPP
+
 treatment. Afterwards, cell viability was 
measured by MTT colorimetric assay and performed as stated above. 
 
7.2.4. Conclusion 
As part of a collaborative project, compounds from the University of the Western Cape, 
School of Pharmacy drug-design group compound library were screened for 
antimycobacterial activity. Various coumarin derivatives, originally designed and synthesized 
as multifunctional neuronal enzyme inhibitors, demonstrated noteworthy antimycobacterial 
activity. 
The coumarins substituted with a N-benzylpiperidine containing moiety on the 7-position and 
a 3-nitrile substitution on the coumarin nucleus (CM9) showed the best MAO-B and ChE 
inhibitory activities. This study identified that structural modification on position 4 and/or 7 
of the coumarin scaffold can be utilized to improve selectivity towards either inhibition of 
neuronal enzymes or antimycobacterial effect. Large substitutions on position 4 (4-
trifluoromethyl moiety) and p-bromo-N-benzylpiperazine compared to N-benzylpiperidine 
substitutions on position 7 increases activity against M. tuberculosis but inversely affects 
monoamine oxidase and cholinesterase inhibition.  
After validation of the antimycobacterial activity observed in the MTS; CM8, CM12, CM14 
(4-metyl substituted) and CM15 (4-trifluoromethyl substituted) were identified as the most 
active compounds in the series.   In addition to activity in standard M. tuberculosis H37Rv, 
we also described activity of selected coumarin derivatives in fluoroquinolone resistant 
bacteria.  Evaluations on three moxifloxacin resistant strains harboring mutations in the 
QRDR of DNA gyrase indicate that the compound in series 1 will likely maintain potency in 
fluoroquinolone resistant mycobacteria. 
The MICs of the four most active compounds were evaluated using two methods i.e. M. 
tuberculosis H37RvMA pMSP12:GFP in GAST-Fe media [32], and M. tuberculosis 
H37Rv:pCHERRY3 [31] in 7H9 + OADC. The MIC values in the GAST-Fe assay were 
consistently lower (2-3 fold lower for CM8, CM12, and CM14 and 14 fold lower for 
CM15).  Difference in inoculum size and the lack and presence of albumin in GAST-Fe and 
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7H9+OADC media respectively was suggested as primary contributing factors to the MIC 
variations. 
As coumarin derivatives are known to bind extensively to blood-soluble proteins, albumin 
binding properties of CM15 and CM14 (with the highest and lowest MIC fold difference 
between assays respectively) was evaluated. Fluorescence quenching of BSA in response to 
compound binding was evaluated in the presence of various concentrations of the 
compounds.  Analysis of fluorescence quenching of tryptophan in BSA indicate that both 
CM14 and CM15 form concentration dependant complexes with BSA. These results suggest 
that albumin binding plays a large role in the observed differences in activity between the 
GAST-Fe and 7H9+OADC assays used in this study.  The more extensive decrease in 
fluorescence observed with CM15 likely indicates a higher binding affinity between CM15 
and thus explains the large MIC differences observed for this compound. This report 
therefore highlights the importance of early consideration of plasma binding properties of 
coumarin derivatives as it was shown here to influence in-vitro evaluations in addition to its 
more commonly considered effect on in-vivo, and future pharmacokinetic behavior of the 
compounds.   
CM8, CM12, CM14 and CM15 showed moderate (CC50: 16.5 – 41.2 µM) cytotoxicity 
compared to the cytotoxic agent emetine (CC50 = 0.06 uM).  These compounds however 
showed low selectivity indices when both the GFP and mCHERRY MIC99 assay results are 
compared to the CC50 results (Table 4). The compounds, in general, were slightly more 
selective towards the mycobacterial strain when using the GFP assay results, with CM15 
showing the best selectivity (SI = 3.16). The slight selectivity was however not retained when 
the results from the mCHERRY assay were used in the SI calculations. These poor selectivity 
indices may limit the further development of these coumarin derivatives. However, the 
structure activity relationships identified in this paper may enable the design of coumarin 
structures with improved antimycobacterial activities and subsequently more favourable 
selectivity indices. 
The viability of SHSY-5Y human neuroblastoma cells was also assessed at different 
concentrations of compounds CM9, CM14 or CM15. Treatment with the compounds at 10 
µM did not significantly affect the viability of the SH-SY5Y cells (p > 0.05). However, at 
higher concentrations (50 µM and 100 µM) the viability of the cells were significantly (p < 
0.001) affected. Neuroprotective ability of the three compounds were therefore evaluated 
atconcentrations between 1 µM and 10 µM. CM9, CM14 and CM15 all demonstrated 
significant and comparable cytoprotection towards MPP
+
 insults to the SH-SY5Y neural 
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cells. As these compounds differ significantly in their neuronal enzyme inhibitory activity it 
can be concluded that enzyme inhibition is not the only factor that plays a role in 
cytoprotection and that other mechanisms of action are involved in the observed 
neuroprotection. 
This article therefore describes the versatile neuronal enzyme inhibitory, neuroprotective and 
antimycobacterial nature of a range of coumarin derivatives. Importantly, comparison of 
corresponding SAR, demonstrates that it is possible to reduce the promiscuous activity of the 
derivatives through careful modification on the coumarin scaffold. Furthermore the article 
highlights the importance of broader evaluation of pharmacological effects of coumarin 
derivatives over and above cytotoxicity assays to identify and afford early limitation of 
unwanted pharmacological effects.  This report also shows that albumin binding properties of 
coumarin derivatives may impact on in-vitro assay results and should therefore be taken into 
consideration even during early evaluations of coumarin-type compounds. 
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7.3 Letters, posters and presentations 
 
The following chapter is a depiction of additional research outputs directly pertaining to 
previous chapters that serves to further illustrate the potential of polycyclic propargylamine 
compounds in the study of neurodegeneration. The chapter comprises several poster and 
podium presentations presented at the various academic conferences attended during the 
course of the study. 
 
List of letters, posters and presentations 
 Poster: Zindo, F.T., Joubert, J., Malan, S.F. 3's Company Pharmacy Conference, 
Lagoon Beach, Cape Town (Poster session, October 2013). 
 Podium presentation 1: Zindo, F.T., Joubert, J., Malan, S.F. 35th Conference of the 
Academy of Pharmaceutical Sciences, Summerstrand Hotel, Port Elizabeth (August 
2014). 
 Letter: Zindo, F.T., Joubert, J., Malan, S.F. S Afr Pharm J, 82, (2), March 2015. 
 Podium presentation 2- 1st Conference of Biomedical and Natural Sciences and 
Therapeutics, Spier Wine Farm, Stellenbosch (October 2018). 
 
The poster: Summarises the biological activities of evaluations conducted on a previous 
series of polycyclic propargylamine and acetylene compounds. (expansion of Article 1, 
Chapter 3). Additional synthetic routes summarised in this poster, include the design and 
synthesis of additional pentacycloundacane propargylamine derivatives (scheme 1) which 
were later evaluated and reported in Article 2, Chapter 4.  
 
Podium presentation 1: Highlights the various structure-activity relationships of the series of 
polycyclic propargylamine and acetylene compounds described in Article 1, Chapter 3. The 
presentation also summarises the molecular modelling studies that led to the development of 
the new series of compounds described in Article 2, Chapter 4. This presentation received the 
Boehringer Ingelheim Young Scientist Award for Laboratory-based research. 
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The letter: Is a summary article published in the South African Pharmaceutical Journal. It 
highlights the work published in Article 1, Chapter 3. 
 
Podium presentation 2: Summarises all the work conducted in this PhD project. It highlights 
the design synthesis and evaluation of various polycyclcic propargylamine derivatives that 
show multifunctional activity which include MAO-B inhibition, VGCC blockade, NMDAR 
antagonism as well as general neuroprotective ability (expansion of Article 2, Chapter 4)  
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Introduction 
 
 
The abnormal death of neurons in the central 
nervous system of individuals suffering from 
neurodegenerative diseases, which include 
Parkinson’s disease, Alzheimer’s disease, 
Huntington’s disease and amyotrophic lateral 
 sclerosis, takes place by an intrinsic cell      
suicide programme, known as apoptosis.1,2  
              This process is triggered by several stimuli, 
and consists of numerous pathways and cascades 
which lead to apoptosis. One such pathway is the excitotoxic process, 
which results from the activation of postsynaptic receptors including 
N-methyl-D-aspartate (NMDA) receptors, and 2-amino-3-(3-hydroxy-
5-methylisoxazol-4-yl)proprionate and kainate receptors. Upon their 
activation, these receptors open their associated ion channel to allow 
the influx of Ca
2+
 and Na+ ions. The excessive influx of calcium, 
together with any calcium release from the intracellular 
compartments, can overwhelm Ca
2+
 regulatory mechanisms and lead 
to cell death.3,4 This mechanism of cell death suggests that the 
receptors and their associated calcium channels serve as drug target 
sites to curb neurodegeneration. It has also been shown that there 
are age-related elevated levels of monoamine oxidase B (MAO-B), 
which not only act indirectly as a trigger to the apoptotic process, but 
also give rise to some of the signs and symptoms associated with 
 
 
 
these disorders.5,6 Therefore, compounds that exhibit MAO-B 
inhibition are more advantageous as neuroprotective agents than 
agents with little or no activity on this enzyme. However, it is 
important to note that the pathogenesis of these complex 
neurodegenerative conditions is not yet fully understood, and 
other ascribed theories of causation include mitochondrial 
dysfunction,7 cholinergic dysfunction,8 oxidative stress8 and metal 
dyshomeostasis.3 
 
Aim 
 
Eight lead compounds, in the form polycyclic propargylamine or 
derivatives thereof, selected from our compound library, were 
reported to exhibit anti-apoptotic activity as they improved cell viability 
by values ranging from 9-41%.9 The reported anti-apoptotic activity of 
these compounds seems to result from some mechanism apart from 
MAO-B inhibition, as these compounds showed little to no activity 
when assayed for MAO-B inhibition at 300 µM. 
 
Thus, the study aimed to assess the lead compounds 1-8 (Figure 1), 
which were developed to serve as multifunctional drugs, for potential 
calcium flux modulatory activity, and to design a new series of 
compounds, based on the findings from calcium flux assays and 
computer modelling studies, with the aim of affording novel 
compounds with improved multifunctional properties. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Novel polycyclic propargylamine and acetylene derivatives (1-8) and the structures of rasagiline (9), selegiline (10), NGP1-01 (11) and MK-801 (12)  
 
 
 
S Afr Pharm J 32 2015 Vol 82 No 2 
Frank Zindo 
http://etd.uwc.ac.za/
223 
 
Cum Laude  
 
 
This new series was designed to halt the apoptotic process and 
eliminate some of the signs and symptoms of neurodegenerative 
disorders by: 
 
• Modulating the calcium influx by antagonising the NMDA 
receptors and blocking the L-type voltage-gated calcium channels 
(VGCC) 
 
• Inhibiting the MAO-B enzyme, thus allowing an increase in the 
depleted neurotransmitter levels in the central nervous system, 
and reducing the concomitant production of hydrogen peroxide 
and other neuronal cell-damaging free radicals
10,11
 
 
• Halting the apoptotic process. 
 
Method 
 
Synthesis 
 
Considering the structures of rasagiline (9) and selegiline (10), 
two well known MAO-B inhibitors with anti-apoptotic activity,12 
the lead series of neuroprotective agents all contained the 
propargylamine functional group or a derivative thereof, 
conjugated to various polycyclic cage moieties. 
 
To synthesize compounds 1-8 (Figure 1), propargylamine, 
propargylbromide or ethynyl magnesium bromide was made to 
react with the pentacycloundecane (PCU) or amantadine to give 
the final compounds. Each compound was synthesized to 
evaluate the activity and benefit of a certain group of atoms in the 
molecule. The structural characterisation of these compounds 
was performed using mass, fourier transform mass, and nuclear 
magnetic resonance, spectroscopy, in combination with single 
crystal X-ray diffraction analysis.
10
 
 
Calcium modulation assays 
 
All derivatives (1-8) were screened at 100 µM for their potential 
inhibitory activity on the VGCC and NMDA receptor channels. 
They were assessed using the fluorescent ratiometric indicator, 
Mag-Fura-2/AM™, and a fluorescent plate reader. KCl- and 
NMDA/ glycine-mediated calcium influx in murine 
synaptoneurosomes was used to evaluate the influence of the 
test compounds on the calcium influx via the VGCC and NMDA 
receptor channels, respectively. Both assays were carried out 
with reference to standard positive controls, i.e. nimodipine, a 
dihydropyridine L-type calcium-channel blocker; NGP1-01 (11), a 
prototype pentacycloundecane compound with neuroprotective 
ability;13-16 and MK-801, a potent high-affinity NMDA receptor 
channel blocker. 
 
Results and discussion 
 
Voltage-gated calcium channel blockade 
 
The adamantine-propargylamine derivative 8 showed the best 
VGCC inhibitory activity (45%); higher than that of NGP1-01 (11) 
(27%). Although structurally similar to 8, the substitution of the 
aromatic moiety of 8 with a propargyl moiety to give the 
disubstituted propargylamine adamantane compound 7, led to a 
significant decrease in VGCC activity (18%). This observation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 a and b: Schematic generated from the Molecular 
Operating Environment® software, showing inactive compound 3 
(Figure 2 a), and a representative molecule of the new 
pentacycloundecylamine-propargylamine series (Figure 2 b), in a 
monoamine oxidase B enzyme active site cavity 
 
 
indicates the importance of including the benzylamine moiety 
within these structures for optimal VGCC activity. 
 
N-methyl-D-aspartate receptor antagonism 
 
The best inhibitory activities were observed for compounds 7 and 
8, of 52% and 59%, respectively. This high activity might be 
attributed to the inclusion of the adamantane moiety, which has 
known NMDA receptor inhibitory activity.
17
 
It is important to note that the concentration at which these lead 
compounds show calcium modulation is too high to ascribe the 
anti-apoptotic activity of these compounds to NMDA receptor 
antagonism and VGCC blockade. Therefore, it is postulated that 
these derivatives exert their effect by acting on one or more other 
mechanisms implicated in neurodegeneration, and unexplored in 
this study. Further studies to elucidate the possible anti-apoptotic 
mechanism of these compounds are underway. 
 
Monoamine oxidase B molecular modelling 
 
The realisation of minimal MAO-B inhibitory activity in the initial 
series led to the development and synthesis of a new series of 
compounds which may potentially exhibit improved MAO-B 
activity when compared to the lead series. Computer-assisted 
simulated docking of the proposed propargylamine derivatives 
was conducted using Molecular Operating Environment® 
software,18 and allowed the design of a series of aza-PCU and 
oxa-PCU compounds (Figure 2a and b and Figure 3), with the 
ability to traverse deeper into the enzyme cavity of the MAO-B 
enzyme (PDB ID: 2V5Z) compared to compounds 1-8. 
 
The compounds are shown in green and the flavin adenine 
dinucleotide co-factor in red. Note that compound 3 merely 
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PCU: pentacycloundecylamine  
Figure 3: Schematic for the synthesis of a new series of aza-pentacycloundecylamine and oxa-pentacycloundecylamine compounds. Reagents and  
conditions: (i) THF 0°C 1 hour, (ii) THF/MeOH and NaBH4 rt 24 hours, (iii) DMF rt 24 hours, (iv) MeOH, acetic acid and NaCNBH3 2 hours 
 
occupies the entrance cavity of the enzyme, and remains distant 
from the flavin adenine dinucleotide co-factor, rendering it 
inactive, while the new series traverses deeper into the enzyme 
cavity to proximate the flavin adenine dinucleotide co-factor, 
allowing for potential binding interactions which may result in 
improved monoamine oxidase B activity. 
 
Synthesis of new analogues 
 
Using the PCU moiety as a scaffold, the new compounds were 
synthesized by virtue of SN2 nucleophilic substitution reactions to 
afford the two series of propargylamine-derived compounds 
(Figure 3). 
 
Biological evaluation of the new series will include calcium 
modulation, MAO-B inhibition and anti-apoptotic assays. The 
findings thereof will allow for further derivation of structural activity 
relationships pertinent to these types of compounds in serving as 
neuroprotective agents. 
 
Conclusion 
 
The compounds in the lead series all had significant anti-
apoptotic activity (6-8) comparable to and better than selegiline 
(1-5). This activity could not be ascribed to MAO-B inhibition as 
these compounds showed little to no activity on the MAO-B 
enzyme, except for two which inhibited the MAO-B enzyme by 
73% at 300 µM. It could also not be ascribed to calcium 
modulation as the best results reported for compounds 2, 4, 7 
and 8 were at a significantly high concentration of 100 µM. The 
initial series of compounds, which had significant anti-apoptotic 
activity, presented interesting leads for the design and 
development of more potent inhibitors. Findings from the 
bioassays performed in the lead series and molecular modelling 
have lead to the design of a new series of PCU-propargylamine 
analogues, which might potentially exhibit a broader spectrum of 
activities, which most importantly might include significant MAO-B 
activity. Compounds that render such multimechanistic activity 
have great potential to serve as future analogues for the 
treatment and management of neurodegenerative disorders. 
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1. Pseudo colour graphs of the apoptosis detection - DePsipherTM assay 
 
Figure 1: Pseudo-colour graphs of the control experiments 
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Figure 2: Pseudo-colour graphs of compounds 9 - 14 
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Figure 3: Pseudo-colour graphs of compounds 15 and 16 
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2. Representative 1H nuclear magnetic resonance spectra 
 
 
Spectrum 1: Compound 9 
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Spectrum 2: Compound 10 
 
Spectrum 3: Compound 11 
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Spectrum 4: Compound 12 
 
Spectrum 5: Compound 13 
 
http://etd.uwc.ac.za/
236 
 
 
Spectrum 6: Compound 14 
 
 
Spectrum 7: Compound 15 
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Spectrum 8: Compound 16 
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1. MAO-B molecular modelling results of compounds 1-12 
2. Representative 1H nuclear magnetic resonance spectra 
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1. MAO-B molecular modelling results of all test compounds 
Table 1: MOE generated docking simulations of compounds 1-12 within the human MAO-B enzyme 
active site. The compounds and FAD cofactor in is indicated in yellow and green respectively. The binding 
interactions with the amino acid residues is shown on the right.  
Compound 
(MAO-B IC50) 
Docking simulation Ligand interactions 
 
 
 
 
1  
(1.91 µM) 
  
 
 
 
 
 
2  
(13.80 µM) 
 
 
 
 
 
 
3 
(100 µM) 
  
 
 
 
 
 
 
4 
(>100 µM) 
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5 
(1.70 µM) 
 
 
 
 
 
 
 
6 
(36.31 µM) 
 
 
 
 
 
 
 
7 
(>100 µM) 
 
 
 
 
 
 
 
8 
(>100 µM) 
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9 
(3.80 µM) 
 
 
 
 
 
 
 
10 
(100 µM) 
 
 
 
 
 
 
 
11 
(14.13 µM) 
 
 
 
 
 
 
 
12 
(28.18 µM) 
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1-1/2% per month or, if less, the maximum rate allowed by applicable law. Unless 
otherwise specifically set forth in the Order Confirmation or in a separate written agreement 
signed by CCC, invoices are due and payable on “net 30” terms. While User may exercise 
the rights licensed immediately upon issuance of the Order Confirmation, the license is 
automatically revoked and is null and void, as if it had never been issued, if complete 
payment for the license is not received on a timely basis either from User directly or 
through a payment agent, such as a credit card company. 
3.3 Unless otherwise provided in the Order Confirmation, any grant of rights to User (i) is 
“one-time” (including the editions and product family specified in the license), (ii) is non-
exclusive and non-transferable and (iii) is subject to any and all limitations and restrictions 
(such as, but not limited to, limitations on duration of use or circulation) included in the 
Order Confirmation or invoice and/or in these terms and conditions. Upon completion of 
the licensed use, User shall either secure a new permission for further use of the Work(s) or 
immediately cease any new use of the Work(s) and shall render inaccessible (such as by 
deleting or by removing or severing links or other locators) any further copies of the Work 
(except for copies printed on paper in accordance with this license and still in User's stock 
at the end of such period). 
3.4 In the event that the material for which a republication license is sought includes third 
party materials (such as photographs, illustrations, graphs, inserts and similar materials) 
which are identified in such material as having been used by permission, User is 
responsible for identifying, and seeking separate licenses (under this Service or otherwise) 
for, any of such third party materials; without a separate license, such third party materials 
may not be used. 
3.5 Use of proper copyright notice for a Work is required as a condition of any license 
granted under the Service. Unless otherwise provided in the Order Confirmation, a proper 
copyright notice will read substantially as follows: “Republished with permission of 
[Rightsholder’s name], from [Work's title, author, volume, edition number and year of 
copyright]; permission conveyed through Copyright Clearance Center, Inc. ” Such notice 
must be provided in a reasonably legible font size and must be placed either immediately 
adjacent to the Work as used (for example, as part of a by-line or footnote but not as a 
separate electronic link) or in the place where substantially all other credits or notices for 
the new work containing the republished Work are located. Failure to include the required 
notice results in loss to the Rightsholder and CCC, and the User shall be liable to pay 
liquidated damages for each such failure equal to twice the use fee specified in the Order 
Confirmation, in addition to the use fee itself and any other fees and charges specified. 
3.6 User may only make alterations to the Work if and as expressly set forth in the Order 
Confirmation. No Work may be used in any way that is defamatory, violates the rights of 
third parties (including such third parties' rights of copyright, privacy, publicity, or other 
tangible or intangible property), or is otherwise illegal, sexually explicit or obscene. In 
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addition, User may not conjoin a Work with any other material that may result in damage to 
the reputation of the Rightsholder. User agrees to inform CCC if it becomes aware of any 
infringement of any rights in a Work and to cooperate with any reasonable request of CCC 
or the Rightsholder in connection therewith. 
4. Indemnity. User hereby indemnifies and agrees to defend the Rightsholder and CCC, and 
their respective employees and directors, against all claims, liability, damages, costs and 
expenses, including legal fees and expenses, arising out of any use of a Work beyond the 
scope of the rights granted herein, or any use of a Work which has been altered in any 
unauthorized way by User, including claims of defamation or infringement of rights of 
copyright, publicity, privacy or other tangible or intangible property. 
5. Limitation of Liability. UNDER NO CIRCUMSTANCES WILL CCC OR THE 
RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL 
OR INCIDENTAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES 
FOR LOSS OF BUSINESS PROFITS OR INFORMATION, OR FOR BUSINESS 
INTERRUPTION) ARISING OUT OF THE USE OR INABILITY TO USE A WORK, 
EVEN IF ONE OF THEM HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH 
DAMAGES. In any event, the total liability of the Rightsholder and CCC (including their 
respective employees and directors) shall not exceed the total amount actually paid by User 
for this license. User assumes full liability for the actions and omissions of its principals, 
employees, agents, affiliates, successors and assigns. 
6. Limited Warranties. THE WORK(S) AND RIGHT(S) ARE PROVIDED “AS IS”. CCC 
HAS THE RIGHT TO GRANT TO USER THE RIGHTS GRANTED IN THE ORDER 
CONFIRMATION DOCUMENT. CCC AND THE RIGHTSHOLDER DISCLAIM ALL 
OTHER WARRANTIES RELATING TO THE WORK(S) AND RIGHT(S), EITHER 
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED 
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR 
PURPOSE. ADDITIONAL RIGHTS MAY BE REQUIRED TO USE ILLUSTRATIONS, 
GRAPHS, PHOTOGRAPHS, ABSTRACTS, INSERTS OR OTHER PORTIONS OF THE 
WORK (AS OPPOSED TO THE ENTIRE WORK) IN A MANNER CONTEMPLATED 
BY USER; USER UNDERSTANDS AND AGREES THAT NEITHER CCC NOR THE 
RIGHTSHOLDER MAY HAVE SUCH ADDITIONAL RIGHTS TO GRANT. 
7. Effect of Breach. Any failure by User to pay any amount when due, or any use by User 
of a Work beyond the scope of the license set forth in the Order Confirmation and/or these 
terms and conditions, shall be a material breach of the license created by the Order 
Confirmation and these terms and conditions. Any breach not cured within 30 days of 
written notice thereof shall result in immediate termination of such license without further 
notice. Any unauthorized (but licensable) use of a Work that is terminated immediately 
upon notice thereof may be liquidated by payment of the Rightsholder's ordinary license 
price therefor; any unauthorized (and unlicensable) use that is not terminated immediately 
for any reason (including, for example, because materials containing the Work cannot 
reasonably be recalled) will be subject to all remedies available at law or in equity, but in 
no event to a payment of less than three times the Rightsholder's ordinary license price for 
the most closely analogous licensable use plus Rightsholder's and/or CCC's costs and 
expenses incurred in collecting such payment. 
8. Miscellaneous. 
8.1 User acknowledges that CCC may, from time to time, make changes or additions to the 
Service or to these terms and conditions, and CCC reserves the right to send notice to the 
User by electronic mail or otherwise for the purposes of notifying User of such changes or 
additions; provided that any such changes or additions shall not apply to permissions 
already secured and paid for. 
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8.2 Use of User-related information collected through the Service is governed by CCC’s 
privacy policy, available online 
here:http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html. 
8.3 The licensing transaction described in the Order Confirmation is personal to User. 
Therefore, User may not assign or transfer to any other person (whether a natural person or 
an organization of any kind) the license created by the Order Confirmation and these terms 
and conditions or any rights granted hereunder; provided, however, that User may assign 
such license in its entirety on written notice to CCC in the event of a transfer of all or 
substantially all of User’s rights in the new material which includes the Work(s) licensed 
under this Service. 
8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed 
by the parties. The Rightsholder and CCC hereby object to any terms contained in any 
writing prepared by the User or its principals, employees, agents or affiliates and purporting 
to govern or otherwise relate to the licensing transaction described in the Order 
Confirmation, which terms are in any way inconsistent with any terms set forth in the Order 
Confirmation and/or in these terms and conditions or CCC's standard operating procedures, 
whether such writing is prepared prior to, simultaneously with or subsequent to the Order 
Confirmation, and whether such writing appears on a copy of the Order Confirmation or in 
a separate instrument. 
8.5 The licensing transaction described in the Order Confirmation document shall be 
governed by and construed under the law of the State of New York, USA, without regard to 
the principles thereof of conflicts of law. Any case, controversy, suit, action, or proceeding 
arising out of, in connection with, or related to such licensing transaction shall be brought, 
at CCC's sole discretion, in any federal or state court located in the County of New York, 
State of New York, USA, or in any federal or state court whose geographical jurisdiction 
covers the location of the Rightsholder set forth in the Order Confirmation. The parties 
expressly submit to the personal jurisdiction and venue of each such federal or state court.If 
you have any comments or questions about the Service or Copyright Clearance Center, 
please contact us at 978-750-8400 or send an e-mail to info@copyright.com. 
v 1.1 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777. 
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Rights to Published Article - ISSN: 0223-5234 
 
PermissionsFrance <permissionsfrance@elsevier.com> 
Tue, Mar 27, 2018 at 1:30 
PM 
To: FRANK TAPIWA ZINDO <2918291@myuwc.ac.za> 
 
Issy-Les-Moulineaux, 27-March-2018 
  
To the attention of Frank T Zindo 
  
Dear Sir, 
As per your request below, we hereby grant you permission to reprint the material detailed in your 
request at no charge in your thesis subject to the following conditions: 
  
1. If any part of the material to be used (for example, Figures) has appeared in our publication with credit or 
acknowledgement to another source, permission must also be sought from that source. If such permissions are 
not obtained then that materials may not be included in your publication. 
  
2. Any modification of the material is likely to harm the moral right of the authors and therefore should be first 
submitted and approved by the authors who are the sole owner of the moral right. 
  
3. Suitable and visible acknowledgement to the source must be made, either as a footnote or in a reference list at 
the end of your publication, as follows: 
“Reproduced from Authors name. Article title. Journal title year; volume 
number(issue number):first page-last page. Copyright © year [if applicable: name 
of learned society, published by] Elsevier Masson SAS. All rights reserved.” 
4. Your thesis may be submitted to your institution in either print or electronic form. 
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5. Reproduction of this material is confined to the purpose for which permission is hereby given. 
  
6. This permission is granted for non-exclusive world English rights only.  For other languages please reapply 
separately for each one required.  Permission excludes use in an electronic form other than submission.  Should 
you have a specific electronic project in mind please reapply for permission. 
  
7. Should your thesis be published commercially, please reapply for permission. 
Yours sincerely, 
Best Regards 
Regina 
Regina Lavanya Remigius 
Senior Copyrights Coordinator, GR - Copyrights 
ELSEVIER | Global Book Production 
+91 44 4299 4670 office 
r.remigius@elsevier.com 
www.elsevier.com 
From: FRANK TAPIWA ZINDO [mailto:2918291@myuwc.ac.za]  
Sent: Tuesday, February 27, 2018 11:35 AM 
To: PermissionsFrance <permissionsfrance@elsevier.com> 
Subject: Rights to Published Article - ISSN: 0223-5234 
*** External email: use caution *** 
  
[Quoted text hidden] 
 
  
Disclaimer - This e-mail is subject to UWC policies and e-mail disclaimer published on our website 
at: https://www.uwc.ac.za/Pages/emaildisclaimer.aspx 
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If you are not the author of this article and you wish to reproduce material from it in a third party 
non-RSC publication you must formally request permission using RightsLink. Go to 
our Instructions for using RightsLink page for details. 
Authors contributing to RSC publications (journal articles, books or book chapters) do not need to 
formally request permission to reproduce material contained in this article provided that the correct 
acknowledgement is given with the reproduced material. 
Reproduced material should be attributed as follows: 
 For reproduction of material from NJC:  
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If the material has been adapted instead of reproduced from the original RSC publication 
"Reproduced from" can be substituted with "Adapted from". 
In all cases the Ref. XX is the XXth reference in the list of references. 
If you are the author of this article you do not need to formally request permission to reproduce 
Figures, diagrams etc. contained in this article in third party publications or in a thesis or 
dissertation provided that the correct acknowledgement is given with the reproduced material. 
Reproduced material should be attributed as follows: 
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 For reproduction of material from all other RSC journals:  
[Original citation] - Reproduced by permission of The Royal Society of Chemistry 
If you are the author of this article you still need to obtain permission to reproduce the whole 
article in a third party publication with the exception of reproduction of the whole article in a thesis 
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Information about reproducing material from RSC articles with different licences is available on 
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If you are the author of this article you do not need to formally request permission to reproduce 
Figures, diagrams etc. contained in this article in third party publications or in a thesis or 
dissertation provided that the correct acknowledgement is given with the reproduced material. 
Reproduced material should be attributed as follows: 
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